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Neutrophils are the key effector cells of innate immunity, rapidly recruited to defend the host 
against invading pathogens. They deploy pre-formed proteases packaged within cytoplasmic 
granules, generate reactive oxygen species and release neutrophil extracellular traps (NETs). 
However, these anti-microbial strategies can also cause substantial bystander tissue injury. 
Infected and inflamed tissues are profoundly hypoxic, and this oxygen depletion both 
compromises neutrophil-mediated bacterial killing and enhances the secretion of destructive 
granule contents. Persistent neutrophilic infiltration of hypoxic tissues characterises diseases 
such as chronic obstructive pulmonary disease (COPD), which is also associated with 
endothelial dysfunction. Proteases such as neutrophil elastase (NE) have been implicated in 
COPD pathogenesis but the precise mechanisms of neutrophil-mediated tissue damage are 
unknown. 
In this thesis, I show that hypoxia synergises with neutrophil priming agents to enhance the 
release of NE in a PI3Kγ-dependent manner, with hypoxic supernatants inducing substantial 
endothelial cell dysfunction and death. To further identify potential histotoxic mediators, I used 
a proteomics approach to provide a full (and entirely novel) characterisation of the hypoxic 
versus normoxic neutrophil secretome, revealing upregulation of a number of protein 
candidates (both granule-associated and, surprisingly, a subset of cytoplasmic proteins) 
following hypoxic incubation and stimulation. As this unexpected pattern of protein release did 
not segregate with neutrophil granule contents, alternative secretion mechanisms were 
examined; however, hypoxia did not enhance the release of NETs or neutrophil-derived 
microvesicles. Importantly, neutrophils isolated from exacerbating COPD patients, compared 
with those from healthy controls, exhibited even further augmented release of selected 
cytotoxic granule (NE, resistin and neutrophil gelatinase-associated lipocalin) and cytoplasmic 
(cyclophilin A) proteins under hypoxia. Furthermore, a plasma signature of increased protease 
(NE and proteinase 3) activity was identified in COPD versus healthy control plasma.  
In conclusion, hypoxia engenders a destructive neutrophil phenotype, with enhanced release 
of histotoxic proteins and increased capacity to cause endothelial injury. This may contribute 
to local and distant tissue damage in the clinical setting of COPD, with further relevance to a 
wide range of chronic inflammatory diseases, underpinned by endothelial dysfunction.  
 
Acknowledgements 
First and foremost I would like to thank my supervisors, Alison Condliffe and Wei Li, for their 
unwavering support, guidance and encouragement during my PhD studies. When Alison 
moved to Sheffield to take up a well-deserved Professorship, I knew that she would continue 
to supervise me with the same care and dedication that she had provided right from the start 
of my PhD. I could not have hoped for more intelligent, capable, conscientious and 
approachable supervisors.  
I would especially like to thank my sponsor, Edwin Chilvers, whose door was always open for 
advice and I very much appreciate many insightful scientific discussions. The lab environment 
cultivated by Edwin ensured both intellectual stimulation and fun social occasions - I had a 
wonderful time! 
Throughout my PhD studies I have received help from numerous colleagues in Cambridge 
and Sheffield. I would particularly like to thank Alexi Crosby, Paul Upton, Anne-Katrien Stark 
and Sabine Suire for their donation of mouse legs, and Elisabet Ferrer and Merete Long for 
their substantial assistance with microvesicles, even in the face of adversity! I would also like 
to thank Arlette Vassallo for her help with the ROS assay, which worked perfectly every time!  
My office and lab colleagues in the Morrell, Chilvers and Summers groups, notably Arlette 
Vassallo, Alex Wood, Kim Hoenderdos, Ben Dunmore, Alexi Crosby, Elisabet Ferrer and Eleo 
Fox, made the lab a joy to work in. I especially value the firm friendship of Arlette and Alex, 
who kept me plied with tea and wine, and kept me sane – or thereabouts! 
I would like to express my gratitude to the Wellcome Trust and the British Medical Association 
Foundation for Medical Research for funding me and for all the blood donors who made this 
work possible.  
Finally, I’d like to give a very special thanks to my mum, and my partner, Ruaridh Buchanan, 
who now know nearly as much about neutrophils as I do!  You were always there for me with 
unswerving support, and helped me to relax, recharge and keep going in the face of frustration. 
I could not have done my PhD without you. 
  
 
Declaration ………………………………………………………………………………..……..….. 1 
Abstract …………………………………………………………………………………..……..…… 2 
Acknowledgements ……………………………………………………………………..……..…… 3 
List of Figures ……………………………………………………………………………..….….…. 8 
List of Tables ……………………………………………………………………………..….….….. 9 
List of Abbreviations ………………………………………………………………………………. 10 
1 Introduction .................................................................................................................. 13 
1.1 The innate immune system ................................................................................... 13 
1.2 Neutrophils ........................................................................................................... 13 
1.2.1 Effector functions of neutrophils ........................................................................ 14 
1.2.1.1 Priming and activation ................................................................................ 14 
1.2.1.2 Recruitment ................................................................................................ 15 
1.2.1.3 Phagocytosis and Reactive Oxygen Species .............................................. 16 
1.2.1.4 Granule formation and composition ............................................................ 17 
1.2.1.5 Degranulation ............................................................................................. 18 
1.2.1.6 Degranulation: receptors and intracellular signalling pathways ................... 20 
1.2.1.7 Degranulation: vesicle trafficking and fusion machinery.............................. 22 
1.2.1.8 Degranulation: differential exocytosis ......................................................... 22 
1.2.1.9 Neutrophil Extracellular Traps .................................................................... 25 
1.2.1.10 Neutrophil-derived microvesicles ................................................................ 26 
1.2.1.11 Apoptosis and clearance ............................................................................ 27 
1.2.1.12 Role of neutrophils in disease .................................................................... 27 
1.2.2 The impact of hypoxia on neutrophils ................................................................ 29 
1.2.2.1 Relevance of hypoxia to neutrophils ........................................................... 29 
1.2.2.2 Sensing of hypoxia by neutrophils .............................................................. 30 
1.2.2.3 Effect of hypoxia on neutrophil recruitment ................................................. 31 
1.2.2.4 Effect of hypoxia on phagocytosis and ROS generation ............................. 32 
1.2.2.5 Effect of hypoxia on degranulation ............................................................. 33 
1.2.2.6 Effect of hypoxia on NET production .......................................................... 34 
1.2.2.7 Effect of hypoxia on neutrophil-derived microvesicle generation ................. 35 
1.2.2.8 Effect of hypoxia on neutrophil apoptosis ................................................... 35 
1.2.2.9 Overall effect of hypoxia on neutrophil functions ........................................ 36 
1.2.3 The role of neutrophils in COPD ........................................................................ 38 
1.3 Endothelial cells .................................................................................................... 40 
1.3.1 The role of neutrophils in endothelial dysfunction and cardiovascular disease .. 41 
1.3.1.1 Direct neutrophil-endothelial interactions .................................................... 41 
1.3.1.2 Interaction of endothelium with secreted neutrophil products ..................... 42 
1.3.1.3 Interaction of endothelium with neutrophil-derived microvesicles ................ 44 
1.3.2 The role of neutrophils in endothelial dysfunction and cardiovascular disease in 
COPD  ......................................................................................................................... 45 
1.4 Summary .............................................................................................................. 46 
1.5 Hypothesis and aims ............................................................................................. 47 
1.5.1 Hypothesis ........................................................................................................ 47 
1.5.2 Specific aims ..................................................................................................... 47 
 
2 Materials and methods ................................................................................................. 49 
2.1 Materials ............................................................................................................... 49 
2.2 Neutrophils ........................................................................................................... 53 
2.2.1 Neutrophil preparation ....................................................................................... 53 
2.2.1.1 Neutrophil isolation from human whole blood ............................................. 53 
2.2.1.2 Neutrophil isolation from murine bone marrow ........................................... 55 
2.2.1.3 Generation of neutrophil supernatants ........................................................ 55 
2.2.1.4 Optimisation of neutrophil cell lysate generation ......................................... 56 
2.2.1.5 Generation of neutrophil cell lysates ........................................................... 61 
2.2.2 Working under hypoxia ...................................................................................... 61 
2.2.3 Neutrophil functional assays .............................................................................. 62 
2.2.3.1 Assessment of shape change .................................................................... 62 
2.2.3.2 Assessment of apoptosis by morphology ................................................... 64 
2.2.3.3 Assessment of apoptosis by flow cytometry ............................................... 65 
2.2.3.4 Assessment of neutrophil reactive oxygen species production ................... 65 
2.2.3.5 Assessment of neutrophil extracellular trap production ............................... 66 
2.2.4 Neutrophil degranulation assays ....................................................................... 67 
2.2.4.1 Assessment of neutrophil elastase release................................................. 67 
2.2.4.2 Optimisation of the NE activity assay for murine neutrophils ...................... 67 
2.2.4.3 Assessment of human NE release with PI3Kinase inhibition ...................... 69 
2.2.4.4 Assessment of NE release from murine neutrophils with PI3Kinase 
mutations .................................................................................................................. 69 
2.2.4.5 Assessment of MPO release ...................................................................... 70 
2.2.5 Protein detection methods ................................................................................. 70 
2.2.5.1 Sample preparation for gel electrophoresis ................................................ 70 
2.2.5.2 SDS-PAGE................................................................................................. 71 
2.2.5.3 Western blotting ......................................................................................... 72 
2.2.5.4 Silver staining ............................................................................................. 73 
2.3 Endothelial Cells ................................................................................................... 73 
2.3.1 Endothelial cell culture ....................................................................................... 73 
2.3.2 Endothelial cell functional assays ...................................................................... 74 
2.3.2.1 Assessment of endothelial ICAM-1 expression by flow cytometry .............. 74 
2.3.3 Endothelial cell viability assays .......................................................................... 75 
2.3.3.1 Assessment of cell detachment by immunofluorescence ............................ 75 
2.3.3.2 Assessment of cell viability by MTT assay .................................................. 75 
2.3.3.3 Assessment of apoptosis by flow cytometry ............................................... 76 
2.4 Proteomics ............................................................................................................ 79 
2.4.1 Generation of neutrophil supernatants for proteomics ....................................... 79 
2.4.2 Two dimensional difference gel electrophoresis ................................................ 79 
2.4.3 10-plex tandem mass tag-labelled mass spectrometry ...................................... 82 
2.4.4 Quantification of supernatant resistin, NGAL, cyclophilin A, S100A9, S100A8 and 
S100A8/A9 by ELISA ................................................................................................... 84 
2.5 Microvesicles ........................................................................................................ 84 
2.5.1 Microvesicle isolation from Histopaque®-1077-prepared neutrophils................. 84 
2.5.2 Quantification of neutrophil-derived microvesicles by flow cytometry ................. 86 
2.5.3 Preparation of microvesicle lysates for western blotting ..................................... 86 
 
2.6 COPD study .......................................................................................................... 87 
2.6.1 COPD patient recruitment ................................................................................. 87 
2.6.2 Obtaining plasma and serum from whole blood ................................................. 88 
2.6.3 Quantification of Aα-Val360 and Aα-Val541 ........................................................... 88 
2.6.4 Quantification of plasma microvesicles by flow cytometry .................................. 89 
2.7 Statistics ............................................................................................................... 89 
3 Effect of hypoxia on NE release and neutrophil-mediated endothelial dysfunction ....... 92 
3.1 Introduction ........................................................................................................... 92 
3.2 Confirmation of the neutrophil hypoxic response ................................................... 93 
3.3 The effect of different priming agonists on hypoxic NE release ............................. 94 
3.4 Investigation of the mechanism of NE release under hypoxia ............................... 97 
3.4.1 The effect of hypoxia on NET production ........................................................... 97 
3.4.2 The effect of PI3K signalling modulation on the release of NE under hypoxia ... 98 
3.4.2.1 The effect of PI3K inhibitors on the release of NE from human neutrophils 
under hypoxia ......................................................................................................... 100 
3.4.2.2 The effect of PI3K isoform mutations in murine neutrophils on NE release 
under hypoxia ......................................................................................................... 103 
3.5 The effect of hypoxia on neutrophil-induced pulmonary artery endothelial cell 
dysfunction .................................................................................................................... 105 
3.5.1 The effect of neutrophil supernatants on endothelial cell activation ................. 105 
3.5.2 The effect of hypoxia on neutrophil-induced endothelial cell detachment ........ 106 
3.5.3 The effect of hypoxia on neutrophil-induced endothelial cell death .................. 108 
3.6 Discussion .......................................................................................................... 113 
4 Effect of hypoxia on the neutrophil secretome ............................................................ 120 
4.1 Introduction ......................................................................................................... 120 
4.2 2D Difference Gel Electrophoresis ...................................................................... 122 
4.3 Optimisation of neutrophil supernatant generation for TMT-labelled MS ............. 125 
4.4 Characterisation of the normoxic versus hypoxic neutrophil secretome by 10-plex 
tandem mass tag-labelled mass spectrometry (TMT-MS) .............................................. 132 
4.5 Biochemical validation of differentially regulated proteins identified by TMT-MS . 137 
4.6 The role of NDMV secretion in the differential protein release from neutrophils 
under hypoxia ................................................................................................................ 142 
4.6.1 Quantification of NDMV release from normoxic and hypoxic neutrophils ......... 142 
4.6.2 Evaluation of cyclophilin A protein content of NDMVs from normoxic and hypoxic 
neutrophils ................................................................................................................. 143 
4.7 Discussion .......................................................................................................... 147 
5 Effect of hypoxia on neutrophil function in exacerbating COPD patients .................... 156 
5.1 Introduction ......................................................................................................... 156 
 
5.2 Investigation of COPD versus healthy neutrophil secretion of proteins upregulated 
in the hypoxic secretome ............................................................................................... 158 
5.2.1 The effect of hypoxia on the release of NE and MPO from COPD versus healthy 
neutrophils ................................................................................................................. 158 
5.2.2 The effect of hypoxia on the release of resistin, NGAL and cyclophilin A from 
COPD versus healthy neutrophils .............................................................................. 161 
5.3 COPD versus healthy plasma content of proteins upregulated in the hypoxic 
neutrophil secretome ..................................................................................................... 164 
5.4 The COPD versus healthy plasma content of microvesicles ............................... 166 
5.5 Discussion .......................................................................................................... 166 
6 Discussion ................................................................................................................. 173 
6.1 Overview ............................................................................................................. 173 
6.2 Discussion of results ........................................................................................... 174 
6.2.1 Differential effects of priming agents on hypoxic degranulation ....................... 174 
6.2.2 Role of PI3K signalling in hypoxic degranulation ............................................. 175 
6.2.3 Possible mechanisms of endothelial damage by hypoxic supernatants ........... 178 
6.2.4 Proteomic analysis of the neutrophil secretome............................................... 180 
6.2.5 Potential mechanisms of “differential degranulation” ....................................... 181 
6.2.6 Enhanced release of cytoplasmic proteins ....................................................... 181 
6.2.7 Translation to COPD and beyond .................................................................... 182 
6.3 Future research avenues .................................................................................... 185 
6.3.1 Investigating the role of hypoxia-upregulated proteins in mediating clinically 
relevant endothelial damage ...................................................................................... 185 
6.3.2 Investigating how hypoxia impacts neutrophil intracellular signalling and granule 
trafficking pathways to enhance histotoxic protein release ......................................... 187 
6.4 Conclusions ........................................................................................................ 188 
7 Appendices ................................................................................................................ 190 
7.1 10-plex TMT-MS and data analysis parameters .................................................. 190 
7.1.1 LC-MS/MS ....................................................................................................... 190 
7.1.2 Data analysis ................................................................................................... 191 
7.2 Proteins identified by 10-plex TMT-MS ............................................................... 192 
7.3 Publications arising from this thesis .................................................................... 199 
7.3.1 Papers ............................................................................................................. 199 
7.3.2 Abstracts ......................................................................................................... 199 




List of Figures 
 
Figure 1.1: Neutrophil signalling pathways involved in degranulation .................................. 20 
Figure 1.2: Control of differential granule exocytosis ........................................................... 24 
Figure 1.3: Neutrophil functions under conditions of normoxia versus hypoxia .................... 37 
Figure 2.1: Isolation of neutrophils from human whole blood ............................................... 54 
Figure 2.2: Expression of total AKT by western blot ............................................................ 57 
Figure 2.3: The ability of monoclonal versus polyclonal antibodies to detect pAKT and AKT 
by western blot .................................................................................................................... 58 
Figure 2.4: The effect of different buffers and lysate preparation methods on pAKT and AKT 
protein detection by western blot ......................................................................................... 60 
Figure 2.5: Analysis of media pH, pO2 and pCO2 ................................................................ 62 
Figure 2.6: Gating strategy and quantification of neutrophil shape change by flow cytometry
 ........................................................................................................................................... 63 
Figure 2.7: Assessment of neutrophil apoptosis by morphology .......................................... 64 
Figure 2.8: Gating strategy for assessment of neutrophil apoptosis by flow cytometry ........ 66 
Figure 2.9: The effect of an NE-selective inhibitor on the detection of supernatant NE activity
 ........................................................................................................................................... 68 
Figure 2.10:  The effect of priming agonists and an NE-selective inhibitor on the detection of 
murine supernatant NE activity ........................................................................................... 69 
Figure 2.11: Gating strategy for assessment of HPAEC apoptosis by flow cytometry: 
baseline and compensation................................................................................................. 77 
Figure 2.12: Gating strategy for assessment of HPAEC apoptosis by flow cytometry: 
supernatant treatment ......................................................................................................... 78 
Figure 2.13: 2D DIGE analysis by Decyder 2D DIA software .............................................. 81 
Figure 2.14: Gating strategy for isolated NDMV quantification by flow cytometry ................ 87 
Figure 2.15: Gating strategy for plasma microvesicle quantification by flow cytometry ........ 90 
Figure 3.1: The effect of hypoxia on neutrophil apoptosis ................................................... 95 
Figure 3.2: The effect priming agonists and hypoxia on NE release .................................... 96 
Figure 3.3: The effect of hypoxia on NET production .......................................................... 99 
Figure 3.4: The effect of PI3K inhibition on the hypoxic regulation of AKT phosphorylation101 
Figure 3.5 The effect of PI3K inhibition on the hypoxic regulation of NE release ............... 102 
Figure 3.6: The effect of hypoxia on NE release from murine neutrophils with PI3Kδ or PI3Kγ 
mutations .......................................................................................................................... 104 
Figure 3.7: The effect of hypoxia and neutrophil supernatants on endothelial-leukocyte 
ICAM-1 expression by flow cytometry ............................................................................... 107 
Figure 3.8: The effect of neutrophil supernatants on HPAEC detachment by confocal 
microscopy ........................................................................................................................ 109 
Figure 3.9: The effect of neutrophil supernatants on HPAEC survival by MTT assay ........ 111 
Figure 3.10: The effect of neutrophil supernatants on HPAEC survival by flow cytometry . 112 
Figure 4.1: The effect of buffer and precipitation on neutrophil supernatant protein content
 ......................................................................................................................................... 124 
Figure 4.2: Analysis of hypoxic versus normoxic neutrophil supernatant protein content by 
2D DIGE ........................................................................................................................... 126 
Figure 4.3:  The effect of protease inhibitors on neutrophil supernatant protein content .... 127 
Figure 4.4: The effect of small molecule protease inhibitors on neutrophil supernatant protein 
content .............................................................................................................................. 129 
 
Figure 4.5: The effect of small molecule protease inhibitors on neutrophil morphology ..... 130 
Figure 4.6:  Optimised protease inhibition strategy ............................................................ 131 
Figure 4.7: Comparison of TCA-precipitation and spin column protein concentration ........ 132 
Figure 4.8: Characterisation of the normoxic versus hypoxic neutrophil secretome by TMT-
MS .................................................................................................................................... 136 
Figure 4.9: The effect of hypoxia on resistin, NGAL and cyclophilin A release from 
neutrophils by ELISA......................................................................................................... 138 
Figure 4.10: The effect of hypoxia on S100A8 and S100A9 release from neutrophils by 
ELISA ............................................................................................................................... 140 
Figure 4.11: The effect of hypoxia on S100A9 release from neutrophils by western blot ... 141 
Figure 4.12: Comparison of neutrophil isolation methods and the effect of hypoxia on NDMV 
release .............................................................................................................................. 144 
Figure 4.13: Neutrophil-derived microvesicle and supernatant content of annexin A1 and 
cyclophilin A by western blot ............................................................................................. 145 
Figure 4.14: Quantification of neutrophil-derived microvesicle content of annexin A1 and 
cyclophilin A by western blot ............................................................................................. 146 
Figure 4.15: Visualisation of MVs from neutrophils and endothelial cells by electron 
microscopy ........................................................................................................................ 151 
Figure 5.1: Quantification of healthy versus COPD neutrophil shape change by flow 
cytometry .......................................................................................................................... 159 
Figure 5.2: The effect of hypoxia on NE and MPO release from healthy and COPD 
neutrophils ........................................................................................................................ 162 
Figure 5.3: The effect of hypoxia on resistin and NGAL release from healthy and COPD 
neutrophils ........................................................................................................................ 162 
Figure 5.4: The effect of hypoxia on cyclophilin A release from healthy and COPD 
neutrophils ........................................................................................................................ 163 
Figure 5.5: The healthy versus COPD plasma content of Aα-Val360 and Aα-Val541 ............ 164 
Figure 5.6: The healthy versus COPD plasma content of resistin, NGAL and cyclophilin A by 
ELISA ............................................................................................................................... 165 
Figure 5.7: Healthy versus COPD plasma microvesicle content ........................................ 167 
Figure 6.1: The effect of neutrophil supernatants on IL-1β ................................................ 179 
 
List of Tables 
Table 1.1: Contents of neutrophil granules .......................................................................... 19 
Table 2.1: Antibodies .......................................................................................................... 52 
Table 4.1: Comparison of protein concentration methods ................................................. 123 
Table 4.2: Proteins significantly increased in normoxia ..................................................... 134 
Table 4.3: Proteins significantly increased in hypoxia........................................................ 135 
Table 5.1: Clinical and demographic data ......................................................................... 160 
Table 7.1: Proteins increased in normoxia ........................................................................ 192 
Table 7.2: Proteins increased in hypoxia ........................................................................... 195 
Table 7.3: Differentially regulated proteins identified by 10-plex TMT-MS compared with 
published secretomes and sepsis patient plasma ............................................................. 198 
 
 
List of Abbreviations 
 
2D DIGE  Two dimensional difference gel electrophoresis 
α1AT   α1 antitrypsin 
AEBSF  4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride 
ALI    Acute lung injury  
ATP    Adenosine triphosphate  
ARDS    Acute respiratory distress syndrome 
BALF   Bronchoalveolar lavage fluid  
BSA    Bovine serum albumin  
BMP9    Bone morphogenetic protein 9 
Ca2+    Calcium ion  
CaCl2    Calcium chloride  
CAM   Cell adhesion molecule 
CF   Cystic fibrosis 
CGD   Chronic granulomatous disease 
CHX   Cycloheximide 
COPD    Chronic obstructive pulmonary disease  
CRP   C-reactive protein 
CVD   Cardiovascular disease 
DAPI   4',6-diamidine-2'-phenylindole dihydrochloride 
DMB   o-dianisidine dihydrochloride 
DMSO   Dimethyl sulfoxide  
DTT   Dithiothreitol 
EDTA    Ethylenediamine tetraacetic acid  
EGTA   Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
ELISA    Enzyme-linked immunosorbent assay  
ECM   Extracellular matrix  
ER    Endoplasmic reticulum  
FACS   Fluorescence-activated cell sorting 
FC   Fold change 
FCS   Foetal calf serum 
FDR   False discovery rate 
FIH    Factor inhibiting HIF  
FITC    Fluorescein isothiocyanate  
FMD   Flow-mediated dilatation 
fMLP    N-formyl-methionyl-leucyl-phenylalanine  
GAP   GTPase-activating protein 
GDP   Guanosine diphosphate 
GEF   Guanine nucleotide exchange factor 
GM-CSF  Granulocyte-macrophage colony-stimulating factor  
GPCR    G-protein coupled receptor  
GTP    Guanosine triphosphate  
H2O2    Hydrogen peroxide  
HCl   Hydrochloric acid 
HIF    Hypoxia-inducible factor  
HOCl   Hypochlorous acid 
 
HPAEC  Human pulmonary artery endothelial cell 
HPLC   High performance liquid chromatography 
HRE    Hypoxia response element  
HRP    Horseradish peroxidase  
HUVEC  Human umbilical vein endothelial cell 
IBD   Inflammatory bowel disease 
ICAM-1   Intercellular adhesion molecule-1  
IEF   Isoelectric focusing 
I/R   Ischaemia/reperfusion 
IL   Interleukin  
IMDM    Iscove's modified dulbecco's medium  
IP3    Inositol 1,4,5-trisphosphate  
ITAM   Immunoreceptor tyrosine-based activation motif 
kDa    Kilodalton  
kPa    Kilopascal  
LPS   Lipopolysaccharide 
LTB4    Leukotriene B4  
Mg2+    Magnesium ion  
MMP    Matrix metalloproteinase 
MPO    Myeloperoxidase  
MS   Mass spectrometry 
mTOR   Mammalian target of rapamycin 
MTT   3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
MV   Microvesicle 
NaCl   Sodium chloride 
NADP    Nicotinamide adenine dinucleotide phosphate  
NDMV   Neutrophil-derived microvesicle 
NE    Neutrophil elastase  
NET    Neutrophil extracellular trap  
NF-κB    Nuclear factor-κB  
NGAL   Neutrophil gelatinase-associated lipocalin 
OSA   Obstructive sleep apnoea 
PAD4   Peptidylarginine deiminase 4 
PAF    Platelet activating factor  
PAFR   PAF receptor 
PAGE    Polyacrylamide gel electrophoresis  
PBMC   Peripheral blood mononuclear cells 
PBS+/+   Phosphate-buffered saline with calcium/magnesium chloride  
PBS-/-   Phosphate-buffered saline without calcium/magnesium chloride 
PCA   Principal component analysis 
PET   Positron emission tomography 
PFA   Paraformaldehyde 
PH   Pulmonary hypertension 
PHD    Prolyl hydroxylase domain  
PI3K    Phosphoinositide 3-kinase  
PIP2   Phosphatidylinositol-(4,5)-bisphosphate 
PIP3    Phosphatidylinositol-(3,4,5)-trisphosphate  
PLC    Phospholipase C  
 
PMA    Phorbol myristate acetate  
PMSF   Phenylmethylsulfonyl fluoride 
pO2   Partial pressure of oxygen 
PPP    Platelet-poor plasma  
PR3   Proteinase 3 
PRP    Platelet-rich plasma  
PVDF   Polyvinylidene fluoride 
ROS    Reactive oxygen species  
RA   Rheumatoid arthritis 
RBC   Red blood cells 
rTEM   reverse trans-endothelial migration 
SDS    Sodium dodecyl sulphate  
SNAP   Synaptosome associated protein 
SNARE   Soluble NSF-attachment protein receptor  
TB   Tuberculosis 
TCA   Trichloroacetic acid 
TGF    Transforming growth factor  
TLR   Toll-like receptor 
TMT-MS  Tandem mass tag-labelled mass spectrometry 
TNFα    Tumour necrosis factor-α  
TNFR   TNF receptor 
VAMP    Vesicle-associated membrane protein 
VEGF   Vascular endothelial growth factor 
vHL    von Hippel-Lindau  















1.1 The innate immune system 
The innate immune system, comprising physical barriers, and chemical and cellular 
components, protects the body from invading pathogens. The anatomical barriers of the 
respiratory system include the muco-ciliary escalator, whereby micro-organisms trapped by 
mucus in the airways are propelled towards the pharynx by the co-ordinated action of cilia, 
and the epithelial surface lining, which provides a structural barrier and secretes a variety of 
host defence molecules, including defensins and lysozyme. Additionally, resident alveolar 
macrophages are the primary phagocytic cells of the uninflamed lower airways, scavenging 
inhaled pathogens and environmental particles at the interface between air and lung tissue. 
Once a pathogen breaches these initial barriers, the ensuing inflammatory response initiated 
by the release of cytokines and chemicals from injured cells recruits the professional cells of 
the innate immune system. 
1.2 Neutrophils 
Neutrophils are largely absent from the healthy lung, which has resident defences including 
the muco-ciliary escalator, antimicrobial peptides and proteins produced by airway epithelial 
cells, and alveolar macrophages. If these are overcome, neutrophils are recruited from the 
circulation, rapidly recognising and eliminating pathogens via a number of cytotoxic 
mechanisms, and modulating both the innate and adaptive host inflammatory response. 
Neutrophils also contribute to the recruitment of other immune cells, thereby amplifying the 
inflammatory cascade. Their striking cytological structure sheds light on several effector 
functions and is reflected in nomenclature: their cytoplasm contains numerous bactericidal 
granules and hence they are often termed granulocytes, and the characteristic multi-lobed 
nucleus confers the deformability to squeeze through cell junctions, giving rise to the term 
‘polymorphonuclear leukocyte’ or polymorph.  Neutrophils comprise 50% to 70% of circulating 
white blood cells and are generated in the bone marrow at a rate of 1011 per day, increasing 
to up to 1012 per day at times of infection (1). Neutrophil homeostasis is maintained through a 
controlled balance of granulopoeisis within and release from the bone marrow, margination in 
intravascular pools (including the liver and spleen), tissue recruitment, and cell death and 
clearance (2). Neutrophil half-life is thought to be short, with a generally accepted survival of 
8-12 h in the circulation and 1-2 days in the tissues, although this can be modulated by the 
inflammatory response (3). However, some recent studies have challenged this paradigm, 
indicating a circulatory neutrophil lifespan of up to several days (reviewed in (4)).  
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In order to prevent inappropriate triggering within the circulation, neutrophils are required to 
undergo a two-step activation process, whereby an initial “priming” stimulus  (first described 
by Guthrie et al. (5)) generates a pre-activated (primed) phenotype, which results in a 
substantially enhanced cytotoxic response upon encountering an activating stimulus or 
environment, such as a bacterial focus of infection. Once in the vicinity of their prey, 
neutrophils employ myriad trapping and killing mechanisms, including organism engulfment 
by phagocytosis, production of reactive oxygen species (ROS), phagosome-fusion or 
exocytosis (degranulation) of granules containing multiple antimicrobial proteins and 
proteases, and release of neutrophil extracellular traps (NETs). Subsequently, neutrophils are 
cleared: apoptotic cells are predominantly removed via phagocytosis by macrophages 
(efferocytosis), which hastens the resolution of inflammation. Although neutrophils are 
extremely well adapted for their dual role of immune surveillance and the elimination of 
invading pathogens, damage to host tissue from excessive or persistent neutrophilic 
inflammation has been implicated in the pathogenesis of numerous diseases, including both 
acute (e.g. acute respiratory distress syndrome, ARDS) and chronic (e.g. chronic obstructive 
pulmonary disease, COPD) inflammatory lung diseases. 
1.2.1 Effector functions of neutrophils 
1.2.1.1 Priming and activation 
In health, circulating neutrophils are quiescent but upon exposure to a wide range of priming 
agents, including cytokines such as granulocyte-macrophage colony-stimulating factor (GM-
CSF) and tumour necrosis factor α (TNFα), or phospholipid mediators such as platelet 
activating factor (PAF), they are able to transition from an inactive state to an adhesive, primed 
phenotype. Primed neutrophils rapidly become less deformable (6), which may promote their 
retention in vascular beds (7). Priming also induces rapid shedding of L-selectin (which 
mediates initial neutrophil rolling interactions with endothelium) and increases the surface 
expression and enhances the function of β2 integrin (CD11b/CD18, MAC-1), which binds 
endothelial surface cell adhesion molecules (CAMs) to mediate firm adhesion to the vessel 
wall (8). Together, these changes promote migration of neutrophils through the vascular 
endothelium to sites of infection and/or tissue injury. Critically, priming agonists also markedly 
potentiate the neutrophil’s response to subsequently encountered activating stimuli, such as 
bacterial formylated peptide (fMLP), allowing swift initiation and potent augmentation of 
pathogen seeking (chemotaxis), ensnaring (e.g. NET release) and killing (e.g. ROS 
production) mechanisms in order to enhance bactericidal capacity (reviewed in (9)). Individual 
priming agents, however, result in subtly different regulation of phenotypic changes. For 
example, TNFα- and PAF-priming of neutrophil β2 integrin upregulation and activation display 
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distinct kinetic and functional profiles, with TNFα producing a sustained β2 integrin activation 
but PAF-induced activity declining within minutes of agonist treatment (8). Several priming 
agents, e.g. GM-CSF, increase neutrophil longevity by delaying apoptosis, thus extending the 
inflammatory response but, in contrast, TNFα can exert either a pro- or anti-apoptotic effect, 
which is both concentration- and time-dependent (10). 
1.2.1.2 Recruitment 
Circulating neutrophils constantly patrol the endothelium for signs of inflammation and 
infection. Stimulation of the endothelium by inflammatory mediators, such as TNFα, 
upregulates endothelial selectins (e.g. E-selectin) which bind their glycosylated ligands on 
neutrophils (e.g. PSGL-1). This induces tethering and rolling of neutrophils along the blood 
vessel wall such that, once the degree of interaction is sufficient, the rolling neutrophil 
becomes captured. Chemokines, such as IL-8, decorate the endothelial surface; chemokine 
receptor ligation initiates priming of arrested neutrophils to induce mobilisation of intra-cellular 
integrin stores and conformational changes of cell surface-expressed integrins, which can 
then bind endothelial CAMs, e.g. ICAM-1, an essential process for firm adhesion. In response 
to priming and endothelial adhesion, neutrophils develop a polarised morphology, with 
cytoskeletal F actin polymerisation at the leading edge, enabling directional movement and 
facilitating trans-endothelial migration (reviewed in (11)). 
Neutrophil migration towards sites of inflammation and infection, a process termed 
chemotaxis, is directed by chemoattractant concentration gradients. Chemoattractant control 
of neutrophil migration is complex as the in vivo milieu is a dynamic environment, comprising 
multiple chemoattractant signals in intricate concentration, spatial and temporal patterns. 
Successful homing requires neutrophils to display multiple receptors, including those for 
chemoattractants released by the endothelium (e.g. leukotriene B4, LTB4) and so called “end 
target” chemoattractants, released in the immediate vicinity of the infective or inflammatory 
stimulus (e.g. bacterial fMLP). Foxman et al. have shown that neutrophil chemotaxis is a 
multistep process with sequential navigation through a series of gradients (12). Initially thought 
to be predominantly phosphoinositide-3-kinase (PI3K)-dependent (13), it has now been 
demonstrated that there is an intracellular signalling hierarchy with end target 
chemoattractants signalling though p38 MAPK (14).  
The traditional neutrophil recruitment paradigm of tethering, rolling, firm adhesion, crawling 
and finally endothelial transmigration is context-dependent. In the lung, neutrophils leave the 
pulmonary circulation though capillaries, as opposed to the post-capillary venule exit route 
from the systemic circulation. As a consequence of the unique lung microvasculature (an 
extensive alveolar capillary network), pulmonary neutrophil sequestration is reliant, at least in 
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part, on rheological changes due to space constraints and, in this situation, integrin-
independent pulmonary neutrophil accumulation has been shown (15).  
Two aspects of neutrophil behaviour described recently in animal models may contribute to 
neutrophil recruitment and to its resolution, although their significance in humans is currently 
uncertain. Firstly, neutrophils have the capacity to promote their own rapid and massive 
recruitment in ‘swarms’, largely choreographed by the release of the priming agent LTB4 
(reviewed in (16)). This may be beneficial, walling off infection (17), or detrimental due to  
vascular occlusion (18). Secondly, movement of primed neutrophils from the extravascular 
tissue back into the vascular lumen has been described: reverse trans-endothelial cell 
migration (rTEM). Colom et al. demonstrated neutrophil rTEM in a murine model of 
ischaemia/reperfusion (I/R) injury, which was dependent on proteolytic cleavage of the 
endothelial junctional adhesion molecule JAM-C by the neutrophil granule protease neutrophil 
elastase (NE) and was associated with the development of a systemic inflammatory response 
secondary to the local sterile injury (19). Thus, rTEM may also contribute to endothelial injury 
and remote organ dysfunction. 
1.2.1.3 Phagocytosis and Reactive Oxygen Species 
Neutrophils are professional phagocytes with the ability to recognise and rapidly ingest 
pathogens. The process is initiated by ligation of phagocytic receptors, either by endogenous 
components of the particle or by host-derived opsonins (antibodies or complement 
components). Target particles are engulfed into the phagosome, a plasma membrane-derived 
vacuole formed by extension of neutrophil pseudopods which surround and enclose the 
particle. Phagocytic receptor ligation initiates a phosphorylation cascade, allowing recruitment 
of multiple adaptor and signalling proteins to facilitate pseudopod extension by means of 
dynamic changes in the actin cytoskeleton (reviewed in (20)). When initially formed, 
phagosomes are not intrinsically antimicrobial. As they mature into phagolysosomes, 
microbicidal activity is acquired by vacuole fusion with endocytic compartments, including 
cytosolic granule populations, containing abundant proteases and antimicrobial peptides (21–
23) and subunits of NADPH oxidase, assembly of which enables ROS production (24).  
Generation of ROS through activation of the NADPH oxidase electron transport chain plays a 
critical role, killing many (though not all) pathogens. NADPH oxidase is an electron donor 
which reduces molecular di-oxygen to form superoxide anion, spontaneous or catalytically-
driven dismutation of which yields a range of antimicrobial ROS (reviewed in (25)). The 
prevailing view of the role of ROS in bacterial killing has been the generation of highly toxic 
oxidants in the presence of myeloperoxidase (MPO), which then catalyses the oxidation of 
halides, including cytotoxic hypochlorous acid (HOCl). However, Segal and colleagues have 
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challenged this dogma, suggesting that the primary role of NADPH oxidase is electron delivery 
to the phagosome, with the compensatory cation influx alkalinising the vacuolar pH so that it 
is optimal for antibacterial protease activity (26). Controversially, as generation of HOCl by 
MPO has long been thought to be fundamental to phagosomal antimicrobial activity, there is 
minimal peroxidase and chlorinating activity of MPO at this alkaline pH. It may be that this 
mechanism is more important in situations outside the phagosome, such as an incompletely 
phagocytosed particle. Still, Green et al. maintain that HOCl is vital for ingested bacterial 
killing, demonstrating that decreased chlorination in the phagosome halved killing of S. aureus 
(27), and modifications of host proteins by HOCl may provide further active antimicrobial 
species, such as chloramines. Whether ROS act directly or indirectly, the importance of this 
mechanism for neutrophil-mediated pathogen handling is highlighted by chronic 
granulomatous disease (CGD), a rare genetic disorder caused by a defective NADPH oxidase 
complex. As a consequence, these patients suffer severe recurrent infections with fungi and 
several species of bacteria (28). 
1.2.1.4 Granule formation and composition 
As the name “granulocyte” suggests, neutrophils contain various granule populations, 
enclosing multiple antimicrobial proteins and proteases, as well as a reserve of adhesion 
molecules and receptors. In order to effect pathogen killing, these granules can either fuse 
with the phagosome, releasing their cytotoxic contents into the phagocytic vacuole to destroy 
ingested micro-organisms, or with the plasma membrane, secreting their arsenal of proteins 
extracellularly, termed degranulation. The fate of granule fusion is determined by the potency 
of the activating stimulus.  
Granulopoiesis is temporally-regulated during neutrophil maturation, initiated as myeloblasts 
differentiate into promyelocytes. Although in reality they comprise a spectrum, each granule 
sub-type contains a broadly different protein cargo, and this differential protein composition 
has led to granule classification. The first to be formed are the azurophil (primary) granules, 
followed sequentially by the specific (secondary) and then gelatinase (tertiary) granules, and 
finally by the secretory vesicles. The prevailing hypothesis of granule heterogeneity is that of 
protein targeting by timing of biosynthesis, proposed by Borregaard et al., whereby 
concomitantly formed proteins are directed into granules together, and different granule sub-
types are formed as protein expression changes during neutrophil maturation (29). This is 
exemplified by forced expression of neutrophil gelatinase-associated lipocalin (NGAL), 
(usually synthesised in metamyelocytes and targeted to specific granules) in the promyelocytic 
HL-60 cell line, which instead resulted in its packaging into azurophil granules (30). However, 
it has also been shown that active sorting of proteins to granules occurs; for example, patients 
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lacking the β3A subunit of adaptor protein 3 (AP3; Hermansky-Pudlak type 2 syndrome) have 
a dramatic reduction of azurophil granule NE content (31), although it is not clear whether this 
is due to a failure of localisation, insufficient retention or enhanced degradation of this 
protease. 
In depth characterisation of granule sub-types has been performed, with cell fractionation and 
proteomic techniques describing granule protein composition; this is relatively distinct between 
sub-types although there is a degree of overlap, particularly between specific and gelatinase 
granules (32,33) (see Table 1.1). MPO is the defining protein of azurophil granules, hence 
they are designated peroxidase-positive, with other major constituents including serine 
proteases (e.g. NE, proteinase 3 (PR3) and cathepsin G). Specific granules contain abundant 
lactoferrin and matrix metalloproteinase-8 (MMP-8, collagenase), whilst the exemplar protein 
of gelatinase granules is MMP-9 (gelatinase). Specific and gelatinase granules also contain 
the membrane subunits of NADPH oxidase (p22phox and gp91phox), which are delivered to the 
NADPH oxidase complex to enable ROS production. Secretory vesicles are smaller than 
granules and have an endocytic origin, containing plasma proteins as well as receptors which 
can be mobilised to the neutrophil surface, e.g. MAC-1 and the fMLP receptor. It is noteworthy 
that in addition to proteases, neutrophil granules also contain anti-proteases, such as α1 
antitrypsin (α1AT) and secretory leukocyte protease inhibitor, which may act to restrain the 
pro-inflammatory effects of exocytosis (34,35).  
1.2.1.5 Degranulation 
Neutrophil granule exocytosis can be initiated by a range of stimuli, e.g. fMLP, with granule 
release augmented by priming agents, e.g. PAF. Neutrophils express a variety of cell surface 
receptor classes, including Fc receptors, adhesion receptors (e.g. integrins), G protein 
coupled receptors (GPCRs), cytokine receptors (e.g. TNF receptors, TNFRs) and innate 
immune receptors (e.g. toll-like receptors, TLRs), responsible for the control of neutrophil 
effector functions (reviewed in (36)). Although neutrophil degranulation signalling pathways 
are not completely delineated, activation of integrins (37), Fc receptors (38) and GPCRs (39) 
has been implicated. Receptor ligation initiates intracellular signalling cascades; the precise 
signalling pattern likely depends on the range, concentration and context of external stimuli, 
and downstream signalling events may occur in parallel. However, these pathways converge 
on common degranulation effector mechanisms, principally cytoskeletal rearrangement, and 




Table 1.1: Contents of neutrophil granules 
Compiled from the following references: (32,33,40–42) 
Azurophil Granules Specific Granules Gelatinase Granules 
Matrix Matrix Matrix 




▪ α1 antitrypsin 
▪ α mannosidase 
▪ Azurocidin 
▪ Bacterial permeability 
increasing protein 
▪ β glucuronidase 
▪ β glycerophosphatase 
▪ Cathepsins G and C 
▪ Defensins 
▪ Epididymal secretory 
protein E1 




▪ Neutrophil elastase 




▪ 14-3-3 protein 
zeta/delta 
▪ α1 antitrypsin 
▪ Apolipoprotein B 
receptor 
▪ β2 microglobulin 
▪ Cathelicidin 
▪ Collagenase (MMP8) 
▪ Coronin 1A 
▪ γ glutamyl hydrolase 
▪ Folate receptor γ 




▪ ICAM 3 
▪ Integrin α M 
▪ Lactoferrin 









▪ Olfactomedin 4 
▪ Pentraxin 3 
▪ Resistin 
▪ Secretory leukocyte 
protease inhibitor 
▪ Sialidase 
▪ Talin 1 
▪ 14-3-3 protein 
zeta/delta 
▪ Acetyltransferase 
▪ Apolipoprotein B 
receptor 
▪ Arginase 1 
▪ β2 microglobulin 
▪ Cathelicidin 




▪ ICAM 3 
▪ Integrin β 2 
▪ Leukocyte 
specific protein 1 
▪ Lysozyme 
▪ Ficolin 1 
▪ Ras-related 
protein Rab 11B 
▪ Ras GTPase 
activating like 
protein IQGAP1 
▪ Talin 1 
▪ Transcobalamin 1 
 
Membrane Membrane Membrane 
CD63, CD68 
Presenilin 1 
V type H+ ATPase 
 
CD11b/CD18, CD66a, 
CD66b, CD15, CD45, CD177 
Cytochrome b558 
Fibronectin R, Laminin R, 


























Figure 1.1: Neutrophil signalling pathways involved in degranulation 
β2 integrins and Fc receptors, coupled to an immunoreceptor tyrosine-based activation motif 
(ITAM, which is phosphorylated by Src family kinases), signal through the Syk tyrosine kinase 
to activate downstream pathways resulting in cytoskeletal reorganisation (e.g. via Rac2) and 
a rise in intracellular calcium (Ca2+). GPCR ligation leads to dissociation of the heterotrimeric 
G protein into Gα and Gβγ subunits. Gα and/or the G adaptor protein, β arrestin, may activate 
Src family kinases. The Gβγ dimer triggers two parallel signalling events: 1) activation of 
phospholipase C (PLC) β hydrolyses PIP2, generating diacylglycerol (DAG) and IP3, which 
enables calcium release from the endoplasmic reticulum (ER) intracellular stores; 2) activation 
of PI3Kγ induces the production of PIP3 by phosphorylation of PIP2, signalling through the AKT 
signalling cascade and activating Rac2. Depletion of ER calcium is sensed, thus opening 
plasma membrane ion channels to allow influx of extracellular calcium. The ultimate result of 
all of these processes is to allow granule translocation and exocytosis.  
 
1.2.1.6 Degranulation: receptors and intracellular signalling pathways 
Both integrins and Fc receptors signal through Src tyrosine kinases, with Hck, Fgr and Lyn 
being the most relevant family members in neutrophils. These Src tyrosine kinases are able 
to phosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs) coupled to β2 
integrins and Fc receptors, with subsequent signal transduction mediated by association of 
the Syk tyrosine kinase with phosphorylated ITAMs. Localisation of scaffolding proteins 
through activation of these tyrosine kinases promotes actin and microtubule polymerisation, 
recruitment of further signalling proteins such as the adaptor protein SLP-76, and a rise in 
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intracellular calcium (43,44), leading to granule exocytosis. Several key downstream pathways 
are activated, with degranulation mediated through phospholipase C (PLC) γ2, and Rho 
GTPase (e.g. Rac) signalling. Murine neutrophils lacking PLCγ2 (45), Syk (46) or both Hck 
and Fgr (47) could still adhere to a fibrinogen surface, but failed to degranulate in response to 
TNFα following β2 integrin or Fc receptor ligation. An additional tyrosine kinase, Pyk2, has 
been implicated in integrin-induced neutrophil degranulation, although deficiency did not 
produce as profound a defect in degranulation since its role is further downstream (48). These 
studies have demonstrated both detrimental (failure to clear pathogens (48)) and beneficial 
(protection from the development of arthritis (45)) consequences in murine in vivo models, 
both thought to result from impaired degranulation. 
GPCRs (including fMLP and PAF receptors) are heterotrimeric proteins which, upon 
activation, dissociate into Gα and Gβγ subunits; the majority of neutrophil signal transduction 
is thought to occur through the Gβγ fragment. Gβγ activates two parallel pathways: activation 
of phospholipase Cβ (PLCβ) generates inositol-trisphosphate (IP3) from phosphatidylinositol-
(4,5)-bisphosphate (PIP2), resulting in release of calcium from intracellular stores, and 
activation of PI3Kγ generates phosphatidylinositol-(3,4,5)-trisphosphate (PIP3) from PIP2, with 
subsequent signalling through the AKT cascade. Both the elevated calcium (49) and AKT 
activation (50) lead to granule exocytosis, and pan-PI3K inhibition or genetic deletion of the 
AKT2 isoform have been shown to inhibit degranulation (50,51).  
Interestingly fMLP, which ligates GPCRs, also initiates Src kinase activation, and 
pharmacological inhibition or genetic deletion (Hck-/-Fgr-/-Lyn-/-) of Src tyrosine kinase activity 
prevented fMLP-induced azurophil and specific granule release in a p38 MAPK-dependent 
manner (52). The mechanism of GPCR activation of Src family kinases remains unclear but 
may be via the Gα subunit or β arrestins (GPCR-associated adaptor proteins) (53). Further 
receptor cross-talk is demonstrated by GPCR-dependent PIP3 regulation of the Rho GTPase 
Rac via its activator P-Rex1 (a guanine exchange factor, GEF) (54). 
Translocation and exocytosis of granules requires a rise in intracellular calcium, which occurs 
in a biphasic fashion, initially released from intracellular stores and then entering from the 
extracellular space as the intracellular stores become depleted (55). Although the exact 
effectors of calcium-dependent degranulation are currently poorly characterised, examples of 
proteins which are influenced by calcium transients and involved in degranulation include 
annexins (56) and the vesicle docking facilitator, Munc13-4 (57). Calcium also plays a role in 
neutrophil polarisation via regulation of AKT, Src family kinases and Rho GTPases, and this 
modulation of the cytoskeleton may represent another method of control of degranulation (58). 
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1.2.1.7 Degranulation: vesicle trafficking and fusion machinery 
Granule trafficking to the target phagosomal or plasma membrane, in conjunction with actin 
and microtubule dynamics, is predominantly controlled by Rac and Rab GTPases, which 
facilitate granule migration by orchestrating cytoskeletal rearrangement. Vesicle-membrane 
tethering, docking and fusion is then regulated by Munc family proteins and SNAREs (soluble 
NSF-attachment protein receptors) (reviewed in (59)).  
Rac and Rab GTPases are “molecular switches”, alternating between an inactive GDP-bound 
and an active GTP-bound form. Guanine exchange factors (GEFs) are GTPase activators, 
facilitating exchange of GDP for GTP, whereas GTPase-activating proteins (GAPs) actually 
inactivate GTPases by promoting their GTPase activity. Rac2 is particularly important in 
human neutrophils, mediating actin dynamics (and hence degranulation) through the 
formation of free actin filament ends, which regulates actin assembly (60). Functional 
characterisation of Rabs and their effector molecules is currently limited. However, one well-
described example is granule-associated Rab27a, which can bind the effector molecule JFC1. 
JFC1 reduces the activity of GMIP (a RhoA-GAP), which facilitates actin depolymerisation 
around the granule, allowing access to the vesicle docking zone (61).  
Once the granule is able to access the membrane exocytic region, docking is mediated by 
Munc proteins, e.g. Munc 13-4, which is also a Rab27a effector and exhibits calcium-
dependent control of SNARE complex formation (57). The SNARE complex requires 
interaction of vesicle (granule) proteins (v-SNAREs), which comprise various vesicle-
associated membrane proteins (VAMPs), with target plasma membrane proteins (t-SNAREs), 
including syntaxins and synaptosome-associated proteins (SNAPs) in order to effect granule-
membrane fusion (reviewed in (41)).    
1.2.1.8 Degranulation: differential exocytosis 
Granule subtypes are not mobilised equally; granule exocytosis is regulated by both the 
external stimulus and the associated secretory machinery (Figure 1.2).  
Sequential control of granule subtypes is regulated by the strength of the degranulation 
stimulus. Tightly linked with the order of granule development, the last granules to be formed 
are the most easily mobilised. Regulation of exocytosis in this manner is logical, as the 
hierarchy of release correlates with granule protein function. Initial mobilisation of secretory 
vesicles is able to supply the neutrophil surface with the receptors required for transmigration 
without liberating histotoxic proteins, which could harm the vascular endothelium. 
Subsequently, secretion of gelatinase and specific granules allows release of MMPs, such as 
gelatinase and collagenase, which can degrade the extracellular matrix (ECM), enabling 
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neutrophil transit through host tissues towards sites of infection. Only once neutrophils have 
reached these inflammatory areas, where pathogen numbers and inflammatory stimuli are at 
the highest concentrations, is the toxic cargo of the azurophil granules unleashed. Azurophil 
granules, therefore, require the strongest stimulus for degranulation, which is dependent upon 
the concentration of intracellular free calcium (49): Sengeløv et al. showed an in vivo hierarchy 
of granule subtype mobilisation, with complete mobilisation of secretory vesicles, and 38%, 
22% and 7% release of gelatinase, specific and azurophil granules, respectively, from 
neutrophils in skin blister exudate, dependent on intracellular calcium concentration (37), 
which was preserved on further stimulation with fMLP.  
The precise secretory machinery associated with a particular granule is also linked to its 
classification and function. Neutrophils display a non-redundant role for Rac2 in the secretion 
of azurophil granules: neutrophils from mice deficient in Rac2 showed absent azurophil 
granule exocytosis whereas specific and gelatinase granule release was unaffected (62). 
Equally, murine neutrophils deficient in Bcr and Abr (Rac-GAPs) had increased cytochalasin 
B/fMLP-induced Rac2 activity which led to elevated MPO and NE release, whilst lactoferrin 
and MMP-9 release was unaffected (63). In fact, only a subset of azurophil granules have the 
required secretory machinery to be released into the extracellular space. Subcellular 
fractionation and immunoelectron microscopy has shown that Rab27a is located 
predominantly on gelatinase and specific granules, with lesser localisation to azurophil 
granules (64). Monfregola et al. demonstrated that Rab27a was necessary for secretory 
azurophilic granules to fuse with the plasma membrane but in Rab27a deficient mice, 
azurophil granules lacking this protein were still able to fuse with the phagosome. However, 
Munc13-4 (present on all three granule subtypes) was required for both fusion mechanisms 
(65).  
Further regulation of differential granule fusion and mobilisation is mediated by Src tyrosine 
kinases and v-SNAREs. The Src family member, Hck, was found to be localised to azurophil 
granules and translocated toward the phagosome (66) whereas Fgr was associated with 
specific granules, with an increase in the plasma membrane fraction after fMLP-treatment 
(67). VAMP-2 and SNAP-23, both enriched on specific and gelatinase granules, directed 
fusion with the plasma membrane whereas VAMP-7, predominantly sited on azurophil 
granules, guided fusion with the phagosome as well as plasma membrane (41,68). Thus, a 
number of differential secretory control mechanisms result in the majority of azurophil granules 
being preferentially targeted to the phagosome rather than the surface membrane, unlike 
specific and gelatinase granules. Inadvertent leakage of azurophil granules from incompletely 
closed phagosome vacuoles can occur during “frustrated phagocytosis”, where there is an 
overwhelming excess of pathogens, or an organism or surface which is too large to engulf, 
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such as immune complex deposition on the vascular endothelium. . Here, release of histotoxic 
proteins can cause host tissue injury, e.g. NE-mediated vascular injury in thrombo-
haemorrhagic vasculitis in response to complement C3 deposition (69). Importantly, priming 
can also overcome the degranulation ‘braking’ mechanisms and primed cells can release 
significant quantities of azurophil contents to the extracellular space. Whilst endogenous and 
concomitantly released anti-proteases may restrain damage, these protective mechanisms 
may be overpowered in certain environments, such as infected airways (e.g. in cystic fibrosis 
(CF) and bronchiectasis (70,71)). 
 
 
Figure 1.2: Control of differential granule exocytosis 
Gradated granule exocytosis is dependent on intracellular calcium (Ca2+) concentration. 
Secretory vesicles (SV) are mobilised most easily. Azurophil (AG), but not specific (SG) or 
gelatinase (GG), granule secretion is dependent on Rac2. The Src family kinase, Hck, guides 
AG for phagolysosome fusion whereas Fgr guides SG for plasma membrane fusion. Rab27a 
directs all granules for plasma membrane fusion; AG lacking Rab27a can still fuse with the 
phagolysosome. Munc 13-4 is required for both plasma membrane and phagolysosome 
fusion. SG and GG docking/fusion SNARE complexes comprise VAMP-2, SNAP-23 and 
syntaxins 4/6 whereas AG SNAREs comprise VAMP-7 and syntaxin 4. VAMP-7 can also direct 




1.2.1.9 Neutrophil Extracellular Traps 
Neutrophil extracellular traps (NETs) were first described by Brinkmann et al. in 2004 (72) and 
are expulsions of decondensed chromatin, studded with antimicrobial proteins and proteases 
(including NE and MPO) into the extracellular space. NET release is stimulated by a range of 
pro-inflammatory mediators, e.g. IL-8 and S. aureus. The classical molecular pathway 
initiating NET release relies on ROS generation by the NADPH oxidase complex, and 
pharmacological inhibition of NADPH oxidase abrogates NET generation; similarly, 
neutrophils from CGD patients are unable to release NETs (73). NETosis, the process of NET 
formation, also relies on histone citrullination and NE, which are thought to accomplish 
chromatin decondensation by histone digestion. Neutrophils from mice lacking NE or 
peptidylarginine deiminase 4 (PAD4), which catalyses histone hyper-citrullination, were 
unable to produce NETs (74,75). ROS-independent early (within 10 minutes of the stimulus) 
NETosis has also been described, but is still dependent on PAD4 and NE (76). 
It has been hypothesised that NET production is a host defence mechanism, capable of 
trapping and killing micro-organisms, but this remains contentious. NETs have been shown to 
attach to various pathogens in vivo (77), although it has been suggested that this adherence 
may be utilised by some organisms to form biofilms (78). There is also conflicting evidence for 
a direct microbicidal effect of NETs: Brinkmann et al. reported that in the presence of 
cytochalasin D, phagocytosis was inhibited with preserved NET production but neutrophils 
were still able to kill S. aureus, an effect which was abolished with the addition of DNAse (72). 
In contrast, Menegazzi et al. showed no microbicidal effect of NETs, with entrapped S. aureus 
released alive on addition of DNAse (79). Differences in the extent of bacterial killing in these 
studies depended on the timing of DNAse addition (to dismantle NETs). NETosis was initially 
thought to be a form of neutrophil cell death distinct from apoptosis, not stimulating clearance 
by macrophages but rather chromatin disassembly by nucleases (80). However, situations 
where live neutrophils produce NETs and remain functional have been described: Pilsczek et 
al. showed release of NETs from live neutrophils through nuclear membrane blebbing and 
vesicle budding (81), and Yipp et al. visualised intact NETosing neutrophils with retained ability 
to move chemotactically towards and phagocytose live bacteria (82). Furthermore, as NET 
formation is an active process whereupon the distinct nuclear and granular architecture is 
rearranged, such that a number of granule-derived enzymes, including NE and MPO, are 
released extracellularly in association with chromatin, NETosis has the potential to cause host 
tissue injury due to high local concentrations of histotoxic proteases. 
Massive NET formation has been reported in several pulmonary diseases, including asthma, 
COPD, CF, respiratory syncytial virus bronchiolitis, influenza and bacterial pneumonia 
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(reviewed in (83)). For example, sputum NETs in COPD were correlated with  disease severity 
and microbial dysbiosis, as well as reduced neutrophil phagocytic capacity (84). CF sputum 
contains abundant NETs (85) which increase sputum viscosity (86) and might additionally 
cause protease-dependent airway damage. NETs have also been associated with vascular 
pathology; for example NETs promote endothelial cell activation and increased 
thrombogenicity through the concerted action of IL-1α and cathepsin G (87). Intravascular 
NETs have been shown in several conditions, including sepsis, vasculitis and atherosclerosis, 
and may promote thrombosis in addition to endothelial activation (reviewed in (88)).  Hence, 
the role of NETs in driving a range of diseases is under investigation.  
1.2.1.10 Neutrophil-derived microvesicles 
Microvesicles (MVs) are small membrane-bound microparticle structures released by multiple 
cell types, including neutrophils, which have gained rapid recent interest as a novel 
intercellular communication network. MVs are 0.1 - 1 μm in diameter and are released from 
cell plasma membranes by an exocytic enzyme-regulated budding/blebbing process. MVs are 
distinct from even smaller extracellular vesicle structures, such as exosomes, which are pre-
formed particles of less than 100 nm in diameter, generated by exocytosis of multi-vesicular 
bodies from the endocytic-lysosomal compartment (89). MVs commonly feature externalised 
phosphatidylserine, due to calcium stimulation of scramblase and floppase activity, and 
contain components derived from the parent cell, including RNA, lipids and protein. As well as 
detecting MVs by their exposed phosphatidylserine, e.g. by annexin V binding, membrane 
proteins can be used as markers of MV origin; for example, neutrophil-derived MVs (NDMVs) 
contain CD66b (90). Initially thought to be inert cellular debris, the potential for MVs to act as 
vehicles of intercellular communication has now been recognised. MVs can transfer their 
contents to other cells, including different cell types, altering their phenotype and with the 
potential to instigate activation, e.g. by mobilisation of cytokines or ligands. For example, 
Slater et al. showed that NDMVs could transfer MPO to intestinal epithelial cells, which 
impaired mucosal wound healing (91) and Salanova et al. demonstrated that platelet-derived 
MVs could transfer functional glycoprotein IIb/IIIa receptors to neutrophils (92). Moreover, 
release of active enzyme in NDMVs may play a role in the inflammatory response. For 
example: cleavage of adhesion molecules by NDMV-associated MMP-9 in vitro facilitated 
intestinal transepithelial neutrophil migration through disrupted intercellular junctions (93). 
NDMVs are a heterogeneous population, varying in protein composition depending on the 
method of generation. Differences in morphology and protein abundance have been observed, 
dependent on whether NDMVs were produced spontaneously or after stimulation of opsonin 
receptors (94). Furthermore, MVs released from neutrophils in fluid suspension had a distinct 
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proteome compared with those from neutrophils adhered to a human umbilical vein endothelial 
cell (HUVEC) monolayer, sharing only 50% of their content (95). As well as varying in 
composition, NDMVs generated by these differing methods also exerted diverse effects on 
endothelial cell gene expression in vitro, demonstrating both that they are biologically active 
and that the functional effect of MVs in vivo may depend on the precise conditions under which 
they are formed. This may explain the conflicting literature addressing the pro and anti-
inflammatory properties of NDMVs (including (96–99), discussed in section 1.3.1.3).  
1.2.1.11 Apoptosis and clearance 
Neutrophils are terminally differentiated and pre-programmed to undergo constitutive 
apoptosis, resulting in their short survival times. However, apoptosis can be delayed at sites 
of infection and inflammation by signals from both pathogens, e.g. lipopolysaccharide (LPS), 
and/or the host, e.g. GM-CSF (100). Apoptosis can be initiated through the extrinsic pathway, 
i.e. ligation of cell surface death receptors such as FAS, or the intrinsic pathway, instigated by 
intracellular oxidative stress leading to release of cytochrome C from mitochondria and 
consequent caspase activation (101). Electron microscopy studies have revealed neutrophils 
to have comparatively few mitochondria (102) and bioenergetic profiling has demonstrated a 
reliance on glycolytic respiration for energy production rather than mitochondrial oxidative 
phosphorylation (103), with the predominant function of these organelles in neutrophils 
thought to be regulation of cell death. Challenging this dogma, however, recent discoveries 
have suggested greater metabolic and energetic flexibility than previously thought (104). 
Apoptotic neutrophils signal for efferocytosis by changes in cell surface receptors and 
membrane composition, such as externalisation of phosphatidylserine. Their phagocytosis 
inhibits pro-inflammatory cytokine production by macrophages and limits the potential for host 
tissue damage by safe removal of potentially histotoxic neutrophil contents, accelerating the 
path towards resolution of inflammation. 
1.2.1.12 Role of neutrophils in disease 
Neutrophils are superbly equipped to carry out their role of host defence, armed as they are 
with multiple pathogen containing and killing mechanisms, and the ability to orchestrate the 
immune response to microbial invasion. Although once thought to function purely as killing 
machines, we now appreciate that neutrophils can shape the immune landscape through 
communication with multiple cell types. For example, neutrophil-derived granule products, 
such as defensins and cathelicidins, allow communication with the adaptive immune system 
by inducing CD4+ and CD8+ T cell chemotaxis, in addition to their antimicrobial agenda (105). 
Under certain culture conditions, neutrophils can acquire functional properties of antigen 
presenting cells, expressing MHCII and co-stimulatory molecules (106). Although these 
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attributes confer a complex and plastic role for neutrophils, the crucial neutrophil function 
remains host defence against invading pathogens, well-illustrated by the increased 
susceptibility of patients with neutrophil defects such as Chediak Higashi syndrome (impaired 
degranulation) or CGD (impaired respiratory burst) to severe and recurrent infections (107).  
Neutrophils are designed to rapidly eliminate pathogens. However, if they do not encounter 
pathogens within a short timeframe, for example in the context of sterile inflammation where 
neutrophils adherent to inflamed endothelial surfaces may encounter circulating cytokines 
such as TNFα, large amounts of oxidants can be released (108). Coupled with granule 
exocytosis of histotoxic proteins and proteases, neutrophils have the capacity to cause 
extensive bystander tissue injury. Ideally, the release of toxic oxidants and proteases should 
be delayed until the cells reach a focus of inflammation/infection but primed neutrophils in the 
systemic circulation have been identified in disease states, including ARDS (109) and bacterial 
sepsis (110), potentially contributing to disease pathogenesis and endothelial dysfunction. It 
has been demonstrated in an in vivo human model that primed circulating neutrophils are 
preferentially retained in the pulmonary vasculature, which facilitates “de-priming” of these 
cells and their release back into the systemic circulation (7) but failure of this de-priming 
process could contribute not only to lung tissue damage but also to endothelial injury and 
remote organ dysfunction. Raised circulating levels of potentially histotoxic neutrophil-derived 
proteins have been found in inflammatory situations, including sepsis (111) and COPD (112–
114), where most (e.g. resistin and NGAL) but not all (e.g. cyclophilin A) are neutrophil granule 
components. Neutrophil proteins, such as MPO and NE, can also be externalised by the 
generation of NETs. As well as causing direct cytotoxicity, with the ability to induce epithelial 
and endothelial cell death (115), NETs have been implicated in remote organ injury (116) and 
even associated with the promotion of cancer metastases (117). Neutrophils present within 
tumours can develop a pro-tumorigenic phenotype, driven by transforming growth factor β 
(TGFβ) within the tumour microenvironment (118), and release of neutrophil matrix-degrading 
proteins, e.g. serine protease-activated MMPs, can promote tumour cell invasion (119).  
Hence, neutrophils are a double-edged sword, playing an essential role in host defence but 
also a pathogenic role in both acute and chronic inflammatory diseases. Neutrophil function 
must therefore be tightly controlled to prevent host tissue damage from inappropriate or 




1.2.2 The impact of hypoxia on neutrophils 
1.2.2.1 Relevance of hypoxia to neutrophils 
Neutrophils are generated within the bone marrow, which is a significantly hypoxic 
microenvironment; using two-photon phosphorescence lifetime microscopy of live mice, in 
vivo bone marrow oxygen tensions have been recorded as low as 1.3 kPa (120). Furthermore, 
staining with pimonidazole, a 2-nitroimidazole compound which indicates oxygen levels below 
1.3 kPa, demonstrated sequestering of haematopoietic stem cells in the most hypoxic areas 
of the bone marrow architecture (121), and low oxygen tension favoured the maintenance of 
haematopoetic stem cells in vitro (122). Therefore, hypoxia appears to play a critical role in 
neutrophil development.  
Under physiological conditions, circulating neutrophils released from the bone marrow 
encounter a wide range of oxygen tensions, transiting rapidly from a pO2 of 13 kPa in main 
arteries, to 7 kPa in arterioles and 3-4 kPa in capillaries and venules (123). Due to the short 
oxygen diffusion capacity, normal tissue oxygenation can be even lower (physiological 
hypoxia), demonstrated in striated muscle (124), colonic epithelium (125) and the skin, despite 
being bathed in ambient oxygen (126). In pathological situations, systemic hypoxaemia, which 
can arise from various lung pathologies, such as fibrosis and emphysema, results in a further 
reduction of oxygen delivery to tissues. Moreover, significant amplification of this tissue 
hypoxia can occur in inflammation, infection or ischaemia (pathological hypoxia) due to 
damaged vasculature, compartmentalisation of infection, and high metabolic activity of 
pathogens and host cells. In addition to these well-described mechanisms, Lee et al. have 
described hypoxaemia secondary to LTB4-driven neutrophil swarming in a mouse fungal 
sepsis model, which resulted in capillaritis with neutrophils continuously lining alveolar walls, 
compounded by alveolar haemorrhage (18), and Campbell et al. have demonstrated depletion 
of local oxygen by transmigrating neutrophils in a murine model of colitis, which contributed to 
epithelial HIF stabilisation (127). 
Profound tissue hypoxia has been demonstrated in several pathological conditions by various 
in vitro and in vivo methods: by microelectrode measurement of ulcers (mean pO2 = 2.39 kPa) 
(128); by blood gas analysis of abscesses (median pO2 = 3.74 kPa) (129); by hypoxia inducible 
factor (HIF) staining (which is detected maximally at 0.5% oxygen (130)) in COPD (131), 
bronchitis (132) and inflammatory bowel disease (IBD) (133); by pimonidazole staining 
(indicating pO2 <1.3 kPa) of lung tissue in respiratory infection (134); by luminescence-based 
in vivo optical imaging in skin infection (mean pO2 = 2.66 kPa) (135) and by [18F]-
fluoromisonidazole positron emission tomography (PET)  imaging (indicating pO2 <1.3 kPa) 
in humans with pulmonary tuberculosis (TB) (136). Furthermore, hypoxia itself can cause 
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inflammation, as demonstrated by increased vascular leak in a mouse model of acute hypoxia 
(137), increased serum levels of IL-6 and CRP in healthy climbers at high altitude (138), and 
impaired resolution of pulmonary infection in hypoxic mice (139). Conversely, resolution of 
inflammation has been shown experimentally to correlate with an increase in oxygen tension, 
and supra-physiological oxygen levels can promote resolution of certain infections (85).  
1.2.2.2 Sensing of hypoxia by neutrophils 
Neutrophils may be exposed to profound levels of hypoxia and, as the frontline mediators of 
host defence, need to be able to function successfully in such hypoxic environments. 
Neutrophil sensing and adaptation to surrounding oxygen tensions is dependent on the prolyl 
and asparaginyl hydroxylase enzymes, which control expression of the hypoxia-inducible 
transcription factor HIF. HIF is a heterodimeric protein, comprising a constitutively expressed 
β subunit and a hydroxylase-regulated α subunit; the predominant α subtype present in 
neutrophils is HIF-1 (142). Under normoxia, prolyl hydroxylase-containing enzymes (PHDs) 
direct HIF-1α for proteasomal degradation via the von Hippel Lindau (vHL) protein complex, 
whilst factor inhibiting HIF (FIH) inactivates HIF transcription by preventing binding of the 
transcription co-factor p300. PHDs and FIH display an absolute requirement for dioxygen, 
Fe(II) and 2-oxoglutarate. Under hypoxia, the lack of dioxygen reduces hydroxylase activity, 
allowing stabilisation of HIF-1α, which then translocates to the nucleus and binds HIFβ. The 
HIF heterodimer binds hypoxia response elements (HREs), thereby regulating the neutrophil’s 
response to local oxygen tensions by promoting the transcription of hypoxia-responsive 
genes. Bioenergetic profiling has demonstrated that neutrophils rely predominantly on non-
oxidative glycolytic respiration for ATP production, and neutrophils deficient in HIF-1α have 
reduced ATP levels (143). It has also been shown that pro-inflammatory signals can stabilise 
HIF; for example:  Peyssonnaux et al. demonstrated that HIF-1α expression was induced by 
LPS in a TLR4-dependent manner in macrophages (144). The induction of HIF-1α mRNA by 
TLR-induced nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signalling 
is likely important in these pro-inflammatory environments, with a further increase in NFκB 
regulated by HIF-1α under hypoxic conditions (145). However, HIF-driven hypoxia-adaptation 
processes depend on transcription of effectors, and neutrophils may need more rapid 
adaptability. In other cell lines, hypoxia regulated the phosphorylation status of the 
translational control protein mTOR (mammalian target of rapamycin) and its effectors (146), 
and regulated T-plastin-mediated membrane trafficking (147), both in a HIF-independent 
manner. In neutrophils, hypoxia has been shown to reduce ROS production (148) and 
increase degranulation (149) in a HIF-independent fashion (see sections 1.2.2.4 and 1.2.2.5). 
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1.2.2.3 Effect of hypoxia on neutrophil recruitment 
Neutrophil firm adhesion to endothelium prior to transmigration is mediated predominantly by 
the interaction of neutrophil β2 integrins (e.g. MAC-1) with endothelial ligands, such as ICAM-
1. The literature supports a hypoxia-mediated increase in β2 integrin expression (148,150–
153) with only one study, which allowed re-oxygenation following neutrophil isolation, finding 
no difference (154). Reports of ICAM-1 expression in response to hypoxia are conflicting:  
Antonova et al. showed no difference in ICAM-1 levels of endothelial cells cultured under 
hypoxic conditions (155), whereas Yoon et al. demonstrated increased ICAM-1 in a murine 
hindlimb ischaemia model. Such discrepancies may reflect species differences or the in vitro 
vs in vivo experimental approaches. Importantly, as a more integrated outcome, several 
studies have shown increased neutrophil adhesion to the endothelium under hypoxia 
(152,156,157). Along with the apparent increase in neutrophil adhesion, studies of neutrophil 
transmigration in the hypoxic environment have shown it to be enhanced. Hypoxia increased 
neutrophil transmigration in vitro in a model of intestinal I/R, which was β2 integrin and CD47-
dependent (158), and in vivo in rodent models of acute systemic hypoxia, assessing 
mesenteric endothelial neutrophil transmigration by intravital microscopy (159), or by MPO 
quantification in multiple organs (160).  
Investigation of the effect of hypoxia on chemotaxis has also produced contradictory results. 
Extravasated neutrophils undergo shape change to a polarised morphology, which is essential 
for directional movement towards sites of infection and inflammation. McGovern et al. showed 
no change in IL-8-induced human neutrophil shape change, or chemotaxis towards IL-8, fMLP 
or LPS under hypoxia (148), and, similarly, Peyssonnaux et al. found no difference in 
chemotaxis towards fMLP through an endothelial cell monolayer between wildtype, HIF-1α-
deficient or vHL-deficient murine neutrophils (161). Rotstein et al. showed reduced chemotaxis 
of human neutrophils towards fMLP and zymosan-activated serum under hypoxia in a gel 
migration assay (162) whereas, in contrast, Ma et al. demonstrated increased polarisation of 
differentiated human neutrophil-like HL-60 cells after exposure to hypoxia (163), and Wang 
and Liu showed enhanced chemotaxis of neutrophils isolated from hypoxic volunteers towards 
fMLP (153). Discrepancies here are likely due to variation in cell type studied, true hypoxia vs 
manipulation of HIF-1α, and re-oxygenation of cells isolated from hypoxic donors prior to in 
vitro assays. 
Studies of neutrophil recruitment, reflecting a composite outcome of adhesion, transmigration 
and chemotaxis, are more likely to replicate the true physiological environment, with its myriad 
signals. However, reports of neutrophil recruitment under hypoxia are again inconsistent and 
context-dependent. In a murine model of chemical irritant-induced cutaneous inflammation, 
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myeloid HIF-1α deletion abrogated neutrophil tissue infiltration and vHL deletion promoted 
infiltration (143). Conversely, pharmacological HIF-1α stabilisation either diminished 
neutrophil recruitment (in murine uropathogenic Escherichia coli bladder infection) (164) or 
had no impact (in murine S. aureus skin infection) (165), perhaps because the skin is already 
hypoxic as noted above. Similarly, in a mouse model of group A Streptococcus cutaneous 
infection, wildtype, HIF-1α-null or vHL-null neutrophils showed no difference in recruitment up 
to 24 h (161). Likewise, in a mouse model of Pseudomonas aeruginosa keratitis, HIF-1α siRNA 
knockdown showed no difference in neutrophil recruitment at 24 h, although recruitment was 
increased at day 5 (166). Conflict between these studies may be explained by variations in 
time, inducing agent (i.e. infectious vs non-infectious) and tissue (hypoxic or non-hypoxic) site, 
and also suggests that HIF manipulation does not equate precisely to true hypoxia. At present, 
there is no clear understanding of how hypoxia influences neutrophil recruitment and 
variations between studies indicate that the effect is likely to be context-dependent. 
1.2.2.4 Effect of hypoxia on phagocytosis and ROS generation 
The majority of studies suggest that phagocytosis by neutrophils is increased under hypoxia. 
Whole blood neutrophils collected from volunteers exposed to acute hypoxia showed 
enhanced phagocytosis of zymosan (167) and isolated neutrophils from acutely hypoxaemic 
volunteers demonstrated increased phagocytosis of E. coli, together with enhanced basal or 
E. coli-stimulated expression of opsonic and complement receptors (153), which are important 
for pathogen recognition. Similarly, phagocytosis of zymosan by neutrophils isolated from 
rabbits after experimental acute ischaemia (168) and phagocytosis of E. coli by neutrophils 
isolated from hypoxic pre-conditioned rats (169) were both increased. Following hypoxic 
exposure, neutrophil isolation and subsequent in vitro assays were performed in atmospheric 
oxygen; however, the Simms group demonstrated increased expression of most opsonic 
receptors and phagocytosis of S. aureus and E. coli, with in vitro assays performed under 
hypoxia in an air-tight chamber (170,171). The same group initially saw reduced expression 
of certain Fcγ neutrophil opsonic receptors under hypoxia but the hypoxic increase could be 
restored by the RDGS-binding epitope of fibronectin (172). Furthermore, integrin signalling via 
cross-linked VLA-5 and VLA-6 receptors on both fluid-phase and adherent neutrophils 
increased FcγIIIbR and MAC-1 expression under hypoxia (173). Indeed, modulation by matrix 
proteins in low oxygen tensions may more accurately reflect the in vivo environment. Further 
evidence that hypoxia can increase phagocytosis is that neutrophils isolated from patients with 
loss-of-function vHL mutations (which mimic hypoxia by impeding degradation of HIF) 
displayed enhanced phagocytosis of Streptococcus pneumoniae under normoxia which could 
be further enhanced under hypoxia (174). In contrast, our group also found that, although 
isolated neutrophils from healthy volunteers incubated under hypoxia had enhanced CD11b 
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expression, phagocytosis of S. pneumoniae was preserved but not increased (148). Two 
further studies have shown no effect of hypoxia on phagocytosis: Almzaiel et al. demonstrated 
no difference in phagocytosis of S. aureus under hypoxia with an increase in phagocytosis 
under hyperoxia, although these assays were performed with HL60 cells (175); and Berger et 
al. showed no change in phagocytosis of P. aeruginosa by neutrophils treated with HIF-1α 
inhibitor 17-DMAG, although this compound also caused a decrease in apoptosis and increase 
in necrosis which is inconsistent with the established literature on HIF-1α modulation of 
neutrophil apoptosis, suggesting a possible toxic effect (166). 
Phagocytosis and bacterial killing are tightly linked to ROS production, although the 
microbicidal activity of ROS is highly context-dependent and varies with bacterial species. 
Data regarding the impact of hypoxia on ROS generation are once again conflicting. When 
cell isolation and in vitro experiments were performed under normoxia, neutrophils isolated 
from hypoxic human donors or mice showed increased ROS production (153,154,169). This 
increase might reflect the re-oxygenation process, and potential clinical correlates include 
obstructive sleep apnoea (OSA) (176) and I/R injury (177). However, when in vitro assays 
were conducted under hypoxic conditions, neutrophils isolated from normoxic donors 
demonstrated decreased intracellular and extracellular superoxide production, which could be 
restored by re-oxygenation (148). In contrast, genetic and pharmacological HIF-1α 
manipulation did not affect ROS release (161,165). As modulation of HIF-1α signalling did not 
recapitulate data generated under true hypoxia, it seems logical that ROS production depends 
on oxygen availability, and that the decrease seen under hypoxic conditions is likely due to a 
fundamental lack of molecular oxygen.  
Using assessment of S. aureus bacterial killing as a surrogate for ROS production, as S. 
aureus killing is predominantly ROS-dependent (178), hypoxia impaired bacterial killing both 
in vitro (148,179) and in vivo (skin infection and pneumonia models (140,180)). Data 
generated from our laboratory support the hypothesis that impaired ROS production and 
consequent S. aureus killing under hypoxia is due to lack of molecular oxygen, as hypoxia did 
not change the expression of NADPH oxidase subunits, and addition of pyocyanin (which 
oxidises intracellular NADPH) did not increase ROS generation under hypoxia (148). Overall, 
the literature to date suggests that hypoxia increases phagocytosis by neutrophils but reduces 
ROS production, with a subsequent defect in ROS-dependent bacterial killing. 
1.2.2.5 Effect of hypoxia on degranulation 
Although few studies have examined the effect of hypoxia on neutrophil degranulation, the 
consensus is that hypoxia augments granule exocytosis. Data generated from our laboratory 
demonstrated that release of the azurophilic granule proteins, NE and MPO, was increased 
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under hypoxia, measuring supernatant NE protein content (148), and NE and MPO activity 
(149), as well as release of the specific granule protein lactoferrin, and the gelatinase granule 
protein MMP-9. This effect occurred rapidly (within 2 h), was not prevented by cycloheximide, 
and could not be recapitulated by pharmacological HIF-1α stabilisation, together suggesting 
a HIF-independent mechanism. Similarly, neutrophils isolated from healthy volunteers 
subjected to acute hypoxia showed increased NE release ex vivo (154), and isolated 
neutrophils incubated with Mycobacterium tuberculosis-infected monocytes released more NE 
and the specific granule protein, MMP-8, under hypoxia. In addition to evidence of an acute 
HIF-independent increase in degranulation, several studies have suggested HIF-dependent 
changes in neutrophil granule protein mRNA or protein content. Peyssonnaux et al. showed 
an increase in murine CRAMP (analogous to the human specific granule protein 
cathelicidin/LL-37) mRNA and protein content under hypoxia, which was similarly increased 
in vHL-deficient cells and absent in HIF-1α-deficient cells. Additionally, both NE and cathepsin 
G activity was increased vHL-null in murine neutrophils, with the opposite true of HIF-1α-null 
cells (161). Likewise, HIF-1a siRNA knockdown reduced protein levels of beta defensins and 
CRAMP in a mouse model of pseudomonal infection (166), and pharmacological stabilisation 
of HIF-1α revealed upregulation of genes encoding LL-37 in human neutrophils (181). 
However, a HIF-independent control of granule exocytosis would allow quicker adaptation in 
the rapidly changing inflammatory environments encountered by neutrophil “responders”. HIF-
dependent mechanisms may be relevant to neutrophils encountering prolonged hypoxia; 
circulating neutrophil granule content may be modulated in chronically hypoxaemic patients, 
thus contributing further to granule protein secretion. As noted above, the majority of granule 
biosynthesis occurs in the bone marrow, which is constitutively profoundly hypoxic, hence the 
impact of systemic hypoxia on this process is currently uncertain. 
It has been proposed that increased release of granule contents under hypoxia is detrimental, 
for example driving cavity formation and matrix degradation in TB (136,182). However, 
Christoffersson et al. showed that hypoxia-induced vascular endothelial growth factor (VEGF)-
A signalling in a mouse model of avascular transplanted pancreatic islets recruited a subset 
of MMP-9hi neutrophils, which were instrumental in allowing revascularisation and implantation 
of transplanted tissue, with impaired angiogenesis in MMP-9-deficient mice (183). This 
demonstrates a potential beneficial role for increased neutrophil degranulation in vivo, 
enhancing phagocyte access to sites of inflammation.  
1.2.2.6 Effect of hypoxia on NET production 
There has been limited investigation into the impact of hypoxia on NET production with 
variable results reported, depending on whether assays were performed under true hypoxia 
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or with HIF manipulation. McInturff et al. demonstrated reduced NETosis and extracellular 
bacterial killing in response to pharmacological and genetic HIF-1α knockdown (184). 
Similarly, Zinkernagel et al. showed increased bacterial killing with pharmacological 
stabilisation of HIF-1α, which was maintained in the presence of a phagocytosis inhibitor but 
abrogated by the addition of DNAse, although there was no observed effect on NET production 
(165). However, although Vӧllger et al. showed increased NETosis with pharmacological HIF-
1α stabilisation in a ROS-dependent manner (185), the same group showed a decrease in 
NET production under true hypoxia (186), consistent with data from our laboratory (149). As 
NETosis is predominantly dependent on NADPH generation of ROS (73), and hence reliant 
on oxygen availability, it is logical that NETosis under true hypoxia would be reduced, although 
it appears that HIF-1α signalling also has a role to play; the complex in vivo interplay of these 
linked but opposing influences remains to be elucidated. 
1.2.2.7 Effect of hypoxia on neutrophil-derived microvesicle generation 
To date, few studies have looked at NDMV release in the context of hypoxia, with no studies 
investigating the direct effect of hypoxic neutrophil incubation on MV generation. Chen et al. 
showed that volunteers exercising under hypoxic conditions had increased circulating NDMVs 
and proposed that this contributes to increased vascular thrombotic risk in acute hypoxia by 
MV-mediated thrombin generation (187). Tremblay et al. demonstrated an increase in 
circulating NDMVs at high altitude (3800 m, approximately 13% oxygen), which correlated with 
a reduction in brachial flow-mediated dilatation (FMD) (188), although Ayers et al. did not find 
any difference in NDMV numbers at moderate altitude (2590 m, approximately 15% oxygen) 
compared with sea level (21% oxygen) (189). In a disease setting, Priou et al. found increased 
levels of NDMVs in patients with OSA, which correlated with the degree of cyclical nocturnal 
hypoxia, though re-oxygenation may be as relevant here as the level of hypoxia; furthermore, 
treatment of endothelial cells with MVs isolated from OSA patients with an increased oxygen-
desaturation index (more than ten desaturation episodes per hour) caused increased 
adhesion molecule expression, which the authors propose may be a mechanism responsible 
for promoting endothelial dysfunction (190). 
1.2.2.8 Effect of hypoxia on neutrophil apoptosis 
Along with pro-inflammatory cytokines, hypoxia is able to modulate the neutrophil apoptotic 
threshold, delaying constitutive neutrophil apoptosis in a concentration-dependent and 
reversible manner through HIF-1α mediation of NFκB signalling. This hypoxic survival effect 
can be prevented by the NFκB inhibitors gliotoxin and parthenolide, and is abrogated in HIF-
1α-deficient murine neutrophils, which also demonstrate decreased NFκB activity (145). 
Further evidence for control of survival by hypoxia and/or HIF includes: delayed apoptosis 
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exhibited by neutrophils from patients with loss-of-function mutations in vHL, which usually 
targets HIF-1α for degradation (174); delayed resolution of inflammation in a zebrafish tail 
transection model due to a reduction of neutrophil apoptosis and retention of neutrophils at 
the site of injury in response to genetic or pharmacological stabilisation of HIF-1α (191); and 
prolonged ex vivo neutrophil survival from healthy subjects exposed to acute hypoxia (68% 
O2) (154). The hypoxic survival effect was also apparent in neutrophils isolated from patients 
with OSA, which is characterised by intermittent hypoxia/reoxygenation (192). 
Hypoxia increases β2 integrin protein expression under the control of HIF-1 at the 
transcriptional level (151) which potentially also contributes to the hypoxic survival effect as β2 
integrins have been implicated in the regulation of neutrophil apoptosis in addition to their role 
in adhesion. Whether the effect is pro or anti-apoptotic depends critically on the inflammatory 
environment; β2 integrin clustering or activation with endothelial ligands, such as ICAM-1, 
delays apoptosis through AKT and MAPK-ERK signalling, whilst β2 integrin activation in the 
presence of death-inducing agonists, such as TNF-α, can potentiate apoptosis, with a 
reduction in pro-survival AKT signalling (193).  
In addition to HIF-1α, two further mediators of hypoxic neutrophil survival have been identified:  
MIP-1β is a chemokine secreted by hypoxic granulocytes which confers survival when co-
incubated with normoxic neutrophils (145), and PHD3, whose expression is upregulated in 
hypoxia, prolongs neutrophil survival independent of HIF-1α by control of pro-apoptotic SIVA-
1. This translated to a PHD3-deficiency phenotype of accelerated neutrophil apoptosis and 
enhanced resolution of inflammation in murine models of acute lung injury (ALI) and colitis 
(194). Conversely, increased lethality was demonstrated in a PHD3 knockout murine model 
of abdominal sepsis, although this was thought to be predominantly due to enhanced pro-
inflammatory activity of PHD3-deficient macrophages (195). 
1.2.2.9 Overall effect of hypoxia on neutrophil functions 
Overall, hypoxia appears to enhance neutrophil phagocytosis but impair killing of certain 
bacteria (e.g. S. aureus) due to a reduction in ROS production, increased degranulation and 
delayed apoptosis. The effect of hypoxia on NET generation is less clear but it is likely 
reduced. Thus, the augmented extracellular release of histotoxic granule products, the 
potential for increased pathogen survival (and escape), and the persistence of neutrophilic 
inflammation in hypoxic conditions markedly increases the capacity of this destructive 





Figure 1.3: Neutrophil functions under conditions of normoxia versus hypoxia 
Under normoxia, bacteria such as S. aureus are ingested into the phagosome. Pathogen 
killing is effected by the release of cytotoxic granule proteins and proteases, accompanied by 
ROS (O2-) generated from molecular oxygen via NADPH oxidase, into the phagosome. 
Neutrophils may either undergo NETosis (further trapping pathogens) or apoptosis and 
clearance.  Under hypoxia, phagocytosis is maintained or enhanced but ROS-dependent 
killing is reduced due to the lack of oxygen availability, with the potential for pathogen escape. 
Increased extracellular release of toxic granule contents and prolonged neutrophil survival 
increases the potential for host tissue damage. Figure reproduced with permission from Lodge 
et. al, Hypoxic regulation of neutrophil function and consequences for Staphylococcus aureus 




1.2.3 The role of neutrophils in COPD  
COPD is a progressive inflammatory lung disease due to inhalational exposures, 
predominantly cigarette smoking, diagnosed by fixed airflow obstruction and characterised by 
intermittent exacerbations. Neutrophilic inflammation is a principal feature of COPD and 
correlates with disease severity, persisting despite cessation of smoking (197), even in the 
absence of an infectious driver (198). Patients with COPD suffer recurrent infection-driven 
exacerbations, which are a leading cause of mortality and functional decline, suggesting that 
there is impaired ability of these neutrophils to combat infection (199). Furthermore, in 
circumstances of prolonged or heightened inflammation when soluble mediators are present, 
or during frustrated phagocytosis, stimuli can promote neutrophil degranulation, releasing 
extracellular histotoxic antimicrobial proteins and proteases which can exacerbate host tissue 
damage. Complicating this picture, there is considerable heterogeneity between patients with 
COPD, and the diagnosis encompasses both chronic bronchitis (persistent cough with daily 
mucus production) and emphysematous (alveolar destruction and air space enlargement) 
phenotypes. 
There is abundant evidence that release of histotoxic neutrophil proteins contributes to tissue 
injury, and hence disease pathogenesis in COPD. NE has long been incriminated: NE is 
capable of causing lung epithelial damage, degrading multiple components of the ECM and 
increasing mucus secretion (200); NE induces the pathological features of COPD in animal 
models (201) and NE-deficient mice are protected from cigarette smoke-induced emphysema 
(202); NE is elevated in sputum from COPD patients, compared with smoking controls without 
airway obstruction, and correlates with decline in lung function (203); and plasma 
concentrations of the NE-specific fibrinogen cleavage product Aα-Val360, providing a “footprint” 
of NE activity in vivo, correlate with COPD severity (204).  
However, translation of NE inhibitors as therapy for patients with acute or chronic neutrophilic 
lung disease has proved inconclusive to date, perhaps reflecting the more complex array of 
neutrophil-secreted proteins with the capacity for damage. The proteinase PR3 has been more 
recently implicated in this setting. Although it displays a lower rate of elastolysis than NE, PR3 
is more abundant in neutrophils and has increased activity in COPD sputum, with a further 
increase during exacerbations (205). Additionally, COPD sputum contains elevated levels of 
the neutrophil granule protein MPO (206) and metalloproteinases MMP-8 and MMP-9 (207). 
MPO, which promotes oxidative damage, correlates with lung function decline, and MPO 
inhibition prevents acute lung inflammation and emphysema progression in animal models of 
both short and long term cigarette smoke exposure (208,209). MMPs regulate ECM turnover, 
enabling neutrophil migration, but also have the capacity to cause substantial ECM 
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degradation and damage (210). MMP-8 and -9 sputum and plasma levels correlate with lung 
function decline and progression of emphysema in COPD patients (211) and broad spectrum 
MMP inhibitors have been shown to attenuate emphysema progression in some animal 
models (212). 
One theory of COPD progression, supported by the COPD-like pathology that occurs in α1AT 
deficiency, is that it reflects an imbalance of protease and anti-protease activity. Even in the 
presence of active anti-proteases, proteases such as NE are able to diffuse at least 10 μm 
into the tissue before sequestration, and NE in complex with α-2-macroglobulin retains its 
proteolytic activity (213). Moreover, high concentrations of neutrophil proteases at the point of 
release from the granule can exceed the concentration of surrounding anti-proteases in the 
local microenvironment, “quantum proteolysis” (214), and NE bound to the neutrophil surface 
remains catalytically active yet resistant to anti-protease inhibition (215). Hence, there is 
abundant evidence suggesting that neutrophil degranulation releases a range of histotoxic 
agents which contribute significantly to lung tissue injury in COPD. 
Abnormalities have been reported in neutrophils from COPD patients. Sapey and colleagues 
demonstrated that such neutrophils exhibit aberrant chemotaxis in vitro, with increased 
migratory speed but impaired accuracy towards a range of chemo-attractants; these 
abnormalities were consistent across all severities of COPD but were not found in healthy 
smokers or in patients with α1AT deficiency (216). They postulated that this abnormal 
migration may contribute to surrounding host tissue damage in COPD, but also report that this 
response may be amenable to correction by manipulating intracellular signalling pathways; 
improved chemotaxis was shown after treatment of COPD patient neutrophils in vitro with a 
pan-PI3K inhibitor (216) or with the 3-hydroxy-3-methylglutaryl coenzyme-A reductase 
inhibitor simvastatin (217), which has previously been shown to increase the expression of 
PTEN, a phosphatase which antagonises the PI3K-AKT signalling pathway (218). Although at 
the early stages of exploration, proteomic analysis of neutrophils from COPD patients 
compared with either sulphur mustard-exposed patients (exposure during warfare with long-
term pro-inflammatory consequences) or healthy controls has revealed distinct COPD 
neutrophil profiles (219–221). However, it is important to note that due to the aforementioned 
heterogeneity within the COPD diagnosis, it is unlikely that there is a single entity comprising 
the “COPD neutrophil”. It is probable that COPD patient neutrophils display variable 
abnormalities and, at the other end of the spectrum, some patients may have normal 
neutrophil function, although these cells will still be functioning within a persistently inflamed 
and hypoxic environment.  
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Patients with severe COPD are frequently systemically hypoxic. However, more profound 
tissue hypoxia exists in areas of inflammation, infection and microcirculatory impairment, 
independent of systemic oxygen tensions, demonstrated in airway tissue (136,222) and 
atherosclerotic vasculature (223,224). Thus, even in mild COPD, neutrophils in disease-
associated tissues and microcirculatory beds are exposed to severe hypoxia, which will be 
compounded by systemic hypoxia. As detailed in section 1.2.2, hypoxia delays neutrophil 
apoptosis, prolongs their presence at sites of injury, enhances the release of antimicrobial 
(and potentially histotoxic) products and, despite promotion of phagocytosis, the reduction in 
ROS production under true hypoxia can impair bacterial killing. As such, hypoxia promotes a 
destructive neutrophil phenotype with compromised ability to combat pathogens but enhanced 
capacity for host tissue damage and delayed resolution of inflammation. 
In addition to progressive lung damage, COPD is associated with endothelial dysfunction and 
accelerated cardiovascular disease (CVD), even after adjusting for shared risk factors, 
including smoking (225,226). Patients with COPD are at substantially increased risk of future 
acute arterio-vascular events, such as myocardial infarction and stroke (227), and CVD is a 
leading cause of morbidity and mortality in this group (228,229). Analysis of large datasets 
(including nearly 300,000 patients) and meta-analysis of 29 separate studies has shown at 
least a two-fold increased risk of having CVD in COPD patients compared with non-COPD 
patients or the general population (230), with an even higher risk (e.g. up to seven-fold for 
peripheral arterial disease) in younger patient cohorts (35 – 54 years) (231) and following a 
severe COPD exacerbation (232). Evidence is accumulating that inflammation, vascular tissue 
damage (for example, by neutrophil-derived proteases) and oxidative stress are important 
biological mechanisms linking COPD and CVD (233), with increased arterial wall stiffness and 
markers of systemic inflammation, such as CRP, identified in COPD patients compared with 
control smokers without airflow obstruction (234). 
1.3 Endothelial cells 
The endothelial blood vessel lining is responsible for the regulation of vascular tone, smooth 
muscle cell migration, cellular adhesion and resistance to thrombosis. Endothelial dysfunction, 
frequently occurring as a maladaptive response to pathological stimuli, is a failure of the 
endothelium to perform these physiological roles. It leads to increased vascular smooth 
muscle tone, upregulated expression of CAMs (including the leukocyte-endothelial adhesion 
molecule ICAM-1), increased thrombosis (in part due to endothelial cell death) and 
compromised barrier function (reviewed in (235)). Diminished barrier function, and hence 
increased vascular permeability, occurs in a range of inflammatory diseases and in sepsis, 
with associated organ dysfunction. Malfunction of these endothelial processes also initiates 
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and promotes atherosclerosis and atherothrombosis, resulting in cardiovascular complications 
in advanced disease. However, endothelial dysfunction manifests much earlier and can be 
detected in the absence of symptoms, e.g. by ultrasound assessment of arterial diameter in 
response to endothelium-mediated shear stress-induced vasodilatation (FMD) or 
measurement of circulating biomarkers, such as soluble CAMs (236). In addition to traditional 
risk factors, such as hypertension, dyslipidaemia and smoking, inflammation has been linked 
to the progression of CVD; multiple chronic inflammatory diseases have been associated with 
increased cardiovascular morbidity and mortality, including rheumatoid arthritis (RA), IBD and 
COPD (225,235), although the mechanism(s) of immune-mediated endothelial dysfunction 
remain to be fully elucidated. 
1.3.1 The role of neutrophils in endothelial dysfunction and cardiovascular 
disease 
Neutrophils have emerged in recent years as one of the key players in atherogenesis. They 
aggravate endothelial dysfunction, accumulate in atherosclerotic lesions, and neutrophil-
derived proteases promote plaque instability and trans-endothelial migration. Myriad studies 
support an association of increased neutrophil/lymphocyte ratio with increased arterial 
stiffness (237), and an inverse correlation of the apnoea-hypopnoea index (indicating 
intermittent hypoxia) with FMD has been demonstrated in OSA (238). Primed circulating 
neutrophils have been identified in hyperlipidaemic patients (239), and 
hypercholesterolaemia-induced neutrophilia correlated with the extent of atherosclerotic lesion 
formation, which was reduced in neutropaenic mice (240).  
1.3.1.1 Direct neutrophil-endothelial interactions 
Dysregulated neutrophil-endothelial interaction has been shown to impair endothelial barrier 
function. Co-culture of neutrophils with pulmonary vascular endothelial cell monolayers 
increased endothelial release of angiopoietin-2, a mediator which promotes blood vessel 
destabilisation and is elevated in ALI; depletion of peripheral neutrophils in a murine 
haemorrhage shock model reduced plasma and lung angiopoietin-2, and reduced vascular 
leak and indices of lung tissue injury (241). Further, Gill et al. demonstrated neutrophil-
mediated microvascular endothelial apoptotic cell death, with resultant increased vascular 
leak, in a mouse sepsis model which could be ameliorated by peripheral neutrophil depletion 
or antibody blockade of CD18-binding (242). Interestingly, neutrophils isolated from septic 
patients, particularly those with ARDS, reduced endothelial barrier integrity to a greater extent 
than healthy control neutrophils when applied to venous monolayers (243). Neutrophil 
activation in the microcirculation can cause capillary malperfusion due to external 
compression of the microvasculature from accumulated fluid in the interstitial compartment. 
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This phenomenon of “capillary no-reflow” has been demonstrated in several I/R models, and 
could be attenuated by induction of neutropaenia or blockade of CD18-, ICAM-1- and P-
selectin-dependent neutrophil-endothelial adhesion (244). Neutrophils and endothelial cells in 
this setting will be exposed to a profoundly hypoxic milieu, with the potential to affect the 
responses of both cell types and their interactions. 
P-selectin is contained within endothelial Weibel-Palade bodies, release of which could be 
primed by hypoxia with subsequent enhanced neutrophil recruitment; in a murine cardiac 
transplantation model, P-selectin-null hearts had reduced graft neutrophil infiltration and 
increased graft survival when compared with wildtype (245). Moreover, small interfering RNA 
(siRNA) silencing of multiple CAMs (ICAM-1, ICAM-2, VCAM-1, E-selectin, P-selectin) 
decreased neutrophil recruitment into ischaemic myocardium and reduced post-MI neutrophil 
recruitment into atherosclerotic lesions in mice (246). Intriguingly, transfer of active MPO 
(which can perpetuate inflammation and tissue injury through pro-inflammatory cytokine and 
ROS release) has been demonstrated from neutrophils to endothelial cells, which was β2 
integrin-dependent but degranulation-independent (247). Substantial neutrophil accumulation 
within atherosclerotic plaques has been demonstrated (248), localised adjacent to areas of 
endothelial cell apoptosis (249) and associated with rupture-prone lesions (250). Intravital 
microscopy has allowed visualisation of in vivo thrombosis, revealing a key role for neutrophils, 
which accumulated prior to platelets at sites of endothelial injury and were critical for thrombus 
formation following laser-induced injury in mice (251).   
1.3.1.2 Interaction of endothelium with secreted neutrophil products 
Neutrophils secrete a variety of potentially pro-atherogenic factors which have been implicated 
in endothelial dysfunction, including cytokines, ROS, and antimicrobial proteins and 
proteases, released by either granule exocytosis or NET generation. Activated neutrophils 
release mediators such as TNFα, which induces actin stress fibre formation and increased 
permeability via phosphorylation of cytoskeletal proteins, and IL-8, which increases PI3Kγ-
mediated vascular permeability via phosphorylation and internalisation of the endothelial 
junctional protein VE-cadherin (252). Interestingly, the release of TNFα from neutrophils is 
increased by inhibition of GSK-3, a known negative regulator of HIF-1 (253). Neutrophil-
generated ROS can contribute to endothelial barrier dysfunction by a number of mechanisms, 
including disruption of junctional proteins, cytoskeletal reorganisation into stress fibres, 
activation of permeability-enhancing signalling pathways and promotion of neutrophil-
endothelial adhesion (254).  
Neutrophil granule proteins may contribute to endothelial dysfunction, and their release is 
augmented in the inflammatory setting. The extent of this damage may be even greater in 
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COPD if neutrophils display impaired directionality, hence increasing the capacity for collateral 
damage. Extracellular release of MPO and hydrogen peroxide from neutrophils catalyses ROS 
production and these products are capable of oxidative modification of low density 
lipoproteins; both MPO and markers of MPO-catalysed halogenation have been identified in 
atherosclerotic lesions (255), and inhibition of the peroxidation and halogenation activity of 
MPO in vitro reduced endothelial oxidative stress and permeability (256). Furthermore, levels 
of plasma low density lipoprotein 3-chlorotyrosine (a specific footprint of MPO-HOCl activity) 
were increased in patients with CVD, and MPO has emerged as a prognostic marker in 
patients with acute coronary syndrome, heart failure and peripheral vascular disease (257). 
NE mediates endothelial dysfunction and atherogenesis in several ways: NE treatment of 
pulmonary artery endothelial cells caused apoptosis in vitro (258), pre-treatment with elastase 
inhibitors prevented I/R-induced neutrophil adherence and extravasation in feline mesenteric 
venules (259), and NE has been detected in atherosclerotic plaques, where it can activate 
both other neutrophil proteases, e.g. MMP-9, and pro-inflammatory endothelial cytokines, e.g. 
IL-1β (260,261). Moreover, NE cleavage of the macrophage receptor CD163 resulted in 
reduced clearance of haemoglobin, which favours atherosclerotic plaque destabilisation (262). 
Genetic and pharmacological inhibition of NE decreased experimental murine atherosclerosis 
(263), and higher circulating NE levels in patients with angina are associated with an increased 
risk of future cardiovascular events (264). Similarly, MMP-9 has been shown to cause 
apoptosis of cultured endothelial cells (265), has been detected in atherosclerotic plaques 
(260), and blockade of MMP-9 reduced atherosclerosis in mice (265). Higher circulating MMP-
9 levels are associated with increased aortic stiffness (266) and MMP-8 and -9 were implicated 
in aortic rupture in a case report of S. aureus pneumonia (267). Neutrophils also contribute to 
the progression of atherosclerosis by recruitment of other immune cells: deposition of mouse 
neutrophil CRAMP (homologue of human LL-37) on the inflamed endothelium of large arteries 
promoted adhesion of both neutrophils and monocytes in vivo (268). Several granule proteins, 
including MPO, NE and CRAMP/LL-37, are associated with NETs, which have been shown to 
promote endothelial cytotoxicity (measured by lactate dehydrogenase release) in vitro in a 
histone- and MPO-dependent manner (115). NETs have been observed in pulmonary 
capillaries ex vivo from septic mice and were able to bind to vascular endothelium and platelet-
leukocyte aggregates in vivo, although the significance of this for endothelial damage or 
thrombus formation was unclear (269). However, elevated levels of circulating DNA and 
chromatin have been associated with coronary atherosclerosis and future cardiac events in 
humans (270), and pharmacological prevention of NETosis improved endothelium-dependent 
relaxation in mouse models of obesity and systemic lupus erythematosus (271,272), and could 




1.3.1.3 Interaction of endothelium with neutrophil-derived microvesicles 
NDMVs are present in small amounts in physiological conditions but have been reported to 
be robustly increased during inflammation: elevated circulating NDMVs have been detected 
in vasculitis, pneumonia, sepsis and atherosclerosis, and also in the bronchoalveolar lavage 
fluid (BALF) of ARDS patients (reviewed in (274)). However, whether their role is pro- or anti-
inflammatory remains unclear.  
Proponents of pro-inflammatory NDMV effects include Mesri et al., who showed that MVs from 
phorbol myristate acetate- (PMA) or fMLP-treated neutrophils induced endothelial cell 
activation in vitro, upregulating IL-6 release (96);  Pitanga et al., who showed that calcium 
ionophore-treated neutrophils generated MVs containing active MPO which caused 
endothelial cell injury with loss of cell membrane integrity and morphological damage, such as 
cell blebbing (97); Pluskota et al. who demonstrated that NDMVs could induce platelet P-
selectin expression, which was pro-thrombotic (275); Nolan et al. who showed that neutrophils 
treated with a nitric oxide synthase inhibitor generated L-selectin- and PSGL-1-expressing 
MVs, which enhanced neutrophil trans-endothelial migration in vitro (276); and Hong et al., 
who demonstrated that children with active ANCA-positive vasculitis had more serum NDMVs 
than those with inactive disease. In vitro, ANCA isolated from these patients could stimulate 
the release of MVs from primed neutrophils and these NDMVs could activate endothelial cells, 
increasing ICAM-1, IL-6 and IL-8 expression (277).  
In contrast, others have produced evidence for anti-inflammatory effects: Lim et al. 
demonstrated that extravasating neutrophils in the mouse cremaster muscle deposit CD18-
positive MVs, contributing to the maintenance of endothelial barrier integrity after neutrophil 
transmigration (278); Gasser et al. showed that MVs from fMLP or C5a-treated neutrophils 
increased the release of anti-inflammatory TGFβ1 from human monocyte-derived 
macrophages and reduced LPS-stimulated TNFα and IL-8 secretion (99); and Dalli et al. 
showed that MVs from fMLP or PAF-treated neutrophils contained annexin A1 which mediated 
reduced neutrophil adhesion to a HUVEC monolayer in vitro and, when injected intravenously, 
decreased neutrophil recruitment to an IL-1β inflamed murine air pouch (98). Dalli et al. 
additionally showed that NDMVs have different contents and, hence, functional properties, 
depending on whether they were produced from in vitro neutrophils in suspension or adherent 
to an endothelial monolayer. Overall, it is clear that the effect of NDMVs is highly context-





1.3.2 The role of neutrophils in endothelial dysfunction and cardiovascular 
disease in COPD 
Multiple studies provide evidence for an increased burden of both endothelial 
dysfunction/subclinical CVD (226) and overt CVD (227,228) in COPD independent of 
traditional risk factors, including smoking. Inflammation is thought to play a key role: COPD 
patients with biomarkers of persistent systemic inflammation have increased all-cause 
mortality (279); COPD patients display excessive aortic inflammation compared with healthy 
ex-smokers (280); the risk of MI and ischaemic stroke is substantially increased following an 
acute exacerbation of COPD (232,281), a situation where there may be both systemic and 
local hypoxia and primed circulating neutrophils; leukocyte count is an independent predictor 
of impaired FMD in COPD (234); multi-analyte profiling has revealed an association of markers 
of neutrophilic inflammation and endothelial dysfunction (serum CRP, MPO and VEGF) with 
COPD severity (282); and primed peripheral blood neutrophils exhibiting delayed apoptosis 
have been identified ex vivo from COPD patients (283,284).  
Elevated circulating levels of neutrophil proteins and proteases have been observed in COPD. 
For example, serum MMP-9 is increased in COPD patients compared with healthy controls 
(285) and correlates with systolic hypertension and arterial stiffness (266), and increased 
serum MPO levels are associated with worse cardiovascular outcomes in COPD patients 
(286). Several studies have demonstrated an increase in the expression of neutrophil 
adhesion molecules, such as MAC-1, in COPD (287,288) although the effect on neutrophil 
trans-endothelial migration is less certain: Woolhouse et al. showed enhanced adhesion and 
transmigration of COPD neutrophils compared with healthy controls and smokers without 
COPD (289) whereas Mackarel et al. demonstrated that, despite increased adhesion, there 
was reduced transmigration of neutrophils isolated from patients with either COPD, CF/non-
CF bronchiectasis or pneumonia (290). However, kinetic studies have shown increased 
retention of radiolabelled neutrophils in the pulmonary circulation in smokers compared with 
non-smokers (291). Furthermore, pulmonary microvascular blood flow was reduced in COPD, 
even in patients with mild disease and was distinct from emphysematous areas (292). Recent 
unpublished in vivo data from our laboratory show increased accumulation of radiolabelled 
neutrophils in the lungs of clinically stable COPD patients, comparable to the accumulation 
seen in healthy volunteers treated with inhaled LPS (personal communication, Dr Nicola 
Newman). This delayed transit time may provide an increased opportunity for neutrophil 
transmigration and, hence, endothelial and pulmonary damage. Although trans-endothelial 
passage usually causes only transient barrier disturbance, profound junctional disruption can 
occur under pathological circumstances, such as COPD, where circulating and migrating 
neutrophils are already primed to release their cytotoxic cargo.  
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Chronic and progressive hypoxia is a fundamental feature of COPD and has been linked to 
endothelial dysfunction. Hypoxia induced an endothelial response similar to that seen in 
systemic inflammation, with upregulation of inflammatory mediators, such as PAF, and 
increased expression of cell adhesion molecules (293). Additionally, hypoxia potentiated 
endothelial injury in a murine systemic LPS-mediated inflammatory model of high altitude 
cerebral oedema (294). The degree of hypoxia correlated with CRP, a systemic marker of 
inflammation, in COPD patients (295), and endothelial dysfunction of ex vivo pulmonary 
arteries correlated with the partial pressure of arterial oxygen in COPD patients undergoing 
lung transplantation (296). Furthermore, pulmonary hypertension (PH) is a common 
complication of COPD; it is characterised by pulmonary vascular remodelling and intimal 
obstructive proliferation of distal pulmonary arteries eventually leading to right heart failure, 
and the main driving factors are thought to be chronic hypoxia and inflammation. The 
estimated prevalence of PH in COPD is variable, and has been reported between 23% and 
50% depending on the study population and diagnostic methods used; however, multiple 
studies have shown that the presence of PH has a negative impact on survival in COPD 
patients (reviewed in (297)). Neutrophilic inflammation has been implicated in the 
pathogenesis of PH in COPD: mice subjected to intra-tracheal instillation of elastase 
developed emphysema and PH (298); elastase inhibition could reverse hypoxia-induced PH 
in rats (299); mice deficient in MPO were protected from hypoxia-induced PH, and increased 
plasma NE and MPO were detected in PH patients, with high MPO levels associated with 
increased mortality (300). The only treatment demonstrated to have a beneficial survival effect 
for patients with co-existent COPD and PH is long term oxygen therapy, which has also been 
shown to partially reduce pulmonary artery pressure in these patients (301), although its effect 
on inflammation remains unclear. 
1.4 Summary 
Neutrophils are armed with an array of effective antimicrobial weapons, including cytotoxic 
granule proteins and proteases. As infected and inflamed tissues can be profoundly hypoxic, 
neutrophils are required to work efficiently under these conditions. However, hypoxia can 
synergise with inflammatory signals, such as cytokines, to promote a highly destructive 
neutrophil phenotype, which not only enhances pathogen killing mechanisms but also 
increases the capacity for bystander tissue injury. Direct and indirect neutrophil interactions 
with the endothelium have been implicated in promoting endothelial dysfunction and 
contributing to the development of atherosclerosis in this scenario. Neutrophilic inflammation 
under hypoxic conditions characterises diseases such as COPD, which is associated with 
multiple systemic complications as a consequence of endothelial dysfunction, including CVD 
and PH. Neutrophils from COPD patients, as well as exhibiting intrinsic migratory 
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abnormalities, may contribute to tissue damage via enhanced release of granule proteins (e.g. 
NE and MPO), a signal which may be augmented by hypoxia. However, the precise 
mechanisms and agents responsible for neutrophil-mediated tissue damage in these hypoxic 
environments are unknown, particularly with respect to the vascular manifestations, and will 
therefore be the focus of my thesis.  
 
1.5 Hypothesis and aims 
1.5.1 Hypothesis 
Hypoxia synergises with inflammatory cytokines to engender a destructive neutrophil 
phenotype with enhanced release of histotoxic proteins, which contributes to endothelial 
dysfunction in COPD. 
1.5.2 Specific aims 
Chapter 3 
1) To investigate the mechanism of enhanced degranulation by hypoxic neutrophils 
2) To establish the impact of hypoxia on neutrophil-mediated endothelial cell damage 
Chapter 4 
3) To quantitatively identify proteins in the hypoxic versus normoxic neutrophil secretome 
which might mediate endothelial injury 
4) To explore the mechanism(s) of differential protein release from neutrophils under hypoxia 
versus normoxia 
Chapter 5 
5) To examine whether neutrophils or plasma from exacerbating COPD patients exhibit a 















2 Materials and methods 
2.1 Materials 
Amersham Biosciences (Buckinghamshire, UK): Percoll®, dextran 500 (mw 500,000, 
dissolved in sterile 0.9% saline (6% w/v) and stored at 4ºC)  
APEXBIO (Texas,USA): PI3Kδ inhibitor (CAL-101) 
Baxter Healthcare (Berkshire, UK): Sterile 0.9% sodium chloride (NaCl) solution 
BD Biosciences (Embodegen, Belgium): Falcon polypropylene tubes (50, 15 and 14 ml), 50 
ml syringes, Cellfix™, Annexin V-FITC/PI apoptosis detection kit I 
BioCytex (Marseille, France): Megamix beads 
Biolegend (London, UK): LEGEND MAX™ Human MRP8/14 (S100A8/A9, calprotectin) ELISA 
kit with pre-coated plate 
Bio-Rad (California, USA): DC colorimetric protein assay, Quick Start™ Bradford Protein 
Assay, Precision Plus Protein™ Dual Color Standard, PROTEAN® II electrophoresis system,  
BosterBio (California, USA): Human thioredoxin PicoKine™ ELISA kit with pre-coated plate  
Cloud-Clone Corp. (Texas, USA): Human S100A9 ELISA kit with pre-coated plate 
Corning (New York, USA): 100mm sterile tissue culture petri dishes, T75 sterile tissue culture 
flasks, 5ml round bottom polystyrene FACS tube (Falcon®), 70µm cell strainer (Falcon®) 
Elabscience (Texas, USA): Human cyclophilin A ELISA kit with pre-coated plate (assay range 
1.25 ng/ml – 80 ng/ml) 
GE Healthcare (Buckinghamshire, UK): ECL (Enhanced Chemiluminescence) system, 
Vivaspin 2 MWCO 3000 concentrator columns, cyanine 3/5 dyes, IPG buffer, IEF gel strip 
(Immobiline™ Drystrip pH 3-10), 600 Ruby Standard Dual-Cooled Vertical Gel Unit 
Gibco (Maryland, USA): trypsin 0.05%, sterile distilled water, Iscove's Modified Dulbecco's 
Medium (IMDM) 
Greiner Bio-One Ltd (Gloucestershire, UK): ELISA plate (flat bottomed, high binding), 6-,12- 
and 96-well sterile culture plates 
Hospira Venisystems (Berkshire, UK): sterile 19 gauge Butterfly needles  
Invitrogen (Paisley, UK): rhodamine phalloidin F actin stain, TrypLE select enzyme (1X) 
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Life Technologies (Paisley, UK): Enzchek® elastase assay kit, penicillin (10 μg/ml), 
streptomycin (25 μg/ml) 
Lifespan Biosciences (Seattle, USA): Human S100A8 ELISA kit with pre-coated plate 
Lonza (Slough, UK): primary human pulmonary artery endothelial cells, EGM™-2 Bulletkit™, 
foetal calf serum (FCS) 
Martindale Pharmaceuticals Ltd (Essex, UK): sterile calcium chloride (CaCl2), sterile sodium 
citrate  
Merck Ltd. (Nottingham, UK): May-Grünwald-Giemsa stain, sodium thiosulphate 
pentahydrate, luminol 
Miltenyi Biotec (Surrey, UK): MACS mouse neutrophil isolation kit, QuadroMACS™ Separator, 
3ml LS columns 
National Diagnostics (Nottingham, UK): Protogel, stacking buffer and resolving buffer 
Oxford Biosystems (Oxford, UK): Human cyclophilin A ELISA kit with pre-coated plate (assay 
range 0.39 ng/ml – 25 ng/ml) 
PanReac Applichem (Barcelona, Spain): 4-(2-aminoethyl)benzenesulfonyl fluoride 
hydrochloride (AEBSF) 
PeproTech (London, UK): recombinant murine tumour necrosis factor α (TNFα), recombinant 
murine granulocyte macrophage colony-stimulating factor (GM-CSF) 
Premier Foods (St Albans, UK): Marvel milk powder 
Promocell (Heidelberg, Germany): Endothelial cell growth medium MV kit 
Radiometer (Copenhagen, Denmark): ABL80 Basic automated blood gas analyser qualichek 
calibration kit 
RayBiotech (Georgia, USA): human resistin and NGAL ELISA kits with pre-coated plates 
R&D Systems (Oxfordshire, UK): recombinant human GM-CSF, recombinant human TNFα 





Sigma-Aldrich, (Dorset, UK): Eppendorf (Safe-Lock microfuge tubes, PCR clean, 1.5 ml and 
2 ml), Pasteur pipettes, phosphate buffered saline (PBS) with (PBS+/+) or without (PBS-/-) 
calcium chloride and magnesium chloride, Histopaque®-1077, cytochalasin B from Drechlera 
dematioidea, N-formyl-methionyl-leucyl-phenylalanine (fMLP), PI3Kγ inhibitor (AS605240), 
PI3Kδ inhibitor (IC87114), α1 antitrypsin from human plasma, dimethyl sulfoxide (DMSO), 
glycine, sodium dodecyl sulphate (SDS), Trizma (tris(hydroxymethyl)aminomethane, tris 
base), ammonium persulfate (APS), tetramethylethylenediamine (TEMED), dithiothreitol 
(DTT), bromophenol blue, tissue culture grade bovine serum albumin (BSA), Tween-20, 
polyvinylidene fluoride (PVDF) membrane, Triton X-100, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT), trichloroacetic acid (TCA), paraformaldehyde (PFA), 
sodium azide 0.1 M solution, ethanol, formaldehyde, silver nitrate, Ponceau S, ammonium 
acetate, ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 
ethylenediamine tetraacetatic acid (EDTA), leupeptin, pepstatin A, aprotinin, sivelestat, 
sodium orthovanadate, sodium chloride, tetramisole, sodium pyrophosphate, sodium fluoride, 
β glycerophosphate, phenylmethylsulfonyl fluoride (PMSF), RIPA buffer, cOmplete™ mini 
EDTA-free protease inhibitor cocktail tablets (Roche), hydrogen peroxide (H2O2), o-dianisidine 
dihydrochloride (DMB), horseradish peroxidase type VI  
Spherotech (Illinois, USA): SPHERO™ Accucount blank particles 2.0-2.4µm 
ThermoFisher Scientific (Massachusetts, USA): Prolong gold antifade mountant with DAPI, 
acetone, NuPAGE pre-cast 1.0 mm 12% 12 well polyacrylamide gels, NuPAGE MES SDS 
running buffer, XCell SurelockTM Mini-Cell electrophoresis system, sodium carbonate 
decahydrate, glycerol, acetic acid, Nalgene™ high speed centrifuge tubes (30ml), Pierce™ 
660nm protein assay, PagerulerTM Plus Prestained Protein Ladder, Mark12™ Unstained 
Standard, Restore PLUS western blot stripping buffer, TMT10-plex isobaric label reagents, 
SYTOX™ green nucleic acid stain 
Tocris Bioscience (Bristol, UK): Platelet Activating Factor (PAF) 
VWR International (Leicestershire, UK): DPX mountant, methanol, 0.5ml tubes PCR clean, 




Table 2.1: Antibodies 
The antibodies shown in the table were obtained and used at the concentrations indicated. 
Incubation times are specified in individual western blot (WB) and fluorescence-activated cell 






































rabbit human poly 1:1000 nil WB 
S100A9 Abcam 
ab63818 





rabbit human poly 1:1000 nil WB 
annexin A1 GeneTex 
GTX101070 
rabbit human poly 1:2000 nil WB 
β actin Abcam 
ab8227 














































2.2.1 Neutrophil preparation 
2.2.1.1 Neutrophil isolation from human whole blood 
Ethical permission for taking peripheral blood from healthy volunteers (REC reference 
06/Q0108/281) was obtained from the Cambridge Local Research Ethics Committee.  
Neutrophils were isolated from whole blood by dextran sedimentation and centrifugation over 
discontinuous plasma-Percoll® gradients. All equipment and reagents were sterile, and all 
reagents used at room temperature unless otherwise stated. The isolation was conducted 
under sterile conditions in a laminar flow cell culture hood (Microflow Class II cabinet). All 
neutrophil centrifugation was undertaken using a Hettich Rotina 420R (Hettich Zentrifugen, 
Tuttlingen, Germany). 
40-240 ml whole blood from healthy volunteers was collected by venepuncture into 50 ml 
syringes using 19 gauge butterfly needles. Blood was transferred gently into 50 ml 
polypropylene Falcon tubes containing 3.8% sodium citrate (1 ml per 10 ml blood). Whole 
blood was centrifuged at 300g, acceleration 9, brake 3 for 20 min. Platelet-rich plasma (PRP) 
supernatant was aspirated into new 50 ml tubes and centrifuged at 1400g, acceleration 9, 
brake 9 for 20 min. After centrifugation, the platelet-poor plasma (PPP) supernatant, was 
aspirated into new 50 ml tubes and the platelet pellet discarded. To make autologous serum, 
10 ml PRP was aspirated into a separate sterile glass container prior to centrifugation and 
thoroughly mixed with 220 µl 10 mM CaCl2. The pellet from the initial centrifugation of whole 
blood, containing leukocytes (white blood cells, WBC) and erythrocytes (red blood cells, RBC), 
was sedimented with dextran to remove RBC:  2.5 ml 6% dextran (pre-warmed to 37ºC) per 
10 ml pellet was added, made up to 50 ml total volume with sterile 0.9% NaCl (pre-warmed to 
37ºC) and mixed gently. RBC were sedimented for 20-40 min until the RBC pellet reached its 
original (post-centrifugation) volume. After sedimentation, the WBC-containing top layer was 
aspirated and the sedimented RBC discarded. WBC were centrifuged at 260g, acceleration 9, 
brake 9 for 5 min. The supernatant was discarded and the WBC-containing pellet was re-
suspended gently in 2 ml PPP. Percoll® (pre-cooled to 4ºC) was diluted in PPP to make 42% 
and 51% gradients. 2 ml WBC in PPP were transferred to 15 ml polypropylene tubes. Firstly, 
the 42% Percoll® gradient and, secondly, the 51% gradient, were underlaid using a glass 
Pasteur pipette. Gradients were centrifuged at 150g, acceleration 1, brake 0 for 14 min (Figure 
2.1A). The top layer of cells at the 42%/PPP interface, containing peripheral blood 
mononuclear cells (PBMCs, Figure 2.1B), was aspirated and discarded. The lower layer of 
cells at the 51%/42% interface, containing granulocytes (Figure 2.1C), was carefully aspirated 
using a plastic Pasteur pipette and re-suspended gently in the remaining PPP. The 
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granulocytes were centrifuged at 256g, acceleration 9, brake 9 for 5 min. The supernatant was 
discarded and the cell pellet gently re-suspended. Cells were washed in 50 ml PBS-/- (pre-
warmed to 37ºC) by centrifuging at 256g, acceleration 9, brake 9 for 5 min. Prior to 
centrifugation,100 µl were removed by P200 Gilson using a cell saver pipette tip to make the 
purity slide cytospin. 20 µl were removed for haemocytometer cell count. The cells were then 
washed in 50 ml PBS+/+ (pre-warmed to 37ºC) by centrifuging at 256g, acceleration 9, brake 
9 for 5 min. The supernatant was discarded and the cell pellet gently re-suspended to be used 
in further experiments. By this method the efficiency of neutrophil recovery was >80%, and 
the neutrophil isolate was >95% pure with less than 1% monocyte contamination. Cytospins 
to count neutrophil purity were made by centrifugation in a Shandon Cytospin 3 centrifuge, 
300 rpm for 3 min. To assess purity, the cells were fixed in methanol and subsequently stained 
with May-Grünwald-Giemsa (Figure 2.1B&C). Cells were counted using light microscopy 
(Olympus CX31). 
 
Figure 2.1: Isolation of neutrophils from human whole blood 
A: Photograph of plasma-Percoll® gradient following centrifugation. Mononuclear cells 
comprise the upper cell layer between plasma and 42% Percoll®; granulocytes comprise the 
lower cell layer at the interface of 42% and 51% Percoll®. B&C: Representative 
photomicrograph of cytospins, stained with May-Grünwald-Giemsa, from the upper 
mononuclear (B) and lower granulocyte (C) cell layers (x40 magnification, scale bar indicates 
10µm).   
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2.2.1.2 Neutrophil isolation from murine bone marrow 
Mouse strains: E1020K heterozygote or D910A homozygote mice bred on a C57BL/6J 
background with strain-matched wildtype controls were kindly provided by Professor Klaus 
Okkenhaug (Babraham Institute, Cambridge, Home Office License Numbers PPL 80/2248 
and 70/7661). PI3Kγ-/- mice bred on a C57BL/6 E129 background with strain-matched wildtype 
controls were kindly provided by Dr Len Stephens (Babraham Institute, Cambridge, PPL Home 
Office License Number PPL 70/8100). Additional C57BL/6J wildtype mice were kindly 
provided by Professor Nicholas Morrell (University of Cambridge, Home Office License 
Number PPL 70/8850). All mice were aged between 8-15 weeks. 
Neutrophils were isolated from murine femoral bone marrow by negative immunomagnetic 
selection using a MACS neutrophil isolation kit. All equipment and reagents were used at 4ºC 
throughout. Bone marrow was obtained by flushing femurs with MACS buffer (PBS-/-, pH 7.2, 
0.5% BSA, 2 mM ethylenediamine tetraacetatic acid (EDTA)) through a 70 µm sterile cell 
strainer. Total cell number was determined with a haemocytometer. The cell suspension was 
centrifuged at 300g for 10 min and the supernatant discarded. The cell pellet was re-
suspended in MACS buffer (25*108 cells/ml), mixed with neutrophil biotin-antibody cocktail (1 
µl per 1*106 cells, proprietary recipe) and incubated for 10 min at 4ºC. Cells were washed in 
20 ml MACS buffer (300g, 10 min) and the supernatant discarded. The cell pellet was re-
suspended in MACS buffer (12.5*108 cells/ml), mixed with anti-biotin microbeads (2 µl per 
1*106 cells) and incubated for 15 min at 4ºC. Cells were washed in 20 ml MACS buffer (300g, 
10 min) and the supernatant discarded. The cell pellet was re-suspended in MACS buffer 
(2*108 cells/ml) and subjected to magnetic separation using a QuadroMACS™ Separator and 
3 ml LS columns. Columns were initially rinsed with 3 ml MACS buffer. The cell suspension 
was then applied and the neutrophil-rich flow-through collected in a fresh 15 ml polypropylene 
tube. Columns were washed thrice with 3 ml MACS buffer and the filtrate collected. 20 µl 
neutrophil suspension was removed for haemocytometer cell count and 100 µl removed to 
make the purity slide cytospin before centrifuging the cell suspension (300g, 5 min). The 
supernatant was discarded and the cell pellet washed in 50 ml serum-free PBS-/- (300g, 5 
min). The supernatant was discarded and the cell pellet washed in 50 ml serum-free PBS+/+ 
(300g, 5 min). The supernatant was discarded and the cell pellet gently re-suspended to be 
used in further experiments. 
2.2.1.3 Generation of neutrophil supernatants  
Human neutrophil supernatants were generated as previously published (149), with the 
modifications described below. Freshly isolated neutrophils were re-suspended in normoxic 
or hypoxic IMDM at a concentration of 11.1*106/ml. Aliquots of 270 µl (3*106 neutrophils) were 
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transferred to 2 ml Eppendorfs and incubated under normoxia or hypoxia in a thermomixer 
(37ºC, 450 rpm) for 4 h. After 4 h, cells were treated with GM-CSF (10 ng/ml, 30 min, final 
concentration), TNFα (20 ng/ml, 30 min, final concentration) or PAF (1 µM, 5 min, final 
concentration), and subsequently fMLP (100 nM, 10 min, final concentration), or IMDM control, 
with a final volume of 1 ml. After treatment, samples were centrifuged (13,000 rpm, 10 s, MSE 
Micro Centaur microfuge) to pellet cells, and supernatants were harvested. Unless otherwise 
stated, human neutrophil supernatants for all experiments were generated by this method.  
Murine neutrophil supernatants were generated similarly. Freshly isolated murine bone 
marrow neutrophils were re-suspended in normoxic or hypoxic IMDM at a concentration of 
11.1*106/ml - 18.5*106/ml. Aliquots of 270 µl (3-5*106 neutrophils, depending on total number 
isolated from murine bone marrow) were transferred to 2 ml Eppendorfs and incubated under 
normoxia or hypoxia in a thermomixer (37ºC, 450 rpm) for 4 h. Neutrophil numbers were kept 
consistent between conditions and genotypes within individual experiments. After 4 h, cells 
were treated with murine GM-CSF (10 ng/ml, 30 min), murine TNFα (10 ng/ml, 30 min), or 
cytochalasin B (5 µg/ml, 5 min), and subsequently fMLP (10 µM, 10 min), or IMDM control, 
with a final volume of 400 µl. Cells were pelleted (13,000 rpm, 10 s, MSE Micro Centaur 
microfuge) and supernatants harvested. 
2.2.1.4 Optimisation of neutrophil cell lysate generation 
It is challenging to generate neutrophil lysates as disruption to cell and internal membranes 
upon addition of lysis buffer can result in significant protein degradation following liberation of 
the abundant proteases and phosphatases contained within the granules. This was apparent 
when performing western blotting (see Table 2.1 for all antibody details) for AKT (#9272) and 
phosphorylated-AKT(ser473) (pAKT, #9271). Initially, lysates were prepared by adding 
hypotonic lysis buffer (10 mM Tris pH 7.8, 1.5 mM EDTA, 10 mM KCl, 500 µM dithiothreitol 
(DTT), 1 mM sodium orthovanadate, 2 mM tetramisole, one cOmplete™ mini EDTA-free 
protease inhibitor cocktail tablet 1 tablet/4 ml) to cell pellets on wet ice and vortexing every 15 
min for a total of 60 min before centrifugation (3100g, 5 min) to remove debris, in accordance 
with the protocol previously established in our laboratory. Using this lysate preparation 
method, probing for pAKT (#9271) and AKT (#9272) by western blotting (see section 2.2.5.3 
for method) demonstrated extremely variable AKT protein bands compared with β actin 
loading control (Figure 2.2A), and complete inability to visualise any protein bands for pAKT. 
Further investigation revealed that AKT was being cleaved into fragments of a lower molecular 




Figure 2.2: Expression of total AKT by western blot 
Isolated neutrophils were incubated under normoxia (21% O2, N) or hypoxia (0.8% O2, H) for 
4 h. Cells were treated with GM-CSF (10 ng/ml, 15 min, GM) or IMDM control (C) in the 
presence or absence of PI3K inhibitors (IC87114, 3 µM, δ; AS605240, 3 µM, γ). Cell lysates 
were prepared with the addition of hypotonic lysis buffer on wet ice and subjected to SDS-
PAGE; western blotting was performed with A&B: anti-AKT (#9272) and A: anti-β actin. 
 
Firstly, I wished to investigate the ability of these antibodies to detect AKT and pAKT proteins, 
using lysates from other cell types as a positive control. I therefore trialled polyclonal anti-
pAKT (#9271) against monoclonal anti-pAKT (#4060, kindly provided by Professor Klaus 
Okkenhaug), and polyclonal anti-AKT (#9272) against monoclonal anti-AKT (#4691) (Table 
2.1). Lysates from PDGF-stimulated smooth muscle cells (kindly provided by Dr Paul Upton, 
University of Cambridge) and unstimulated or anti-IgM stimulated B cells (kindly provided by 
Dr Valentina Carbonaro, Babraham Institute) were used as positive controls (Figure 2.3). This 
test demonstrated that monoclonal anti-pAKT (#4060, Figure 2.3B) and polyclonal anti-AKT 
(#9272, Figure 2.3C) were better able to detect pAKT and AKT protein, and that bands of 
correct molecular weight were seen in the positive control samples but degraded protein was 
seen in my samples. These antibodies were therefore used for all future pAKT/AKT western 







Figure 2.3: The ability of monoclonal versus polyclonal antibodies to detect pAKT and 
AKT by western blot 
Isolated neutrophils were incubated under normoxia (N) or hypoxia (H) for 4 h and treated with 
GM-CSF (10 ng/ml, 15 min). Neutrophil lysates were prepared with the addition of hypotonic 
lysis buffer on wet ice. Lysates from PDGF-stimulated smooth muscle cells (P) at 1, 5 and 10 
min, and lysates from unstimulated (-) or anti-IgM-stimulated (+) B cells (BC) were used as 
controls. All lysates were subjected to SDS-PAGE; western blotting was performed with A: 
polyclonal anti-human pAKT (#9271), B: monoclonal anti-human pAKT (#4060), C: polyclonal 




Secondly, I wished to investigate the capacity of different buffers and lysate preparation 
methods to inhibit protein degradation in my samples. I therefore trialled three different lysis 
buffers: 
Buffer 1) 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM EDTA, 20 mM ethylene glycol-bis(β-
aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 2.5 mM sodium pyrophosphate, 1 mM β 
glycerophosphate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium fluoride, 1% 
Triton-X 100, 10 µg/ml leupeptin, 10 µg/ml aprotinin and 10 µg/ml pepstatin A  
Buffer 2) Radioimmunoprecipitation assay (RIPA) buffer, 20 mM EDTA, 20 mM EGTA, 1 mM 
PMSF, 1 mM sodium fluoride, 1% Triton-X 100, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 10 
µg/ml pepstatin A and one cOmplete™ mini EDTA-free protease inhibitor cocktail tablet (1 
tablet/4 ml buffer) 
Buffer 3) 250 mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS and one cOmplete™ mini EDTA-
free protease inhibitor cocktail tablet (1 tablet/4 ml buffer) 
and three different preparation methods:  
1) Addition of lysis buffer to cell pellet at room temperature, vortexing (30 s) every 15 min 
for 60 min 
2) Addition of lysis buffer to cell pellet on wet ice, vortexing (30 s) every 15 min for 60 min 
on wet ice 
3) Snap freezing of cell pellet immediately on dry ice, addition of lysis buffer to frozen 
pellet, warming and vortexing (30 s) before boiling with agitation (99ºC, 550 rpm, 10 
min) and freezing again on dry ice 
This trial demonstrated the best protein recovery with buffer 3 in combination with snap 
freezing of the neutrophil pellet on dry ice prior to lysis buffer addition (Figure 2.4A). This 
method was employed for all further lysate preparation and gave good protein recovery for 





Figure 2.4: The effect of different buffers and lysate preparation methods on pAKT 
and AKT protein detection by western blot  
Isolated neutrophils were incubated under normoxia (N) or hypoxia (H) for 4 h. Cells were 
treated with GM-CSF (10 ng/ml, 15 min, GM) or IMDM control (C) in the presence or absence 
of PI3K inhibitors (IC87114, 3 µM, δ; AS605240, 3 µM, γ). A: Cell lysates were prepared with 
the addition of Buffer 1 (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 20mM EDTA, 20 mM EGTA, 
2.5 mM sodium pyrophosphate, 1 mM β glycerophosphate, 1 mM PMSF, 1 mM sodium 
fluoride, 1% Triton-X 100, 10 µg/ml leupeptin, 10 µg/ml aprotinin and 10 µg/ml pepstatin A), 
Buffer 2 (RIPA buffer plus 20mM EDTA, 20 mM EGTA, 1 mM PMSF, 1 mM sodium fluoride, 
1% Triton-X 100, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml pepstatin A and one 
cOmplete™ mini EDTA-free protease inhibitor cocktail tablet, 1 tablet/4 ml buffer) or Buffer 3 
(250mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS and one cOmplete™ mini EDTA-free 
protease inhibitor cocktail tablet, 1 tablet/4 ml buffer) at room temperature (RT), on wet ice 
(wet) or dry ice (dry). B&C: Cell lysates were prepared with the addition of Buffer 3 on dry ice. 
Lysates were subjected to SDS-PAGE. Western blotting was performed with A&C: anti-AKT 




2.2.1.5 Generation of neutrophil cell lysates  
Freshly isolated neutrophils were re-suspended in normoxic or hypoxic IMDM at a 
concentration of 11.1*106/ml. Aliquots of 900 µl (10*106 neutrophils) were transferred to 2 ml 
Eppendorfs. For some experiments, PI3K inhibitors were added prior to incubation: AS605240 
(PI3Kγ-selective inhibitor, 3 µM) or IC87114 (PI3Kδ-selective inhibitor, 3 µM). Cells were 
incubated under normoxia or hypoxia in a thermomixer (37ºC, 450 rpm) for 4 h. After 
incubation, cells were treated with GM-CSF (10 ng/ml, 15 min), PAF (1 μM, 5 min) or IMDM 
control, with or without subsequent fMLP (100 nM, 10 min). After treatment, samples were 
centrifuged (13,000 rpm, 10 s, MSE Micro Centaur microfuge) to pellet cells, and supernatants 
were harvested. Cell pellets were snap frozen immediately on dry ice and 200 µl lysis buffer 
were added (250 mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS, and one cOmplete™ mini 
EDTA-free protease inhibitor cocktail tablet, 1 tablet/4 ml buffer). Samples were warmed, 
vortexed (30 s), boiled with agitation (99ºC, 550 rpm, 10 min) and then centrifuged (3100g, 5 
min) to remove debris. Aliquots of 50 µl cell lysate were stored at -80ºC.  
2.2.2 Working under hypoxia 
Hypoxic experiments were conducted in a SCI-tive Dual hypoxia workstation (Baker Ruskinn) 
(Figure 2.5A). Levels of O2 and CO2, set via a programmable touch screen control, were 
maintained by gas feeds of 100% N2, 100% CO2 and compressed air. The chamber is 
accessed by three glove ports with attached sleeves, which maintain an airtight seal around 
the user’s arms. To introduce an item into the chamber, it was placed into the central airlock 
which was flushed with nitrogen for 160 seconds to reach a level of 1.0% O2. This enabled 
introduction of items into the chamber’s central workspace without re-oxygenation.  
The pre-set working levels for hypoxia were 0.8% O2 and 5.0% CO2, which had been 
previously optimised for IMDM media (302). The pH of normoxic and hypoxic IMDM was 
measured over 5 h to ensure no pH difference during the experimental incubation timecourse 
(Figure 2.5B).  
All equipment and reagents were equilibrated in hypoxia for at least 3 h prior to commencing 
the experiment. Unless otherwise stated, the levels for all experiments carried out under 
hypoxia were 0.8% O2 and 5.0% CO2. The % O2 within the workstation could be assessed in 
two ways:  by interrogation of the workstation trend log, which records actual internal % O2 
every minute, and by attaching a calibrated oxygen sensor to a port on the side of the 
workstation, which accessed the inner workspace. However, as the workstation controls the 
oxygen tension within the chamber, rather than the oxygen tension experienced by the cells 
re-suspended in hypoxic media, it was also important to check the gaseous partial pressures 
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of O2 and CO2 in the media. This was achieved with an ABL80 Basic automated blood gas 
analyser. Due to the expense and limited lifespan of the calibration and QC solutions, the pH, 
pO2 and pCO2 of hypoxic equilibrated media was periodically checked at regular intervals to 
ensure that the required levels were being maintained (Figure 2.5C). Correlation of media gas 
analysis values with workstation O2 assessments confirmed that the required level of hypoxia 
was achieved and stable. The workstation was maintained at 37ºC and 70% humidity 
throughout experiments. 
 
Figure 2.5: Analysis of media pH, pO2 and pCO2 
IMDM was incubated under normoxia (room air, 50 ml Falcon, bead bath at 37ºC) or hypoxia 
(0.8% O2 and 5.0% CO2, 100 mm diameter petri dish, hypoxia workstation at 37ºC). A: 
photograph showing the SCI-tive Dual hypoxia workstation. B: pH was measured hourly under 
normoxia or hypoxia using a benchtop pH meter. C: After 3 h hypoxic incubation, samples of 
IMDM were taken using a 1 ml syringe with an airtight cap and immediately assessed for pH, 
pCO2 and pO2 using an ABL 80 blood gas analyser. Data represent mean ± SEM, B: n=3, C: 
n=10. 
2.2.3 Neutrophil functional assays 
2.2.3.1 Assessment of shape change 
Freshly isolated neutrophils were re-suspended in PBS+/+ at a concentration of 5*106/ml. 90 
µl aliquots of cells were transferred to 2 ml Eppendorfs in a thermomixer at (37ºC, 450 rpm).  
Cell were treated with fMLP (100 nM) or PBS+/+ control. Cells were fixed at baseline (control) 
or after 30 min (control and fMLP) by adding 250 µl Cellfix™ and placing on ice for 1 min. 90 
µl from each sample were transferred to separate 14 ml polypropylene round-bottomed FACS 
tubes and 500 µl ice-cold PBS-/- added. Shape change was analysed by flow cytometry (BD 
FACSCanto II), gating on single granulocytes, and assessing change in forward scatter 
(Figure 2.6A-C). In response to a chemoattractant stimulus, activated (shape changed) 
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neutrophils become flattened and elongated, due to remodelling of the actin cytoskeleton, 
which increases their forward scatter profile. Figure 2.6D shows that basal neutrophils were 
not shape-changed but there was a significant increase in forward scatter correlating with an 
increase in % shape changed cells with fMLP (p<0.0001), confirming that I was able to isolate 
un-primed responsive neutrophils. 
 
Figure 2.6: Gating strategy and quantification of neutrophil shape change by flow 
cytometry 
Neutrophils were treated with fMLP (100 nM) or PBS+/+ (control). Cells were fixed at baseline 
or after 30 min. Shape change was assessed by flow cytometric analysis of forward scatter 
(BD FACSCanto II). A-C: Representative flow plots of A: control 0 min, B: control 30 min and 
C: fMLP-treated 30 min forward scatter area (FSC-A) vs side scatter area (SSC-A), gating on 
neutrophils, with corresponding histograms of FSC-A below. D: Quantification of shape 
change expressed as FSC-A positive cells as % of total singlet neutrophil population. Results 
represent mean ± SEM, n=5, ****=p<0.0001, one way ANOVA, Tukey’s multiple comparisons. 
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2.2.3.2 Assessment of apoptosis by morphology 
Freshly isolated neutrophils were re-suspended in normoxic or hypoxic IMDM, containing 10% 
autologous serum and 0.5% penicillin/streptomycin (50 U/ml), to give a final concentration of 
5*106/ml. 135 µl aliquots of cells were added to a 96 well plate and treated with GM-CSF (1 
ng/ml), PAF (1 μM) or IMDM control at the start of incubation. Cells were incubated at 37ºC 
under normoxia or hypoxia for 20 h. After incubation, neutrophil apoptosis was quantified by 
morphology, and/or flow cytometry. 
For morphologic assessment, neutrophils were harvested by gently pipetting up and down 
using cell saver tips. Cytospins were made by centrifugation in a Shandon cytospin 3 
centrifuge, 300 rpm for 3 min. Cells were fixed in methanol (4 min) and stained with May-
Grünwald-Giemsa. Morphology was examined by oil-immersion light microscopy (Olympus 
CX31, 100x magnification). Apoptotic neutrophils have a distinctive morphologic appearance:  
condensation of chromatin leads to loss of the multi-lobed nucleus (darkly staining pyknotic 
nuclei), and there is cell shrinkage and vacuolation of the cytoplasm (Figure 2.7). A minimum 
of 300 cells per slide in randomly selected fields of view were counted in order to quantify 
neutrophil apoptosis. 
 
Figure 2.7: Assessment of neutrophil apoptosis by morphology 
Cytospins were stained with May-Grünwald-Giemsa and examined at 100x magnification 
under oil immersion. Photomicrograph show A: non-apoptotic and B: apoptotic neutrophils, 




2.2.3.3 Assessment of apoptosis by flow cytometry 
For flow cytometric assessment, neutrophils were harvested by gently pipetting up and down 
using cell saver tips and transferred to cooled FACS tubes. All reagents were pre-cooled to 
4ºC and kept on ice. Cells were centrifuged at 4ºC, 256g, acceleration 9, brake 9 for 5 min. 
Supernatants were discarded and cell pellets gently re-suspended in 100 µl 1x binding buffer 
(1:10 dilution 10x stock binding buffer) containing 5% FITC-AnV and 5% PI. For compensation, 
cells were re-suspended in 100 µl 1x binding buffer (unstained), 100µl 1x binding buffer with 
5% AnV (AnV single stained) or 100 µl 1x binding buffer with 5% PI (PI single stained). 
Samples were vortexed and stained on ice for 20 min, protected from light. The reaction was 
then quenched by adding 400 µl 1x binding buffer to each tube. Flow cytometry (BD 
FACSCanto II) was performed using the blue (488 nm excitation; 530/30 filter) and red (633 
nm; 660/20 filter) lasers. Annexin V binds phosphatidylserine which is externalised on the 
membrane of apoptotic cells; PI is a nuclear stain which can penetrate necrotic cells, allowing 
assessment of membrane integrity. The gating strategy is shown in Figure 2.8: AnV-/PI- 
staining indicated viable non-apoptotic cells, AnV+/PI- staining indicated early apoptotic cells 
and AnV+/PI+ staining indicated late apoptotic or necrotic cells. Unstained and single-stained 
samples were used to set compensation. Results were analysed using FlowJo version 10 
software.  
2.2.3.4 Assessment of neutrophil reactive oxygen species production 
Extracellular ROS production was quantified by chemiluminescence. The chemiluminescent 
probe luminol is oxidized by ROS in the presence of an exogenously applied peroxidase 
catalyst, such as horseradish peroxidase (HRP), yielding light emission which can be 
measured with a luminometer. As HRP cannot cross the neutrophil cell membrane, the 
luminol/HRP-dependent chemiluminescence detects extracellular ROS production. Freshly 
isolated neutrophils were re-suspended in PBS+/+ at a concentration of 5*106/ml. Aliquots of 
180 µl were transferred to 2 ml Eppendorfs and incubated in a thermomixer (37ºC, 450 rpm). 
Cells were treated with TNFα (20 ng/ml, 30 min), PAF (1 µM, 5 min) or PBS control before 
addition of luminol (1 µM, 3 min). Luminol-treated cells were transferred into an opaque 96-
well plate containing HRP (62.5 U/ml) and chemiluminescence measured immediately with a 
luminometer. The luminometer injector was primed prior to ROS analysis and cells in all wells 
were treated with fMLP (100 nM) at baseline via the injector. ROS kinetics were measured for 
10 min and extracellular ROS production was expressed as raw peak height in relative light 





Figure 2.8: Gating strategy for assessment of neutrophil apoptosis by flow cytometry 
Neutrophils were incubated under normoxia (A&C) or hypoxia (B&D) for 20 h. Cells were 
treated at baseline with GM-CSF (1 ng/ml, C&D) or IMDM control (A&B). After 20 h, cells were 
stained with FITC-AnV and PI and apoptosis assessed by flow cytometry (BD FACSCanto II). 
A-D:  Representative flow plots of FITC-AnV (y axis) and PI (x axis) staining. Q1 shows 
AnV+/PI- (apoptotic) cells, Q2 shows AnV+/PI+ (late apoptotic/necrotic) cells, Q3 shows AnV-
/PI+ (necrotic) cells (though most necrotic cells are AnV+), Q4 shows AnV-/PI- (viable) cells. 
Cells per quadrant as % of total neutrophils are indicated. 
2.2.3.5 Assessment of neutrophil extracellular trap production 
Freshly isolated neutrophils were re-suspended at 1x106/ml in normoxic or hypoxic IMDM, 
containing the cell impermeable nucleic acid stain SYTOX™ green (5 μM). This established 
method allows objective quantification of extracellular DNA, which equates to NETosis 
provided the cells are not necrotic (e.g. (303)). Aliquots of 200 µl (2*105) cells were transferred 
to a 96 well plate. At baseline, three wells were permeabilised with 0.5% Triton-X and 
fluorescence absorbance (indicating total cellular DNA content) measured after 30 min (peak 
signal). Remaining cells were treated at the beginning of incubation with GM-CSF (10 ng/ml), 
PAF (1 µM) or IMDM control, and fluorescence absorbance (indicating extracellular DNA) 
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measured hourly. For some experiments, cells were treated after 4 h normoxic/hypoxic 
incubation with GM-CSF (10 ng/ml, 30 min), and subsequently fMLP (100 nM, 10 min). Here, 
fluorescence absorbance was measured at baseline, 4 h and after treatment. As a positive 
control, cells were treated with PMA (20 nM) at baseline and incubated under normoxia for 4 
h. SYTOX green fluorescence was measured with a Victor 3 multilabel plate reader (Perkin 
Elmer), reading fluorescence absorbance at 485/535 nm. NET production was expressed as 
extracellular DNA as % of total baseline DNA, calculated by subtracting fluorescence at 
baseline from the fluorescence at each time point and then dividing by the fluorescence values 
of lysed cells. All experimental values were standardized to total DNA.  
2.2.4 Neutrophil degranulation assays 
2.2.4.1 Assessment of neutrophil elastase release 
Supernatant NE activity was quantified by Enzchek® elastase activity assay, which measures 
the ability of NE to cleave non-fluorescent (quenched) BODIPY labelled-DQ-elastin substrate, 
into fluorescent fragments. DQ-elastin substrate (reconstituted in distilled water (dH2O) to 1 
mg/ml) was diluted 1:20 in 1x reaction buffer and 100 µl added to required wells of a 96 well 
enzyme-linked immunosorbent assay (ELISA) plate. 100 µl undiluted sample were added to 
DQ-elastin wells in duplicate. 100 µl 1x reaction buffer or IMDM were added as negative 
control. Whether the observed proteolytic activity was the result of elastase was determined 
by addition of the selective NE inhibitor N-Methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl 
ketone (Figure 2.9), supplied with the kit (10 mg/ml in DMSO). 50 µl elastase inhibitor (10 µM), 
or 1x reaction buffer control, were added to required wells of a 96 well ELISA plate. DQ-elastin 
substrate (1 mg/ml in dH2O) was diluted 1:10 in 1x reaction buffer and 50 µl added to each 
well. 100 µl undiluted supernatant sample were added to DQ-elastin wells in duplicate. 100 µl 
1x reaction buffer or IMDM were added as negative control. 100 µl porcine pancreatic 
elastase, supplied with the kit, (PPE, 0.2 U/ml) was added as positive control. For all 
experiments, plates were incubated in the dark at room temperature and fluorescence 
measured at 485/535 nm by Victor 3 multilabel fluorescence plate reader (Perkin Elmer) at 
exactly 30 min. Background fluorescence in negative control wells was averaged and 
subtracted from each sample reading. 
2.2.4.2 Optimisation of the NE activity assay for murine neutrophils 
Supernatants were assessed for NE activity by Enzchek® elastase activity assay, exactly as 
described in section 2.2.4.1. Compatibility of the kit with murine NE was tested by the addition 
of the selective elastase inhibitor N-Methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone, 
10mg/ml in DMSO), using the protocol for determining NE inhibition exactly as described in 
section 2.2.4.1. Addition of the NE-selective inhibitor abrogated the NE response (Figure 
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2.10A), indicating that the Enzchek® kit was able to detect murine NE activity. In order to 
maximise NE release from murine neutrophils, several priming agonists were examined, with 
supernatants generated under normoxia only as cell numbers were limited. Cytochalasin B 
was the only priming agent to enable NE release from murine neutrophils substantially above 
baseline control (Figure 2.10A) so was used for all further experiments with these cells. As the 
intention of using murine neutrophils was to interrogate the contribution of PI3K signalling to 
the hypoxic uplift of NE release, the ability of hypoxia to affect NE release from cytochalasin 
B and fMLP-treated murine neutrophils was tested. Hypoxia increased NE release from 
cytochalasin B and fMLP-treated neutrophils (Figure 2.10B) although, as the NE activity was 
lower than that seen in human neutrophil supernatants, the assay plate was incubated 
overnight at 37ºC. This allowed optimisation of enzyme activity and, as the Enzchek® assay 
is continuous, kinetic data could be obtained at multiple timepoints. For subsequent 
experiments, a 20 h timepoint was chosen to take fluorescence readings. 
 
 
Figure 2.9: The effect of an NE-selective inhibitor on the detection of supernatant NE 
activity 
Human neutrophils were re-suspended in IMDM under normoxic or hypoxic (0.8% O2 and 5% 
CO2) conditions. Neutrophils (11.1*106/ml) were treated with PAF (1 μM, 5 min) and fMLP (100 
nM, 10 min), or IMDM control, in the presence or absence of NE-selective inhibitor N-
Methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone (10 mg/ml). Cells were pelleted and 
supernatant NE activity measured by Enzchek® assay. Results represent mean ± SEM, n=3; 





Figure 2.10:  The effect of priming agonists and an NE-selective inhibitor on the 
detection of murine supernatant NE activity 
Murine neutrophils were re-suspended in IMDM under normoxia or hypoxia. Neutrophils 
(18.5*106/ml) were treated with A: murine TNFα (10 ng/ml, 30 min), murine GM-CSF (10 ng/ml, 
30 min) or A&B: cytochalasin B (5 µg/ml, 5 min), and subsequently fMLP (10 µM, 10 min), or 
IMDM control, in the presence or absence of NE-selective inhibitor N-Methoxysuccinyl-Ala-
Ala-Pro-Val-chloromethyl ketone (10 mg/ml). Supernatant NE activity was measured by 
Enzchek® assay at 20 h. A: Results represent mean, n=1; B: Results represent mean ± SEM, 
n=2.  
2.2.4.3 Assessment of human NE release with PI3Kinase inhibition 
Freshly isolated neutrophils were re-suspended in normoxic or hypoxic IMDM at a 
concentration of 11.1*106/ml. Aliquots of 270 µl (3*106 neutrophils) were transferred to 2 ml 
Eppendorfs. In order to investigate the effects of inhibition of PI3K signalling on neutrophil 
function, PI3K inhibitors were added prior to incubation:  AS605240 (PI3Kγ-selective inhibitor, 
3 µM), IC87114 (PI3Kδ-selective inhibitor, 3 µM) or CAL-101 (PI3Kδ-selective inhibitor, 100 
nM). PI3K inhibitors were used at concentrations previously published (304) or at 
concentrations optimised in functional neutrophil assays in our laboratory to allow isoform 
selectivity. Cells were then incubated for 4 h under normoxia or hypoxia, and treated with PAF 
(1 µM, 5 min), and subsequently fMLP (100 nM, 10 min), or IMDM control. Supernatants were 
harvested and NE activity was quantified as described in section 2.2.4.1. 
2.2.4.4 Assessment of NE release from murine neutrophils with PI3Kinase mutations 
To further investigate the role of the PI3Kδ isoform in the hypoxic regulation of NE release, 
neutrophils were isolated from mice with an activating (E1020K) or kinase-dead (D910A) 
mutation of PI3Kδ (kindly provided by Professor Klaus Okkenhaug, Babraham Institute). To 
further investigate the role of the PI3Kγ isoform in the hypoxic regulation of NE release, 
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neutrophils were isolated from mice deficient in PI3Kγ (PI3Kγ-/-) (kindly provided by Dr Len 
Stephens, Babraham Institute).    
Femurs were obtained from E1020K heterozygote or D910A homozygote C57BL/6J mice, or 
PI3Kγ-/- C57BL/6 E129 mice, aged between 8-15 weeks. Each experiment was conducted 
alongside the appropriate strain-matched wildtype controls. Neutrophils were isolated from 
murine femoral bone marrow by negative immunomagnetic selection, exactly as described in 
section 2.2.1.2 and supernatants generated as described in section 2.2.1.3, treating cells with 
cytochalasin B (5 µg/ml, 5 min) and fMLP (10 µM, 10 min), conditions optimised previously 
(section 2.2.4.2). Cells were pelleted (13,000 rpm, 10 s, MSE Micro Centaur microfuge) and 
supernatants carefully harvested. Supernatants were assessed for NE activity by Enzchek® 
elastase activity assay, as described in section 2.2.4.1.  
2.2.4.5 Assessment of MPO release 
Supernatant MPO activity was quantified by measurement of the hydrogen peroxide (H202)-
dependent oxidation of o-dianisidine dihydrochloride (DMB) by MPO. Neutrophil supernatants 
were generated as described in section 2.2.1.3. In addition, to allow assessment of total 
cellular MPO content, 3*106 pelleted neutrophils were re-suspended in 200 µl PBS-/-, lysed 
with 3 µl Triton X-100 (10%), vortexed, and the resulting lysates harvested. To measure MPO 
activity, the following reagents were added to 50 µl of cell supernatants/lysates:  300 µl BSA 
(0.025% in PBS+/+), 250 µl PBS-/- (0.1 M, pH 6.2), 50 µl H202 (0.01% in dH2O) and 50 µl DMB 
(1.25 mg/ml in dH2O). Samples were incubated at 37ºC for 15 min before the addition of 50 µl 
sodium azide (0.1% in dH2O) on ice to stop the reaction. Duplicate 200 µl aliquots per sample 
were transferred to a 96 well plate and absorbance read immediately at 450 nm using a 
spectrophotometer (Biorad). MPO activity was expressed as % of total MPO from lysed cells. 
2.2.5 Protein detection methods 
2.2.5.1 Sample preparation for gel electrophoresis  
Samples for SDS polyacrylamide gel electrophoresis (SDS-PAGE) were prepared from 
neutrophil lysates or supernatants.  
Neutrophil lysate protein concentration was determined by Bio-Rad DC colorimetric protein 
assay (compatible with up to 10% SDS), which is based on the reaction of protein with an 
alkaline copper tartrate solution, and the subsequent reduction of Folin reagent. The reduced 
species, proportionate to the protein concentration in the sample, have a characteristic blue 
colour which can be measured by reading absorbance. 20 µl sample was added to 25 µl 
copper tartrate solution in a 96 well plate, and then incubated with 200 µl Folin reagent for 15 
min. Absorbance was measured at 595nm using a spectrophotometer (Biorad) and protein 
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concentration determined from a standard curve generated by known concentrations of BSA, 
enabling equal protein loading per well.  
Protein concentrations of supernatants were not determined prior to sample loading as the 
overall protein concentrations were low and it was expected that supernatants from hypoxic 
vs normoxic stimulated neutrophils would contain more protein due to enhanced 
degranulation. Also, there was no protein which was known to be consistent between normoxic 
and hypoxic conditions. Therefore, BSA (250 µg/ml) was added to each neat supernatant 
sample to allow correction for loading by Ponceau S staining following SDS-PAGE, with equal 
volumes from equal original cell numbers loaded onto gels.  
For some experiments, neutrophil supernatants were precipitated in 1.5 ml Eppendorfs with 
10% TCA on ice for 1 h. Samples were then centrifuged (20,000g,15 min) and supernatants 
carefully removed with a P1000 Gilson pipette. Samples were washed with ice-cold acetone 
and centrifuged (20,000g, 10 min). Supernatants were carefully removed, the pellets were re-
suspended in 20 μl 50 mM Tris-HCl, pH 8.4, and vortexed, and proteins were allowed to 
dissolve for 15 min. 
Reducing buffer (10 mM DTT, 250 mM Tris-HCl pH 6.8, 40% glycerol, 4% SDS, 0.02% 
bromophenol blue) was added to all lysate/supernatant samples (1:4). Samples were boiled 
with agitation (99ºC, 550 rpm, 10 min) and were then ready for SDS-PAGE. 
2.2.5.2 SDS-PAGE 
12 or 15% resolving gels and 4% stacking gels were cast with Protogel (30% (w/v) acrylamide: 
0.8% (w/v) bisacrylamide) and polymerisation was catalysed by the addition of 0.1% 
ammonium persulfate (APS) and 0.1% tetramethylethylenediamine (TEMED). After the 
resolving gel had set, 4% stacking gel was poured above, with the insertion of 10 or 15 well 
combs to create wells. SDS-PAGE was performed using the PROTEAN® II electrophoresis 
system. For some experiments, 12 well pre-cast 12% polyacrylamide gels were used using 
the XCell SurelockTM Mini-Cell electrophoresis system. 
Samples (prepared as described in section 2.2.5.1) were loaded into wells. Using the 
PROTEAN® II system, samples were run through the stacking gel (100 V, 15 min) and 
subsequently through the resolving gel (150 V, 1 h) in running buffer (25 mM Tris, 192 mM 
glycine, 0.1% SDS). When using the SurelockTM system, samples were run through the pre-
cast gel (180 V, 40 min) in NuPAGE® MES running buffer (50 mM Tris base, 1 mM EDTA, 
0.1% SDS,  50 mM 2-(N-morpholino)ethanesulfonic acid). One lane was used for molecular 
weight markers, according to the molecular weight of the protein studied or gel staining method 
to be used (either Precision Plus Protein™ Dual Color Standard or PagerulerTM Plus 
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Prestained Protein Ladder for western blot, or Mark12™ Unstained Standard for silver gels). 
Following electrophoresis gels were gently removed and either silver stained or proteins 
transferred to membranes for western blotting. 
2.2.5.3 Western blotting 
All steps were performed at room temperature unless otherwise stated. Gels were transferred 
onto methanol soaked polyvinylidene fluoride (PVDF) membranes (75 V, 2 h) in ice-cold 
transfer buffer (24 mM Trizma base, 193 mM glycine, 10% methanol) using the Trans-blot 
system. After transfer, PVDF membranes were placed on a shaker (30-40 rpm) and washed 
twice in PBS-Tween (PBS-/- with 0.1% Tween-20, PBS-T) for 1 min, taking care to keep 
membranes moist at all times. For supernatant samples with BSA added as a standard, 
membranes were stained with Ponceau S for 20 min, washed once with dH2O for 1 min and 
then scanned, which enabled correction for sample loading by analysis of BSA band 
densitometry (66.5 kDa). Subsequently, all membranes were blocked in 5% BSA (for 
subsequent probing with pAKT and AKT antibodies) or 5% milk (for subsequent probing with 
all other primary antibodies) in PBS-T (30-40 rpm, 1 h).  
After blocking, the primary antibody (see Table 2.1 for dilutions) was incubated with 
membranes in either 2.5% BSA (for pAKT and AKT) or 2.5% milk (for all other primary 
antibodies) overnight (30-40 rpm, 4ºC). The following day, membranes were washed thrice 
(PBS-T, 10 min) and then incubated with HRP-conjugated goat anti-rabbit secondary antibody 
(1:5000) in either 2.5% BSA or 2.5% milk (the same agent used for the primary antibody, 30-
40 rpm, 1h). After incubation, membranes were washed thrice (PBS-T, 10 min), removed from 
the shaker and covered with ECL (Enhanced Chemiluminescence detection reagents 1 and 2 
mixed 1:1) for 1 min to detect HRP-tagged proteins. Protein bands were detected by 
chemiluminescence, either by using a gel documentation (Gel Doc) automatic imaging system 
with GeneSys control software (Syngene, Cambridge, UK) or by exposure to auto radiographic 
film in the dark (1 s to 20 min exposure). For cell lysate samples, membranes were then 
incubated with stripping buffer (30-40 rpm, 15 min), re-blocked in 5% milk (30-40 rpm, 1 h) 
and probed for β actin (1:5000 in 2.5% milk, 30-40 rpm, 1 h) to confirm equal sample loading. 
Subsequent washes, secondary antibody probing and chemiluminescent detection was 
performed exactly as described above. Protein band densitometry analysis was performed 
using ImageJ software. Densitometry values for the protein of interest were obtained by 




2.2.5.4 Silver staining 
Following SDS-PAGE, gels were placed on a shaker (30-40 rpm) and washed twice (dH2O, 
10 min). Gels were then fixed (30% ethanol, 10% acetic acid, 30 min), washed thrice (30% 
ethanol, 10 min) and sensitized in thiosulphate solution (370 µg/ml in dH2O, 1 min). Gels were 
washed twice (dH2O, 1 min) and silver stained (0.2% silver nitrate, 0.03% formaldehyde, 30 
min) before washing once (dH2O, 1 min). Gels were developed until protein bands were visible 
(6% sodium carbonate decahydrate, 5 µg/ml thiosulphate solution, 0.02% formaldehyde) and 
the reaction terminated with the addition of 10% acetic acid. Finally, gels were washed in dH2O 
to remove background and scanned. 
2.3 Endothelial Cells 
2.3.1 Endothelial cell culture 
Primary human pulmonary arterial endothelial cells (HPAECs, Lonza) were used to investigate 
the potentially damaging effects of hypoxic neutrophils. Cell stocks were checked periodically 
for mycoplasma. Cell culture was conducted under sterile conditions in a laminar flow cell 
culture hood (Microflow Class II cabinet). All endothelial centrifugation was undertaken using 
a 5810R centrifuge (Eppendorf, Hamburg, Germany).  
HPAECs were cultured in 75 cm2 sterile cell culture flasks (T75) in EGM-2 medium with 0.1% 
gentamicin/amphotericin B and 10% foetal calf serum (FCS). Cell aliquots of 1*106 cells were 
removed from liquid nitrogen storage, defrosted and added to a flask with 15 ml EGM-2 
medium supplemented with 10% FCS. After 24 h the medium was replaced to remove any 
DMSO present in the freezing solution. Cells were visually checked daily for signs of infection 
and medium was replaced every 48 h. Once cell monolayers had reached confluence, the 
medium was aspirated and the cell layer washed with 5 ml sterile PBS. 4 ml 1x trypsin was 
added to the flask and incubated at 37ºC for 3-5 min. Subsequently, flasks were gently tapped, 
and trypsinised cells viewed under an inverted microscope to ensure they had detached. 8 ml 
FCS-containing media were added to quench the trypsin reaction. Re-suspended cells were 
then transferred to a sterile 50 ml polypropylene Falcon tube and two 10 µl aliquots removed 
in order to count cells on a haemocytometer. Cells were centrifuged at 300g, acceleration 9, 
brake 9 for 5 min and the supernatant discarded. Pelleted cells were gently re-suspended and 
either transferred to sterile tissue culture plates for experiments, seeded into a new T75 flask 
in EGM-2 with 10% FCS to continue passaging, or frozen in freezing media (2*106 cells/ml) 




2.3.2 Endothelial cell functional assays 
2.3.2.1 Assessment of endothelial ICAM-1 expression by flow cytometry 
To assess the capacity of neutrophil supernatants to alter endothelial-leukocyte adhesion 
molecule expression, HPAEC expression of ICAM-1, which mediates firm adhesion of 
neutrophils to endothelial cells, was measured by flow cytometry. HPAECs were used at 
passage 10-12 to ensure consistency. 100,000 cells in 1 ml EGM-2 medium supplemented 
with 10% FCS were added to required wells of a sterile 12 well plate and grown to confluence 
(24-48 h) in either normoxia or hypoxia (0.8% O2). Once cell monolayers were confluent, 
media was aspirated and 1 ml supernatants from normoxic vs hypoxic, PAF&fMLP-treated vs 
control neutrophils, were added to required wells in the presence of 2% human autologous 
serum. The presence of serum is required to allow upregulation of ICAM-1 in this in vitro 
system (personal communication, Dr Sarah Appleby). HPAECs were incubated with neutrophil 
supernatants at 37ºC under normoxia or hypoxia for 24 h. 
After 24 h incubation, HPAECs were washed briefly in PBS-/- and 1x trypsin added. Cells were 
incubated for 5 min at 37ºC under normoxia or hypoxia as before. After incubation, the plate 
was gently tapped and the trypsin reaction quenched by addition of twice volume neutralising 
EGM-2 with 10% FCS. Cells were collected by gently pipetting up and down, and transferred 
to a 96 well plate. Cells were pelleted by centrifugation at 400g, acceleration 9, brake 9, 5 min 
(necessitating removal from hypoxia to access the centrifuge). Media was subsequently 
discarded and cells immediately fixed (1% paraformaldehyde (PFA) in PBS-/-, 10 min). After 
fixing, cells were washed in PBS-/- by centrifugation at 400g, acceleration 9, brake 9 for 5 min 
and then re-suspended in blocking buffer (5% FBS in 0.5% PBS-BSA, 10 min, 4ºC). Cells 
were stained with APC-anti-CD54 (anti-ICAM-1, Table 2.1), isotype control or PBS-/- 
(unstained). The plate was incubated for 30 min in the dark at 4ºC. After incubation, cells were 
washed in PBS-/- by centrifugation at 400g, acceleration 9, brake 9 for 5 min. Supernatants 
were discarded, pelleted cells re-suspended in staining buffer (0.09% sodium azide in 1% 
FCS-PBS) and stored in the dark at 4ºC until flow cytometric analysis was carried out.  
ICAM-1 expression was measured by flow cytometry (BD FACSCanto II) using the red (633 
nm excitation; 660/20 filter) laser. Cells were gated on singlet HPAECs, and change in MFI 
was measured. APC-stained ICAM-1 positive cells, identified by comparison with the gated 
isotype control population, were expressed as % of the total singlet HPAEC population. 




2.3.3 Endothelial cell viability assays 
2.3.3.1 Assessment of cell detachment by immunofluorescence 
To assess the ability of neutrophil supernatants to cause endothelial cell detachment, HPAECs 
were stained with rhodamine-phalloidin (binds F-actin) and DAPI (4',6-diamidine-2'-
phenylindole dihydrochloride: stains DNA in the nucleus). HPAECs were used at passage 10-
12 for consistency. 30,000 cells in 200 µl EGM-2 with 10% FCS were added to required wells 
of a sterile 96 well optical plate and grown to confluence (24 h). In order to be able to assess 
protease-mediated damage and the potential for rescue by α1AT, this experiment was 
conducted in serum-free conditions as serum contains multiple anti-proteases. Hence, 
neutrophil supernatants were diluted in endothelial specific media to prevent damage due to 
lack of growth factors over a 24 h incubation period. 100 µl supernatants from normoxic vs 
hypoxic, PAF&fMLP-treated vs control neutrophils were incubated in the presence or absence 
of α1AT (46 µg/ml, 10 min) and diluted 1:1 in serum-free EGM-2. Media was aspirated from 
HPAECs and 200 µl neutrophil supernatants (prepared as above) were added to wells in 
duplicate and the plate incubated at 37ºC. After 24 h the samples/media were aspirated and 
cells fixed in 3.5% PFA in PBS-/- (20 min). Cells were washed briefly thrice in PBS-/- and 
permeabilised in 0.5% Triton X-100 in PBS+/+ (10 min).  Cells were washed thrice in PBS-/- 
and non-specific staining was blocked by 0.5% BSA-PBS (30 min). Cells were washed thrice 
in PBS-/- and cells incubated with rhodamine phalloidin (1:200 in 0.1% BSA-PBS, 30 min). 
Cells were washed thrice with PBS-/- and mounted in ProLong Gold antifade reagent with 
DAPI. Plates were kept in the dark at 4ºC until imaging with a Leica Sp5 confocal microscope. 
Three random fields of view were imaged in a central position for duplicate wells. Cell 
detachment was quantified with Image J and expressed as % detachment of whole field of 
view.   
2.3.3.2 Assessment of cell viability by MTT assay 
The MTT toxicity assay allows the spectrophotometric quantification of cell viability. The 
tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is reduced 
to purple formazan by NADPH-dependent oxidoreductase enzymes in living but not dead cells.  
HPAECs were used at passage 10-12 for consistency. For the same reasons as above, this 
experiment was conducted in serum-free conditions with neutrophil supernatants diluted in 
EGM-2 media. 30,000 cells in 200 µl EGM-2 with 10% FCS were added to required wells of a 
sterile 96 well plate and grown to confluence (24 h). 100 µl supernatants from normoxic vs 
hypoxic, PAF&fMLP-treated vs control neutrophils were incubated in the presence or absence 
of α1AT (46 µg/ml, 10 min) and diluted 1:1 in serum-free EGM-2. Media was aspirated from 
HPAECs and 200 µl neutrophil supernatants/EGM-2 were added to wells in duplicate. EGM-
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2/IMDM (1:1), EGM-2 alone, or IMDM alone were added to control wells and the plate 
incubated at 37ºC. 
After 24 or 48 h, samples/media were aspirated and 100 µl MTT (500 µg/ml in IMDM) per well 
added for 2 h. Subsequently, the MTT solution was aspirated and purple formazan crystals 
were dissolved in 100 µl isopropanol. Absorbance was read immediately at 550 nm using a 
spectrophotometer (Biorad), correlating directly with the number of viable cells per well. 
2.3.3.3 Assessment of apoptosis by flow cytometry 
The ability of neutrophil supernatants to cause endothelial cell apoptosis was measured by 
flow cytometric analysis of AnV and PI staining. For this experiment, HPAECs were used at 
passage 7 as the previous endothelial cell stocks had been exhausted and Promocell media 
was used instead of EGM-2 as stocks from Lonza were unavailable due to manufacturing 
issues.  100,000 cells in 1 ml Promocell media with 5% FCS were added to required wells of 
a sterile 12 well plate and grown to confluence. As this assay is very sensitive, conditions were 
optimised to avoid induction of apoptosis by cell manipulation: cells were quiesced overnight 
to synchronise the cell cycle, thereby removing variability which might arise from growth 
signalling in different cell cycle phases, and TrypLE select enzyme was used to detach cells 
as it is reported to be more gentle than trypsin (personal communication, Dr Andrew Cowburn). 
Prior to treatment, HPAEC were quiesced overnight in media containing antibiotics and 0.1% 
FCS but no growth factors. Media was aspirated from HPAECs and 800 µl supernatants from 
normoxic vs hypoxic, PAF&fMLP-treated vs control neutrophils were added to wells. 
Promocell media alone (where the majority of cells were expected to be viable) or Promocell 
media with TNFα (10 ng/ml) and cycloheximide (20 µg/ml, CHX) (where the majority of cells 
were expected to be apoptotic) were added to control wells and the plate incubated at 37ºC 
for 6 h. After treatment, supernatants/media were removed into sterile 50 ml Falcon tubes and 
cells in the 12 well plate were detached with 1x TrypLE select enzyme before adding to the 
corresponding Falcon. Wells were washed with Promocell media and added to corresponding 
Falcons. Cells were pelleted by centrifugation (300g, 5 min), media aspirated and cells re-
suspended in 1x binding buffer supplied with the annexin V-FITC apoptosis detection kit (1*106 
cells/ml). 50 µl cells from each sample were transferred into a separate well to be used for 
compensation. 100 µl sample was stained with FITC-AnV (1:20) and PI (1:20) for 15 min in 
the dark before quenching with 200 µl 1x binding buffer. FITC-AnV or PI single stained, and 
unstained cells were used for baseline and compensation. Flow cytometry (BD LSRFortessa) 
was performed using the blue (488 nm excitation; 530/30 filter) and yellow (561 nm excitation; 






Figure 2.11: Gating strategy for assessment of HPAEC apoptosis by flow cytometry: 
baseline and compensation 
HPAEC were incubated for 6 h with either supernatants from normoxic vs hypoxic, PAF/fMLP-
treated vs unstimulated neutrophils, Promocell media alone, or Promocell media containing 
TNFα (10 ng/ml) and CHX (20 µg/ml). Mixed HPAEC from all conditions were A: unstained or 
B: single stained with FITC-AnV. HPAEC treated with C: Promocell media alone or D: 
Promocell media with TNFα and CHX were stained with FITC-AnV and PI. Staining was 
assessed by flow cytometry (BD LSRFortessa). A-D:  Representative flow plots of FITC-AnV 
(y axis) and PI (x axis) staining. A&B: unstained and single-stained cells were used to set 
gates. Using this gating strategy, the majority of cells treated with Promocell media alone (C) 
were AnV-/PI- (viable) and the majority of cells treated with Promocell media containing TNFα 







Figure 2.12: Gating strategy for assessment of HPAEC apoptosis by flow cytometry: 
supernatant treatment 
HPAEC were incubated with supernatants from normoxic (A&C) or hypoxic (B&D) neutrophils 
treated with PAF (1 µM) and fMLP (100 nM, C&D) or IMDM control (A&B). After 6 h, HPAEC 
were stained with FITC-AnV and PI and apoptosis assessed by flow cytometry (BD 
LSRFortessa). A-D:  Representative flow plots of FITC-AnV (y axis) and PI (x axis) staining. 
Q1 shows AnV+/PI- (apoptotic) cells, Q2 shows AnV+/PI+ (late apoptotic/necrotic) cells, Q3 
shows AnV-/PI+ (necrotic) cells (though most necrotic cells are AnV+), Q4 shows AnV-/PI- 




2.4.1 Generation of neutrophil supernatants for proteomics 
In order to perform a screen of the proteins released by normoxic vs hypoxic neutrophils, 
supernatants were generated to quantitatively compare the normoxic vs hypoxic proteomes. 
Neutrophil supernatants contain several active proteases with the ability to cleave other 
proteins present in the sample. Hence, I carefully and thoroughly optimised the anti-protease 
strategy to ensure that the supernatants contained sufficient protein for proteomic analysis 
and that other proteins of interest were not degraded within this experimental system. Previous 
studies employing proteomic approaches to examine neutrophil supernatants have either 
used no (documented) protease inhibitors (305,306), EGTA alone (307,308), or a combination 
of leupeptin, 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF), pepstatin A 
and EDTA (309). As my anti-protease protocol is therefore completely novel, this optimisation 
is described in section 4.3 of the results. The final optimised methodology, used to prepare 
samples for 10-plex TMT-MS, is described here.  
Freshly isolated neutrophils were re-suspended at a concentration of 11.1*106/ml in normoxic 
or hypoxic IMDM containing either a combination of EDTA (1 mM) and the NE-selective 
inhibitor sivelestat (10 µM), or no protease inhibitors (in order to be able to test supernatant 
NE activity in parallel). Aliquots of 270 µl (3*106 neutrophils) were transferred to 2 ml 
Eppendorfs and incubated under normoxia or hypoxia in a thermomixer (37ºC, 450 rpm) for 4 
h. Cells were then treated with PAF (1 µM, 5 min) and subsequently fMLP (100 nM, 10 min), 
or IMDM control, with a final reaction volume of 1 ml. Both PAF and fMLP were diluted in 
IMDM with or without protease inhibitors (EDTA and sivelestat), as indicated by the previous 
incubation, to ensure that final concentrations of the inhibitors were constant throughout. Cells 
were pelleted (13,000 rpm, 10 s, MSE Micro Centaur microfuge) and the supernatants 
carefully harvested.  
2.4.2 Two dimensional difference gel electrophoresis 
Two dimensional difference gel electrophoresis (2D DIGE) was performed as a pilot 
experiment to inform plans for mass spectrometry. This technique separates proteins in the 
first dimension by pH, using isoelectric focusing (IEF), and subsequently in the second 
dimension by molecular weight, using SDS-PAGE. Gel fluorescence imaging allows detection 
of changes in protein abundance between fluorescently-labelled samples.  
Supernatants from normoxic vs hypoxic PAF and fMLP-treated neutrophils were generated as 
described in section 2.4.1, although for this experiment all cells were re-suspended in IMDM 
containing the protease inhibitors EDTA (2 mM), EGTA (2 mM), sivelestat (1 µM) and AEBSF 
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(1 mM), and inhibitors were also added at the specified concentrations after 2 h and 4 h 
incubation. AEBSF was omitted in later experiments as it was found to induce cell death (see 
section 4.3, Figure 4.5). Samples were precipitated overnight with 5x volume ammonium 
acetate (0.1 M in 100% methanol, -80ºC) as TCA-precipitation was not compatible with 2D 
DIGE. Following precipitation, samples were transferred to 1.5 ml Eppendorfs, centrifuged 
(20,000g, 10 min, room temperature) and the supernatant discarded. Pellets were washed 
twice with 80% 0.1 M ammonium acetate (20,000g, 2 min) and then washed once with acetone 
(20,000g, 2 min). The supernatant was discarded and the pellets air-dried for 5 min. Protein 
pellets were re-suspended in urea buffer (6 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonate (CHAPS), 5 mM magnesium acetate, 10 mM Tris pH 
8.5). Pellets from 24 technical replicates per condition were combined to ensure sufficient 
protein for labelling. Samples are described in this section as “normoxia activated” or “hypoxia 
activated”, referring to oxygenation status and PAF/fMLP-treatment of the cells. 
2D DIGE was performed by Renata Feret (Gel Analysis Technician, Cambridge Centre for 
Proteomics (CCP)). The protein content of each sample was quantified by Quick Start™ 
Bradford Protein Assay, which is compatible with the urea buffer. Equal amounts (20 µg) of 
both samples were labelled with cyanine fluorescent dyes as any disparity in protein amount 
between samples may result in less abundant proteins not being labelled. “Normoxia 
activated” was labelled with Cy5 (250 pM/µl), and “hypoxia activated” with Cy3 (250 pM/µl) for 
30 min in the dark before the reaction was quenched with lysine (10 mM) for 10 min in the 
dark. Both samples were combined and sample buffer (8 M urea, 4% CHAPS, 2% DTT, 2% 
immobilised pH gradient (IPG) buffer [pH 3-10 non linear (NL)]) added for 15 min in the dark. 
For IEF, the combined sample was applied to a rehydration tray in rehydration solution (8 M 
urea, 4% CHAPS, 0.2% DTT, 1% IPG buffer [pH 3-10 NL], 0.002% bromophenol blue) and 
the IEF gel strip (Immobiline™ Drystrip pH 3-10 NL, 24 cm) placed on top to absorb the 
sample. The strip was covered in mineral oil overnight to prevent drying. The following day, 
the strip was then placed in a PROTEAN® i12™ IEF system with running parameters as 
follows:  50 V, 12 h; 500 V 1 h; 1000 V 1 h; 8000 V, 6 h. Following IEF, the strip was removed, 
incubated with reducing equilibration buffer (6 M urea, 75 mM Tris pH 8.8, 30% glycerol, 2% 
SDS, 1% DTT) for 15 min and then incubated with alkylating equilibration buffer (6 M urea, 75 
mM Tris pH 8.8, 30% glycerol, 2% SDS, 2.5% iodoacetamide) for 15 min, before being 
subjected to SDS-PAGE using a 600 Ruby Standard Dual-Cooled Vertical Gel Unit with 
running parameters as follows:  20 mA, 15 min; 40 mA until samples reach the bottom of the 
gel. The gel was removed and scanned with a Typhoon 9400 Variable Mode Imager. 
Fluorescence parameters were: Cy5 (normoxia activated) 633 nm laser excitation (red), 670 
nm emission; Cy3 (hypoxia activated) 532 nm laser excitation (green), 580 nm emission. 
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Scanned images were processed for optimal pixel intensity (ImageQuant TL software, GE 
Healthcare) and analysed with DeCyder 2D software (version 5.2, GE Healthcare). The 
Differential In-gel Analysis (DIA) module allows protein spot detection and quantitiation of 
images produced from the same gel. Protein spots were automatically detected by the 
software and manually checked for appearance and correct matching. The fold change 
threshold between spots, i.e. the magnitude of the spot volume ratio between the two gels, 
was set at 2.0. Figure 2.13 shows an example of manual spot selection where a protein is 
present in only one image.  
 
Figure 2.13: 2D DIGE analysis by Decyder 2D DIA software  
Cy3 and Cy5 fluorescent images from the scanned 2D DIGE were analysed by Decyder 2D 
DIA. Protein spots were automatically selected by the software, indicated by green 
(unchanged), blue (increased) or red (decreased) boundaries. The protein spot selected 
(yellow) is shown below the gel as a localised three-dimensional representation. Here, a peak 
at the selected spot is present in the left-hand side gel (Cy3, hypoxia activated) but not in the 




2.4.3 10-plex tandem mass tag-labelled mass spectrometry  
Based on the results of 2D DIGE, which showed a number of obvious changes in protein 
abundance between normoxia and hypoxia activated samples, I proceeded to 10-plex tandem 
mass tag (TMT)-labelled mass spectrometry (MS), which enables protein identification and 
quantification. In this process up to ten protein samples can be labelled with different isotopic 
mass tags. These tags have an identical chemical structure and nominal mass but a variable 
substituted isotope, which allows quantitative data to be obtained: the peptide fragmentation 
process generates mass reporter ions with a mono-isotopic mass difference from the cleaved 
tags, and each tag is unique for one labelled sample, therefore allowing quantification of 
relative protein expression (310). 
Prior to performing the planned TMT-labelled MS experiment for n=10 samples, I undertook a 
pilot experiment to inform the feasibility of TMT-labelling. One supernatant from hypoxic PAF 
and fMLP-treated neutrophils was generated in the presence of EDTA and sivelestat, exactly 
as described in section 2.4.1, and TCA-precipitated, exactly as described in section 2.2.5.1. 
Sample processing was performed by Renata Feret (CCP). Protein content was quantified by 
Pierce™ 660nm protein assay, which is compatible with phenol red (present in IMDM media) 
up to 0.5 mg/ml. The total sample (4.7 µg) was reduced with the addition of tris-(2-
carboxyethyl)phosphine (TCEP, 10 mM, 1 h, 55ºC). Free cysteine residues were alkylated 
with iodoacetamide (17 mM) for 30 min in the dark before samples were precipitated overnight 
with acetone (600 µl, -20ºC). Following precipitation, the sample was centrifuged (8000g, 10 
min, 4ºC) and the supernatant carefully discarded. The protein pellet was re-suspended in 
triethyl ammonium bicarbonate (TEAB, 50 mM) and digested into peptides overnight with MS-
grade trypsin (2.5 µg, 37ºC). The peptide sample was then reduced to dryness with a vacuum 
concentrator and subjected to unlabelled MS/MS (120 min), performed by Dr Mike Deery 
(Proteomics Facility Manager, CCP). MS data were analysed by Dr Marco Chiapello 
(Research Data Technician, CCP). Raw data were searched against UniProt Human 
reference proteome (Proteome ID: UP000005640) using Mascot 2.6 (Matrix Science) and 
Proteome Discoverer™ version 2.1 (ThermoFisher Scientific). Due to the relatively low 
complexity of the sample, with a total of 561 proteins identified, TMT-labelling was thought to 
be achievable with a minimum of 25 µg protein per sample.  
Whole blood was collected from n=5 healthy volunteers in order to prepare ten samples for 
10-plex TMT-labelled MS (normoxia and hypoxia activated from each donor). Following 
experiments to optimise the protease inhibitor strategy and other conditions (section 4.3), 
supernatants from normoxic vs hypoxic PAF and fMLP-treated neutrophils were generated 
exactly as described in section 2.4.1. Supernatants from 23 replicates per condition per donor 
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were pooled in order to generate sufficient protein for TMT-labelling. For each experiment, 
one replicate was incubated without protease inhibitors and assessed for NE release by 
Enzchek® assay to ensure a hypoxic uplift of NE release. Supernatants from the remaining 
23 replicates per condition were combined for each donor. As protein precipitation (see section 
4.3) was found to lead to inaccurate/variable protein recovery, protein concentration Vivaspin 
columns were used. The pooled supernatant sample was applied to the top chamber of the 
spin column, after which centrifugation forced the solvent through a semi-permeable 
membrane into a lower chamber, leaving the concentrated protein sample in the upper 
chamber. Pooled samples were sequentially centrifuged (4000g, 4ºC) through 2 ml spin 
columns with a molecular weight cut-off of 3 kDa. Each sample was buffer exchanged with 50 
mM Tris, pH 8.4 (1:1 sample:buffer). Once the total buffer-exchanged 23 ml sample had been 
centrifuged through the spin column, the concentrated protein was re-suspended in 100 µl 
buffer (50 mM Tris, pH 8.4). 
Samples were then processed by Renata Feret (CCP). Protein content was quantified by 
Pierce™ 660nm protein assay. To ensure equal labelling, 27.68 µg (the amount of the least 
abundant sample) of each sample was prepared for labelling with TMT-10-plex isobaric label 
reagents. Samples were adjusted to 100 µl in dissolution buffer (100 mM TEAB) and then 
reduced, alkylated, precipitated and trypsin-digested exactly as described above for the pilot 
experiment. Following digestion, each of the ten peptide samples was labelled with a unique 
10-plex isobaric tag (4 µl, 1 h) as follows: normoxia (N) donor 1, tag 130N; hypoxia (H) donor 
1, tag 126; N2, tag 127C; H2, tag 131; N3, tag 129C; H3, tag 128N; N4, tag 129N; H4, tag 
130C; N5, tag 128C; H5, tag 127N. Labelling was quenched with 5% hydroxylamine for 15 
min and the samples were then combined and reduced to dryness with a vacuum 
concentrator. In order to remove the salts and buffers used during preparation, which may 
interfere with ionisation, the dried sample was subjected to C18 solid-phase extraction using 
Sep-Pak cartridges, eluting with 75% acetonitrile/0.5% acetic acid, before further vacuum 
concentration to dryness. Given the relatively low number of proteins per sample (as assessed 
by previous gel electrophoresis and the pilot unlabelled MS/MS), fractionation was not 
performed. 
MS/MS was performed by Dr Mike Deery (CCP) using an Orbitrap Fusion™ Lumos™ Tribrid™ 
mass spectrometer (ThermoFisher Scientific). MS data were analysed by Dr Marco Chiapello 
(CCP). TMT-MS and data analysis methods and parameters were provided by CCP, and are 




2.4.4 Quantification of supernatant resistin, NGAL, cyclophilin A, S100A9, 
S100A8 and S100A8/A9 by ELISA 
Resistin, NGAL, cyclophilin A, S100A9 homodimer, S100A8 homodimer, and S100A8/A9 
heterodimer content of supernatants from normoxic vs hypoxic PAF&fMLP-treated neutrophils 
were quantified by commercial sandwich-based ELISA with pre-coated plates. Preliminary 
experiments determined the appropriate dilutions to ensure readings fell within the standard 
curve. To serve as an example method, the protocol for resistin will be detailed. All steps were 
undertaken at room temperature. The supplied plate was pre-coated with anti-human resistin 
capture antibody; samples (100 μl, 1:10 dilution in assay diluent supplied with the kit) and 
standards (1.4-400 pg/ml, diluted in assay diluent supplied with the kit) were incubated in a 
96-well plate for 2.5 h with gentle shaking. Wells were then washed four times (wash buffer 
supplied with kit), and incubated with biotinylated resistin detection antibody (100 μl) for 1 h. 
After four washes, HRP-conjugated streptavidin (100 μl), which binds biotin with high affinity, 
was added for 45 min. After four washes, 3,3’,5,5’-tetramethylbenzidine (TMB) substrate 
solution (100 μl) was added and the plate incubated for 30 min in the dark. Wells containing 
resistin turned blue with a colour intensity proportional to the resistin concentration in the 
original sample. The reaction was terminated by the addition of a stop solution, which turned 
the blue wells yellow, and the absorbance at 450 nm immediately measured with a 
spectrophotometer. A standard curve was generated by plotting absorbance against the 
corresponding concentrations of human resistin standard. The concentration of resistin 
present in the samples (which were run in duplicate concurrently with the standards) was 
determined from the standard curve by interpolation. ELISAs for NGAL, cyclophilin A, S100A8 
homodimer, S100A9 homodimer and S100A8/A9 heterodimer were all based on the same 
sandwich principle and steps (similar to those described above) were conducted exactly as 
per manufacturers’ instructions. 
2.5 Microvesicles 
2.5.1 Microvesicle isolation from Histopaque®-1077-prepared neutrophils 
The study of NDMVs is challenging and requires dedicated detection systems that were not 
readily available in the University of Cambridge Department of Medicine. Hence, I collaborated 
with Dr Victoria Ridger (Senior Lecturer in Vascular Biology, University of Sheffield), who has 
considerable expertise in MV isolation and detection techniques (311), and an established 
protocol for NDMV isolation currently ongoing in her laboratory (276). Previous optimisation of 
this protocol has shown that optimal NDMV yield was obtained from neutrophils isolated by 
Histopaque®-1077 gradients. Therefore, as preliminary experiments attempting to isolate 
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NDMVs from plasma-Percoll®-isolated neutrophils had produced low numbers, I employed 
the Histopaque®-1077 neutrophil isolation method in order to maximise NDMV yield. 
NDMV isolation experiments were performed at the University of Sheffield. Ethical permission 
for taking peripheral blood from healthy volunteers (REC reference SMBRER310) was 
obtained from the Sheffield Research Ethics Committee. All equipment and reagents were 
sterile, and all reagents used at room temperature unless otherwise stated. The isolation was 
conducted under sterile conditions in a laminar flow cell culture hood (Microflow Class II 
cabinet). All neutrophil centrifugation was undertaken using a 5810R centrifuge (Eppendorf, 
Hamburg, Germany). 
For neutrophil isolation from whole blood by Histopaque®-1077 gradients, blood was collected 
from healthy donors into polypropylene tubes containing 3.8% sodium citrate, as described in 
section 2.2. Whole blood was centrifuged at 260g, acceleration 5, brake 0 for 20 min. The 
PRP supernatant was aspirated and discarded. The cell pellet, containing WBC and RBC, was 
sedimented with dextran to remove RBC: 6 ml 6% dextran was added, made up to 50 ml total 
volume with sterile 0.9% NaCl and mixed gently. RBC were sedimented for 20-40 min until 
the RBC pellet reached its original (post centrifugation) volume. After sedimentation, the WBC-
containing top layer was aspirated into a new 50 ml tube, made up to 35 ml with sterile saline 
and very gently overlaid onto 16 ml Histopaque®-1077 (density 1.077 g/ml) using a 10 ml 
stripette with the pipette controller set to the lowest speed. The WBC/Histopaque®-1077 
gradient was centrifuged at 400g, acceleration 5, brake 0 for 25 min. After centrifugation the 
supernatant, containing PBMCs, was aspirated and discarded. The pellet, containing 
granulocytes and red blood cells, was subjected to RBC lysis: the pellet was gently re-
suspended, made up to 20 ml with 0.2% NaCl solution, mixed gently for 30 s, made up to 50 
ml with 1.6% NaCl solution and inverted once. Following RBC lysis, the cells were centrifuged 
at 250g, acceleration 5, break 3 for 7 min. The supernatant was discarded and the neutrophil-
rich cell pellet gently re-suspended. Cells were washed in 50 ml PBS-/- by centrifuging at 
250g, acceleration 5, break 3 for 7 min. Prior to centrifugation,100 µl were removed by P200 
Gilson using a cell saver pipette tip to make the purity slide cytospin. 20 µl were removed for 
haemocytometer cell count. The cells were then washed in 50 ml PBS+/+ by centrifuging at 
250g, acceleration 5, break 3 for 7 min. The supernatant was discarded and the cell pellet 
gently re-suspended to be used in further experiments. 
To isolate NDMVs, fresh Histopaque®-1077-prepared neutrophils and, for comparison, 
plasma-Percoll®-prepared neutrophils (isolated concurrently from the same donor in exactly 
the same manner) were re-suspended in normoxic or hypoxic IMDM at a concentration of 
1*107/ml. Aliquots of 1 ml (1*107 neutrophils) were transferred to 2 ml Eppendorfs and 
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incubated under normoxia or hypoxia in a thermomixer (37ºC, 450 rpm) for 4 h. As it was 
otherwise difficult to obtain sufficient NDMVs for quantification, the standard neutrophil 
treatment condition used in the Ridger laboratory (10 μM fMLP, 1 h) was adopted. Hence, 
after 3 h normoxic or hypoxic incubation, neutrophils were treated with fMLP (10 µM, 1 h), or 
IMDM as control. After treatment, samples were centrifuged at 500g, 4ºC for 5 min to pellet 
cells. Cell pellets were discarded. Cell-free supernatants were harvested and further 
centrifuged at 500g, 4ºC for 5 min. Any remaining pellets were discarded and supernatants 
were carefully harvested and centrifuged at 20,000g, 4ºC for 30 min to pellet MVs. MV-free 
supernatants were harvested, and both supernatants and MV pellets were either used straight 
away or stored at -20ºC for future experiments (as storage at -20ºC has been shown by the 
Ridger group not to have a detrimental effect on NDMV integrity).  
2.5.2 Quantification of neutrophil-derived microvesicles by flow cytometry 
Quantification of isolated NDMVs by flow cytometry was undertaken at the University of 
Sheffield with the assistance of Merete Long (PhD Student, Laboratory of Dr Ridger, University 
of Sheffield). MV pellets were re-suspended in 190 µl sterile filtered PBS-/- with 10 µl (10,000) 
counting beads (SPHERO™ Accucount blank particles 2.0-2.4µm, 1*106/ml). Flow cytometry 
was performed (BD LSRFortessa) using an established protocol and gating strategy: the 
NDMV analysis region was standardised using Megamix beads, a mix of fluorescent beads of 
varied diameters (0.5, 1 and 3 µm), which allowed the MV collection gate to be set (Figure 
2.14A). This gate was used for all NDMV experiments and is regularly calibrated. The addition 
of counting beads to the samples allowed quantification of NDMVs (Figure 2.14B). The 
stopping gate was set to count 1,000 beads (i.e. one tenth of the total beads in the sample). 
The number of NDMVs counted by flow cytometry was multiplied by 10 to give the total number 
of  MVs in the pellet (i.e. the number of NDMVs produced by 107 neutrophils).  
2.5.3 Preparation of microvesicle lysates for western blotting 
NDMV pellets were transferred from -20ºC storage to dry ice, and 25 µl lysis buffer added (250 
mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS and one cOmplete™ mini EDTA-free protease 
inhibitor cocktail tablet, 1 tablet/4 ml buffer). Samples were warmed, vortexed (30 s), boiled 
with agitation (99ºC, 550 rpm, 10 min) and returned to dry ice. Reducing buffer (10 mM DTT, 
100 mM Tris-HCl pH 6.8, 40% glycerol, 4% SDS, 0.02% bromophenol blue) was added to re-
warmed samples (1:4), which were subsequently boiled with agitation (99ºC, 550 rpm, 10 min). 
SDS-PAGE was performed exactly as described in section 2.2.5.2 and western blotting 
performed exactly as described in section 2.2.5.3, with the antibodies noted in Table 2.1. For 
some experiments TCA-precipitated (see section 2.2.5.1) MV-free neutrophil supernatants 





Figure 2.14: Gating strategy for isolated NDMV quantification by flow cytometry 
MVs isolated from fMLP (10 μM)-treated normoxic vs hypoxic neutrophils were quantified by 
flow cytometry (BD LSRFortessa). A: Representative flow cytometry plots indicating the 
NDMV gate set by Megamix size beads of 0.5, 1 and 3 μm. B: Representative flow cytometry 
plots showing gates for isolated NDMVs and counting beads  
 
2.6 COPD study 
2.6.1 COPD patient recruitment 
Ethical approval for this study, involving identifying and taking blood from COPD patients 
during exacerbations, had already been obtained from the Cambridge Local Research Ethics 
Committee (REC reference 08/H0308/281) and was not designed specifically for this study. 
Patients were recruited from an existing ongoing cohort. Exacerbating COPD patients were 
recruited from Cambridge University Hospitals NHS Foundation Trust (Addenbrooke’s 
Hospital) by myself, using electronic patient medical records (Epic software). Inclusion criteria 
were: age < 80 years, a physician diagnosis of COPD, a minimum of 10 pack-years smoking 
history, and a current diagnosis of an exacerbation of COPD (infective or non-infective) by the 
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admitting medical team. Exclusion criteria were: concurrent non-respiratory infection, 
immunodeficiency, anaemia at the time of blood sampling, untreated malignancy, current 
smoker > 5 cigarettes per day, long term oral corticosteroid use, and consolidation on the 
admission chest radiograph. Pragmatically, the decision was taken to include patients who 
had started treatment with antibiotics or oral corticosteroids as initial attempts to exclude such 
patients resulted in very low recruitment. Following recruitment, blood was drawn within 24 h 
of admission. Peripheral venous blood was taken from all patients to obtain plasma (9 ml) and 
serum (4.9 ml), as described in section 2.6.2. From a subset of patients, 40 ml blood was also 
taken for neutrophil isolation, as described in section 2.2. Demographic and clinical data were 
collected (Table 5.1). Age- (within 10 years) and sex-matched healthy volunteers were 
recruited for identical venous blood sampling. However, due to the unpredictable recruitment 
of COPD patients, older age and short timeframe for venepuncture (less than 24 h), it was not 
possible to obtain plasma/serum or perform neutrophil isolation from healthy volunteers in 
parallel at the same time.  
2.6.2 Obtaining plasma and serum from whole blood 
All plasma/serum centrifugation was undertaken using a 5810R centrifuge (Eppendorf, 
Hamburg, Germany). Peripheral venous blood was collected from healthy volunteers or COPD 
patients. To obtain plasma, whole blood was collected into sterile 9 ml S-Monovette® venous 
blood sampling collection tubes containing EDTA. To obtain serum, whole blood was collected 
into sterile 4.9 ml S-Monovette® venous blood sampling collection tubes containing 
polystyrene beads coated with silicate clotting activator. Blood collection tubes were 
centrifuged (3000g, acceleration 9, brake 9, 10 min) and plasma/serum aspirated into 2 ml 
Eppendorfs for storage in 500 µl aliquots at -80ºC. Plasma samples used for MV analysis were 
frozen at -20ºC. 
2.6.3 Quantification of Aα-Val360 and Aα-Val541 
Direct measurement of plasma or serum protease, e.g. NE, activity is difficult as the released 
enzyme is rapidly bound to its substrate or to serum protease inhibitors, such as α1AT. NE 
ELISAs do not always distinguish between free and bound enzyme, and enzyme-inhibitor 
complex assays only detect inactivated NE. An alternative approach was therefore employed, 
using a patented assay (US patent No. 6124107) to detect a NE-specific fibrinogen cleavage 
product in plasma, providing a “footprint” of NE activity. NE cleaves fibrinogen at multiple sites; 
cleavage at the Aα(Val360-Ser361) site generates a small C-terminal fragment and hence 
exposes an Aα-Val360 neo-epitope, which is associated with the stable large protein fragment. 
The assay is a sandwich-based ELISA of Aα-Val360, utilising europium-conjugated IgG as the 
readout. A similar unpatented assay was employed to measure a specific fibrinogen 
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breakdown product of the protease, PR3, which exposes an Aα-Val541 neo-epitope. Access to 
the Aα-Val360 and Aα-Val541 assays was kindly allowed by Professor Robert Stockley (Director 
of the Lung Immunobiochemical Research Group, University of Birmingham), and the assays 
were performed by Paul Newby (Respiratory Sciences Laboratory Manager, University of 
Birmingham). Plasma content of Aα-Val360 and Aα-Val541 was measured in plasma samples 
from healthy volunteers and COPD patients. 
2.6.4 Quantification of plasma microvesicles by flow cytometry 
Plasma was diluted 1:5 in sterile filtered PBS and samples were incubated with an antibody 
mix (1:50 final concentration) of BV421-anti-CD66b, PE-anti-CD41a, APC-anti-CD14, PerCP 
Cy5/5-anti-CD144 and (Table 2.1) on ice for 45 min on a rocker. Samples were centrifuged 
(20,000g, 30 min) to pellet MVs and supernatants were carefully removed. MV pellets were 
re-suspended in 490 µl sterile filtered PBS with 10 µl counting beads. The MV gate was set 
using standardised size calibration beads (Figure 2.15A), and 1,000 counting beads were 
measured per sample. Fluorescence minus one negative controls (i.e. four samples each 
containing a combination of three fluorochromes without the fluorochrome that was being 
measured) and unstained controls were used to set up compensation. Flow cytometric 
analysis (BD LSRFortessa) of the plasma content of CD66b+ (neutrophil parent), CD41a+ 
(platelet parent), CD14+ (monocyte parent), and CD144+ (endothelial cell parent) MVs using 
the violet (355 nm excitation; 450/50 filter), blue (488 nm excitation; 575/26 and 695/40 filters) 
and red (633 nm excitation; 780/60 filter) lasers was performed with the assistance of Ben 
Ward and Merete Long (University of Sheffield) using previously optimised protocols. The 
gating strategy is shown in Figure 2.15. 
2.7 Statistics 
Results are reported as mean ± standard error of the mean (SEM) from (n) independent 
experiments. Statistical analysis was performed on data generated from n≥3 experiments 
using GraphPad Prism version 7 software. A p value of less than 0.05 was considered 
significant. For experiments comparing two groups, normally distributed data were analysed 
by paired or unpaired t-test, and non-normally distributed unpaired data were analysed by 
Mann-Whitney test. Normality was assessed by Shapiro-Wilk normality test if n<8 or 
D’Agostino-Pearson normality test if n≥8. For experiments comparing more than two groups, 
data were analysed by one way analysis of variance (ANOVA) with Tukey’s post hoc 
correction for multiple comparisons. For experiments comparing two variables, e.g. treatment 
(stimulated vs unstimulated) and oxygenation (normoxia vs hypoxia), data were analysed by 
two way ANOVA with Sidak’s post hoc correction for multiple comparisons. For data generated 
from 10-plex TMT-MS, principal component analysis (PCA) and paired t-test analysis were 
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performed by Dr Marco Chiapello; p values were adjusted by the Benjamini-Hochberg false 
discovery rate correction for multiple comparisons (see section 7.1.2). An estimate of the 
required sample size to detect a significant difference between groups for the COPD study 
was calculated using the NE activity data for PAF and fMLP-treated neutrophils from healthy 
volunteers. Based on the sample size calculation: n > [1+(1/κ)] [[(Zα+Zβ)/δ]σ]2 where κ = ratio 
between the two group sample sizes i.e. 1, Zα = 1.96 and Zβ = 0.84, σ = common standard 
deviation, and δ = difference between the two group means, a sample size of 16 would detect 
a fold change of 2 with 80% power (power = 1-β, β = 0.2) and 2-tailed 95% confidence (α = 
0.05).  
 
Figure 2.15: Gating strategy for plasma microvesicle quantification by flow cytometry 
Plasma from COPD patients and age/sex-matched healthy controls was stained for BV421-
anti-CD66b, PE-anti-CD41a, APC-anti-CD14, and PerCP Cy5/5-anti-CD144 and plasma MVs 
quantified by flow cytometry (BD LSRFortessa). A: Representative flow cytometry plots 
showing gates for plasma MVs and counting beads. B: Representative flow cytometry plots 
showing gating strategy for plasma CD66b+ (neutrophil), CD41a+ (platelet), CD14+ (monocyte) 
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3 Effect of hypoxia on NE release and neutrophil-mediated 
endothelial dysfunction 
3.1 Introduction 
Neutrophils are generated within the bone marrow, a significantly hypoxic microenvironment, 
with in vivo measurements in mice demonstrating local oxygen tension as low as 1.3kPa (120). 
The physiological hypoxia experienced by circulating (123) and transmigrated neutrophils in 
healthy tissues (125,126,312) can be further amplified in pathological conditions, such as 
organ inflammation (313) or ischaemia (314). Hypoxia is known to modulate neutrophil 
function; published effects include delayed constitutive apoptosis (145), reduced respiratory 
burst with resultant impairment of ROS-dependent bacterial killing of S. aureus (148), 
augmented degranulation (149), and most (although not all) reports demonstrate increased 
phagocytosis (170,174).  
Previous work in our laboratory has shown that a sustained and consistent cell culture medium 
oxygen tension of ~3kPa can be established using a sealed hypoxia workstation (Baker 
Ruskinn), delivering 0.8% oxygen within the chamber. This oxygen tension was able to 
stabilise HIF-1α in neutrophils (demonstrated by increased stabilisation of HIF-1α protein (145) 
and transcription of the HIF-1α target BNIP (315)), and is also biologically relevant. HIF 
staining has been demonstrated in colonic biopsies from patients with IBD (133) and bronchial 
biopsies from patients with COPD (131), although it is known that HIF can be stabilised by 
inflammatory stimuli as well as by hypoxia (316).  
I wished to extend the previous observation made in our laboratory by Dr Kim Hoenderdos 
that neutrophil degranulation from GM-CSF and fMLP-treated neutrophils is enhanced by 
hypoxia  independent of HIF-1α (315), by investigating degranulation responses for a range 
of physiologically relevant priming agonists under the same hypoxic conditions. In addition, I 
aimed to explore the mechanism of hypoxia-enhanced neutrophil degranulation. Published 
data from our laboratory have implicated PI3K signalling in the modulation of degranulation by 
hypoxia in GM-CSF-primed neutrophils (149). I sought to further investigate this finding, both 
by exploring the contribution of PI3K signalling in hypoxic neutrophils treated with different 
agonists and by utilising neutrophils from transgenic mice with loss- or gain-of-function in 
relevant PI3K isoforms. I additionally investigated whether enhanced granule protein release 
under hypoxia might reflect increased generation of NETs, which are extracellular expulsions 
of decondensed chromatin decorated with granule proteins, including NE and MPO (72).  
Neutrophil granule proteases such as NE and PR3 have been implicated in the pathogenesis 
of chronic inflammatory diseases, including COPD (201,203) and vasculitis (317). Previous 
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published work from our laboratory has demonstrated that supernatants derived from 
neutrophils stimulated under hypoxic vs normoxic conditions cause more damage to epithelial 
cells, in a protease-dependent manner (149). As well as local tissue damage caused by 
adjacent neutrophil degranulation, intravascular degranulation has also been demonstrated, 
for example in sepsis (318) and vasculitis (319). Furthermore, evidence of increased 
circulating NE has been identified in pathologies associated with local or systemic hypoxia, 
including experimental I/R injury (320) and in patients experiencing exacerbations of COPD 
(detected indirectly, by measuring an elastase breakdown product) (204). Chronic 
inflammatory diseases (234,321,322) and hypoxia (188,323,324) are associated with 
endothelial dysfunction, and neutrophils can cause endothelial damage by a variety of 
mechanisms, including ROS production, NETosis and release of proteases (254). I therefore 
wished to investigate whether hypoxia was able to potentiate neutrophil-mediated endothelial 
activation and/or injury by examining the effects of supernatants generated from hypoxic 
neutrophils on human pulmonary artery endothelial cell adhesion molecule expression and 
survival/apoptosis. 
The specific aims of the work presented in this chapter are: 
1. To investigate whether different priming agonists are able to increase stimulated NE release 
under hypoxia 
2. To examine the mechanism of enhanced NE release under hypoxia 
3. To compare the effects of normoxic and hypoxic neutrophil supernatants on pulmonary 
artery endothelial cells 
3.2 Confirmation of the neutrophil hypoxic response 
Hypoxia is known to delay constitutive neutrophil apoptosis in a HIF-1α-dependent manner 
(145). To demonstrate that the hypoxia workstation was maintaining the desired level of 
biologically relevant hypoxia, neutrophil apoptosis was examined to show that these 
previously published results could be recapitulated.  
Isolated neutrophils were incubated under normoxia (21% O2, 5% CO2, 37ºC) or hypoxia 
(0.8% O2, 5% CO2, 37ºC) for 20 h, in the presence or absence of GM-CSF (1 ng/ml). 
Quantification of neutrophil apoptosis by morphology revealed a decrease under hypoxia 
compared with normoxia, in cells cultured in medium alone (31.6 vs 53.4%, p=0.004, Figure 
3.1A); hypoxia did not significantly augment the GM-CSF-mediated survival effect. Flow 
cytometric measurement of neutrophil apoptosis (with the AnV+/PI- population identified as 
early apoptotic cells) was in agreement with the morphological findings (Figure 3.1B). 
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Assessment of apoptosis by two independent methods therefore showed that the hypoxia 
workstation was maintaining a biologically relevant level of hypoxia which could stabilise HIF-
1α, consistent with published literature. 
Hypoxia-driven delayed neutrophil apoptosis could compound the results of functional 
analyses. To establish that the hypoxic survival effect was not responsible for any differences 
seen under the planned experimental conditions, apoptosis was also assessed following a 4 
h incubation period in the absence of serum (another potential experimental confounder as 
apoptosis assays are generally conducted in the presence of serum). Very low levels of 
apoptosis were seen under all conditions at 4 h as expected. Morphological assessment of 
neutrophil cytospins demonstrated no significant difference in apoptosis between normoxia 
and hypoxia in untreated, GM-CSF/fMLP or PAF/fMLP-treated cells, with all treatments 
applied precisely as planned for future functional and biochemical assays (Figure 3.1C). Thus, 
the hypoxia workstation delivers hypoxia but, at the selected 4 h time points, differential 
survival should not confound my assessment of degranulation. 
3.3 The effect of different priming agonists on hypoxic NE release 
Our group has previously shown that hypoxia significantly increased NE release from activated 
neutrophils. This was demonstrated by ELISA for cytochalasin B and fMLP-treated cells (148) 
and by activity assay for GM-CSF and fMLP-treated cells (315). The latter experiment has 
greater physiological relevance, both in terms of stimulus-selection and of the measurement 
of NE activity, given that neutrophils are also capable of releasing the protease inhibitor α1AT 
upon degranulation (34). I wished to extend these observations to a wider range of 
physiologically relevant priming agents, assessing the effect of hypoxia on NE release by 
activity assay. I chose TNFα and PAF as well-established, disease-relevant priming agents 
that signal via TNF-receptors and GPCRs respectively. 
Neutrophils were incubated under normoxia or hypoxia for 4 h, primed with GM-CSF (10 ng/ml, 
30 min), TNFα (20 ng/ml, 30 min) or PAF (1 µM, 5 min), and subsequently activated with fMLP 
(100 nM, 10 min). Supernatant NE activity was assessed by Enzchek® elastase activity assay, 
which measures the ability of elastase to cleave a non-fluorescent substrate into fluorescent 
fragments. Consistent with previous data, there was limited NE release from unstimulated 
(IMDM-treated) cells under normoxic or hypoxic conditions, but hypoxia significantly increased 
NE activity in supernatants from GM-CSF and fMLP-treated neutrophils (1.36*104 ± 4.3*103 







Figure 3.1: The effect of hypoxia on neutrophil apoptosis 
Neutrophils were isolated by discontinuous plasma-Percoll® gradients and incubated under 
normoxia (21% O2) or hypoxia (0.8% O2) for 20 h in IMDM containing 10% autologous serum 
(A&B) or for 4 h in IMDM without serum (C). Cells were treated at baseline with A&B: GM-CSF 
(1 ng/ml) or IMDM control or C: after 4 h with GM-CSF (10 ng/ml, 30 min) or PAF (1 μM, 5 
min), and subsequently fMLP (100 nM, 10 min), or IMDM control. A&C: Cytopsins were stained 
with May-Grünwald-Giemsa for morphological assessment by light microscopy. B: pelleted 
cells were stained with FITC-AnV and PI for flow cytometric assessment. Results represent 
mean ± SEM; A: n=6, B: n=2, C: n=3-4; ** = p<0.01, *** = p<0.001, two way ANOVA, Sidak’s 







Figure 3.2: The effect priming agonists and hypoxia on NE release 
A-E: Neutrophils were isolated by discontinuous plasma-Percoll® gradients and incubated 
under normoxia or hypoxia. After 4 h, cells were treated with A. GM-CSF (10 ng/ml, 30 min) 
B&E. PAF (1 µM, 5 min) C-E. TNFα (20 ng/ml, 30 min) and subsequently fMLP (100 nM, 10 
min) or IMDM control. Supernatant NE activity was measured at 30 min by Enzchek® assay. 
F: Isolated neutrophils were incubated under normoxia and treated with TNFα (20 ng/ml, 30 
min) or PBS control before addition of luminol (1 µM, 3 min), HRP (62.5 units/ml) and ROS 
production analysed in a luminometer following injection of fMLP (100 nM). Data are presented 
as raw peak height in relative light units (RLU). Results represent A-C&E: mean ± SEM or 
D&F: absolute values. A: n=12, B: n=12, C: n=12 (inset: subset of 2 individual donors labelled 
A and B), D: n=12, E: n=3 (subset of C&D), F: n=2 (subset of C-E); **** = p<0.0001, two way 
ANOVA, Sidak’s multiple comparisons test. 
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Hypoxia similarly augmented NE release from PAF and fMLP-treated cells (5.04*104 ± 
1.21*104 AU vs 12.27*104 ± 2.32*104 AU, p<0.0001, Figure 3.2B). Surprisingly, hypoxia did 
not lead to a significant increase in NE release from TNFα and fMLP-treated cells (4.85*104 ± 
1.33*104 AU vs 4.7*104 ± 9.34*103 AU, Figure 3.2C). However, when individual responses 
were examined separately, it became apparent that hypoxia can increase NE release from 
TNFα and fMLP-treated cells from some, but not all donors (Figure 3.2D); indeed a variable 
donor response was observed when neutrophils from two different volunteers were incubated 
and treated simultaneously, ensuring identical treatment and levels of hypoxia (Figure 3.2C 
inset). Further, in a subset of donors whose neutrophils were primed simultaneously with either 
TNFα or PAF, hypoxia consistently increased NE release from PAF and fMLP-treated but not 
TNFα and fMLP-treated cells (Figure 3.2E). However, these neutrophils were responsive to 
TNFα as they were able to produce ROS in response to TNFα-priming under normoxic 
conditions (Figure 3.2F, data generated with the assistance of Dr Arlette Vassallo).  
Overall, these data demonstrate that the hypoxic augmentation of NE release is dependent 
on the specific priming agonist rather than equating to a non-specific “priming” effect. I 
therefore wished to further investigate the mechanism of upregulated degranulation under 
hypoxia. 
3.4 Investigation of the mechanism of NE release under hypoxia 
3.4.1 The effect of hypoxia on NET production 
NETs comprise externalised chromatin beaded with antimicrobial proteins (72) and are 
thought to be a host defence mechanism which facilitates the trapping and killing of 
extracellular pathogens, although they also confer the potential for host tissue damage. 
Pharmacological stabilisation of HIF-1α has been shown to increase NETosis (184,185); 
conversely, pharmacological and genetic HIF-1α knockdown decreased NET production 
(184). I therefore hypothesized that enhanced NE release from neutrophils under hypoxia was, 
at least in part, due to an increase in NETosis. 
Isolated neutrophils were re-suspended in normoxic or hypoxic IMDM, containing the cell 
impermeable nucleic acid stain SYTOX™ green. To explore the effect of the cytokines alone, 
cells were treated at the start of incubation with GM-CSF (10 ng/ml) or PAF (1 µM), and 
fluorescence absorbance (indicating extracellular DNA as a surrogate for NETosis) measured 
hourly. To assess NET production under the exact experimental conditions employed for 
measurement of NE activity (section 3.3), cells were treated after 4 h normoxic vs hypoxic 
incubation with GM-CSF (10 ng/ml, 30 min), and subsequently fMLP (100 nM, 10 min). 
Fluorescence absorbance was measured at baseline, 4 h and after treatment. PMA (20 nM), 
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a pharmacological stimulus, was used as a positive control as it is known to induce massive 
NETosis. Results are expressed as percentage of total cellular DNA content, which was 
established by permeabilising cells with 0.5% Triton-X. 
There was no significant difference in NET release in response to hypoxia alone or in 
combination with GM-CSF (Figure 3.3A), PAF (Figure 3.3B) or GM-CSF and fMLP (Figure 
3.3C). PMA induced dramatic NETosis as previously published, demonstrating that the assay 
was able to detect this process, and which was significantly increased compared with all other 
treatments at 4 h (p<0.01, Figure 3.3C). Altogether, these data do not support a role for 
NETosis in the enhanced NE release under hypoxia. Therefore, I next considered the 
signalling pathways known to regulate classical neutrophil degranulation, in particular the PI3K 
signalling pathway, a key mediator of azurophil granule release. 
3.4.2 The effect of PI3K signalling modulation on the release of NE under 
hypoxia 
A number of signalling pathways involved in degranulation and potentially responsible for the 
hypoxic uplift of NE release from GM-CSF and fMLP-treated neutrophils have previously been 
investigated in our laboratory: Dr Kim Hoenderdos showed that phospholipase C and the 
generation of calcium transients are not central to this response (149). In view of the known 
role of PI3K and in particular PI3Kγ in priming of neutrophil degranulation, I next explored the 
role of this signalling pathway in the hypoxic uplift of degranulation, initially using 
phosphorylation of AKT as a readout of PI3K activity, together with isoform-selective PI3K 
inhibitors. Inhibition of PI3K signalling with the pan-PI3K inhibitor LY294002 completely 
abrogated the hypoxic uplift of NE release from GM-CSF/fMLP-treated neutrophils, although 
substantial inhibition of the normoxic response was also observed (149). Further dissection of 
the PI3K signalling pathway demonstrated that inhibition of the PI3Kγ isoform with AS605240 
could also largely abolish the hypoxic uplift of NE release but that inhibition of the PI3Kδ 
isoform with IC87114 could not (149). I therefore hypothesized that the enhanced NE release 











Figure 3.3: The effect of hypoxia on NET production 
Neutrophils were isolated by discontinuous plasma-Percoll® gradients and incubated under 
normoxia or hypoxia. A&B: Cells were treated at baseline with A. GM-CSF (10 ng/ml) B. PAF 
(1 µM), or IMDM control. NET production was quantified hourly by fluorescence absorbance 
with Sytox Green (5 μM). C: Following 4 h incubation, cells were treated with GM-CSF (10 
ng/ml, 30 min) and subsequently fMLP (100 nM, 10 min) or IMDM control. NET production 
was quantified at baseline, 4 h and after treatment. Cells incubated under normoxia were 
treated at baseline with PMA (20 nM) and NET production quantified at baseline and 4 h. A-
C: NETosis is expressed as extracellular DNA as % of total DNA from triton-X (0.5%) lysed 
neutrophils. Results represent mean ± SEM; A: n=4, B-C: n=3; ** = p<0.01; two way ANOVA, 
Sidak’s multiple comparisons test.  
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3.4.2.1 The effect of PI3K inhibitors on the release of NE from human neutrophils 
under hypoxia 
Working with Dr Kim Hoenderdos and using hypoxia in conjunction with GM-CSF priming to 
align with her previous dataset, I generated neutrophil lysates (as described in section 2.2.1.5) 
from isolated neutrophils (10*106/ml) re-suspended in normoxic or hypoxic IMDM and treated 
with PI3K inhibitors prior to incubation, either AS605240 (PI3Kγ-selective inhibitor, 3 µM), or 
IC87114 (PI3Kδ-selective inhibitor, 3 µM). Prior experiments undertaken by Dr Hoenderdos 
indicated that fMLP induced marked AKT phosphorylation that was not further enhanced by 
hypoxia (149), and hence this was not further explored.  
Cell lysates were subjected to SDS-PAGE and probed for pAKT. Stripped membranes were 
subsequently probed for total AKT and β-actin. In the setting of hypoxia, AKT phosphorylation 
in response to GM-CSF and fMLP was moderately enhanced relative to normoxia (fold change 
from normoxic control: 8.42 ± 1.9 vs 13.37 ± 2.11, p=0.029, Figure 3.4A), although this effect 
was variable between different donors (Figure 3.4B). The PI3Kγ-selective inhibitor completely 
abrogated the phosphorylation of AKT in both normoxic (fold change: 8.42 ± 1.9 vs 1.34 ± 
0.55, p=0.0094, Figure 3.4A) and hypoxic neutrophils (fold change: 13.37 ± 2.11 vs 1.52 ± 
1.1, p<0.0001, Figure 3.4A), whilst the PI3Kδ inhibitor did not. Given that GM-CSF signals via 
a tyrosine kinase-coupled receptor, it was surprising that inhibition of PI3Kγ abolished the 
primed and hypoxic-primed phosphorylation of AKT, whilst the use of a PI3Kδ inhibitor had 
little impact on the hypoxic response. 
Since the above results suggested possible involvement of PI3Kγ in mediating the hypoxic 
uplift of NE in GM-CSF-primed cells, I decided to pursue this further using PAF, which in my 
hands gave more consistent and robust effects on NE release, and which signals via a GPCR 
more likely to link to PI3Kγ. Initially, I investigated whether NE release in PAF-primed hypoxic 
neutrophils displayed the same profile of inhibition with isoform-selective PI3K inhibitors as 
did GM-CSF. Given the uncertain contribution of PI3Kδ inhibition, previously showing a minor 
reduction of the hypoxic uplift of NE release (149), I utilised two separate PI3Kδ-selective 
inhibitors, namely IC87114 and CAL-101 (the latter is a licensed drug, Idelalisib, used to treat 
haematological malignancy) to examine this effect more thoroughly. Prior to normoxic/hypoxic 
incubation, cells were treated with AS605240 (PI3Kγ-selective inhibitor, 3 µM), IC87114 
(PI3Kδ-selective inhibitor, 3 µM) or CAL-101 (PI3Kδ-selective inhibitor, 100 nM). After 4 h, 
neutrophils were treated with PAF (1 µM, 5 min) and subsequently fMLP (100nM, 10 min), or 
IMDM control. NE release was measured by Enzchek® assay. Similar to the pattern observed 
with GM-CSF-primed neutrophils, PI3Kγ inhibition significantly reduced NE release from PAF 
and fMLP-treated neutrophils under hypoxia (4.96*103 ± 1.26*103 AU vs 5.75*104 ± 6.77*103 




Figure 3.4: The effect of PI3K inhibition on the hypoxic regulation of AKT 
phosphorylation 
Isolated neutrophils were incubated under normoxia (N) or hypoxia (H) for 4 h. Cells were 
treated with GM-CSF (10 ng/ml, 15 min) or IMDM control in the presence or absence of PI3K 
inhibitors (IC87114, 3 µM; AS605240, 3 µM). Cell lysates were subjected to SDS-PAGE; 
western blotting was performed with anti-pAKT(Ser473), anti-AKT and anti-β actin. A: fold 
change in pAKT was quantified by densitometry using ImageJ. B: representative images from 
2 donors. Results represent mean ± SEM; n=7; # is the difference in pAKT in comparison with 
unstimulated normoxic neutrophils in the absence of PI3K inhibitors; * = p<0.05, ** = p<0.01, 




under normoxia, showing that PI3Kγ inhibition completely abolished the hypoxic augmentation 
of NE release. PI3Kδ inhibition with CAL-101, compared with no inhibitor treatment, had a 
similar but less marked effect on the magnitude of NE release from hypoxic neutrophils 
(3.29*104 ± 5.65*103 AU vs 5.75*104 ± 6.77*103 AU, p=0.0101, Figure 3.5) but IC87114 did 
not significantly reduce NE release under hypoxia (3.91*104 ± 1.02*104 AU vs 5.75*104 ± 
6.77*103 AU, p=0.0701, Figure 3.5). In contrast to PI3Kγ inhibition, there was a trend towards 
increased NE release under hypoxia compared with normoxia in the setting of PI3Kδ inhibition 
but this increase did not reach statistical significance with either inhibitor. PI3Kγ inhibition also 
prevented the significant increase in NE release from unstimulated vs stimulated normoxic 
cells; however, whilst CAL-101 had a similar effect, IC87114 did not reduce stimulated NE 
release under hypoxia. This might reflect either off-target effects of CAL-101 or failure of 
IC87114 to fully inhibit PI3Kδ. Altogether, these experiments show that PI3Kγ is essential for 
PAF-primed fMLP-stimulated degranulation in both normoxia and hypoxia, with possible 
combinations of both PI3Kγ and PI3Kδ isoforms to the hypoxic uplift effect. To further clarify 
these contributions, I decided to take advantage of available transgenic mouse strains with 
absent or enhanced PI3Kγ and PI3Kδ activity. 
 
Figure 3.5 The effect of PI3K inhibition on the hypoxic regulation of NE release 
Isolated neutrophils were incubated under normoxia or hypoxia in the presence or absence of 
IC87114 (3 µM), CAL-101 (100 nM) or AS605240 (3 µM). After 4 h, cells were treated with 
PAF (1 µM, 5 min) and subsequently fMLP (100 nM, 10 min), or IMDM control. Supernatant 
NE activity was measured at 30 min by Enzchek® assay. Results represent mean ± SEM; 
n=4-6; # is the difference in NE release in comparison with unstimulated normoxic neutrophils 
in the absence of PI3K inhibitors; * or # = p<0.05, **** = p<0.0001; two way ANOVA, Sidak’s 
multiple comparisons test. 
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3.4.2.2 The effect of PI3K isoform mutations in murine neutrophils on NE release 
under hypoxia 
The above experiments suggested involvement of PI3Kγ and perhaps PI3Kδ but with a couple 
of uncertainties – namely, whether the apparent impact of the PI3Kδ inhibitors might reflect 
off-target effects, and the possibility that PI3Kγ inhibition was simply inhibiting degranulation 
rather than specifically the hypoxic uplift of degranulation. I therefore investigated PI3K 
modulation of NE release in neutrophils from transgenic mice with abolished or enhanced 
activity of these isoforms. To assess the role of PI3Kδ, neutrophils were isolated from the 
femoral bone marrow of C57BL/6J wildtype mice, or C57BL/6J mice with an activating 
(E1020K heterozygote (325)) or kinase-dead (D910A homozygote (326)) mutation of PI3Kδ 
(obtained from Professor Klaus Okkenhaug, Babraham Institute), using negative 
immunomagnetic selection, exactly as described in section 2.2.1.2. To assess PI3Kγ, 
neutrophils were isolated from the femoral bone marrow of C57BL/6 E129 wildtype mice, or 
C57BL/6 E129 mice lacking the catalytic subunit of PI3Kγ (p110γ-/- (327)) (obtained from Dr 
Len Stephens, Babraham Institute).  
Murine neutrophils primed with PAF or murine GM-CSF and stimulated with fMLP did not 
generate significant extracellular NE activity (Figure 2.10A). Cells were therefore primed with 
cytochalasin B to allow optimal stimulation of NE release (see section 2.2.4.2). Murine 
neutrophils (3-5*106) were incubated under normoxia or hypoxia for 4 h before treatment with 
cytochalasin B (5 µg/ml, 5 min) and subsequently fMLP (10 µM, 10 min), or IMDM control. 
Supernatants were assessed for NE activity by Enzchek® elastase activity assay. As 
observed in similar experiments with human neutrophils (315), the release of NE from 
cytochalasin B and fMLP-treated wildtype murine neutrophils was significantly enhanced 
under hypoxia, compared with normoxia (2.66*105 ± 5.07*104 AU vs 1.49*105 ± 1.47*104 AU, 
p=0.0176, Figure 3.6A). The release of NE from cytochalasin B and fMLP-treated murine 
neutrophils with activating or kinase-dead PI3Kδ mutations was no different from wildtype, and 
the hypoxic enhancement of NE release was wholly maintained (Figure 3.6B), although no 
statistical analysis could be performed on n=2 experiments; further mice were unfortunately 
not available to perform an additional experiment. However, the hypoxic increase in NE 
release from murine neutrophils deficient in PI3Kγ was completely abolished (1.53*105 ± 
8.08*103 AU vs 1.85*105 ± 1.16*104 AU for wildtype mice, p=0.0058; 1.53*105 ± 1.17*104 AU 
vs 1.53*105 ± 9.06*103 AU for PI3Kγ-/- mice, p>0.9999, Figure 3.6C), although the ability of 






Figure 3.6: The effect of hypoxia on NE release from murine neutrophils with PI3Kδ or 
PI3Kγ mutations 
Femoral bone marrow neutrophils were isolated from A: wildtype B: E1020K, D910A and 
wildtype or C: p110γ-/- and wildtype mice by negative immunomagnetic selection. A-C: Isolated 
neutrophils were incubated under normoxia or hypoxia for 4 h, before treatment with 
cytochalasin B (5 µg/ml, 5 min) and subsequently fMLP (10 µM, 10 min), or IMDM control. 
Supernatant NE activity was measured at 20 h by Enzchek® assay. Results represent mean 
± SEM; A: n=9, B: 3 mice per genotype per experiment, n=2 independent experiments, C: 3-
4 mice per genotype per experiment, n=5 independent experiments; * = p<0.05, ** = p<0.01, 
two way ANOVA, Sidak’s multiple comparisons test. 
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Despite documented differences between human and murine neutrophils regarding the roles 
of PI3Kγ and PI3Kδ isoforms (328), these results support my results from human cells 
indicating a non-redundant role for PI3Kγ but not PI3Kδ in the hypoxic augmentation of NE 
release.  I therefore moved on to explore the consequences of this enhanced secretion on 
endothelial cells. 
3.5 The effect of hypoxia on neutrophil-induced pulmonary artery endothelial 
cell dysfunction 
Neutrophil inflammatory disorders, such as COPD, are characterised by bystander tissue 
damage and are often also associated with systemic endothelial dysfunction. COPD patients 
have increased arterial wall stiffness and markers of systemic inflammation (for example CRP) 
when compared with control smokers without airflow obstruction (234), and furthermore have 
considerably more cardiovascular comorbidities, even when corrected for shared risk factors, 
such as smoking (225,227). I therefore hypothesized that hypoxia synergises with systemic 
neutrophil priming to promote a destructive neutrophil phenotype with the capacity to cause 
endothelial cell damage and/or activation, which is biologically relevant to endothelial 
dysfunction observed in patients with chronic inflammatory disease. To investigate this, I 
incubated supernatants derived from normoxic/hypoxic PAF and fMLP-treated neutrophils 
with primary HPAEC monolayers and assessed cell activation and detachment/death. 
3.5.1 The effect of neutrophil supernatants on endothelial cell activation 
Neutrophil adhesion molecules interact with endothelial ligands to mediate adhesion and 
transmigration. Neutrophil integrins (e.g. MAC-1) interact with endothelial immunoglobulin-like 
adhesion molecules, in particular ICAM-1, to mediate firm adhesion and neutrophil trans-
endothelial migration. Several studies have shown increased neutrophil adhesion to the 
endothelium under hypoxia (152,156,157), with one study showing reversal after re-
oxygenation (156). Since endothelial cells ‘display’ neutrophil priming agents such as PAF on 
their surface (329), and since hypoxia is a feature of the sluggish microcirculation seen in 
sepsis/infection, this process could contribute both to endothelial dysfunction and persistent 
tissue neutrophilia seen in chronic inflammatory disease. I therefore wished to extend my 
study of the effects of normoxic and hypoxic neutrophil supernatants to determine their effects 
on endothelial cell ICAM-1 expression. 
To assess endothelial cell activation in the presence of neutrophil supernatants, ICAM-1 
expression was measured. HPAECs (passage 10-12) were grown to confluence and 
incubated under normoxia (21% O2) or hypoxia (0.8% O2) with undiluted supernatants 
generated from normoxic vs hypoxic, PAF/fMLP-treated or control (IMDM) neutrophils for 24 
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h in the presence of 2% human serum. Following supernatant exposure, HPAECs were 
trypsinised, fixed (1% PFA), blocked (5% FBS in 0.5% PBS-BSA) and stained with APC-
conjugated anti-ICAM-1, and MFI was quantified by flow cytometry.  
Supernatants from PAF and fMLP-treated hypoxic neutrophils applied to normoxic HPAECs 
led to a significant increase in ICAM-1 expression when compared to the equivalent 
supernatants from normoxic neutrophils (MFI: 92.97 ± 10.88 vs 52.53 ± 7.32, p=0.037, Figure 
3.7A). Surprisingly, the expression of ICAM-1 by hypoxic HPAECs treated with hypoxic 
supernatants was significantly less than normoxic HPAECs treated with hypoxic supernatants 
(MFI: 34.6 ± 6.17 vs 92.97 ± 10.88, p=0.0101, Figure 3.7A) and indeed did not differ from 
normoxic HPAECs treated with normoxic supernatant. Results were similar whether total MFI 
or the percentage of cells positive for APC (ICAM-1) was assessed (Figure 3.7B).  
These data demonstrate opposing roles for hypoxia in the regulation of ICAM-1 expression, 
acting both indirectly, through its effect on secretion from stimulated neutrophils, and also 
directly, by blunting the ability of endothelial cells to upregulate ICAM-1 expression in response 
to hypoxic supernatants. The overall effect may be context-dependent (further discussed in 
section 3.6). I next proceeded to examine the ability of hypoxia to elicit neutrophil-mediated 
endothelial cell damage/death. 
3.5.2 The effect of hypoxia on neutrophil-induced endothelial cell detachment 
To investigate the ability of neutrophil supernatants to cause endothelial cell detachment, 
HPAECs were stained with rhodamine-phalloidin (F-actin) and DAPI (nucleus), and assessed 
using confocal microscopy. Confluent HPAECs were incubated with supernatants from 
normoxic vs hypoxic PAF and fMLP-treated vs control (IMDM) neutrophils. As we have 
previously demonstrated that neutrophil supernatant-induced epithelial cell detachment can 
be rescued by the addition of the serine protease inhibitor α1AT (149), HPAECs were also 
incubated with supernatants in the presence or absence of α1AT (46 µg/ml), added to 
supernatants 10 min prior to HPAEC treatment. Since human serum contains abundant α1AT 
it was not used in these experiments; instead, supernatants were diluted 1:1 in serum-free 
EGM-2 (endothelial cell-specific media) to avert detrimental effects due to lack of growth 
factors over the 24 h treatment period. After treatment, HPAEC monolayers were fixed and 
stained as described in section 2.3.3.1. Three randomly selected fields from duplicate wells 
were imaged (Leica Sp5 confocal microscope, Figure 3.8A). Cell detachment was quantified 







Figure 3.7: The effect of hypoxia and neutrophil supernatants on endothelial-
leukocyte ICAM-1 expression by flow cytometry 
Isolated neutrophils were incubated under normoxia or hypoxia. After 4 h incubation, 
neutrophils were treated with PAF and fMLP, or IMDM control exactly as described previously. 
After treatment, neutrophils were pelleted and supernatants harvested. HPAECs were grown 
to confluence in a 12 well plate and exposed to normoxia (21% O2) or hypoxia (0.8% O2) for 
24 h prior to treatment with neutrophil supernatants (SN) in the presence of 2% human serum 
under normoxic or hypoxic conditions as indicated. After 24 h, supernatants were aspirated 
and HPAECs pelleted and stained with APC-conjugated anti-ICAM-1 prior to flow cytometric 
analysis. Data are presented as A: median fluorescence intensity or B: APC-positive HPAECs 
(compared with isotype control) as % of total single cells. Results represent mean ± SEM, 




Supernatants from hypoxic PAF and fMLP-treated neutrophils caused significantly more 
HPAEC detachment than supernatants from control neutrophils (55.04 ± 13.71% vs 25.88 ± 
9.25%, p=0.0007) and from normoxic stimulated neutrophils (55.04 ± 13.71% vs 37.31 ± 
13.23%, p=0.0206, Figure 3.8B). There was no significant difference in HPAEC detachment 
resulting from treatment with normoxic control vs stimulated neutrophil supernatants. The 
inclusion of α1AT during incubation prevented the detachment caused by supernatants from 
both normoxic (19.5 ± 8.75% vs 37.31 ± 13.23%, p=0.0299) and hypoxic (23.16 ± 8.66% vs 
55.04 ± 13.71%, p=0.0003) stimulated neutrophils (Figure 3.8B). These data demonstrate that 
hypoxia increases the capacity of PAF and fMLP-treated neutrophils to cause HPAEC 
detachment in a protease-dependent manner. 
3.5.3 The effect of hypoxia on neutrophil-induced endothelial cell death 
It is possible that supernatant proteases were able to lift HPAECs from the plate surface by 
cleaving adhesion molecules, rather than detachment resulting from supernatant-induced cell 
damage/death. Hence, the detachment assay (section 3.5.2) would be giving a surrogate 
readout of supernatant protease concentration rather than direct damage per se. Therefore, 
the ability of neutrophil supernatants to cause endothelial cell death was explored by MTT 
toxicity assay, which allows the spectrophotometric quantification of cell viability, and by flow 
cytometric analysis of apoptosis.  
Confluent HPAECs (passage 10-12) were incubated with supernatants generated from 
normoxic vs hypoxic, PAF and fMLP -treated vs control (IMDM) neutrophils in the presence or 
absence of α1AT (46 µg/ml) exactly as described above (section 3.5.2), diluted 1:1 in serum-
free endothelial medium EGM-2. After 24 or 48 h, samples/media were aspirated and survival 
(expressed as fold-change compared to normoxic control supernatants) was assessed by the 
MTT assay (Section 2.3.3.2).  
After 24 h, there was a modest but significant decrease in HPAEC survival between cells 
treated with hypoxic supernatants from control (IMDM) vs PAF/fMLP-treated cells (fold 
change: 1.03 ± 0.05 vs 0.79 ± 0.03, p=0.036, Figure 3.9A), but no significant difference 
between the equivalent normoxic control and stimulated samples (fold change: 0.9 ± 0.06 vs 
0.79 ± 0.03, p=0.28, Figure 3.9A). In the presence of α1AT, the reduction in HPAEC survival 
with hypoxic supernatant treatment was not apparent, suggesting a protective effect of serine 
protease inhibition. Since these effects were relatively modest, I extended the incubation time 





Figure 3.8: The effect of neutrophil supernatants on HPAEC detachment by confocal 
microscopy 
Supernatants from normoxic (N) vs hypoxic (H) PAF/fMLP (P) or control (IMDM)-treated 
neutrophils were prepared exactly as previously. Confluent HPAEC were incubated with 
supernatants diluted 1:1 with serum-free EGM-2 media for 24 h in the presence or absence of 
α1AT (46 µg/ml). HPAEC were fixed and stained with rhodamine-phalloidin and DAPI. A: 
representative confocal images. B: quantification of cell detachment using ImageJ, expressed 
as % detachment of whole field of view. Results represent mean ± SEM; n=5; # is the 
difference in detachment in comparison with hypoxic PAF/fMLP-treated HPAEC in the 




Treatment with supernatants from PAF and fMLP-treated neutrophils for 48 h demonstrated a 
significant reduction in HPAEC survival between cells treated with supernatants from hypoxic 
vs normoxic stimulated neutrophils (fold change: 0.76 ± 0.04 vs 0.93 ± 0.04, p=0.0031, Figure 
3.9B). Although the inclusion of α1AT gave some protection, there remained a trend (which 
approached but did not reach significance) to reduced HPAEC survival when treated with 
hypoxic vs normoxic stimulated supernatants (fold change: 0.75 ± 0.06 vs  0.92 ± 0.09, 
p=0.055, Figure 3.9B). Of note, HPAEC treated with supernatants from hypoxic stimulated vs 
unstimulated neutrophils had significantly decreased survival, both in the absence (p<0.0001) 
or presence of α1AT (p=0.0007). These data show that HPAEC death induced by 
supernatants from hypoxic PAF and fMLP-treated neutrophils after 48 h is partially but not 
completely rescued by serine protease inhibition. Overall, the results from MTT assessment 
of HPAEC survival indicate that supernatants from hypoxic PAF-primed activated neutrophils 
cause more endothelial cell death, which is at least partly protease-dependent. However, the 
MTT assay does not quantify the survival/death of detached cells nor does it determine the 
mode of cell death.  
In order to explore the nature of cell death further, I investigated the ability of neutrophil 
supernatants to induce HPAEC apoptosis or necrosis using flow cytometry. Since apoptosis 
detection by this method precedes cell death, I employed a shorter (6 h) time point. As the 
assay is very sensitive, conditions were optimised to avoid induction of apoptosis by cell 
manipulation. Confluent HPAECs (passage 7) were incubated with undiluted supernatants 
generated from normoxic vs hypoxic, PAF and fMLP-treated vs control (IMDM) neutrophils. 
After 6 h cells were stained with FITC-AnV and PI. Viable, apoptotic and necrotic cells were 
quantified by flow cytometry: AnV-/PI- staining indicated viable non-apoptotic cells, AnV+/PI- 
staining indicated early apoptotic cells and AnV+/PI+ staining indicated late apoptotic or 
necrotic cells. The gating strategy is shown in Figure 2.12. 
Consistent with my detachment and MTT survival data, supernatants from hypoxic PAF and 
fMLP-treated neutrophils significantly decreased HPAEC viability when compared with 
supernatants from control neutrophils (27.55 ± 7.1% vs 33.48 ± 8.48% AnV-/PI-, p=0.0328) 
and from normoxic stimulated neutrophils (27.55 ± 7.1% vs 44.68 ± 2.08% AnV-/PI-, p=0.0016, 
Figure 3.10A), with an associated increase in AnV+/PI- apoptotic cells (Figure 3.10B). There 
was no significant difference in viable HPAEC resulting from treatment with normoxic control 
vs stimulated neutrophil supernatants. Interestingly, the same hypoxic decrease in HPAEC 
viability observed with stimulated neutrophil supernatants was seen after exposure to 
supernatants from unstimulated neutrophils (33.48 ± 8.48% vs 47.25 ± 4.79% AnV-/PI-, 
p=0.003, Figure 3.10A). These results demonstrate that, in contrast to the detachment and 
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MTT survival data, hypoxia increases the capacity of both unstimulated and PAF/fMLP-treated 
neutrophils to cause HPAEC apoptosis.  
 
Figure 3.9: The effect of neutrophil supernatants on HPAEC survival by MTT assay 
Isolated neutrophils were incubated under normoxia or hypoxia. After 4 h incubation, 
neutrophils were treated with PAF and fMLP, or IMDM control. After treatment, neutrophils 
were pelleted and supernatants harvested. HPAEC were grown to confluence in a 96 well 
plate and exposed to neutrophil supernatants diluted 1:1 with EGM-2 media (serum free) for 
A: 24 h or B: 48 h, in the presence or absence of α1AT (46 µg/ml). Supernatants were 
aspirated and cell survival quantified by MTT assay. Cell survival is expressed relative to 
HPAEC treated with normoxic control supernatant. Results represent mean ± SEM; A: n=4-7, 
B: n=6-12; * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, two way ANOVA, Sidak’s 






Figure 3.10: The effect of neutrophil supernatants on HPAEC survival by flow 
cytometry 
Isolated neutrophils were incubated under normoxia or hypoxia. After 4 h incubation, 
neutrophils were treated with PAF and fMLP, or IMDM control. After treatment, neutrophils 
were pelleted and supernatants harvested. HPAEC were grown to confluence in a 12 well 
plate and exposed to neutrophil supernatants for 6 h. Supernatants were aspirated and 
pelleted HPAEC stained with FITC-AnV and PI for flow cytometric assessment. A: analysis of 
viable (AnV-PI-) HPAEC as % of total population. B: viable (AnV-PI-), apoptotic (AnV+PI-) and 
necrotic (AnV+PI+) HPAEC as % of total single cell population. Results represent mean ± SEM; 





Areas of infection and inflammation can be profoundly hypoxic, as demonstrated in numerous 
settings in vitro and in vivo, including COPD and lung infection (131,134,136). The vasculature 
can also be hypoxic, demonstrated in vivo in rabbit atherosclerotic aortae (330) and in human 
atherosclerotic carotid arteries (331). Patients with lung disease and impaired gas exchange 
(e.g. COPD) are frequently systemically hypoxaemic. Systemic hypoxia increased leukocyte-
endothelial adhesion in rat cremaster venules (152) and hypoxia has been shown in multiple 
studies to increase circulating pro-inflammatory cytokines, such as TNFα and IL-6 (138,332). 
Conversely, myeloid HIF-1α deletion decreased circulating pro-inflammatory cytokines, 
including TNFα and IL-1β, in a murine LPS sepsis model (333). Neutrophil priming, e.g. by 
circulating cytokines, is regarded as a prerequisite for neutrophil-mediated cellular damage; 
primed circulating neutrophils have been identified in stable (334,335) and exacerbating (283) 
COPD patients, and also in patients with ARDS, correlating with oxygenation status (7). We 
therefore hypothesized that systemic neutrophil priming synergises with hypoxia to promote a 
destructive neutrophil phenotype with the capacity to cause endothelial cell damage and/or 
activation, which is biologically relevant to endothelial dysfunction observed in patients with 
chronic inflammatory disease. 
Initially, I explored the role of hypoxia in promoting degranulation from TNFα and PAF-primed 
neutrophils in addition to the published interaction with GM-CSF, to determine whether 
hypoxia synergises with all or just a subset of priming agents. TNFα and PAF are established 
neutrophil priming agents with relevance to lung diseases associated with both endothelial 
dysfunction and local and systemic hypoxia. TNFα has been implicated in the pathogenesis 
of ALI (336). Several studies have detected increased sputum (337) and circulating (338) 
TNFα in COPD patients, with one study showing an inverse correlation of plasma TNFα with 
the arterial partial pressure of oxygen (339). Furthermore, serum TNFα is one of a panel of six 
biomarkers identified by the ECLIPSE study as associated with increased exacerbation 
frequency and mortality in COPD patients (279); however, this and other studies (221) suggest 
that TNFα may be a marker of smoking rather than COPD, at least during the stable state. 
Sputum TNFα seems more consistently elevated during acute exacerbations (340,341) and it 
seems likely that TNFα plays a role in COPD pathogenesis as TNF receptor (TNFR) deficient 
mice are partially protected from cigarette-induced emphysema and lung inflammation (342). 
PAF, a pro-inflammatory phospholipid, plays an important role in ALI: in a model of acid 
aspiration-induced lung injury, mice deficient for the PAF receptor (PAFR) were protected, 
whereas mice overexpressing PAFR died rapidly with profound lung inflammation, pulmonary 
oedema and impaired oxygenation (343). PAF has also been shown to contribute to the 
pathogenesis of experimental cigarette smoke-induced COPD, where PAFR antagonism 
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could attenuate the development of emphysema (221), and is elevated in systemic conditions 
associated with hypoxia and endothelial injury, for example in I/R injury (344) and acute 
pancreatitis (345). Finally, plasma levels of PAF were elevated in patients with sepsis and 
even further increased in those with multiple organ dysfunction (346), which is indicative of 
endothelial dysfunction.  
Possible explanations for the observed inconsistent response of TNFα-primed NE release 
under hypoxia include donor variability and oxygen sensitivity of exocytosis signalling 
pathways. It has been observed in our laboratory that the magnitude of the respiratory burst 
in response to TNFα-priming varies considerably between individuals (personal 
communication, Professor Edwin Chilvers). Further, polymorphisms in the TNFA gene have 
been associated with more severe COPD and enhanced neutrophil migration (347). It is also 
possible that the concentration of TNFα used was maximal for some subjects; however, in 
experiments performed in parallel on the same cells, PAF induced more NE release than TNFα 
in the context of hypoxia, making this explanation less likely. Neutrophils contain both TNFR1 
and TNFR2, which might allow donor-dependent differential signalling in the context of 
degranulation. In my hands, hypoxia reliably synergised with PAF priming of fMLP-induced 
NE release, and the magnitude of this response was greater than that seen with GM-CSF. I 
therefore adopted PAF as the key mediator for further studies in this thesis. 
Since NETosis could plausibly explain extracellular NE release and Branitzki-Heinemann et 
al. had previously observed enhanced NETosis with pharmacological HIF1α stabilisation 
(185), I assessed the impact of true hypoxia (rather than modulation of HIF) on NET formation, 
using the same experimental conditions as for my degranulation assays. In agreement with a 
previous report, I in fact saw a non-significant reduction of NET production under true hypoxia 
(186), although the baseline value under normoxia was already very low. NETosis is partially 
dependent on NADPH production of ROS; neutrophils from patients with CGD (who have 
impaired or absent NADPH oxidase function), display diminished NET release that is restored 
by pharmacological induction of ROS (73). The requirement of ROS (and hence molecular 
oxygen) likely explains the difference between HIF stabilisation and hypoxia on NET release.  
Published work from our laboratory, focused on GM-CSF-primed neutrophils (including my 
data shown in Figure 3.4), suggested an important role for PI3Kγ (but not PLC or calcium 
transients) in mediating the hypoxic uplift of degranulation. PAF ligates a GPCR, whose βγ 
subunit can directly activate PI3Kγ, hence it was logical to explore this pathway in the current 
work by examining the impact of hypoxia on PAF-primed neutrophil degranulation. PI3Kγ 
mediates several neutrophil functions, although most of these have not been assessed in the 
context of hypoxia. Neutrophils from mice lacking functional PI3Kγ have impaired oxidative 
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burst, migration and recruitment (13), and the early generation of PIP3 in response to fMLP 
stimulation for both human peripheral blood neutrophils and murine bone marrow-derived 
neutrophils is PI3Kγ-dependent (328). Both PI3Kγ and δ are fundamental to neutrophil 
function, although their roles are often temporally distinct and context-dependent (348). 
Previous reports have suggested that there is considerable cross-talk between Class IA 
(α/β/δ) and IB (γ) PI3Ks. For example, mouse neutrophils lacking functional PI3Kγ have a 
marked reduction in chemotaxis but it has also been shown that PI3Kδ activity plays a role in 
directional chemotaxis (349), and in some situations, such as GM-CSF-mediated prolonged 
neutrophil survival, there is complete functional redundancy between isoforms (304). Despite 
documented differences between human and murine neutrophils regarding the roles of PI3Kγ 
and PI3Kδ isoforms (328), my combined data from human cells treated with isoform-selective 
inhibitors and cells from transgenic mice support a non-redundant role for PI3Kγ in the hypoxic 
augmentation of NE release. However, the mechanism(s) by which hypoxia might modulate 
PI3Kγ activity are unclear and warrant further investigation. Studies in different cell types have 
demonstrated that hypoxia upregulates both PI3Kγ expression (350) and AKT phosphorylation 
(351); however, previous published data that cycloheximide does not prevent the hypoxic 
enhancement of degranulation (149) argues against increased PI3Kγ expression mediating 
this effect. Of note, in a mouse model of I/R, Alloatti et al. showed that PI3Kγ signalling 
mediated PAF-induced NO release and depression of cardiac contractility, and that PI3Kγ-null 
hearts had improved post-ischaemic recovery (352). 
Although I have focused on PI3K signalling, a number of pathways and signalling molecules 
are important in regulating neutrophil degranulation, including the p38 and ERK pathways, 
SRC-kinases and phospholipase D (353), as well as intracellular trafficking and small GTPase 
activation. Whilst a detailed exploration of these pathways in the setting of hypoxia would have 
been of considerable interest, the time constraints of a PhD precluded my exploring all of these 
potential avenues. Whilst I focused instead on establishing the potential biological relevance 
of my findings, prospective plans for further investigation into the hypoxic regulation of 
degranulation are further discussed in Section 6.3.  
In addition to local tissue damage, chronic inflammatory diseases, such as COPD, are 
associated with systemic endothelial dysfunction and excess cardiovascular morbidity and 
mortality (225,227). Similarly, activation of neutrophils with anti-MPO or anti-PR3 vasculitic 
autoantibodies has been shown to injure vascular endothelial cells (354), and patients with 
vasculitis have increased prevalence of atherosclerosis (322). Neutrophil granule contents 
have also been shown to induce endothelial activation or damage directly. Neutrophils can 
transfer enzymatically active MPO to endothelial cells, promoting vascular inflammation (247); 
treatment of bovine pulmonary artery endothelial cells with NE or PR3 induced apoptosis 
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(258); NE, PR3 and MMP-9 were all able to cleave the proteolytically activated GPCR 
proteinase receptor 1 (PAR1), which induced endothelial cell stress fibre formation and 
apoptosis (265,355); and reduction of neutrophil MMP-9 by siRNA or pharmacological 
inhibition reduced murine atherosclerosis in vivo. Since hypoxia has been shown to enhance 
the release of NE, MPO, and MMP9 (149), it seemed plausible that hypoxic neutrophils would 
have enhanced capacity to lead to endothelial cell dysfunction and/or damage. Based on the 
above reports, I explored the impact of hypoxic neutrophil supernatants on HPAEC adhesion 
molecules, detachment, and death/apoptosis.  
I found that hypoxic neutrophil supernatants led to increased ICAM-1 expression of HPAECs 
that had been cultured as monolayers in normoxic settings. Since neutrophils circulate 
between the arterial and venous circulations, cells exposed to hypoxia will encounter normoxic 
endothelial cells. This would be more marked in the setting of I/R injury, when vessel occlusion 
may ‘trap’ cells in a hypoxic environment before perfusion is restored by physiological 
processes or therapeutic interventions (e.g. stent placement). Additionally, in the setting of 
local or systemic infection or inflammation, neutrophils may be delayed in the microvascular 
circulation. Whilst I have used higher concentrations of PAF than are usually present in the 
circulation, inflamed endothelial cells express PAF (329) and hence the local exposure of 
adherent neutrophils may be significant. Furthermore, multiple inflammatory mediators 
circulate in the setting of infection and inflammation, and these may have additive effects, 
although I have not explored this possibility.  
The effect of hypoxia in attenuating the increase in endothelial ICAM-1 seen in response to 
treatment with supernatants from hypoxic PAF and fMLP-stimulated neutrophils is somewhat 
surprising and the mechanism for this has not been explored, although it is possible that the 
hypoxic exposure had a detrimental effect on endothelial cells which was not obvious by light 
microscopic visualisation. In the literature, reports of endothelial ICAM-1 expression in 
response to hypoxia are conflicting: Antonova et al. showed no difference in endothelial cell 
ICAM-1 levels cultured under hypoxic conditions (155), whereas Yoon et al. demonstrated 
increased ICAM-1 in a murine hindlimb ischaemia model (356) and Pinsky et al. demonstrated 
hypoxia-induced exocytosis of Weibal-Palade bodies (storage granules containing pre-formed 
P-selectin) from endothelial cells in a rodent model of cardiac ischaemia, which may mediate 
enhanced neutrophil adhesion (245). Such discrepancies may reflect species differences, in 
vitro vs in vivo experimental approaches or the degree and duration of hypoxia.  
Existing evidence suggests possible synergy between hypoxia and PAF signalling in 
mediating neutrophil-induced endothelial dysfunction: hypoxia increased ICAM-1-mediated 
neutrophil adherence to HUVECs in a PAF-dependent manner in vitro (293) and, similarly, 
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hypoxia increased neutrophil adhesion to porcine coronary endothelium in a PAF-dependent 
manner, although ICAM-1 was not assessed (357); PAF receptor antagonism was 
cardioprotective following myocardial I/R in mice (344); and blockade of ICAM-1 or the PAF 
receptor reduced neutrophil-endothelial adhesion and transmigration in a mouse model of 
mesenteric I/R injury (358). These observations suggest it would be relevant to further explore 
the impact of hypoxia on HPAEC expression of ICAM-1; of interest, a preliminary experiment 
suggested that the addition to hypoxic endothelial cells of supernatants derived from hypoxic 
stimulated neutrophils primed with GM-CSF rather than PAF in fact led to an increase in ICAM-
1 expression. This intriguing result needs to be further defined; it may suggest that the 
secretome of hypoxic and primed neutrophils varies according to the specific priming agent. 
This would align with and add to data presented in the following chapter, analysing the hypoxic 
neutrophil secretome in more detail.   
As noted above, numerous studies have demonstrated neutrophil-mediated endothelial 
damage. My data reveal that supernatants from hypoxic neutrophils cause more endothelial 
cell detachment and death in vitro than do matched supernatants generated from normoxic 
cells. Aligning well with my results, Vercellotti et al. showed that PAF and fMLP-treated 
neutrophils caused detachment of cultured human endothelial cells (359), Koshio et al. 
demonstrated endothelial apoptosis due to degranulation from cytochalasin B and fMLP-
treated neutrophils (360) and Jerke et al. showed endothelial cytoskeletal architecture 
disruption from ANCA-stimulated neutrophil supernatants (361). Despite neutrophil-mediated 
endothelial cell detachment and apoptosis being well established, these studies were all 
conducted under conditions of ambient oxygen; the novelty of my data derives from the 
inclusion of hypoxia, which has relevance to a range of pathological situations as noted above.  
Neutrophil proteases have been implicated in mediating endothelial damage, for example in 
hypoxia-induced PH, with some protection afforded by in vivo serine protease inhibition (362). 
It is intriguing that in my experiments, endothelial injury could not be completely reversed by 
α1AT, indicating a small but significant protease-independent damage component. It is 
possible that the decreased survival recalcitrant to α1AT, observed at 48 but not 24 h, was 
partly due to protease-independent cell detachment, particularly given I used serum-free 
conditions to exclude the α1AT present in serum. Additionally, the degree of endothelial death 
did not fully correlate with NE activity in the applied supernatants, for example supernatants 
from hypoxic unstimulated neutrophils caused a similar degree of endothelial cell apoptosis 
as supernatants from hypoxic stimulated neutrophils. It would be informative to establish 
whether protease inhibition is able to abrogate the increase in endothelial cell apoptosis 
caused by supernatants from both stimulated and unstimulated hypoxic neutrophils, although 
time constraints prevented further exploration of the mechanism of this injury during my PhD. 
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However, when taken together, these results suggest that agents in addition to proteases 
contribute to neutrophil-mediated endothelial dysfunction. This is entirely plausible as 
neutrophil granules have many potentially damaging proteins that do not have protease 
activity. I therefore wished to interrogate the hypoxic neutrophil secretome in order to identify 













4 Effect of hypoxia on the neutrophil secretome 
4.1 Introduction 
Proteomics is the analysis of the entire protein complement (proteome) of a biological system, 
such as a cell or biological fluid, in a defined setting. As the proteome is dynamic and 
potentially modulated by multiple factors (e.g. source and associated environmental stimuli), 
it is important to interpret proteomic studies in the context of precise study conditions. Having 
identified that supernatants from hypoxic neutrophils cause extensive endothelial cell damage, 
which is not completely prevented by serine protease inhibition (section 3.5), I wished to 
perform an independent new quantitative proteomic characterisation of the hypoxic vs 
normoxic neutrophil secretome (secreted proteins). This would be entirely novel, would 
identify differentially regulated proteins with the potential to contribute to this supernatant-
induced endothelial dysfunction, and might also yield insights into the mechanism(s) by which 
hypoxia regulates protein secretion. 
Separation techniques for complex protein/peptide samples in proteomic studies include gel 
electrophoresis, in one (separation by molecular weight) or two (separation by pH and 
molecular weight) dimensions, and high performance liquid chromatography (HPLC: 
separation by variable interactions with adsorbent material within a column), with subsequent 
identification by mass spectrometric (MS) analysis. Simultaneous labelling, e.g. by 2D 
difference gel electrophoresis (2D DIGE) or multiplex tandem mass tag mass spectrometry 
(TMT-MS), allows quantification of relative protein abundance between concurrently analysed 
samples. 2D DIGE enables a fairly rapid global view of the proteome, with differential protein 
abundance quantified by comparing two fluorescent dyes within the same gel. Differences in 
sample protein abundance from more than one experiment can be quantified by inter-gel 
analysis. However, this method can be laborious and expensive if MS is subsequently used 
to identify proteins present in individual spots, and there are limitations of 2D DIGE in 
displaying the complete range of proteins within a sample. Furthermore, spot fusion or co-
migration can lead to ambiguous identification, and quantification is difficult if proteins are 
present in multiple isoforms. Multiplex TMT-MS involves labelling of individual protease-
digested samples with unique isobaric tags, which give rise to a cleavage product with a 
specific mass-to-charge ratio for each sample. In this manner, up to 10 samples can be 
subjected to MS simultaneously, eliminating the technical variability arising from multiple MS 
runs. The abundance of all identified proteins can then be quantified and compared for each 
sample. However, it is time-consuming and requires a substantial amount of protein per 
sample. Since 2D DIGE requires less protein, I chose to perform an initial 2D DIGE study to 
give an overview of the normoxic vs hypoxic secretome, enabling rapid demonstration of any 
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obvious differences in protein abundance, before proceeding to protein identification by 10-
plex TMT-MS for characterisation of the neutrophil secretome. 
In the context of my experimental setup, proteomic analysis posed two significant challenges. 
Firstly, I needed to ensure that secreted neutrophil proteases did not degrade other proteins 
within the supernatant prior to examination. This is because MS peptide identification is 
dependent on the predicted molecular weight of peptides generated by digestion of the intact 
full length protein with a specific protease (usually trypsin). Therefore, samples partially 
degraded by other proteases present would not give rise to the expected peptides and would 
hinder protein target identification. As it was therefore important to prevent digestion of 
proteins within the sample by other abundant secreted proteases, such as NE, I carefully 
optimised the anti-protease strategy for neutrophil supernatant generation. Secondly, I needed 
to generate supernatant samples with sufficient protein content (a minimum of 25 μg) and 
concentration (≥2 mg/ml) to allow TMT labelling. As the neutrophil supernatant samples were 
too dilute (1-4 μg/ml) to be used in the proteomic experiment directly, I needed to optimise the 
protein concentration method, maximising efficiency, accuracy, consistent protein recovery 
between samples and compatibility with the subsequent proteomic analysis. 
Although proteomics is a powerful investigative tool, analysis of the vast amount of data 
produced by tandem MS is not straightforward. A critical step is that of protein inference, i.e. 
assembling peptides identified from tandem MS spectra into protein lists. Not only can 
ambiguity arise from peptide sequences which are shared between different proteins or protein 
isoforms, but comparison of database search engines and protein inference software has 
demonstrated variable results (363). As it is therefore vital to validate proteomic data by 
independent replication of the experiment using a different experimental strategy, I selected a 
number of differentially regulated protein candidates, identified by TMT-MS, to take forward 
for validation by ELISA. 
Analysis of the pattern of significantly upregulated proteins in the hypoxic supernatants 
provided by the proteomic study demonstrated that these proteins did not entirely segregate 
with discrete granule populations, suggesting that an alternative secretion mechanism was 
involved. Neutrophils are known to produce MVs, which contain small packages of proteins, 
and secretome proteins may derive from MV release as well as degranulation. Therefore, I 
investigated the impact of hypoxia on the release of NDMVs and whether this mechanism 
was, at least in part, responsible for the differential release under hypoxia vs normoxia of 




The specific aims of the work presented in this chapter are: 
1. To provide a preliminary overview of the differential protein release under hypoxia vs 
normoxia using 2D DIGE. 
2. To optimise the anti-protease and protein concentration strategies for neutrophil 
supernatant generation for TMT-MS proteomic analysis.  
3. To quantitatively identify proteins differentially released by neutrophils under hypoxia vs 
normoxia using 10-plex TMT-MS. 
4. To validate the proteomic results by alternative biochemical methods for selected 
differentially regulated proteins.  
5. To explore possible mechanisms of enhanced protein secretion from hypoxic neutrophils. 
4.2 2D Difference Gel Electrophoresis 
Before undertaking expensive and complex whole secretome mass spectrometric analysis, a 
pilot 2D DIGE study without MS protein identification, which required less sample, was 
performed to confirm that I could detect differential protein release between hypoxic and 
normoxic samples.  
Because the supernatants are relatively dilute, a concentration step was required. For 2D 
DIGE, proteins must be natively charged in order to undergo fluorescent labelling and 
isoelectric focusing (IEF). Therefore, negatively-charged SDS buffer and conventional protein-
denaturing TCA precipitation could not be used (see Table 4.1). Ammonium acetate 
precipitation and a urea-based buffer were therefore trialled alongside the TCA 
precipitation/SDS buffer method to test whether they achieved similar protein recovery. 
Furthermore, small molecule protease inhibitors were used rather than inhibitors that are 
proteins themselves, such as α1AT and leupeptin, to avoid the latter obscuring other 
supernatant proteins in the 2D DIGE analysis. Hence, neutrophils were incubated under 
normoxia or hypoxia in the presence of the protease inhibitors EDTA (2 mM), EGTA (2 mM), 
the NE-selective inhibitor sivelestat (1 µM) and serine protease inhibitor AEBSF (1 mM). 
Inhibitors were added at these concentrations at baseline, 2 h and 4 h. Cells were then treated 
with PAF (1 μM, 5 min) and fMLP (100 nM, 10 min). Supernatants were precipitated with either 
TCA (section 2.2.5.1) or ammonium acetate (section 2.4.2). Protein pellets from TCA- or 
ammonium acetate-precipitated supernatants were re-suspended in either SDS- or urea-
based buffers, prior to SDS-PAGE and silver staining. Silver gel analysis demonstrated 
broadly similar protein recovery with both precipitation methods and both buffers. (Figure 4.1),  
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Therefore, neutrophil supernatants were prepared for 2D DIGE by ammonium acetate 
precipitation and re-suspension in urea buffer. Of note, there did not appear to be more protein 
in the hypoxic than normoxic samples and in some lanes (e.g. TCA precipitation/SDS buffer) 
there was a suggestion of lesser protein recovery from the hypoxic samples; this guided 
subsequent protease inhibitor strategies (section 4.3).  
 
Figure 4.1: The effect of buffer and precipitation on neutrophil supernatant protein 
content 
Neutrophils were re-suspended in IMDM under normoxia (N) or hypoxia (H) in the presence 
of EDTA (2 mM), EGTA (2 mM), AEBSF (1 mM) and sivelestat (1 μM). Protease inhibitors 
were also added to all samples at these concentrations after 2 h and 4 h incubation, giving a 
final concentration of 3 mM AEBSF and 3 µM sivelestat prior to stimulation. Cells were then 
treated with PAF (1 μM, 5 min) and fMLP (100 nM, 10 min) (P). Neutrophil supernatants were 
TCA- (T) or ammonium acetate- (A) precipitated and re-suspended in SDS- (S) or urea- (U) 
based buffer before SDS-PAGE and silver staining. Image from n=1 experiment. 
 
Neutrophil supernatants were prepared exactly as described in section 2.4.2. 2D DIGE was 
performed by Renata Feret (CCP). Equal amounts of both samples were labelled with cyanine 
fluorescent dyes; “normoxia activated” (i.e. generated from normoxic PAF and fMLP-treated 
cells) was labelled with Cy5, and “hypoxia activated” (i.e. generated from hypoxic PAF and 
fMLP-treated cells) labelled with Cy3. The two samples were subsequently mixed and 
subjected to IEF, followed by SDS-PAGE. Fluorescent images were generated, with 
125 
 
“normoxia activated” visualised as red (Figure 4.2A) and “hypoxia activated” visualised as 
green (Figure 4.2B). Overlaid scanned images (Figure 4.2C) were analysed with DeCyder 2D 
software. The fold change threshold of the volume ratio between automatically detected (and 
manually checked) protein spots in the two overlaid images was set at 2.0. Gel analysis 
indicated a number of proteins which were differentially abundant when comparing normoxic 
vs hypoxic supernatants (Figure 4.2C&D), suggesting that more detailed protein identification 
and quantification by TMT-MS would be both feasible and informative in showing differentially 
regulated protein release under hypoxia. 
4.3 Optimisation of neutrophil supernatant generation for TMT-labelled MS 
Since neutrophil supernatants contain active proteases with the ability to cleave other proteins 
present in the sample which could thus compromise MS identification, anti-protease strategies 
were necessary, in particular to combat the enhanced protease release following hypoxic 
incubation. As noted above, the hypoxic samples prepared for 2D-DIGE did not contain a 
higher protein content than the normoxic equivalents as might be expected, hence further 
optimisation was undertaken. Initially, a combination of several protease inhibitors was 
employed. Freshly isolated neutrophils were re-suspended in normoxic or hypoxic IMDM 
containing either: no protease inhibitors; α1AT (46 µg/ml) and a protease inhibitor cocktail 
tablet (cOmplete™ mini EDTA-free protease inhibitor cocktail); or a combination of α1AT (46 
µg/ml), EDTA (20 mM), EGTA (20 mM), leupeptin (12.5 µg/ml), pepstatin A (12.5 µg/ml) and 
a protease inhibitor cocktail tablet. Cells were incubated under normoxia or hypoxia for 4 h 
before treatment with PAF and fMLP, or IMDM control, exactly as previously described. 
Supernatants were TCA precipitated, subjected to SDS-PAGE and silver stained (see section 
2.2.5). Although ammonium acetate precipitation was needed for 2D DIGE sample 
preparation, for the following anti-protease optimisation silver gel experiments, TCA 
precipitation was used as the method was more rapid and required lower volumes (see Table 
4.1). Silver staining confirmed better protein recovery with the addition of protease inhibitors 
(Figure 4.3). Protein recovery was best with α1AT and a protease inhibitor cocktail tablet, 
rather than the combination of α1AT, EDTA, EGTA, leupeptin, pepstatin A and a protease 
inhibitor cocktail tablet. EDTA and EGTA were employed to inhibit MMPs but as they chelate 
divalent cations (the mechanism of MMP inhibition), lower protein recovery in their presence 
at these high concentrations (20 mM) likely reflects inhibition of degranulation due to chelation 





Figure 4.2: Analysis of hypoxic versus normoxic neutrophil supernatant protein 
content by 2D DIGE 
Isolated neutrophils were re-suspended in IMDM under normoxia or hypoxia in the presence 
of EDTA (2 mM), EGTA (2 mM), AEBSF (1 mM) and sivelestat (1 µM). Protease inhibitors 
were also added to all samples at these concentrations after 2 h and 4 h incubation. Cells 
were then treated with PAF and fMLP exactly as described previously. Ammonium acetate-
precipitated supernatants were fluorescently labelled with red Cy5 (normoxia) or green Cy3 
(hypoxia). Mixed samples were subjected to IEF and SDS-PAGE (2D DIGE) and fluorescent 
images were produced from the scanned gel. A. Fluorescent image of normoxic supernatant 
proteins using Cy5 parameters (633nm excitation, 670nm emission, red). B. Fluorescent 
image of hypoxic supernatant proteins using Cy3 parameters (532nm excitation, 580nm 
emission, green). C. Fluorescent Cy5 and Cy3 images were overlaid for analysis; green spots 
represent proteins increased in hypoxia, red spots represent proteins increased in normoxia, 
yellow spots represent unchanged proteins. D: Differential In-gel Analysis (DIA) software 
analysis of protein spots. Yellow boundaries indicate proteins with a volume ratio >2.0. Images 




Figure 4.3:  The effect of protease inhibitors on neutrophil supernatant protein content 
Neutrophils were re-suspended in IMDM under normoxia (N) or hypoxia (H) in the presence 
or absence of protease inhibitors: either α1AT (46 µg/ml), EDTA (20 mM), EGTA (20 mM), 
leupeptin (12.5 µg/ml), pepstatin A (12.5 µg/ml) and a protease inhibitor cocktail tablet (1 
tablet/4 ml) (ALL); α1AT (46 µg/ml) and a protease inhibitor tablet (AAT); or no protease 
inhibitors (NIL). After 4 h, neutrophils were treated with PAF and fMLP (P), or IMDM control 
(C). TCA-precipitated neutrophil supernatants were subjected to SDS-PAGE and silver 
stained. Representative image from n=2 experiments. 
 
Having demonstrated better supernatant protein recovery in the presence of protease 
inhibitors, small molecule protease inhibitors were trialled, to prevent inhibitors which are 
themselves proteins (α1AT, leupeptin and pepstatin A) obscuring supernatant proteins during 
proteomic analysis. The following inhibitors were used: EDTA, EGTA, sivelestat and AEBSF. 
The previous experiment had suggested reduced protein recovery in the presence of high 
concentrations of EDTA/EGTA, and EGTA chelation of extracellular calcium has been shown 
to reduce/inhibit neutrophil degranulation (149). Therefore, as IMDM contains 1.5 mM CaCl2 
and 0.8 mM MgSO4, and chelation occurs in a 1:1 stochiometric ratio, EDTA and EGTA were 
used at 0.5 mM, in order to exert MMP inhibition whilst also allowing calcium-dependent 
granule exocytosis. Analysis of supernatant NE by Enzchek® assay confirmed the expected 
level of NE activity (i.e. degranulation) in the presence of EDTA and EGTA (both 0.5 mM), 
which was inhibited at higher concentrations (Figure 4.4A).  
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Isolated neutrophils were re-suspended in normoxic or hypoxic IMDM, containing a 
combination of EDTA (0.5 mM), EGTA (0.5 mM), sivelestat (10 µM) and AEBSF (2 mM). 
Higher concentrations of sivelestat and AEBSF were used here as it had been noted in 
previous experiments that protein recovery in hypoxic supernatants seemed less than in 
normoxic samples (Figure 4.1), thought to be due to inadequate protease inhibition under 
hypoxia. After 4 h, cells were treated with PAF and fMLP, or IMDM control. Neutrophil 
supernatants were TCA-precipitated, subjected to SDS-PAGE and silver stained. Surprisingly, 
despite increased sivelestat and AEBSF concentrations, silver staining now consistently 
demonstrated a marked reduction of protein in the hypoxic compared with normoxic 
supernatants, both under control and stimulated conditions, despite demonstration of equal 
protein loading across samples by western blotting for β-actin (Figure 4.4B).  
To further investigate this difference in protein recovery, cytospins of normoxic vs hypoxic PAF 
and fMLP-treated neutrophils, incubated with or without these small molecule protease 
inhibitors, were generated for morphological assessment of the neutrophil pellets. Substantial 
cell death was evident in the presence of protease inhibitors, particularly in the normoxic 
incubation conditions (Figure 4.5A). This suggested that the increased protein content in 
normoxic supernatants was due to cell death and subsequent protein release, rather than 
decreased secretion or lower protein recovery from the hypoxic samples. Cytospins of 
neutrophils exposed to AEBSF, EDTA, EGTA or sivelestat individually, revealed that AEBSF 
was toxic to neutrophils (Figure 4.5B). Although 2D DIGE was performed prior to the discovery 
of AEBSF-induced neutrophil toxicity, it was associated with a lesser difference in protein 
content between conditions and was still thought to be informative. However, I wished to 
eliminate the use of AEBSF before proceeding with TMT-MS.  
To avoid AEBSF-induced cell death, neutrophil supernatants were generated using sivelestat 
and EDTA only. EDTA alone was chosen, rather than the previous combination of EDTA and 
EGTA, because EGTA preferentially binds Ca2+ over Mg2+, with the potential for increased 
inhibition of degranulation. Neutrophils were re-suspended in normoxic or hypoxic IMDM 
containing either no protease inhibitors (for subsequent assessment of degranulation), or a 
combination of EDTA (1 mM), and sivelestat (10 µM). After 4 h, cells were treated with PAF 
and fMLP, or IMDM control. Neutrophil supernatants were TCA-precipitated, subjected to 
SDS-PAGE and silver staining. Silver staining (Figure 4.6A) demonstrated improved recovery 
of protein with this combination of protease inhibitors, particularly in the setting of hypoxia. 
Cytospins of pelleted cells re-suspended in IMDM confirmed viable cells (Figure 4.6B). 
Elastase assay confirmed inhibition of NE in the presence of EDTA and sivelestat (Figure 
4.6C), whilst MPO assay confirmed that degranulation was not inhibited (Figure 4.6D). These 




Figure 4.4: The effect of small molecule protease inhibitors on neutrophil supernatant 
protein content 
Neutrophils were re-suspended in IMDM under normoxia (N) or hypoxia (H) in the presence 
of A: EDTA and EGTA at the concentrations indicated or B: a combination of EDTA (0.5 mM), 
EGTA (0.5 mM), sivelestat (10 µM) and AEBSF (2 mM). A: After 4 h all cells were treated with 
PAF and fMLP and supernatants were assessed for NE activity by Enzchek® assay. B: After 
4 h, neutrophils were treated with PAF and fMLP (P), or IMDM control (C) and supernatants 
were subjected to SDS-PAGE and silver staining (upper panel). Corresponding cell pellets 
were lysed and probed for β-actin by western blotting (lower panel). A: n=2-3, B: Images 




Figure 4.5: The effect of small molecule protease inhibitors on neutrophil morphology  
Neutrophil cytospins were stained with May-Grünwald-Giemsa. Cells were re-suspended in 
normoxic (N) or hypoxic (H) IMDM in the presence (+) or absence (-) of protease inhibitors 
(PI: EDTA (0.5 mM), EGTA (0.5 mM), sivelestat (10 µM) and AEBSF (2 mM)). After 4 h, 
neutrophils were treated with PAF and fMLP (P). A: incubation with/without PI. B: incubation 
with individual inhibitors as indicated. A&B: x40 magnification, arrows indicate examples of 





Figure 4.6:  Optimised protease inhibition strategy 
Neutrophils were re-suspended in IMDM under normoxia (N) or hypoxia (H) in the presence 
(+) or absence (-) of sivelestat (10 µM) and EDTA (1 mM). After 4 h, cells treated with PAF 
and fMLP (P), or IMDM control (C). A: TCA-precipitated supernatants were subjected to SDS-
PAGE and silver stained. B: Cytospin stained with May-Grünwald-Giemsa was generated from 
pelleted neutrophils incubated with sivelestat and EDTA; x40 magnification, scale bar 
represents 10 µm. C: Supernatant NE activity was measured by Enzchek® assay. D: MPO 
activity was measured by DMB-based MPO assay. A&B: representative images from n=2 
experiments, C&D: Results represent mean ± SEM, n=3; *=p<0.05, **=p<0.01; two way 
ANOVA, Sidak’s multiple comparisons test 
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As TMT-MS required a minimum of 25 μg protein to allow effective sample labelling, the 
protein concentration method was evaluated. As each 1 ml supernatant sample contained 
between 1-2 μg protein, 24 replicates were prepared per condition (the maximum capacity of 
the thermomixer), with a resultant 24 ml produced. Since TCA and ammonium acetate 
precipitation methods are not ideal for handling large sample volumes (Table 4.1), spin 
columns were deemed the best option. A test sample of pooled neutrophil supernatant was 
spin-column concentrated and compared with TCA-precipitation by subsequent SDS-PAGE 
and silver staining. Spin column concentration showed similar protein recovery when 
compared with previous gels, which was consistent between replicate samples, whereas the 
TCA-precipitated pellet was not re-suspended properly (a recognised problem) (Figure 4.7). 
Hence, spin column protein concentration was used to prepare samples for TMT-MS.  
 
Figure 4.7: Comparison of TCA-precipitation and spin column protein concentration 
Supernatants from normoxic and hypoxic, PAF and fMLP-treated neutrophils (in the presence 
of sivelestat (10 µM) and EDTA (1 mM)) were pooled. The combined sample was either TCA-
precipitated (500 μl) or concentrated using a spin column with a molecular weight cut off of 3 
kDa (3 ml). The equivalent of 500 μl original pooled supernatant was loaded per well, 
subjected to SDS-PAGE and silver stained. Replicate samples generated from one spin 
column were compared. Representative image from n=2 experiments.   
 
4.4 Characterisation of the normoxic versus hypoxic neutrophil secretome by 
10-plex tandem mass tag-labelled mass spectrometry (TMT-MS) 
Informed by preliminary 2D DIGE analysis showing evidence of differential protein release 
under hypoxia vs normoxia and by the optimisation strategy outlined above, 10-plex TMT-MS 
was undertaken to fully characterise the hypoxic vs normoxic neutrophil secretome of five 
healthy donors simultaneously. Isolated neutrophils were re-suspended in IMDM under 
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normoxia or hypoxia in the presence of EDTA and sivelestat and treated with PAF and fMLP. 
For each experiment, cells in one 2 ml Eppendorf were incubated without protease inhibitors 
and assessed for NE release by Enzchek® assay to ensure a hypoxic uplift of elastase 
release. The remaining supernatants per condition were pooled in order to generate sufficient 
protein for TMT-MS labelling. The proteins in the pooled supernatant samples were 
concentrated using spin columns with a molecular weight cut-off of 3 kDa. Equal amounts of 
each sample were prepared for TMT-MS by Renata Feret (CCP). 10-plex TMT-MS was 
performed by Dr Mike Deery (CCP) and the raw data were analysed by Dr Marco Chiapello 
(CCP), with the parameters described in section 2.4.3 and appendix 7.1. 
Satisfactory TMT labelling efficiency (96.95%, measured by CCP) was achieved (see section 
7.1.2). PCA (a statistical technique used to visualise data variance, section 7.1.2) indicated 
separation of the normoxic and hypoxic samples by PC1 (which accounts for the largest data 
variability, Figure 4.8A). A total of 1245 proteins were identified by MS, 717 of which were 
present in all 10 samples. Of these 717 proteins, 199 had both a false discovery rate (i.e. the 
proportion of false peptide spectrum matches, assessed by comparison with a decoy protein 
database, FDR) of <0.01, and were also differentially regulated between normoxia and 
hypoxia (see section 7.2, Table 7.1 (normoxia upregulated) and Table 7.2 (hypoxia 
upregulated)). 63 of these proteins were significantly changed (adjusted p value<0.05) 
between normoxia and hypoxia; 35 were increased in normoxia (Table 4.2) and 28 were 
increased in hypoxia (Table 4.3).  
The 199 differentially regulated proteins with FDR <0.01 are represented by volcano plot 
(Figure 4.8B). These data confirmed that the granule protein MPO (log2FC 1.64, adj. p 
value=0.006), previously shown by alternative biochemical assays to be increased in hypoxic 
neutrophil supernatants (149), was also increased in hypoxic supernatants when examined 
by proteomic methods, although NE (log2FC 0.68, adj. p value=0.25) was not significantly 
increased in this experimental setting (discussed in section 4.7). Additional granule proteins, 
including NGAL (log2FC 0.88, adj. p value=0.004) and resistin (log2FC 0.92, adj. p 
value=0.004), were also increased in hypoxic supernatants. Surprisingly, some proteins which 
were increased under hypoxia are predominantly cytoplasmic, e.g. cyclophilin A (log2FC 0.52, 
adj. p value=0.03), and although more cytoplasmic proteins were detected at higher levels in 
normoxic supernatants, some granule-associated proteins were increased in the normoxic 
relative to the hypoxic samples, e.g. leukocyte elastase inhibitor (log2FC 0.86, adj. p 
value=0.006) and leukocyte specific protein 1 (log2FC 0.91, adj. p value=0.01). Taken 
together, these data suggest that, whilst the release of the majority of granule proteins is 
increased in hypoxia, the differential protein release may not be purely mediated by enhanced 
degranulation and that alternative mechanisms warrant consideration.   
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Table 4.2: Proteins significantly increased in normoxia 
Proteins significantly increased in normoxia (adj. p value <0.05) which were present in all 10 
samples with a FDR <0.01 are listed in order of the magnitude of the fold change (FC).  The 
p value was adjusted by the Benjamini-Hochberg FDR correction for multiple comparisons.  
Accession Description Adj. p 
value 
FC Location MV 
presence 
Q5TCU8 Tropomyosin beta chain 0.001 11.855 CYT N 
P10599 Thioredoxin  0.017 3.909 CYT N 
E7EX29 14-3-3 protein zeta/delta 0.015 3.844 S/G Y 
P52566 Rho GDP-dissociation inhibitor 2 0.004 3.802 CYT Y 
P08670 Vimentin 0.006 3.766 CYT Y 
O00299 Chloride intracellular channel protein 1 0.030 2.918 ? Y 
P11021 78 kDa glucose-regulated protein 0.009 2.873 CYT N 
E9PK25 Cofilin-1 0.023 2.753 CYT Y 
E7EMB3 Calmodulin 0.026 2.488 ? Y 
P62993 Growth factor receptor-bound protein 2 0.004 2.478 CYT N 
P20700 Lamin-B1 0.004 2.435 NUC Y 
Q32MZ4 Leucine-rich repeat flightless-interacting 
protein 1 
0.004 2.337 NUC/ 
CYT 
N 
P06737 Glycogen phosphorylase, liver form 0.025 2.217 ? Y 
P32942 Intercellular adhesion molecule 3 0.015 2.149 S/G Y 
Q9Y490 Talin-1 0.015 2.116 S/G Y 
O15144 Actin-related protein 2/3 complex subunit 
2 
0.031 2.086 CYT Y 
P06702 Protein S100-A9 0.013 2.084 CYT Y 
P52209 6-phosphogluconate dehydrogenase, 
decarboxylating 
0.013 1.950 CYT Y 
P26038 Moesin 0.019 1.878 S Y 
P33241 Leukocyte-specific protein 1 0.013 1.878 S/G Y 
P18206 Vinculin 0.015 1.816 CYT Y 
P30740 Leukocyte elastase inhibitor 0.006 1.813 A Y 
Q96C19 EF-hand domain-containing protein D2 0.027 1.794 ? Y 
A6NIZ1 Ras-related protein Rap-1b-like protein 0.009 1.749 SV Y 
P35579 Myosin-9 0.012 1.631 CYT Y 
Q29963 HLA class I histocompatibility antigen, 
Cw-6 alpha chain 
0.039 1.627 PM N 
P61247 40S ribosomal protein S3a 0.028 1.528 ? N 
P02042 Hemoglobin subunit delta 0.049 1.492 ? Y 
E7EQR4 Ezrin 0.023 1.473 ? N 
P08133 Annexin A6 0.035 1.458 ? Y 
P31146 Coronin-1A 0.034 1.451 S/G Y 
Q15907 Ras-related protein Rab-11B 0.015 1.447 G N 
P46781 40S ribosomal protein S9 0.044 1.438 CYT N 
P46940 Ras GTPase-activating-like protein 
IQGAP1 
0.049 1.411 G Y 
P39687 Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
0.043 1.358 ? N 
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Table 4.3: Proteins significantly increased in hypoxia 
Proteins significantly increased in hypoxia (adj. p value <0.05) which were present in all 10 
samples with a FDR <0.01 are listed in order of the magnitude of the fold change (FC).  The 
p value was adjusted by the Benjamini-Hochberg FDR correction for multiple comparisons.  
Accession Description Adj. p 
value 
FC Location MV 
presence 
P62805 Histone H4 0.004 3.587 NUC Y 
P05164 Myeloperoxidase 0.006 3.107 A Y 
A6NC48 ADP-ribosyl cyclase/cyclic ADP-
ribose hydrolase 2 
0.025 2.468 SV Y 
O75083 WD repeat-containing protein 1 0.029 2.382 CYT Y 
Q92820 Gamma-glutamyl hydrolase 0.020 2.143 S Y 
P02788 Lactotransferrin  0.033 2.136 S Y 
A5A3E0 POTE ankyrin domain family 
member F 
0.015 2.074 CYT N 
Q0VD83 Apolipoprotein B receptor 0.025 1.993 S/G Y 
P10124 Serglycin 0.012 1.904 CYT N 
Q9HD89 Resistin 0.004 1.898 A/S Y 
P07737 Profilin-1 0.015 1.890 CYT Y 
A0A087WXL1 Folate receptor gamma 0.029 1.877 S Y 
P11215 Integrin alpha-M 0.004 1.872 S Y 
P16035 Metalloproteinase inhibitor 2 0.034 1.853 G N 
X6R8F3 Neutrophil gelatinase-associated 
lipocalin 
0.004 1.842 S Y 
V9GYM3 Apolipoprotein A-II 0.049 1.769 ? N 
G3V3D1 Epididymal secretory protein E1 0.007 1.765 A N 
P10153 Non-secretory ribonuclease 0.029 1.650 ? Y 
P04217 Alpha-1B-glycoprotein 0.015 1.594 ? Y 
P05107 Integrin beta-2 0.018 1.580 G Y 
P01024 Complement C3 0.032 1.556 ? Y 
P20061 Transcobalamin-1 0.042 1.492 G Y 
P78324 Tyrosine-protein phosphatase 
non-receptor type substrate 1 
0.018 1.449 SV N 
J3KNB4 Cathelicidin antimicrobial peptide 0.039 1.446 S/G Y 
P62937 Peptidyl-prolyl cis-trans 
isomerase A/Cyclophilin A 
0.035 1.438 CYT Y 
P30086 Phosphatidylethanolamine-
binding protein 1 
0.049 1.406 ? N 
A0A075B6H6 Ig kappa chain C region 0.030 1.358 ? Y 
A0A075B6K9 Ig lambda-2 chain C regions 0.049 1.305 ? N 
 
Tables 4.2 and 4.3: Location data were compiled using the following references: 
(32,33,42,306,318,364,365) and the Uniprot database (www.uniprot.org). Presence (Y) or 
absence (N) of proteins within NDMVs was confirmed by searching supplementary data tables 
from the following references: (95,366). Abbreviations: azurophil (A), specific (S), gelatinase 
(G) granules; secretory vesicles (SV); cytoplasm (CYT); nucleus (NUC); plasma membrane 




Figure 4.8: Characterisation of the normoxic versus hypoxic neutrophil secretome by 
TMT-MS 
Isolated neutrophils were re-suspended in IMDM under normoxia or hypoxia in the presence 
of EDTA (1 mM) and sivelestat (10 µM) for 4 h and then treated with PAF and fMLP. Spin 
column-concentrated supernatants were trypsin-digested and individually labelled with unique 
10-plex isobaric tags. The mixed sample was subjected to MS/MS. A: PCA of normoxic (N, 
blue) and hypoxic (H, red) supernatants, with normoxic and hypoxic samples for individual 
donors linked by dotted lines. Dashed line indicates separation of normoxic vs hypoxic 
samples by PC1. B: volcano plot representation of differential protein expression between 
paired normoxic and hypoxic supernatants. Vertical dotted line represents log2fold change 
(FC) of protein abundance = ±1. Horizontal dotted line represents a significance level of adj.  
p value=0.05; proteins above this line are significantly changed (adj. p value < 0.05). Selected 
proteins are labelled in red. B: n=5; paired t-test, p value adjusted by the Benjamini-Hochberg 
false discovery rate correction for multiple comparisons. 
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4.5 Biochemical validation of differentially regulated proteins identified by 
TMT-MS 
Based on a combination of the magnitude of the increase, novelty and biological plausibility 
for a role (either injurious or protective) in endothelial dysfunction, five candidate proteins 
identified by TMT-MS were taken forward for validation in alternative biochemical assays. 
These candidates comprised three proteins which were increased in hypoxic supernatants 
(resistin, NGAL and cyclophilin A (peptidyl-prolyl cis-trans isomerase A)), and two proteins 
which were increased in normoxic supernatants (thioredoxin and S100A9).   
Firstly, regarding proteins identified as increased in the hypoxic vs normoxic secretome by 
TMT-MS: resistin was increased 1.9-fold (adj. p value=0.004), NGAL was increased 1.8-fold 
(adj. p value=0.004) and cyclophilin A was increased 1.4-fold (adj. p value=0.035). These 
targets were taken forward for validation by ELISA, using freshly generated supernatants from 
different donors. Isolated neutrophils were incubated under normoxia or hypoxia for 4 h before 
treating with PAF and fMLP. Supernatants were assessed for resistin (predominantly in 
azurophil granules), NGAL (predominantly in specific granules) and cyclophilin A (a 
cytoplasmic protein) content by commercial ELISA. Hypoxia increased the release of resistin 
(232 ± 30.36 pg/ml vs 173.3 ± 19.15 pg/ml, p=0.0209, Figure 4.9A), NGAL (4.764 ng/ml ± 
0.647 ng/ml vs 2.875 ± 0.469 ng/ml, p=0.0053, Figure 4.9C) and cyclophilin A (0.0082 ± 
0.0025 OD450nm vs 0.0 OD450nm [all readings below the threshold of detection], p=0.0171, 
Figure 4.9E) from PAF and fMLP-treated neutrophils when compared with normoxia. These 
results were fully in accordance with the proteomic data. 
Secondly, regarding proteins identified as increased in the normoxic vs hypoxic secretome by 
TMT-MS: thioredoxin was increased 3.9-fold (adj. p value=0.017) and S100A9 was increased 
2.1-fold (adj. p value=0.013). These targets were taken forward for validation by ELISA. 
However, it was not possible to detect thioredoxin in any supernatant by ELISA, as all readings 
were below the lowest value set by the standards (156 pg/ml; assay range 156 pg/ml – 10,000 
pg/ml). This was despite trialling neat neutrophil supernatants, the protein-concentrated 
supernatants remaining from the TMT-MS experiment, and supernatants in combination with 
the non-denaturing detergent, Triton-X100 (in case membrane lipoproteins were preventing 





Figure 4.9: The effect of hypoxia on resistin, NGAL and cyclophilin A release from 
neutrophils by ELISA 
Isolated neutrophils were re-suspended in IMDM under normoxia or hypoxia for 4 h and then 
treated with PAF and fMLP. Supernatants were harvested and assessed for A&B: resistin, 
C&D: NGAL or E: cyclophilin A content by commercial ELISA. Data from A&C are represented 
in B&D to show individual paired normoxic and hypoxic samples for resistin (B) and NGAL (D) 
linked by dotted lines for each donor. Data are presented as A-D: supernatant protein 
concentration, E: absorbance at OD450nm minus baseline as ELISA readings for several 
samples were below the lowest value set by the standards (1.25 ng/ml; Elabscience ELISA 
assay range 1.25 ng/ml – 80 ng/ml). Results represent mean ± SEM; A: n=17, C&E: n=7;           




In contrast to the TMT-MS data, there was no significant difference between normoxia and 
hypoxia in the stimulated neutrophil supernatant content of S100A9 homodimer (6.606 ± 0.655 
ng/ml vs 6.853 ± 0.681 ng/ml, p=0.6, Figure 4.10A) by ELISA. Since S100A9 preferentially 
forms a heterodimer with its binding partner S100A8 (which was not identified as differentially 
regulated by TMT-MS), both the heterodimer and S100A8 homodimer content of neutrophil 
supernatants were also quantified to see if this explained the lack of increase in S100A9 
homodimer in normoxic samples. However, neither the S100A8A9 heterodimer (3.508  ± 0.221 
µg/ml vs 3.262 ± 0.201 µg/ml, p=0.2, Figure 4.10B) nor the S100A8 homodimer (1.427 ± 0.243 
ng/ml vs 1.289 ± 0.151 ng/ml, p=0.3, Figure 4.10C) were significantly different between 
normoxic vs hypoxic supernatants from PAF and fMLP-treated neutrophils by ELISA. Further 
examination by western blot of S100A9 content in supernatants from unstimulated or PAF and 
fMLP-treated neutrophils revealed that S100A9 release was significantly increased upon 
stimulation (5722 ± 1447 AU vs 13670 ± 1618 AU (normoxia), p<0.0001; 6528 ± 1619 AU vs 
13825 ± 2094 AU (hypoxia), p=0.001, Figure 4.11B) but, again, there was no significant 
difference between normoxia and hypoxia (5722 ± 1447 AU vs 6528 ± 1619 AU 
(unstimulated), p=0.8; 13670 ± 1618 AU vs 13825 ± 2094 AU (PAF and fMLP), p=1, Figure 
4.11B). These data do not align with those obtained from the proteomics study; possible 
reasons for this discrepancy are discussed in section 4.7. Given time constraints, I did not 
pursue additional studies of the secreted proteins identified by the proteomics study as 







Figure 4.10: The effect of hypoxia on S100A8 and S100A9 release from neutrophils by 
ELISA 
Isolated neutrophils were re-suspended in IMDM under normoxia or hypoxia for 4 h and then 
treated with PAF and fMLP. Supernatants were harvested and assessed for A: S100A9 
homodimer, B: S100A8A9 heterodimer or C: S100A8 homodimer content by commercial 
ELISA. Data are presented as supernatant protein concentration. Results represent mean ± 







Figure 4.11: The effect of hypoxia on S100A9 release from neutrophils by western blot 
Isolated neutrophils were re-suspended in IMDM under normoxia (N) or hypoxia (H) for 4 h 
and then treated with PAF and fMLP (P) or IMDM control (C). Supernatants were harvested 
and BSA (250 µg/ml) added to each sample. Equal volumes of supernatant were subjected to 
SDS-PAGE. Following protein transfer, the PVDF membrane was stained with Ponceau S, 
and western blotting was subsequently performed with anti-S100A9. A: representative 
western blot for S100A9 (upper panel) and corresponding Ponceau S-stained membrane 
(lower panel). B: Quantification of supernatant S100A9 by densitometry using Image J, 
corrected for loading by densitometry of Ponceau S-stained BSA. A: representative image 
from n=12 experiments. B: Results represent mean ± SEM; n=12; *** = p<0.001, **** = 





4.6 The role of NDMV secretion in the differential protein release from 
neutrophils under hypoxia 
Having established that hypoxia enhances the release of proteins characteristic of neutrophil 
degranulation (section 3.3, reference (149)), it logically followed that a number of granule 
proteins, including NGAL and resistin, were increased in supernatants from hypoxic 
neutrophils. However, the apparent reduction of some granule proteins (e.g. leukocyte 
elastase inhibitor) and increase of a subset of cytoplasmic proteins (e.g. cyclophilin A) in 
hypoxic supernatants was intriguing. Neutrophils, among many other cell types, are able to 
release membrane-bound MVs, spherical structures less than 1 µm in diameter, which contain 
components derived from the parent cell, including proteins (274). Published proteomic data 
analysing NDMVs derived from normoxic cells has detected cyclophilin A, amongst other 
contents (94,95,366). I therefore hypothesized that the mechanism of enhanced release of 
cytoplasmic proteins from neutrophils under hypoxia was increased NDMV secretion. 
4.6.1 Quantification of NDMV release from normoxic and hypoxic neutrophils 
To assess MV release from neutrophils under normoxia vs hypoxia, supernatants were 
subjected to sequential centrifugation, and NDMV content was measured by flow cytometry. 
Dr Victoria Ridger (University of Sheffield) has previously shown that optimal NDMV yields 
were obtained using Histopaque-1077® gradients to isolate neutrophils and a standard 1 h 
incubation with 10 μM fMLP (276). Neutrophils were isolated from whole blood using 
Histopaque®-1077 gradients (see section 2.5.1) and, concurrently from the same donor, by 
plasma-Percoll® gradients (since this method was used for the proteomic studies). Isolated 
neutrophils were re-suspended in normoxic or hypoxic IMDM (1*107/ml) and incubated for 1 
or 4 h. In addition to the standard 4 h incubation, a 1 h timepoint was also chosen to make 
sure that any observed effects were not due to release of apoptotic bodies at the later time 
point and that the delicate NDMVs were not being lost following the more protracted 
incubation. Cells were treated with fMLP (10 µM) 1 h prior to the end of incubation. After 
treatment, cells were pelleted and supernatants sequentially centrifuged to pellet MVs (see 
section 2.5.1). Quantification of NDMVs was undertaken with the assistance of Merete Long 
(PhD student supervised by Dr Victoria Ridger, University of Sheffield), using established 
protocols (section 2.5.2). Pelleted NDMVs were re-suspended in sterile PBS with a known 
number of counting beads and quantified by flow cytometry. Although there was no significant 
difference in NDMV release between normoxia and hypoxia for either isolation method at 4 h, 
in fact NDMV release from Histopaque-1077® isolated neutrophils was higher in normoxia 
compared with hypoxia at the 1 h time point (NDMV count: 18340 ± 5109 vs 9616 ± 2795, 
p=0.0227, Figure 4.12A). These data refute the hypothesis that hypoxia increases NDMV 
release, although it must be acknowledged that the stimulation conditions were not identical. 
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Of note, in my hands the Histopaque-1077® isolated neutrophils were basally shape-changed 
(Figure 4.12B), suggesting priming/activation by the preparative method, but these cells also 
had a blunted response to PAF and fMLP-stimulated ROS production (Figure 4.12C, data 
generated with the assistance of Dr Arlette Vassallo). This may have affected the generation 
of MVs from Histopaque-1077® isolated neutrophils, and it is possible that the longer 
incubation period allowed reversion to a less activated (or de-primed) state. Importantly, these 
results emphasise that the plasma-Percoll® method isolates un-primed but responsive cells.  
4.6.2 Evaluation of cyclophilin A protein content of NDMVs from normoxic 
and hypoxic neutrophils 
NDMVs have been shown to have myriad functions, with both pro- and anti-inflammatory 
effects (reviewed in (274)). Interestingly, studies of NDMV proteomes have identified distinct 
protein signatures which are dependent on the neutrophil stimulus and environment 
(94,95,366). Thus, I hypothesized that the protein composition of NDMVs is regulated by the 
normoxic or hypoxic environment, and that this controlled packaging contributes to the 
differential protein release.  
To investigate whether hypoxia modulates the incorporation of cyclophilin A into NDMVs, I 
performed western blotting for cyclophilin A and the established NDMV marker, annexin A1 
(95,98). Having optimised the method using neutrophils isolated by Hisotpaque-1077® 
gradients, I performed western blotting on NDMV lysates from both Histopaque®-1077 and 
plasma-Percoll® isolated neutrophils, derived from the same donors in parallel, to ensure that 
results were not confounded by the neutrophil isolation method. Neutrophils were re-
suspended in normoxic or hypoxic IMDM for 1 or 4 h (corresponding to the conditions 
previously chosen for flow cytometric analysis) and treated with fMLP 1 h prior to the end of 
incubation. Cells were then pelleted and the supernatants sequentially centrifuged to pellet 
MVs as before. After 4 h incubation, MV-deplete supernatants (generated by pelleting NDMVs 
in the final centrifugation step) were also harvested and then TCA-precipitated. NDMV lysates 
(section 2.5.3) and TCA-precipitated MV-deplete supernatants were subjected to SDS-PAGE, 
and western blotting performed for cyclophilin A and annexin A1 (Figure 4.13). Protein bands 
for annexin A1 (the double-band is standardly detected with this antibody) were visualised in 
NDMV lysates but not supernatants, demonstrating that the latter were not contaminated by 
NDMVs. Importantly, unlike annexin A1, cyclophilin A was detected in MV-deplete 






Figure 4.12: Comparison of neutrophil isolation methods and the effect of hypoxia on 
NDMV release 
Neutrophils were isolated using plasma-Percoll® or Histopaque-1077® gradients as indicated. 
A: Neutrophils were re-suspended in IMDM (1*107/ml) under normoxia or hypoxia. Cells were 
incubated for 1 or 4 h and treated with fMLP (10 µM) 1 h prior to the end of incubation. Cells 
were pelleted and supernatants sequentially centrifuged to pellet MVs. MV pellets were re-
suspended in sterile PBS (190 µl) with counting beads (10 µl, 10,000 beads) and analysed by 
flow cytometry. The MV forward scatter vs side scatter gate was set using standardised size 
calibration beads, and 1,000 counting beads were measured per sample. B: Neutrophils were 
re-suspended in normoxic IMDM (5*106/ml) and treated with fMLP (100 nM) or PBS+/+ 
(control). Cells were fixed at baseline or after 30 min. Shape change was assessed by flow 
cytometric analysis of forward scatter (BD FACSCanto II). C: Neutrophils were re-suspended 
in normoxic PBS+/+ (5*106/ml) and treated with PAF (1 µM, 5 min) or PBS+/+ (unprimed) 
before addition of luminol (1 µM, 3 min) and HRP (62.5 units/ml). ROS production was 
analysed in a luminometer following injection of fMLP (100 nM). Data were generated with the 
assistance of Dr Arlette Vassallo. A&B: Results represent mean ± SEM; A: n=7, B: n=2-3. C: 
Image representative of n=2 experiments. A: *=p<0.05, two way ANOVA, Sidak’s multiple 




There was no significant difference in NDMV annexin A1 content between normoxia and 
hypoxia for any condition (Figure 4.14A&B). Hypoxia, compared with normoxia, resulted in 
increased content of cyclophilin A in MV lysates derived from plasma-Percoll® isolated 
neutrophils at 1 h (28643 ± 16335 AU vs 16951 ± 15930 AU, p=0.0142, Figure 4.14D) but not 
at 4 h. There was no difference in cyclophilin A content for MV lysates derived from 
Histopaque®-1077 isolated neutrophils at either timepoint (Figure 4.14C). As annexin A1 is a 
surrogate for NDMV number, cyclophilin A densitometry was divided by the fold change in 
annexin A1 (relative to normoxic control at 1 h) to assess whether cyclophilin A was 
differentially packaged under normoxia vs hypoxia. However, there was no significant 
difference in cyclophilin A content between normoxia and hypoxia for any condition after this 
correction for NDMV number (Figure 4.14E&F). 
These data do not support the hypothesis that the differential release of cyclophilin A under 
hypoxia is due to increased NDMV protein content. Although an increase of cyclophilin A was 
observed at 1 h for MVs derived from plasma-Percoll® isolated neutrophils under hypoxia, 
there were no significant differences between normoxia and hypoxia at the 4 h (corresponding 
to the previous proteomic and ELISA assessment) timepoint. Additionally, there appeared to 
be more cyclophilin A in MV-free supernatants than NDMV lysates.  
 
 
Figure 4.13: Neutrophil-derived microvesicle and supernatant content of annexin A1 
and cyclophilin A by western blot  
Neutrophils, re-suspended in normoxic (N) or hypoxic (H) IMDM (1*107/ml), were incubated 
for 1 or 4 h and treated with fMLP (10 µM) 1 h prior to the end of incubation. NDMVs were 
isolated at the 1 or 4 h timepoints as indicated by pelleting cells and sequentially centrifuging 
supernatants to pellet NDMVs. MV-deplete supernatants (SN) were also generated after the 
4 h incubation. NDMV lysates and TCA-precipitated SN were subjected to SDS-PAGE, and 
western blotting was performed for annexin A1 and cyclophilin A. Representative images from 




Figure 4.14: Quantification of neutrophil-derived microvesicle content of annexin A1 
and cyclophilin A by western blot 
Neutrophils were isolated by A,C,E: Histopaque-1077® gradients or B,D,F: plasma-Percoll® 
gradients. A-F: Neutrophils were re-suspended in IMDM (1*107/ml) under normoxia or hypoxia 
for 1 or 4 h and treated with fMLP (10 µM) 1 h prior to the end of incubation. Cells were pelleted 
and the supernatants sequentially centrifuged to pellet NDMVs. MV lysates were subjected to 
SDS-PAGE and probed for annexin A1 (A&B) and cyclophilin A (C&D) by western blotting. 
NDMV lysate annexin A1 and cyclophilin A content was quantified by Image J analysis of 
protein band densitometry. E&F: Cyclophilin A content was divided by the fold change in 
annexin A1 (relative to 1 h normoxia) to correct for NDMV number. Results represent mean ± 






The application of proteomics techniques to neutrophil biology has yielded detailed information 
on protein abundance in both healthy and disease states, with relevant functional implications. 
Studies of the whole cell proteome of healthy neutrophils after stimulation with PAF and fMLP 
(367), TNFα and/or GM-CSF (368), or ligation of the formyl peptide receptor like-1 receptor (a 
low affinity fMLP receptor) (369) have revealed multiple up- and down-regulated proteins when 
compared with quiescent neutrophils. Some granule proteins, e.g. MMP-9, were decreased in 
stimulated neutrophils, likely reflecting degranulation (369). Of relevance to my findings in 
Chapter 3 that hypoxia augments NE release from GM-CSF- but not TNFα-primed neutrophils, 
GM-CSF but not TNFα induced a discriminative neutrophil protein profile when compared with 
quiescent neutrophils by PCA (368). Studies of whole cell proteomes of circulating neutrophils 
from rats exposed to surgical trauma (370), and COPD (220) or trauma patients (371), 
compared with healthy controls, have similarly identified multiple differentially regulated 
proteins, with functional implications for cell survival, trafficking and activation. Interestingly, 
Langereis et al. found that the proteomic profile of stable COPD patient neutrophils did not 
match that of TNFα and/or GM-CSF-treated neutrophils from healthy controls using 2D DIGE, 
although protein identification was not performed in this study (220). The authors suggest that 
the disparity is due to the effect of an interplay of multiple inflammatory signals in COPD which 
does not reflect changes induced by treatment with single cytokines. Hypoxia (which was not 
assessed in this study) may also impact the neutrophil proteome, even in stable COPD. 
A few proteomic studies have examined the secretion profile of neutrophils. These studies 
comprise identification of proteins secreted by healthy isolated neutrophils treated with 
ionomycin (309), TNFα or cytochalasin B/fMLP (306), chromofungin or catestatin 
(antimicrobial peptides derived from Chromogranin A) (307), S. aureus leukotoxins (LukE/D) 
(308), or several strains of S. pyogenes (305,306). One study also examined the presence of 
known neutrophil-secreted proteins in the plasma of patients with bacterial sepsis compared 
with healthy controls (306). However, all of these experiments were performed under normoxic 
conditions, and no studies have investigated the effect of hypoxia on the neutrophil secretome. 
Since neutrophil supernatants contain multiple proteases which could hamper subsequent MS 
peptide identification, the anti-protease proteomics strategy was extensively optimised. The 
finding that AEBSF caused substantial neutrophil death was unexpected as, in contrast to 
PMSF, it is reported to be non-toxic. The product information data sheet recommends a 
working concentration of up to 2 mM, although data sheets from other companies suggest 
using a concentration of up to 0.25 mM in cell culture media. The literature on AEBSF-induced 
cytotoxicity is limited as AEBSF is normally employed as a protease inhibitor during the 
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preparation of cell lysates, hence short incubation times would normally be used, and a degree 
of cytotoxicity would likely not be apparent. However, one study has shown that AEBSF in 
solution at a concentration of >75 μM was highly cytotoxic to keratinocytes, with the authors 
suggesting that the mechanism was reactivity of the fluorosulfonyl group with molecules critical 
for cell survival (372). It is probable that the relatively high concentration of AEBSF and lengthy 
incubation times (> 4h, in order to counteract any proteases which may have been released 
from cells prior to stimulation, particularly under hypoxia) used for my initial experiments 
masked the subsequent difference between normoxic and hypoxic samples revealed by silver 
staining when using a lower concentration, which allowed a degree of hypoxic protection. 
Importantly, having recognised that AEBSF was toxic to neutrophils at the concentrations 
necessary for serine protease inhibition during supernatant generation, the anti-protease 
approach was adjusted to ensure neutrophil viability following inhibitor treatment. Having 
established a robust method for the preparation of neutrophil supernatants for TMT-MS, I have 
generated a novel and thorough description of the hypoxic vs normoxic neutrophil secretome.  
Previous published data from our laboratory (149) has shown an increase in the release of the 
granule proteins NE and MPO (azurophil granules), lactoferrin (specific granules) and MMP-
9 (gelatinase granules) from hypoxic neutrophils. Supporting these data, my secretome 
analysis showed a hypoxic upregulation of all of these proteins. However, the hypoxic increase 
in supernatant NE (p=0.25) and MMP-9 (p=0.08) content was not statistically significant (see 
Table 7.2). It is possible that the proteomic detection and analysis methods resulted in 
masking of some true positive identifications (373). Previous data for MMP-9 were generated 
from GM-CSF and fMLP-treated neutrophils, showing an approximate 3-fold increase in 
release under hypoxia by ELISA (149). It is possible that the discrepancy was due to the use 
of different priming agonists. Additionally, donor variability, as demonstrated by the ELISA 
data for normoxic vs hypoxic resistin release (Figure 4.9A), might necessitate an increased 
sample size to detect any difference; the use of five subjects was dictated by the ability to run 
10 samples in parallel. I have previously shown a highly significant increase in supernatant 
NE activity from PAF and fMLP-treated neutrophils under hypoxia (Figure 3.2B). It may be that 
the activity assay is more sensitive than assessment of NE amount. Another potential 
explanation for discordance between the proteomic and activity assay data is that, rather than 
being entirely dependent on the amount of protein, NE activity may be influenced by other 
secreted proteins within the supernatant, such as leukocyte elastase inhibitor, which was 
decreased in hypoxia relative to normoxia by proteomic analysis. Although interaction of 
proteases and their physiological inhibitors is highly relevant in vivo, the use of sivelestat and 
EDTA was necessary in the setting of the proteomics study to prevent protein degradation by 
NE and MMPs prior to peptide analysis. However, neutrophils release other proteases which 
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could have been active in the proteomics study supernatants. PR3, another serine protease, 
is in fact inhibited by high (10 μM) concentrations of sivelestat (despite being NE-selective) as 
the half maximal inhibitory concentration (IC50) is 340 nM but the IC50 of sivelestat for cathepsin 
G is reported as >10μM. MPO, although not a protease, is able to oxidise certain amino acids, 
e.g. methionine, but these variations should not have influenced the TMT-MS results as 
variable oxidation modifications were built into the data analysis parameters. Overall, this 
discrepancy highlights the importance of performing additional biochemical assay 
confirmation. The specific targets identified by proteomic analysis which were selected for 
validation by ELISA were resistin, NGAL and cyclophilin A (increased in hypoxia), and 
thioredoxin and S100A9 (increased in normoxia). 
Both resistin (an adipokine) and NGAL (an iron trafficking protein) are neutrophil granule 
proteins. The majority of resistin is present in azurophil granules (318) whereas the NGAL is 
predominantly found in specific granules (33), although a degree of overlap occurs. Both 
proteins have been implicated in acute, e.g. sepsis (111),  and chronic, e.g. RA and IBD 
(374,375), inflammatory conditions, and increased serum levels of both proteins were shown 
to correlate with the severity of sepsis (111). Although release of these proteins from hypoxic 
neutrophils has not previously been examined, increased resistin levels were present in the 
synovial fluid of patients with RA, a known hypoxic environment, when compared with 
osteoarthritis (374). Furthermore, increased serum resistin has been demonstrated in a rat 
model of chronic intermittent hypoxia (376) and increased circulating NGAL was detected in 
humans exposed to hypobaric hypoxia at high altitude (>5000 m) (377).  
My work demonstrated that both resistin and NGAL were increased in supernatants from 
hypoxic PAF and fMLP-treated neutrophils by proteomic assessment, and this hypoxic 
upregulation was confirmed by subsequent ELISA measurement in independently generated 
samples. These data provide further evidence of a hypoxic enhancement of degranulation, 
although time constraints prevented investigation of the role of PI3K signalling in modulating 
the release of these proteins under hypoxia to align with my previous data on NE. Published 
(normoxic) neutrophil secretomes, have shown active secretion of both resistin and NGAL in 
response to neutrophil treatment with various stimuli in vitro (including cytokines and bacterial 
products). Furthermore, resistin was also shown to be increased in septic patient vs healthy 
control plasma; NGAL, however, was found to be decreased (306) (see Table 7.3). This 
difference may reflect the heterogeneity of the sepsis-inducing agents in this study, which 
included Gram positive and negative bacteria and malaria parasites.  
Surprisingly, the proteins identified by proteomic assessment did not segregate precisely as, 
although the majority were increased in hypoxia, some granule proteins were relatively 
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increased in supernatants from normoxic cells. These data, although not confirmed by 
alternative biochemical assay due to time constraints, suggest that hypoxia does not globally 
increase degranulation. It is possible that hypoxia impacts movement of proteins between 
granules; one study has demonstrated variation in the granule co-localisation of resistin and 
azurocidin, which resulted in a differential secretion profile, dependent on the stimulus used 
(378). Another possibility is that hypoxia is able to direct selective granule release, akin to the 
“piecemeal” degranulation of eosinophils and mast cells (379), although this mechanism of 
secretion has not been described for neutrophils. These data are fascinating and worthy of 
further exploration; potential future research plans in this area are outlined in section 6.3. 
A likewise surprising finding was that, although the majority of cytoplasmic proteins were 
increased in normoxic supernatants, some cytoplasmic proteins, including cyclophilin A, were 
increased in hypoxic supernatants. This was unexpected, given that hypoxia promotes 
neutrophil survival, suggesting that the increase was not due to excess cell death. Cyclophilin 
A is an isomerase which regulates protein folding and trafficking. It has been shown to induce 
neutrophil chemotaxis and secretion of pro-inflammatory molecules from monocytes in vitro 
(380,381), and is associated with several inflammatory conditions, including sepsis (382), 
ulcerative colitis (383), ARDS (where it was more abundant in BALF from non-survivors) (384) 
and RA (where it was detected in the synovial fluid of patients with RA but not osteoarthritis) 
(385). Despite lacking a traditional leader export sequence, cyclophilin A has been shown to 
be actively secreted from a number of cell types, including macrophages in response to LPS 
(386) and cardiac myocytes in response to hypoxia/reoxygenation (387). There remains a 
paucity of literature on its secretion from neutrophils, although it has been detected in 
neutrophil secretomes (see Table 7.3). Given the cytoplasmic location of cyclophilin A in 
neutrophils, a release mechanism alternative to that of degranulation is intriguing. One study 
demonstrated that cyclophilin A release from vascular smooth muscle cells was via a vesicular 
transport mechanism, dependent on VAMP-2 (388). In neutrophils, cyclophilin A has been 
detected in NDMVs from healthy volunteers (95,366). No studies to date have looked directly 
at the release of MVs from hypoxic neutrophils. However, increased circulating NDMVs have 
been identified following complex insults that include a hypoxic component e.g. I/R and high 
altitude (188,389). Our initial hypothesis, therefore, was that cyclophilin A is secreted from 
neutrophils in MVs and that increased NDMV release contributed to enhanced (cytoplasmic) 
protein secretion under hypoxia. 
NDMVs were challenging to isolate. Initial trials aiming to generate NDMVs from plasma-
Percoll® isolated PAF and fMLP-treated neutrophils were performed with the assistance of Dr 
Elisabet Ferrer (University of Cambridge), using an established ultracentrifugation MV 
isolation protocol (390). This method yielded very low numbers in comparison with 
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concurrently isolated MVs from endothelial cells, both by electron microscopy (Figure 4.15) 
and Nanosight analysis, where NDMV numbers were at the very limit of detection and could 
not be confidently quantified (data not shown).  
 
 
Figure 4.15: Visualisation of MVs from neutrophils and endothelial cells by electron 
microscopy 
Supernatants from 4*107 neutrophils (A) and 1*107 blood outgrowth endothelial cells (B) were 
sequentially centrifuged to pellet MVs. MV isolation was performed with the assistance of Dr 
Elisabet Ferrer (University of Cambridge). Fresh MV pellets, re-suspended in sterile filtered 
PBS, were negatively stained with uranyl acetate and visualised by transmission electron 
microscopy, with the assistance of Dr Jeremy Skepper (University of Cambridge). Scale bar 
500 nm, arrows indicate examples of MVs. Representative images from n=3 experiments.  
 
Advice was therefore sought from Dr Victoria Ridger (University of Sheffield), and protocols 
well-established in her laboratory were used to optimise NDMV isolation. Hence, neutrophils 
were isolated using Histopaque-1077® gradients and a higher concentration of fMLP. 
However, the increase in yield was relatively minor and did not reach statistical significance. 
To ensure that the findings generated using the Histopaque-1077® method were not simply 
related to the cell isolation, particularly given my data showing basal neutrophil priming, I 
checked all key results using samples derived from my standard plasma-Percoll® cells. As 
flow cytometric analysis of NDMV number did not support a hypoxic increase in release, we 
then hypothesised that hypoxia may lead to differential packaging of NDMVs and thus impact 
protein release. Western blotting was performed to investigate whether hypoxia modulated 
the NDMV content of cyclophilin A. Although cyclophilin A was detected in NDMV lysates, 
when corrected for NDMV number using the MV marker annexin A1, there was no difference 
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in content between normoxic vs hypoxic NDMV. Furthermore, cyclophilin A (but not annexin 
A1) was detected in MV-free neutrophil supernatants, indicating that its release is partly 
NDMV-independent. Hence, the mechanism of enhanced cyclophilin A release from hypoxic 
neutrophils remains elusive; it would be interesting to investigate the role of PI3K modulation 
in this context, as well as inhibitors of vesicular transport. 
Interestingly, of all the proteins upregulated in hypoxic supernatants, histone H4 (a component 
of NETs) showed the largest fold increase. Although my investigation of NET release by 
measuring extracellular DNA did not reveal an increase under hypoxia, it is important to note 
that this is a surrogate marker of NETosis. Any DNA release from necrotic cells (which may 
be increased under normoxia as hypoxia is a survival signal) could obscure true differences 
in NET generation. Additionally, the literature to date is conflicting (see Section 1.2.2.6). My 
data suggest a possible “NET signature” in hypoxic supernatants; therefore, NETosis may 
contribute to protein release under hypoxia. This could be further investigated with more 
sensitive and specific assays, including ELISA or western blotting to measure citrullinated 
histones, or histones associated with NE or MPO.     
Another surprising finding was the presence of small numbers of blood proteins, such as a 
haemoglobin subunit (increased in normoxia) and immunoglobulins (increased in hypoxia). It 
is possible that the supernatants samples contained haemoglobin due to contamination from 
red blood cells during the neutrophil isolation process as a red cell lysis step was not used but 
this would not explain a significant difference between normoxia and hypoxia, given that the 
neutrophils were split equally between conditions from one original pooled sample. The effect 
of hypoxia on red blood cells is not well defined but it has been reported to induce increased 
cell deformability alongside membrane fragility (391), which would suggest an increase in 
hypoxia in contrast to my observations. The presence of the immunoglobulins, which are 
present in plasma, is perhaps more easily explained. Neutrophil secretory vesicles are 
intracellular storage granules formed by endocytosis and contain a number of plasma proteins, 
which may include immunoglobulins. The observed increase in hypoxia would therefore be 
consistent with enhanced degranulation.  
As well as investigating proteins increased in hypoxic supernatants, I also sought to validate 
proteins that were relatively increased in normoxic supernatants. Thioredoxin and S100A9 are 
both cytoplasmic proteins which have been shown to be actively secreted from other cell types 
(392,393) and, in the case of S100A9, from neutrophils (394). Both have been detected in 
normoxic neutrophil secretomes (see Table 7.3). Thioredoxin, a cytosolic disulphide reductase 
which functions as a ROS scavenger and regulator of redox-sensitive transcription factors has 
been shown to be anti-inflammatory, reducing neutrophil trans-endothelial migration and 
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protecting rabbits from I/R-induced ALI (395,396). S100A9 is a calcium-binding protein, 
preferentially forming a heterodimer (calprotectin) with its partner S100A8, and comprises 
approximately 45% of the neutrophil cytosol (397). There is debate as to whether S100A9 is 
pro- or anti-inflammatory. Proposed anti-inflammatory roles include: anti-oxidant free radical 
scavenging (398) and MMP inhibition (399); S100A9 was protective in a mouse model of LPS-
induced ALI (400), whereas deficiency promoted lung inflammation in pneumonia model (401). 
However, the balance of the literature supports a pro-inflammatory role: S100A9 could 
stimulate neutrophil adhesion, degranulation and pro-inflammatory cytokine release in vitro 
(402–404), and S100A9-deficient mice were protected from mortality in murine models of 
endotoxin-induced shock and pneumonia (401,405). 
The two normoxic protein targets chosen for further analysis did not align with my proteomic 
data. The lower limit of detection of the ELISA used for thioredoxin was not sensitive enough 
to detect the protein in my supernatants, despite using the remainder of the concentrated 
supernatants from the proteomic study. Had time allowed, I would have generated a new set 
of protein-concentrated samples and trialled a more sensitive ELISA. However, as I have 
shown an impact on endothelial cells from unconcentrated supernatants (section 3.5), it seems 
unlikely in the context of this experimental setup that thioredoxin would exert a detectable 
effect, although it would also be important to test that this ELISA was compatible with detection 
of neutrophil supernatant proteins. In contrast to the proteomic data, measurement of S100A9 
by both ELISA and western blot showed no difference between normoxia and hypoxia. As 
S100A9 comprises almost half of the cytosolic protein content, any small differences in cell 
death between normoxia and hypoxia (allowing protein release into the supernatant) may 
account for discrepant results. Although cytospins of neutrophil cell pellets were generated 
prior to proteomic assessment, which did not demonstrate any obvious morphological 
difference between normoxia and hypoxia, apoptosis was not formally assessed. Secretion of 
S100A9 from neutrophils has been shown to be dependent on an intact microtubule network 
(394); another possibility is that the presence of protease inhibitors in proteomic samples 
affected this pathway (e.g. through calcium chelation), thereby influencing S100A9 release. A 
further consideration is that of the technical ability of the ELISA to detect neutrophil 
supernatant proteins as the assay is only validated for serum and plasma samples. It is 
possible that proteases within the supernatant samples were able to cleave the binding 
antibody in the coated plate thereby impairing the capture/detection process. Future 
experiments could test the ELISA validity by the addition of a known quantity of recombinant 
protein to a supernatant sample to ensure that the expected amount is detected in this system. 
Similarly, this technique, in combination with a more sensitive assay, could be used to validate 
the results from my cyclophilin A ELISA (where protein content in the normoxic samples was 
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below the limit of detection) to ensure that the signal from the hypoxic supernatants was 
accurately reflecting protein content rather than due to interference from proteases within the 
supernatant samples. 
My characterisation of the normoxic vs hypoxic neutrophil secretome has important functional 
implications. The hypoxia-upregulated proteins resistin, NGAL and cyclophilin A have all been 
implicated in endothelial dysfunction. Resistin and cyclophilin A increased endothelial cell 
adhesion molecule expression in vitro (406–408), and some studies (e.g. (407)) have shown 
induction of endothelial cell apoptosis by cyclophilin A. Resistin also increased secretion of 
the potent vasoconstrictor endothelin 1 (408), and circulating levels correlated with endothelial 
cell adhesion molecule expression in sepsis (409) and with impaired FMD in normotensive 
individuals (410). Although evidence for direct endothelial injury by NGAL is lacking, it was 
shown to be increased in vulnerable atherosclerotic plaques ex vivo (411), as was cyclophilin 
A (406). Increased circulating NGAL has been detected in patients with coronary heart disease 
(412), and levels were associated with increased arterial stiffness and future cardiovascular 
events (413). High circulating levels of cyclophilin A have been observed in patients with type 
2 diabetes mellitus in association with CVD (414) and cyclophilin A-deficient mice developed 
less severe atherosclerosis in a standard apolipoprotein E-deficient model. Hence, these 
proteins may be responsible for some of the endothelial dysfunction caused by hypoxic 
neutrophil supernatants and therefore represent potential novel therapeutic targets. Plans to 
establish the capacity of these proteins to cause endothelial damage in this context are 
outlined in section 6.3. 
Overall these proteomic data give a detailed characterisation of the normoxic vs hypoxic 
secretome, with biochemical validation of proteins which are upregulated under hypoxia and 
have the potential to cause endothelial damage. I wished to investigate these targets further 
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5 Effect of hypoxia on neutrophil function in exacerbating COPD 
patients 
5.1 Introduction 
Having established that hypoxia differentially regulates protein release from neutrophils and 
that a number of these hypoxia-upregulated proteins have histotoxic capacity, I wished to 
extend my observations to a clinically relevant cohort of patients. COPD is characterised by 
persistent airway neutrophilic inflammation, with increased numbers of neutrophils identified 
both in BALF and within the bronchial epithelium when compared to healthy controls (198). 
Moreover, the degree of airway neutrophilia in COPD correlates with disease severity (415). 
COPD patients are frequently hypoxaemic, particularly during exacerbations, but even in the 
absence of systemic hypoxia, profound local tissue hypoxia can exist in areas of infection 
and/or inflammation (136,222); stabilisation of HIF-1α, which increases exponentially below 
6% oxygen, has been demonstrated in the bronchial epithelium of COPD patients, where 
neutrophilic inflammation is a key disease driver (131).  
Further to our published data showing injury to epithelial cells, I have demonstrated that 
hypoxic neutrophil supernatants also damage endothelial cells. COPD patients have 
increased endothelial dysfunction compared with healthy controls, even after correcting for 
shared risk factors, such as smoking (225). This manifests clinically as cardiovascular 
comorbidity, with an increased incidence of myocardial infarction and stroke in COPD patients 
(227). Several studies have shown that COPD patients have increased vascular inflammation 
and arterial stiffness (226,280), even when those with overt CVD are excluded (234). 
Therefore, as COPD encompasses chronic neutrophilic inflammation in the context of local 
and systemic hypoxia plus endothelial dysfunction, I wished to investigate whether neutrophils 
from COPD patients exhibited a “hypoxic signature”, focusing on my hypoxia-upregulated 
proteins of interest, and whether this was reflected in the plasma. 
Although multiple studies have looked at blood, sputum and BALF protein content in COPD 
(416), with a view towards identifying clinically useful biomarkers, only two studies have looked 
specifically at proteins secreted by COPD patient neutrophils: Blidberg et al. showed no 
difference in IL-8 or macrophage inflammatory protein (MIP)-1α release from TNFα-treated 
COPD vs. healthy neutrophils (417) whereas Baines et al. showed an increase in MMP-9 
release from LPS-treated COPD neutrophils (418). Genetic (335) and proteomic (219,221) 
profiling of peripheral blood neutrophil lysates has demonstrated a number of differences 
between COPD neutrophils compared with healthy controls, including increased elastase 
activity alongside undetectable levels of leukocyte elastase inhibitor (Serpin B1). Regarding 
the protein targets I have identified as upregulated in the hypoxic neutrophil secretome, a role 
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for NE in the pathogenesis of COPD  has long been established (419) but the contribution of 
MPO, resistin, NGAL and cyclophilin A is less clear, although increased sputum MPO and 
NGAL (420), and increased circulating resistin (113), NGAL (112) and cyclophilin A (114) have 
been detected in COPD patients. I therefore hypothesised that neutrophils from exacerbating 
COPD patients would release more NE, MPO, resistin, NGAL and cyclophilin A and that these 
proteins would be increased in COPD patient plasma.  
Despite my not demonstrating a difference in NDMV release under hypoxia compared with 
normoxia in vitro (section 4.6.1), studies have shown increased circulating NDMVs in the 
setting of altitude-associated hypoxia or following hypoxic exercise testing (188,421), 
increased NDMVs in the coronary sinus following percutaneous intervention in patients 
suffering from acute coronary syndrome (422), an association of NDMVs with subclinical 
atherosclerosis burden (423) and increased circulating exosomes (MVs <100 nm) in 
exacerbating COPD patients (424). Given this evidence and as it is possible that my results 
in section 4.6 do not accurately reflect the in vivo situation, I additionally decided to investigate 
the distribution of neutrophil-, monocyte-, endothelial cell- and platelet-derived MVs in COPD 
patient plasma, hypothesising that exacerbating COPD patients have more circulating NDMVs 
than healthy controls.  
The hypothesis driving the work in this chapter is that exacerbating COPD patients have 
increased release of hypoxia-upregulated histotoxic proteins from neutrophils. 
The specific aims of the work presented in this chapter are: 
1. To compare the release of the hypoxia-upregulated protein targets identified by proteomics 
from neutrophils isolated from exacerbating COPD patients vs healthy controls 
2. To compare the content of these hypoxia-upregulated protein targets in plasma from 
exacerbating COPD patients vs healthy controls 
3. To examine the distribution of neutrophil-, monocyte-, endothelial cell- and platelet-derived 




5.2 Investigation of COPD versus healthy neutrophil secretion of proteins 
upregulated in the hypoxic secretome 
Exacerbating COPD patients were recruited from Cambridge University Hospitals NHS 
Foundation Trust. Patients who met the inclusion and exclusion criteria (see section 2.6.1) 
were identified using electronic patient medical records (Epic software) and written consent 
was obtained. Demographic and clinical data are listed in Table 5.1. Venous blood was drawn 
within 24 h of admission to obtain plasma and serum. For a subset of patients, blood was also 
drawn for neutrophil isolation. Age- (within 10 years) and sex-matched healthy controls had 
blood drawn to obtain plasma and serum, with or without neutrophil isolation. As COPD 
patients were older than the healthy volunteers in our database and prior notice for 
venepuncture was short (< 24 h), it was not possible to obtain blood from age- and sex-
matched healthy controls at the same time as COPD patients. Also, given the unpredictable 
timing of COPD patient recruitment, the significant (80 ml) volume of blood required to obtain 
sufficient neutrophils for analysis, and the logistics of performing neutrophil isolations at short 
notice alongside other planned experiments, neutrophils were isolated from fewer COPD 
patients than healthy controls. Overall, plasma samples were obtained from n=12 COPD 
patients and n=14 healthy volunteers whereas neutrophil isolations, as a subset of these 
subjects, were performed for n=7 COPD patients and n=13 healthy volunteers. As the mean 
age of healthy volunteers was 66 years, they inevitably had some comorbidities. However, no 
healthy control had respiratory disease and five healthy controls did not have any past medical 
history. On admission, COPD patients were systemically hypoxic, with a mean oxygen 
saturation of 86%, although it was not possible to determine the duration of hypoxia prior to 
admission. As patients were treated with oxygen by the medical team to maintain saturations 
of 88 – 92%, the mean oxygen saturation at the time of blood sampling was 92%. Oxygen 
saturations were not recorded for healthy volunteers but, as stated, there was no past medical 
history of respiratory disease.  
5.2.1 The effect of hypoxia on the release of NE and MPO from COPD versus 
healthy neutrophils 
Neutrophils were isolated from exacerbating COPD patients using plasma-Percoll® gradients. 
As I wished to examine neutrophil degranulation, it was first important to establish whether 
circulating neutrophils from COPD patients were primed or basally activated, since this might 
modulate degranulation responses. Shape change was measured by flow cytometry at 
baseline, or after 30 min in the presence or absence of fMLP (100 nM), using an established 
protocol from our laboratory (425). The small but significant difference in shape change for 
unstimulated neutrophils between baseline and 30 min likely reflects their incubation in PBS, 
which lacks the nutrients present in IMDM. Importantly, there was no significant difference in 
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shape change between COPD or healthy neutrophils for any condition, indicating that 
circulating COPD neutrophils in these patients were not basally primed or activated and were 
able to fully respond to an exogenous activating stimulus (fMLP: Figure 5.1). Out of the full 
cohort, shape change was not assessed for neutrophils isolated from two COPD patients and 
one healthy control, but the following neutrophil supernatant assays (sections 5.2.1 and 5.2.2) 
did include these subjects.  
 
 
Figure 5.1: Quantification of healthy versus COPD neutrophil shape change by flow 
cytometry 
Neutrophils, isolated from exacerbating COPD patients or healthy controls, were incubated in 
the presence or absence of fMLP (100 nM). Cells were fixed at baseline or after 30 min. Shape 
change was assessed by flow cytometric analysis of forward scatter. Results represent mean 




Table 5.1: Clinical and demographic data 
Data were collected from the Cambridge University Hospitals NHS Foundation Trust electronic 
patient medical record system (Epic software) at the time of recruitment and/or blood 
sampling. Abbreviations: diabetes mellitus (DM), irritable bowel syndrome (IBS), gastro-
oesophageal reflux disease (GORD), benign prostatic hypertrophy (BPH), obstructive sleep 
apnoea (OSA), ischaemic heart disease (IHD), pulmonary embolism (PE), motor neuron 
disease (MND), atrial fibrillation (AF), abdominal aortic aneurysm (AAA), chronic kidney 
disease (CKD), congestive cardiac failure (CCF), white cell count (WCC), C reactive protein 
(CRP). 





Age – mean year ± SD 66±5 70±7 
Male sex – no. (%) 7 (50) 6 (50) 
Smoking history – mean pack 
year ± SD 
5±12 58±33 
Current smoker – no. (%) 0 (0) 3 (21) 
Current no. of cigarettes/day – 
mean ± SD 
0 3±2.5 
WCC – mean ± SD 
 
Neutrophil count – mean ± SD 
 
CRP – mean ± SD 





O2 saturation on admission – 
mean % ± SD 
O2 saturation at venepuncture 
– mean % ± SD 




past medical history 
Type 2 DM, Migraine, IBS, 
GORD, Hypertension, 
Hypercholesterolaemia, 
Hypothyroidism, Gout, BPH 
Hyperthyroidism, Hiatus 




Type 2 DM, Spinal 
stenosis, OSA, 
Hypertension, IHD, PE 
Obesity, Hypothyroidism 
Osteoporosis, Alcohol 
excess, MND, AF 
Hysterectomy, 
Cholecystectomy, 
Resected squamous cell 
lung cancer, Gallstones 
GORD, Glaucoma, AAA, 
Mild bronchiectasis, 
Treated bladder cancer, 







Next, I wished to investigate the release of NE and MPO from COPD vs healthy neutrophils 
in conditions of normal and reduced oxygen tension. Exactly as before, isolated neutrophils 
were incubated under normoxia or hypoxia for 4 h prior to treatment with PAF (1 µM, 5 min) 
and fMLP (100 nM, 10 min), or IMDM control. Supernatant NE activity was assessed by 
Enzchek® elastase activity assay, and MPO activity was assessed by H2O2-dependent 
oxidation of DMB. NE and MPO release from unstimulated neutrophils showed no difference 
between all conditions (Figure 5.2). Comparing PAF/fMLP-treated cells, hypoxia significantly 
increased the release of NE from COPD neutrophils (7.57*104 ± 1.82*104 AU) compared with 
both normoxic COPD neutrophils (4.17*104 ± 8.58*103 AU, p=0.0004) and, notably, with 
hypoxic healthy neutrophils (3.63*104 ± 9.46*103 AU, p=0.005, Figure 5.2A). There was no 
difference in NE release from normoxic COPD compared with normoxic healthy neutrophils 
(4.17*104 ± 8.58*103 AU vs 2.49*104 ± 4.1*103 AU, p=0.58). In comparison, although hypoxia, 
compared with normoxia, increased the release of MPO from both healthy (37.0 ± 6.06 % vs 
20.32 ± 3.19 %, p<0.0001) and COPD (38.64 ± 5.83 % vs 24.33 ± 5.63 %, p=0.0036) 
stimulated neutrophils, there was no difference in MPO release between healthy and COPD 
neutrophils for any condition (Figure 5.2B). This was surprising since both NE and MPO are 
azurophilic granule proteins. However, it must be noted that, due to the logistics of performing 
both assays, the n numbers for these assays were different (with more healthy controls 
included for MPO measurement and more COPD patients included for NE assessment).  
5.2.2 The effect of hypoxia on the release of resistin, NGAL and cyclophilin A 
from COPD versus healthy neutrophils 
Having established that NE release from neutrophils under hypoxia is further enhanced in 
COPD compared with cells obtained from with healthy volunteers, I then examined the release 
of the proteins resistin (predominantly present in azurophilic granules) and NGAL 
(predominantly present in specific granules). These proteins were identified as upregulated 
under hypoxia by proteomic examination of the neutrophil secretome, and subsequently 
validated biochemically by ELISA (see section 4.5). Isolated neutrophils were incubated under 
normoxia or hypoxia for 4 h prior to treatment with PAF and fMLP, or IMDM control. 
Supernatant resistin and NGAL content was assessed by ELISA. Again, resistin and NGAL 
release from unstimulated neutrophils did not differ between any of the conditions assessed 
(Figure 5.3). Comparing PAF/fMLP-treated cells, higher levels of resistin were detected in 
supernatants from hypoxic COPD neutrophils compared with hypoxic healthy neutrophils 
(423.4 ± 67.26 pg/ml vs 250.1 ± 40.95 pg/ml, p=0.0213, Figure 5.3A), although the difference 
in release between normoxia and hypoxia was not significant for either healthy or COPD 
neutrophils. Similarly, the detection of NGAL was increased in supernatants from hypoxic 
COPD neutrophils compared with hypoxic healthy neutrophils (9.1 ± 1.9 ng/ml vs 4.76 ± 0.65 
162 
 
ng/ml, p=0.0114, Figure 5.3B). Hypoxia vs normoxia increased the release of NGAL from 
COPD neutrophils (9.1 ± 1.9 ng/ml vs 6.0 ± 1.46 ng/ml, p=0.0091) but the difference between 
normoxia and hypoxia for healthy neutrophils was not significant (Figure 5.3B).  
 
Figure 5.2: The effect of hypoxia on NE and MPO release from healthy and COPD 
neutrophils 
Neutrophils, isolated from exacerbating COPD patients or healthy controls, were incubated 
under normoxia or hypoxia for 4 h before treatment with PAF and fMLP, or IMDM control. A: 
supernatant NE activity was measured by Enzchek® assay. B: supernatant MPO activity was 
measured by H202-dependent oxidation of DMB, with absorbance read at 450 nm and activity 
expressed as % total activity from triton-X (10%)-lysed neutrophils. Results represent mean ± 
SEM; A: n=6 (COPD), n=7 (healthy); B: n=4 (COPD), n=10 (healthy); ** = p<0.01, *** = 
p<0.001, **** = p<0.0001; two way ANOVA, Sidak’s multiple comparisons test. 
 
Figure 5.3: The effect of hypoxia on resistin and NGAL release from healthy and 
COPD neutrophils 
Neutrophils, isolated from exacerbating COPD patients or healthy controls, were incubated 
under normoxia or hypoxia for 4 h before treatment with PAF and fMLP, or IMDM control. 
Supernatant A: resistin and B: NGAL content were measured by commercial ELISA. Results 
represent mean ± SEM; A&B: n=3-4 (unstimulated neutrophils), n=5-7 (stimulated 
neutrophils); *= p<0.05, **=p<0.01; two way ANOVA, Sidak’s multiple comparisons test. 
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Having investigated the release of granule proteins by COPD neutrophils, I next wished to 
examine the secretion of the cytosolic protein cyclophilin A, which was similarly identified as 
upregulated under hypoxia by proteomic examination of the neutrophil secretome. Isolated 
neutrophils were incubated under normoxia or hypoxia for 4 h prior to treatment with PAF and 
fMLP, or IMDM control. Supernatant cyclophilin A content was assessed by ELISA 
(Elabscience). As the lower limit of detection of the ELISA (1.25 ng/ml) was not sensitive 
enough to allow interpolation of most absorbance readings, cyclophilin A content of neutrophil 
supernatants was measured by absorbance (OD450 – baseline). For PAF and fMLP-treated 
neutrophils, the release of cyclophilin A from COPD compared with healthy neutrophils was 
increased in both normoxia (0.021 ± 0.007 vs 0.0, p=0.029) and hypoxia (0.043 ± 0.011 vs 
0.008 ± 0.003, p=0.0004). Further, hypoxia, compared with normoxia, increased the release 
of cyclophilin A from COPD neutrophils (0.043 ± 0.011 vs 0.021 ± 0.007, p=0.0009, Figure 
5.4). Samples from the same subjects used for the NE assay were employed for ELISA 
measurement of resistin, NGAL and cyclophilin A, with the exception of one different healthy 
control and one fewer COPD patient. 
 
 
Figure 5.4: The effect of hypoxia on cyclophilin A release from healthy and COPD 
neutrophils 
Neutrophils, isolated from exacerbating COPD patients or healthy controls, were incubated 
under normoxia or hypoxia for 4 h before treatment with PAF and fMLP, or IMDM control. 
Supernatant cyclophilin A content was measured by commercial ELISA and is expressed as 
absorbance (OD450 – baseline) as several samples were below the lowest value set by the 
standards (1.25 ng/ml; Elabscience ELISA assay range 1.25 ng/ml – 80 ng/ml). Results 
represent mean ± SEM; n=5-7; * = p<0.05, *** = p<0.001; two way ANOVA, Sidak’s multiple 
comparisons test.  
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5.3 COPD versus healthy plasma content of proteins upregulated in the 
hypoxic neutrophil secretome 
Having established that the hypoxia-upregulated release of NE, resistin, NGAL and cyclophilin 
A was further augmented in supernatants from COPD vs healthy control-derived stimulated 
neutrophils, I wished to investigate whether these proteins were also increased in plasma from 
exacerbating COPD patients vs healthy volunteers. Venous blood was drawn from 
exacerbating COPD patients within 24 h of admission, or age and sex-matched healthy 
volunteers, into sterile EDTA K3 collection tubes. Plasma was obtained by centrifugation of 
blood collection tubes. The data described in this section were obtained from the entire cohort 
of COPD patients and healthy controls. 
Measurement of plasma protease activity, such as NE, is challenging as the activity is rapidly 
quenched by α1AT, and detection of NE by immunoassays may quantify both free and α1AT-
bound inactive enzyme. Two assays, which detected NE- and PR3-specific cleavage products 
of fibrinogen (Aα-Val360 and Aα-Val541 respectively), were therefore employed in collaboration 
with Professor Robert Stockley (University of Birmingham), performed by Paul Newby. These 
novel assays provided a footprint of both NE and PR3 activity in plasma. The Aα-Val360 content 
of COPD plasma was significantly higher than healthy plasma, (12.81 ± 0.68 nM vs 9.91 ± 
0.64 nM, p=0.0048, Figure 5.5A). Similarly, the Aα-Val541 content of COPD plasma was 
significantly higher than healthy plasma (22.73 ± 6.7 nM vs 9.15 ± 2.15 nM, p=0.0228, Figure 
5.5B). These results indicate increased circulating NE and PR3 activity in exacerbating COPD 
patients, although the values for COPD and healthy control samples do overlap in each assay.   
 
Figure 5.5: The healthy versus COPD plasma content of Aα-Val360 and Aα-Val541 
Plasma from exacerbating COPD patients or healthy controls was assessed for content of A: 
Aα-Val360 (NE-specific fibrinogen cleavage product) or B: Aα-Val541 (PR3-specific fibrinogen 
cleavage product). Data were provided by Paul Newby (Birmingham). Results represent mean 
± SEM; n=12 (COPD), n=14 (healthy); A: unpaired t test, B: Mann-Whitney test. 
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Plasma resistin, NGAL and cyclophilin A content was assessed by ELISA. In view of the 
previous difficulty in quantitating cyclophilin A (Figure 5.4), a more sensitive ELISA (assay 
range 0.39 ng/ml – 25 ng/ml; Oxford Biosystems) was employed. There was no significant 
difference between the healthy and COPD plasma content of resistin (1.84 ± 0.21 ng/ml vs 
2.54 ± 0.33 ng/ml, p= 0.13, Figure 5.6A), NGAL (9.34 ± 1.29 ng/ml vs 8.93 ± 1.45 ng/ml, p= 




Figure 5.6: The healthy versus COPD plasma content of resistin, NGAL and 
cyclophilin A by ELISA 
Plasma from exacerbating COPD patients or healthy volunteers was assessed for A: resistin, 
B: NGAL or C: cyclophilin A content by commercial ELISA. Results represent mean ± SEM; 
A: n=12 (COPD), n=14 (healthy), B: n=8 (COPD), n=10 (healthy), C: n=12 (COPD), n=14 




5.4 The COPD versus healthy plasma content of microvesicles 
Despite the fact that previous experiments did not demonstrate a hypoxic increase in NDMVs 
(section 4.6.1), it is noteworthy that 15 of the top 20 proteins upregulated in the hypoxic 
neutrophil secretome have been identified in NDMVs in the literature (Table 4.3). I therefore 
wished to explore whether there was an NDMV pro-inflammatory “signature” in plasma from 
exacerbating COPD patients by examining the relative distribution of neutrophil-, monocyte-, 
endothelial cell- and platelet-derived MVs. Flow cytometric analysis of plasma MV content was 
performed with the assistance of Merete Long (PhD student) in collaboration with Dr Victoria 
Ridger (Sheffield). MVs were stained with BV421 anti-CD66b, APC Cy7 anti-CD14, PerCP 
Cy5/5 anti-CD144 and PE anti CD41a in order to identify neutrophils, monocytes, endothelial 
cells or platelets respectively as the parent cells. Comparing plasma from exacerbating COPD 
patients vs healthy controls, there was no difference in the distribution of NDMVs (17.17 ± 
4.75% vs 10.97 ± 2.96%, p=0.54, Figure 5.7A), monocyte-derived MVs (11.68 ± 3.83% vs 
7.61 ± 2.5%, p=0.42, Figure 5.7B), endothelial cell-derived MVs (4.44 ± 0.62% vs 5.47 ± 
1.46%, p=0.51, Figure 5.7C), or platelet-derived MVs (39.19 ± 7.31% vs 45.32 ± 10.99%, 
p=0.64, Figure 5.7D). There was also no difference in total MV number per µl plasma (2127 ± 
230.9 vs 2734 ± 426.7, p=0.22, Figure 5.7E).  
5.5 Discussion 
By translating my characterisation of the hypoxic neutrophil secretome to a patho-
physiologically and clinically relevant patient group, I have established that peripheral blood 
neutrophils from COPD patients display a more marked (compared to age- and sex-matched 
controls) hypoxic uplift of NE, resistin, NGAL and cyclophilin A release in vitro. NE is well 
established in the pathogenesis of COPD, with the ability to cause experimental emphysema 
in animal models (201), and sputum levels correlating with COPD severity and decline in FEV1 
(203). However, its role in endothelial dysfunction is less well recognised. Recently, and of 
great relevance to the work described in this chapter, murine genetic and pharmacological 
inhibition of NE has been shown to attenuate the development of atherosclerosis (263), and 
higher NE levels are associated with increased risk of cardiovascular events, even after 
adjusting for known risk factors (264). Neutrophils accumulate in atherosclerotic plaques, with 
higher numbers found in eroded or ruptured lesions ex vivo (248), and  in vivo 18F-FMISO PET 
imaging of atherosclerotic rabbit aortae has demonstrated significant vascular hypoxia, 
corroborated by ex vivo immunohistochemistry (330). This locally hypoxic environment may 
increase NE release, which has the potential to promote plaque progression and instability: 
NE, detected in atherosclerotic lesions, was able to potentiate the processing and release of 




Figure 5.7: Healthy versus COPD plasma microvesicle content 
Plasma from exacerbating COPD patients or healthy controls was stained with BV421 anti-
CD66b (neutrophil, A), APC Cy7 anti-CD14 (monocyte, B), PerCP Cy5/5 anti-CD144 
(endothelial cell, C) and PE anti-CD41a (platelet, D). MV pellets, obtained by centrifugation 
(20,000 g), were re-suspended in sterile PBS (490 µl) with counting beads (10 µl) and 
analysed by flow cytometry. The MV forward scatter vs side scatter gate was set using 
standardised size calibration beads, and 1,000 counting beads were measured per sample. 
The MV distribution per parent cell type is expressed as % total MVs (A-D); total MV count per 
µl plasma is shown in panel E. Results represent mean ± SEM; n=5 (healthy), n=6 (COPD); 




Increased circulating resistin levels have also been found in COPD (221,427), and were 
inversely correlated with FEV1, although increased levels were also found in asthmatics and 
smokers in this study (113). Multiple studies support a role for resistin in endothelial 
dysfunction: resistin over-expression promoted myocardial apoptosis, remodelling and left 
ventricular dysfunction in a rat model (428) and circulating resistin is associated with increased 
risk of MI, ischaemic stroke and heart failure (429–431). Increased circulating NGAL has been 
detected in COPD patients, correlating with more frequent exacerbations and hypoxaemia 
(112), although controversy surrounds its association with disease severity, and smoking may 
affect levels (432,433). NGAL has recently been implicated in airway remodelling in COPD 
(434) and, although causality is not proven, higher levels were detected in vulnerable carotid 
artery atherosclerotic plaques (411) and increased plasma levels were associated with 
mortality and major adverse cardiac events following ST-elevation MI (435). Only two studies 
have associated cyclophilin A with COPD: Zhang et al. recently showed increased serum 
levels in COPD patients (114) and Hu et al. detected increased levels in lung tissue from 
smokers, with a further increase in smokers with COPD (436). Extensive evidence supports 
the ability of cyclophilin A to cause endothelial activation and injury (reviewed in (437)), 
including the development of PH in a murine over-expression model (407). My data are the 
first description of enhanced neutrophilic secretion of these proteins under hypoxia in the 
context of COPD, and although I was not able to detect increased levels in the plasma of a 
cohort of exacerbating patients (see below), the literature suggests that these proteins have 
the potential to contribute to cardiovascular comorbidity. Due to time limitations, I was not able 
to examine the effects of these proteins, either alone or in combination, on endothelial cells 
directly; this will be important to establish and also whether inhibition of these proteins is 
protective. 
A limitation of this study was the pragmatic nature of patient recruitment which meant that I 
was unable to control the timing and use of treatments, such as antibiotics and steroids. A 
further challenge was presented by the variable aetiology of an acute exacerbation, e.g. viral 
vs. bacterial stimulus, as well as the heterogeneity in COPD diagnosis; the cause of an acute 
exacerbation may be unclear and identification of a culprit organism is rare. Patients with 
pneumonia, a pathological process distinct from that of an acute exacerbation, were excluded 
from the study. Interestingly, two COPD patients who had blood drawn prior to their chest 
radiograph, which subsequently showed consolidation indicating pneumonia, had basally 
shape changed neutrophils (and were excluded from further analysis). This validates the ability 
of the shape change assay to detect systemic neutrophil priming, and may explain why some 
studies have shown priming of circulating COPD patient neutrophils (283,334,438). It would 
be informative to compare the same COPD patients during exacerbation and in the stable 
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state to investigate whether any differences in neutrophil function are persistent or contributed 
to by acute inflammation. Attempts to recruit these patients for further studies in the stable 
state were hampered by frequent hospital admissions for exacerbations, highlighting the 
burden of disease.  
The mechanism for a further increase in protein release from COPD neutrophils under hypoxia 
remains to be elucidated. I did not observe any difference in shape change between healthy 
and (non-pneumonic) COPD neutrophils, demonstrating that COPD neutrophils were not 
basally primed or activated in my study. These data argue against a primed phenotype 
explaining my observed increase in the release of granule proteins from COPD neutrophils. 
One potential explanation for enhanced protein release is a change in protein or mRNA 
abundance in COPD neutrophils. Although I was not able to perform these experiments due 
to time constraints, this would be important to investigate. Gene array (335) and proteomic 
(219–221) studies of COPD vs healthy neutrophil lysates have shown differential mRNA 
transcript and protein expression. Interestingly, the proteome of peripheral blood COPD 
neutrophils was distinct from that of TNFα and/or GM-CSF-treated healthy neutrophils (220), 
and two diverse COPD proteomic phenotypes were identified, (221), suggesting a complex 
interplay between multiple inflammatory signals, which may include hypoxia. This differential 
mRNA/protein expression is reflected in transcriptomic and proteomic examination of COPD 
patient blood (439,440) and sputum (441) which, although not cell-type specific, has 
suggested a neutrophil signature.  
Although putative HREs have been identified in the promotor regions of NE and MPO (315), 
mRNA transcripts of granule proteins have not been found following neutrophil maturation 
(442) and our previous data showed no change in NE transcription or translation under 
hypoxia in the relevant timeframe of 4-5 h (149). Analysis of changes in rodent neutrophil 
lysate enzymes following abdominal surgery revealed an increase in the cytoplasmic protein, 
cyclophilin A (370), suggesting that inflammation can modulate neutrophil protein content, 
although it is not clear how this would lead to enhanced release of cytoplasmic proteins. 
However, it is possible that exposure to circulating inflammatory cytokines and systemic 
hypoxia may have impacted neutrophil granule protein content in COPD patients prior to ex 
vivo investigation, leading to enhanced release upon stimulation of degranulation. It would be 
valuable to perform a quantitative lysate and secretome proteomic screen of COPD vs healthy 
neutrophils.  
Enhanced protein secretion has been observed from other cell types in COPD: Kawayama et 
al. showed increased release of MMP-9, TNFα and IL-6 from LPS-treated COPD patient 
PBMCs (443). Similarly, augmented neutrophil protein secretion has been shown in other 
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disease states, e.g. increased LTB4 release from PAF-treated asthma patient neutrophils 
(444), which the authors propose was due to mobilisation of intracellular calcium, and, with 
direct relevance to my work, increased resistin release from cytochalasin B/fMLP-treated 
septic patient neutrophils (306). Mechanisms for these observations, however, are lacking. 
Examination of NE and MPO release from COPD vs healthy neutrophils in my study 
demonstrated a number of differences. COPD neutrophils showed an augmented hypoxic 
uplift of NE, which was not apparent from healthy control neutrophils in this experiment, 
whereas hypoxia increased MPO release similarly from both COPD and healthy neutrophils. 
Also, the difference between stimulated and unstimulated cells was much less for MPO than 
NE. This disparity could reflect differences in the assay performance: MPO activity is 
expressed as percentage of the total whereas the NE assay is a kinetic assay read at a specific 
timepoint to give an activity value in arbitrary units. The fact that NE and MPO release do not 
mirror each other is surprising as both are azurophilic granule proteins. Possible explanations, 
apart from assay differences, include: differential granule packaging, mobilisation of different 
granule populations, pre-programmed differences in protein content in diseased neutrophils, 
recruitment of a mechanism of protein release in addition to that of degranulation, or effects 
of other proteins present in the cells/supernatants, including possible degradation of MPO by 
enhanced NE activity.  
Due to time limitations, I was not able to examine NET release or the effect of PI3K inhibition 
on the hypoxic uplift of protein release from COPD neutrophils. It would be interesting to see 
if COPD neutrophils have a higher propensity for NETosis and whether the hypoxic uplift could 
be completely abrogated by PI3Kγ inhibition. Juss et al. found that the pro-survival phenotype 
observed in exacerbating COPD patient neutrophils ex vivo was resistant to pan-PI3K 
inactivation. However, Sapey and colleagues demonstrated that pan-PI3K inhibition of 
neutrophils from COPD patients corrected abnormal migration (216). Whether this aberrant 
signalling is a reflection of exposure of circulating neutrophils to systemic hypoxia and/or 
inflammation remains unclear. These studies suggest that the role of PI3K signalling in COPD 
neutrophils is highly context dependent. It will be important to investigate whether aberrant 
PI3K signalling contributes to my observed enhanced protein release under hypoxia, 
particularly with the advent of clinical PI3K inhibitors.  
Although I found no increase in NDMV release on hypoxic neutrophil incubation, elevated 
levels of plasma exosomes (424) and sputum NDMVs, which correlated with disease severity 
(445), have been found in COPD patients, and both granule proteins, including NE and MPO, 
and cytosolic proteins, including cyclophilin A, have been detected by proteomic examination 
of NDMVs (95,366) from healthy individuals. However, my data did not show any increase in 
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COPD plasma NDMV content compared with healthy controls, although the n number (6) was 
relatively small given the potential heterogeneity of these patient-derived samples, and there 
was a trend for an increased percentage of NDMVs in COPD plasma. However, taken 
alongside my earlier data, it does not seem likely that NDMVs play a significant role in the 
hypoxic uplift of protein secretion, either from healthy volunteers or exacerbating COPD 
patients.  
Surprisingly, my data did not show an increase in the COPD vs healthy plasma content of 
resistin, NGAL or cyclophilin A. It is possible that this was not the correct compartment to 
examine, although more likely that my study numbers were too small as published reports 
have shown that COPD patients have increased circulating resistin (113), NGAL (112) and 
cyclophilin A (114), including 26, 402 and 93 patients, respectively. I have, therefore, set up a 
collaboration with Dr Elizabeth Sapey (Birmingham) to examine the plasma content of these 
proteins in a larger, well-phenotyped cohort of COPD patients. Another potential explanation 
for my results is the secretion of these proteins from other cell types. Resistin is released from 
adipocytes in rodents, whereas release in humans is predominantly from immune cells, 
including those resident in adipose tissue, such as PBMCs and macrophages as well as 
neutrophils (446). Although the majority of NGAL is released from neutrophils, low levels are 
secreted from epithelial cells. Changes in circulating levels may therefore reflect more than 
once cellular source and obscure a plasma neutrophil signature. For example, circulating 
NGAL is increased during acute kidney injury, thought to be due to a combination of increased 
secretion from stressed renal tubular cells, increased neutrophil release and changes in 
protein reabsorption from urine due to renal damage (447). 
My data did show an increase in the COPD vs healthy plasma content of the fibrinogen 
breakdown products Aα-Val360 and Aα-Val541, indicating increased circulating NE and PR3 
activity, respectively, in these patients. Previous studies using the Aα-Val360 assay have shown 
increased content in plasma from patients with α1AT deficiency (448) and COPD, which 
correlated with disease severity (204), although these were not performed in comparison with 
healthy controls. These data support my hypothesis that circulating neutrophils in 
exacerbating COPD patients release more NE, which is able to cause tissue damage, 
including damage to endothelial cells. 
Overall, I have demonstrated an enhanced hypoxic increase in the release of the histotoxic 
proteins NE, resistin, NGAL and cyclophilin A from exacerbating COPD patient neutrophils, 
and an increase in circulating NE and PR3 activity these patients. As such, I have identified 
potential novel therapeutic targets which may be responsible for tissue damage in COPD, 














Neutrophils are recruited rapidly and in great numbers to sites of tissue damage, commonly 
caused by invading pathogens. Circulating neutrophils patrol the endothelium, sensing sites 
of cellular/tissue injury via a range of membrane receptors which respond to cytokines, 
chemokines, and damage or pathogen associated molecular patterns (DAMPs, PAMPs); 
these signals direct neutrophils to regions under attack, where they deploy their powerful 
armamentarium and release pro-inflammatory mediators to summon additional immune cells. 
Neutrophils also migrate to sites of sterile injury; necrotic cells can release mitochondrial 
formylated peptides, closely resembling bacterial formylated peptides which are potent 
neutrophil activators. In this manner, mitochondrial formyl peptides from dying cells directly 
activate neutrophils and facilitate chemotaxis towards damaged tissues, as demonstrated in 
murine sterile lung injury (449), and in the systemic inflammatory response to trauma in 
humans (450). This response may be a pre-emptive call for neutrophils to attend breached 
tissues at risk of microbial invasion or it may be that neutrophils remove cellular debris and 
promote damage resolution, enabling neo-vascularisation by release of matrix-degrading 
metalloproteinases (183). However, at sites of sterile or persistent injury, extracellular release 
of antimicrobial but histotoxic neutrophil proteins and proteases may induce substantial 
collateral tissue damage. This maladaptive immune response has been implicated in a number 
of inflammatory situations, such as I/R injury (451) and vasculitis (69). 
Inflamed and infected tissues are often profoundly hypoxic, and ideally neutrophils should 
work effectively in such low oxygen environments. In COPD, inflamed airways exhibit 
persistent neutrophilic inflammation and have been shown to be severely hypoxic, both in 
animal models (222) and bronchial biopsies from patients (131), notwithstanding their 
proximity to ambient air/oxygen. Despite airway neutrophilia, COPD patients may develop 
chronic bacterial airway colonisation, or suffer recurrent infection-driven exacerbations (452). 
This suggests that COPD neutrophils are not effective at protecting the host from infection and 
are in fact contributing to host tissue injury and disease progression. Patients with advanced 
COPD are often systemically hypoxaemic and, consequently, both tissue and circulating 
neutrophils are exposed to low oxygen levels. COPD patients also suffer excessive 
cardiovascular comorbidity even after correcting for common risk factors such as smoking, 
and CVD accounts for a substantial proportion of COPD patient deaths (up to 60%) (233). 
Laboratory studies of neutrophil function are almost always undertaken at ambient oxygen 
tensions, but it is important to recapitulate the pathological environment to understand how 
neutrophils operate in these hypoxic environments. Published data from our laboratory 
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demonstrate that hypoxic neutrophils fail to eliminate certain pathogens (148), and that 
supernatants from hypoxic vs normoxic neutrophils contain more granule proteases and cause 
more damage to bronchial epithelial cells (149). This suggests that hypoxic environments 
engender a destructive neutrophil phenotype, which contributes to the pathogenesis of 
inflammatory diseases such as COPD. The mechanisms responsible for endothelial 
dysfunction and development of athero-thrombotic disease in COPD remain unclear. 
However, several studies (for example (248)) have shown that neutrophils accumulate in 
atherosclerotic lesions, and that these regions are profoundly hypoxic (330,331). Hence, my 
PhD aimed to investigate the hypothesis that hypoxia promotes neutrophil-mediated 
endothelial damage in COPD.  
My work has extended the description and understanding of the detrimental neutrophil 
phenotype engendered by hypoxia: by increasing the repertoire of agonists that are relevant 
to hypoxic degranulation, by further delineating the mechanism of increased neutrophil 
degranulation under hypoxia, by demonstrating the capability of hypoxic neutrophils to 
damage lung endothelial cells in vitro, and by identifying additional potential histotoxic 
mediators of this damage, which are upregulated in hypoxic neutrophil supernatants. 
Translating these results to the clinical context of COPD, I have shown further upregulation of 
these histotoxic proteins in supernatants from hypoxic COPD neutrophils and detected a 
plasma signature of increased protease (both NE and PR3) activity in these patients. 
Furthermore, my proteomic examination of the neutrophil secretome has suggested a novel 
mechanism of selective protein secretion under hypoxia. My work will instigate future research 
projects and potentially identify novel therapeutic targets. These data could be extrapolated to 
a wide range of neutrophilic inflammatory diseases manifesting endothelial dysfunction, such 
as bronchiectasis, RA and IBD (235,453). 
6.2 Discussion of results 
6.2.1 Differential effects of priming agents on hypoxic degranulation 
In the work presented in this thesis, I have extended the observation that hypoxia markedly 
increased degranulation from GM-CSF-primed neutrophils (149,315) by showing that this 
hyper-secretory response is also present (in fact with a greater and more consistent effect) in 
PAF-primed cells, broadening the relevance to a wider range of inflammatory scenarios. For 
example, PAF has been implicated in the inflammatory response to I/R injury (where 
interruption of blood supply results in severe tissue hypoxia), promoting local neutrophil 
recruitment, oedema and endothelial dysfunction, and also priming circulating neutrophils to 
initiate distant neutrophil-endothelial interactions in multiple vascular beds, resulting in multi-
organ dysfunction and circulatory collapse (454). In contrast, the “hypoxic uplift” of 
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degranulation was not consistently seen with TNFα-primed neutrophils. There are a number 
of possible explanations for this result. Firstly, the concentration of TNFα used might have 
been sufficient to induce a maximal response alone, and it would be interesting to explore the 
interaction of hypoxia with lower concentrations of this cytokine. Secondly, donor variability in 
the magnitude of the response to TNFα-priming, previously observed in our laboratory when 
measuring ROS production, may have obscured differences between normoxia and hypoxia. 
Thirdly, different agonists may be entraining different signalling pathways and hence different 
functional effects. Multiple signal transduction pathways induce the molecular events required 
for priming: GM-CSF ligates type 1 cytokine receptors, initiating signalling via recruitment and 
phosphorylation of Janus kinases (JAKs) and STAT molecules; PAF receptors are GPCR-
linked, initiating a range of signalling pathways following dissociation of the Gα and Gβγ 
subunits; and TNFα can bind either TNF receptor 1 (TNFR1) or TNF receptor 2 (TNFR2), 
triggering pro-inflammatory pathways mediated by JNK and NFκB. The complex mechanisms 
of neutrophil priming and degranulation are still incompletely understood (353), partly due to 
the complicated and inter-linked intracellular signalling pathways involved, and partly due to 
the need to consider the numerous priming and activating agents present in inflammatory 
situations in vivo. For example, PAF (a priming agent) and fMLP (an activating agent) both 
ligate GPCRs; however their activation of downstream MAPK signalling involves different 
pathways, with PAF- but not fMLP-induced phosphorylation of ERK dependent on protein 
kinase C and extracellular calcium influx (455). Despite both TNFα and GM-CSF being priming 
agents, neutrophil transcriptomic analysis using RNA-sequencing has shown they induce 
substantially different gene expression profiles (456). Furthermore, whilst GM-CSF uniformly 
delays neutrophil apoptosis, TNFα may be pro- or anti-apoptotic, dependent on time and 
concentration, suggesting that priming by these agonists is not equivalent (10). In keeping with 
these observations, my data suggest that the increase in neutrophil degranulation under 
hypoxia is dependent on signalling pathways specific to the priming agonist rather than an 
overall “priming event”. 
6.2.2 Role of PI3K signalling in hypoxic degranulation 
Published experiments from our laboratory indicated a role for PI3K signalling in hypoxic 
neutrophil degranulation, as pan- and γ-selective PI3K inhibitors, but not PI3Kδ inhibitors, 
abrogated the hypoxic uplift seen with GM-CSF primed neutrophils (149). Class I PI3Ks are 
heterodimers, signalling through downstream effectors such as AKT, to control a variety of 
processes, including priming of the neutrophil respiratory burst and degranulation. Class IA 
PI3Ks (α/β/δ) are usually activated via tyrosine kinase receptors, while Class IB PI3Ks (γ) are 
primarily activated by GPCR βγ subunits. Both PI3Kγ and δ are fundamental to neutrophil 
function (304). It is possible that the observed role of PI3Kγ in the hypoxic enhancement of 
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neutrophil degranulation is related to its role in (GPCR-linked) fMLP signalling. However, this 
seems unlikely as I did not observe the hypoxic uplift response for TNFα (despite subsequent 
fMLP treatment); in addition, previous experiments have shown that addition of PI3K inhibitors 
immediately prior to fMLP stimulation reduced degranulation under normoxia and hypoxia 
equally, with preserved hypoxic fold-upregulation (149), implying that hypoxia itself entrains 
PI3Kγ signalling pathways, which then mediate the augmented release of neutrophil granule 
contents stimulated by further priming/activation events. Previous reports have shown PIP3 
accumulation occurs in neutrophils in response to GM-CSF treatment via phosphorylation of 
the Class IA PI3K p85 subunit (457,458), and it would be of interest to study p85 
phosphorylation in the setting of hypoxia. At present, the link between hypoxia and PI3Kγ 
activity is unclear, particularly given the short time-frame required to establish the response 
and the lack of a role for the transcription factor HIF (10). Hypoxia does not increase neutrophil 
protein content of either p85 or the catalytic subunits of PI3Kγ and δ, although the levels of 
the PI3Kγ regulatory subunits p101 and p84 were not assessed (Dr Kim Hoenderdos, personal 
communication).   
Using γ- and δ-selective inhibitors, I have also demonstrated a non-redundant role for PI3Kγ 
in the hypoxic enhancement of degranulation from PAF-primed neutrophils, which is logical 
as PAF ligates GPCRs, triggering PI3Kγ activation via the dissociated Gβγ subunit. In order 
to confirm that the PI3Kγ-dependent hypoxic response seen in human neutrophils was not an 
off-target effect or due to a blanket inhibition of granule exocytosis, I confirmed the PI3Kγ-
dependence of this effect using murine neutrophils lacking PI3Kγ. The mechanism by which 
hypoxia modulates PI3Kγ signalling is currently unclear and warrants further investigation, 
particularly in view of the lack of HIF-dependence. In a clear cell renal carcinoma cell line, 
Bienes-Martínez et al. demonstrated that hypoxia was able to augment AKT phosphorylation 
and downstream signals in a HIF-independent manner, which the authors suggested may be 
partly due to effects of low oxygen on PHDs (459). In neutrophils, Xu et al. showed that 
accumulation of ROS in apoptotic cells inhibited PI3Kγ activity (460); a reduction in ROS in 
the setting of hypoxia could allow enhanced PI3Kγ signalling and explain why we observed 
the hypoxic uplift effect under true hypoxia but could not recapitulate this with HIF mimetics 
(149). Another potential mechanism might be for hypoxia to modulate the negative regulation 
of PI3K activity provided by lipid phosphatases such as PTEN, which converts PIP3 to PIP2. 
Recent preliminary data generated by Professor Sarah Walmsley (personal communication) 
have indicated a decrease in the PTEN content of BALF neutrophils from hypoxic compared 
with normoxic LPS-challenged mice, although as noted above the short (4 hour) timecourse 
of my experiments and lack of HIF-dependence suggest that transcriptional regulation of 
protein synthesis is less likely. However, it is possible that hypoxia (de)stabilises proteins 
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involved in this and other signalling pathways independent of protein synthesis, e.g. by altering 
phosphorylation. Investigation of the effect of hypoxia on neutrophil signalling pathways using 
phospho-proteomics would form the basis of an exciting future research project. 
It is possible that hypoxia impacts actin cytoskeletal rearrangement to enhance degranulation 
responses. Hypoxia re-distributes F actin to form cap-like structures (149), and cytoskeletal 
rearrangement is linked to enhanced neutrophil degranulation (461). It is conceivable that 
hypoxic reorganisation of the cytoskeleton and/or plasma membrane facilitates access of 
PI3Kγ to its PIP2 phospholipid substrate. In a breast tumour model, mass spectrometric 
imaging of hypoxic regions identified upregulation of proteins involved in actin cytoskeleton 
regulation and PI3K-AKT signalling by network pathway analysis, with co-localization of 
various lipid species in hypoxic areas (462); however this study employed a HIF-1α-driven 
HRE-fluorescent protein construct to identify areas of hypoxia, suggesting these effects may 
be dependent on HIF-mediated transcription. In keeping with our finding that hypoxic 
degranulation is HIF-independent, Wottawa et al. demonstrated in a breast cancer cell line 
that the actin-bundling protein T-plastin was recruited to the plasma membrane, and mediated 
enhanced endocytic uptake in a manner independent of HIF transcription (147). Although not 
studied in hypoxic conditions, the T-plastin homologue, L-plastin, which is abundant in 
neutrophils, has been shown to be phosphorylated in response to fMLP treatment, dependent 
on PI3K, phospholipase D and/or protein kinase C activity (463). Finally, although it is the 
small GTPase Rac2 that mediates neutrophil actin dynamics and azurophil granule secretion, 
its homologue Rac1 was shown to be upstream of HIF-1α in human embryonic kidney cells, 
and Rac1 activity was increased by hypoxia within 30 minutes in a PI3K-dependent manner 
(464).  
In addition to effects on cytoskeletal reorganisation, hypoxia may modify downstream granule 
transport and docking mechanisms. For example, Rab27a (which in neutrophils directs 
granules to the plasma membrane for fusion) was upregulated and displayed increased 
activity following hepatocyte hypoxia/re-oxygenation in vitro and murine liver I/R injury in vivo; 
Rab27a silencing decreased liver neutrophil numbers and serum NE in this model (465). In 
pancreatic β cells, PI3K signalling promoted Rab27a-mediated actin bundling, which played a 
pivotal role in endocytosis-exocytosis coupling (466), and in murine neutrophils, reduced AKT 
phosphorylation was linked to downregulation of Rab27a with a resultant decrease in azurophil 
granule exocytosis in a tumour setting, which is often a hypoxic environment (467). Hence, 
there is a plausible mechanistic link between hypoxia, cytoskeleton regulation, plasma 
membrane and granule trafficking, and PI3K(γ) signalling.  
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PI3Kγ signalling has been implicated in NET formation (468,469). As neutrophil proteases, 
such as NE and MPO, are released in association with NETs, we considered whether 
increased NETosis might contribute to the hypoxic enhancement of granule protein release. 
In the literature, the effect of hypoxia on NET generation is controversial, with studies showing 
it to be both increased (within hypoxic liver tumours, (117)) or unchanged (neutrophils 
incubated under hypoxia (116)). It is possible that the more complex tumour environment 
provides additional cues for NETosis, to explain these differing results; both studies showed 
that products released by other hypoxic cells could stimulate NET release, which is likely 
relevant in vivo. It might be expected that ROS-dependent NETosis would be decreased under 
true hypoxia, since ROS generation will be limited by the lack of molecular oxygen; however, 
the absolute requirement for ROS has been challenged and is likely agonist-dependent (468). 
Similar to the results obtained by Nakazawa et al. (116), I did not see any difference in NET 
generation between normoxia and hypoxia using precisely the same experimental conditions 
as in my degranulation experiments, so it is unlikely that NETosis contributes significantly to 
the augmented release of neutrophil granule products under hypoxia in this setting. 
6.2.3 Possible mechanisms of endothelial damage by hypoxic supernatants 
In keeping with my finding that hypoxic neutrophil supernatants contain increased active 
degranulation products, and our previous observation that these hypoxic supernatants caused 
extensive airway epithelial cell damage (149), I have shown that supernatants from hypoxic 
compared with normoxic neutrophils also cause substantially more damage (both detachment 
and cell death) to pulmonary artery endothelial cell monolayers. Whilst it is difficult to translate 
the effects of supernatants derived from large numbers of maximally activated neutrophils 
applied to endothelial cells for several hours with the situation in the circulation in vivo, it is 
noteworthy that individual neutrophils will be in direct contact with individual endothelial cells. 
Degranulation enhances the surface expression of NE and other proteases (470), and 
although I did not assess this directly, future work will address this possibility (see below). As 
well as direct cellular injury mediated by granular proteases, modification of other circulating 
mediators may be relevant in vivo. My supervisor, Dr Li, has demonstrated that NE is 
responsible for the proteolytic degradation of BMP9, an endogenous circulating factor which 
promotes endothelial integrity, and supernatants from hypoxic vs normoxic neutrophils 
resulted in significantly more NE-dependent BMP9 cleavage (unpublished data, manuscript in 
preparation). My additional preliminary unpublished data, generated with Kimberley Wiggins 
(PhD student, Laboratory of Dr Murray Clarke, University of Cambridge), showed that 
incubation with hypoxic vs normoxic neutrophil supernatants resulted in more cleavage of a 
precursor of the pro-inflammatory cytokine IL-1β into active fragments (Figure 6.1). Hence, 
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active NE can cause endothelial damage in a tissue culture setting and has the potential to 
initiate further pro-inflammatory events in vivo. 
 
Figure 6.1: The effect of neutrophil supernatants on IL-1β 
Supernatants from normoxic (N) vs hypoxic (H) PAF/fMLP (P) or IMDM (C)-treated neutrophils 
were incubated with pro-IL-1β for 2 h or overnight (ON). Western blotting was subsequently 
performed with anti-IL-1β. Image representative of n=1 experiment. Data generated with 
Kimberley Wiggins. 
 
However, since my results indicated that there was a serine protease-independent component 
to neutrophil-mediated endothelial damage (as cell death could not be completely abrogated 
by the addition of α1AT), I performed a proteomic examination of the normoxic vs hypoxic 
neutrophil secretome. Based on previous data generated in our laboratory showing differential 
secretion from eosinophils under hypoxia (471), it was thought that these data may also give 
mechanistic insights regarding neutrophil protein release under hypoxia. 
Proteomic analysis of the normoxic vs hypoxic secretome revealed a hypoxic enrichment of 
multiple potentially histotoxic proteins but surprisingly, whilst MPO was the most upregulated 
protein in the hypoxic vs normoxic secretome, the increase in NE as measured by proteomic 
analysis did not reach significance (adj. p value=0.25). This discrepancy might reflect the fact 
that a small change in the amount of this protease can lead to larger detectable changes in 
activity. An alternative explanation is a reduction in the concomitant release of inhibitory 
proteins; notably, leukocyte elastase inhibitor was significantly upregulated in normoxic vs 
hypoxic supernatants, suggesting an alteration in the protease-anti-protease balance in the 
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setting of hypoxia. Finally, the complex technical requirements for proteomics (including the 
limited number of samples that can be analysed simultaneously), the expense, and the 
requirement for multiple testing correction methods in data analysis may lead to a failure to 
detect true positives using this demanding methodology (373).  
6.2.4 Proteomic analysis of the neutrophil secretome 
My proteomic dataset was very intriguing for two main reasons. Firstly, the hypoxia-
upregulated histotoxic proteins did not segregate precisely with discrete granule populations, 
with upregulation of some granule-derived proteins in normoxic relative to hypoxic 
supernatants as well as vice versa. Secondly, although most cytoplasmic protein release was 
upregulated under normoxia, some cytoplasmic proteins, including cyclophilin A, were 
increased in hypoxic supernatants, even though hypoxia is a neutrophil survival signal, 
suggesting that they were being actively secreted. Together, these findings suggest that 
hypoxia may drive a novel neutrophil secretion mechanism, as opposed to simply an 
upregulation of classical degranulation. As cyclophilin A has been shown to be secreted from 
other cell types, e.g. cardiac myocytes in response to hypoxia (387), it may be that the 
secretion mechanism for this protein is unique. However, the cytoplasmic protein S100A9, 
which was upregulated under normoxia, has also been shown to be actively secreted (393). 
Although my characterisation of the hypoxic neutrophil secretome is entirely novel, a limited 
number of secretome analyses of normoxic neutrophils treated with various stimuli have been 
performed previously (305–308). Consistent with my findings, their results did show some 
variation in secretome content according to the inciting stimulus: Malmstrӧm et al. treated 
neutrophils with TNFα, heat-killed S. pyogenes, or cytochalasin B/fMLP and observed NGAL 
and MPO release in response to all three treatments but NE release only with cytochalasin 
B/fMLP or heat-killed S. pyogenes, and cathepsin G release only with cytochalasin B/fMLP 
(306). Snäll et al. visualised an increase in azurophil granule co-localisation of resistin and 
azurocidin upon treatment with a specific streptococcal strain, which was not evident on 
stimulation with LPS or fMLP. Furthermore, only fMLP-treatment, when compared with 
streptococcal M1 protein, LPS or PMA, resulted in a differential secretion profile of resistin and 
azurocidin (378). In addition, fusion of different granule subtypes has been observed: 
Bjӧrnsdottir et al. demonstrated fusion of specific and azurophil granules using lactoferrin and 
CD63 as markers, albeit in response to PMA, which is a non-physiological stimulus (472). 
These studies suggest that the inflammatory environment can influence the nature of granule 
subsets that are secreted, which may have a bearing on the precise proteins released during 
degranulation. However, the mechanism(s) by which these events might occur is unknown, 
and how hypoxia might access such mechanisms is likewise uncertain. 
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6.2.5 Potential mechanisms of “differential degranulation” 
The effect of chronic inflammation and hypoxia on granule formation and packaging is 
currently unknown. As granule subtype formation and protein expression is not entirely 
synchronised, there is a degree of granule subtype heterogeneity, for example there are 
defensin-rich and defensin-poor azurophilic granules (473). However, NE vs MPO 
discrepancy within azurophilic granules has not been described for healthy human neutrophils 
in this fashion, although there may be some insights from human disease and animal models. 
Divergence in granule packaging pathways has been revealed by mutations of AP3B1, 
encoding adaptor protein-3 (causing Hermansky-Pudlak syndrome), which resulted in reduced 
NE levels but normal MPO and PR3 levels (474). Moreover, azurophilic NE was absent in 
serglycin-deficient mice, with no effect on MPO, PR3 or cathepsin G (475). Intriguingly, 
serglycin was significantly upregulated in my hypoxic neutrophil secretome analysis (FC 1.9, 
adj. p value = 0.012). It is possible that granule formation during maturation may be modulated, 
for example in chronic inflammatory states, with the potential for serglycin to direct increased 
azurophil granule content of NE. However, this would not explain my results which were 
obtained by short-term incubation of terminally differentiated mature cells. 
A potential mechanism by which hypoxia might result in differential granule protein release is 
by movement of proteins into/between neutrophil granules in a manner analogous to the 
“piecemeal” degranulation described for eosinophils and mast cells, which allows release of 
selected granule-stored proteins. Eosinophils contain cationic proteins and cytokines as pre-
formed pools within secretory granules, which can be released by classical granule fusion with 
the plasma membrane or by piecemeal degranulation, whereby selected proteins or cytokines 
are released via vesicle or vesiculo-tubular sequential emptying of granules. This process 
allows differential secretion which is stimulus-dependent (379). Published data from our 
laboratory have shown that hypoxia promoted IL-8 release but attenuated eosinophil-derived 
neurotoxin release from eosinophils, providing the first evidence of hypoxia selectively 
modulating granulocyte secretion (471); this finding is highly relevant to my work and might 
indicate a mechanism of hypoxic degranulation that is common to the granulocyte lineage. It 
would be informative to visualise the subcellular localisation of my hypoxia-regulated proteins 
to see if a similar mechanism is employed by neutrophils. 
6.2.6 Enhanced release of cytoplasmic proteins 
Intrigued by the surprising observation that hypoxia upregulated the release of certain 
cytoplasmic proteins, I undertook a detailed review of the literature which revealed that the 
majority of my hypoxia-upregulated proteins have been found in NDMVs. I therefore explored 
the impact of hypoxia on NDMV release. As MVs enable multiple cell types to release 
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packages of cytoplasmic proteins and studies have suggested that hypoxia increases the 
release of NDMVs (187,188,190), this represented a plausible mechanism by which 
neutrophils may actively secrete cytoplasmic proteins under hypoxia. NDMVs were 
challenging to isolate in sufficient numbers for analysis, prompting a collaboration with Dr 
Victoria Ridger (University of Sheffield). However, even using her established protocols and 
working in her laboratory alongside her group members with expertise in these methods, I was 
unable to detect an increase in NDMVs under hypoxia. Consistent with this, I did not see any 
difference in NDMVs between COPD patient and healthy control plasma, which alleviated 
concerns that the cell and NDMV isolation techniques might mask differences between 
samples. Furthermore, there was no difference in NDMV content of cyclophilin A between 
normoxia and hypoxia, and cyclophilin A could also be detected in NDMV-free supernatants. 
Thus, my integrated dataset suggests that MV release does not significantly contribute to the 
increased secretion of cytoplasmic proteins from hypoxic neutrophils. Of note, hypoxia is a 
powerful neutrophil survival factor and I have shown no increase in cell death under these 
experimental conditions; if cell death were responsible for the increased detection then other 
cytoplasmic proteins would also have been upregulated in the hypoxic secretome. It would be 
interesting to explore whether cytoplasmic proteins are somehow transferred into granules for 
secretion or whether an alternative mechanism, such as reverse pinocytosis, is instigated. 
6.2.7 Translation to COPD and beyond 
I wished to translate my proteomic findings to a clinically relevant patient group. As noted 
above, COPD is associated with airway neutrophilia and hypoxia, and with excessive 
cardiovascular morbidity. Evidence is emerging that inflammation plays a key role in both the 
progression of airway disease and development of CVD in COPD. I demonstrated a trend 
(which did not achieve statistical significance) to increased NE release from normoxic COPD 
vs healthy control neutrophils, which may reflect a pro-inflammatory or hypoxic signature in a 
subset of these patients. This observation could reflect the primed circulating neutrophil 
phenotype reported in exacerbating COPD patients (283) although I did not observe any 
difference in shape change between untreated COPD and healthy neutrophils. Importantly 
however, I have shown that neutrophils isolated from exacerbating COPD patients release 
even more NE when stimulated under hypoxia than do cells from healthy controls. 
Furthermore, the fold increase in NE release from normoxic vs hypoxic cells was greater for 
COPD than healthy controls, indicating that, rather than just starting from an increased 
baseline, hypoxia is acting to further augment degranulation in these cells. Extrapolating from 
my earlier results, this would confer the potential for causing increased endothelial injury. A 
previous study has shown increased NE activity in neutrophil lysates from COPD patients 
compared with healthy controls (219), although NE content was not measured biochemically 
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and proteomic examination also revealed reduced leukocyte elastase inhibitor (Serpin B1) so 
this may represent a protease/anti-protease imbalance rather than a true increase in NE 
levels. Still, this is physiologically relevant and, as previously noted, my proteomic screen 
confirmed higher levels of leukocyte elastase inhibitor in the normoxic compared with hypoxic 
neutrophil secretome (FC 1.8, adj. p value = 0.013).  
Reflecting these NE data, I showed an increase in resistin and NGAL in COPD vs healthy 
neutrophil supernatants under hypoxia, again demonstrating that the hypoxic upregulation of 
degranulation was increased in the disease population. Further relating the pattern of the 
proteomic data to COPD, I showed a similar hypoxic increase in the release of the cytoplasmic 
protein, cyclophilin A. Taken together, these results suggest that COPD neutrophils exhibit a 
hypoxic hyper-secretory phenotype and may therefore have enhanced capacity for tissue 
damage. These findings are particularly exciting as they may represent novel therapeutic 
targets. Although already associated in the literature with endothelial dysfunction in various in 
vitro and in vivo situations (406,408,413), it would still be important to establish whether these 
proteins cause direct endothelial injury.  
Despite seeing an increase in plasma breakdown products of both NE and PR3 activity in 
COPD, I did not observe a significant increase in resistin, NGAL or cyclophilin A in 
exacerbating COPD patient vs healthy control plasma. It is likely that this experiment was not 
sufficiently powered to detect small changes in these circulating neutrophil proteins (given my 
sample size calculation requirement of a minimum of 16 per group based on my previous NE 
activity data), or the results could have been impacted by the heterogeneity of the COPD 
patient cohort. Indeed, there is likely a spectrum of neutrophil abnormality within this diagnosis 
and it is important to note that changes at a population level may not represent consistent 
features of the disease. 
Plasma levels of these proteins have been shown to vary in the literature in an infection setting: 
plasma resistin was increased in patients with sepsis compared with critically ill non-infected 
patients, and in a mixed group of sepsis patients (with pathogens including S. pyogenes, S. 
pneumoniae, E. coli, Neisseria meningitidis and unknown pathogen), plasma MPO and 
resistin levels were increased overall whereas NGAL was decreased (306). Moreover, 
significantly more resistin was secreted from healthy neutrophils treated with Group A 
Streptococcus than either S. aureus or E. coli (378). It would be informative to pursue plasma 
levels of these proteins in a larger, well-phenotyped COPD patient group, using 




Despite multiple lines of evidence suggesting a prominent role for NE in COPD, phase 2 
clinical trials of the small molecule NE inhibitor, AZD9668, showed no benefit in lung function, 
exacerbation incidence, respiratory symptoms or quality of life (476,477). However, these 
were relatively short-term studies undertaken after significant irreversible airway damage had 
likely already occurred, and neither study included cardiovascular endpoints, which my data 
suggest may be a promising avenue to examine. It has been proposed that the limited clinical 
success of NE inhibitors may be due to a combination of inadequate patient phenotype 
selection, the short study period, the inability to attain stoichiometric equivalent concentrations 
of inhibitor at neutrophil degranulation sites, instability of the inhibitor in vivo, or failure of 
inhibitors to access neutrophils adjacent to the ECM (478). A further reason may be that NE 
inhibition alone is not enough to prevent tissue damage, which would be consistent with my 
results obtained following neutrophil supernatant treatment of endothelial cells. Whilst it is 
difficult to equate the in vitro incubation of neutrophil supernatants and endothelial cells to the 
in vivo pathological setting, the fact that circulating neutrophil granule products, including 
resistin and NGAL, have been associated with worse cardiovascular outcomes (479,480) and 
my demonstration of increased protease activity in COPD vs healthy plasma, make the 
hypoxic uplift of degranulation a biologically plausible mechanism for promoting endothelial 
dysfunction in these patients, in combination with perturbations of circulating inflammatory 
mediators. It would be interesting to pursue my observations in a more sensitive and 
physiologically relevant system, for example assessing the effect of COPD vs healthy 
neutrophil supernatants on neutrophil-endothelial interactions in a flow adhesion system. 
What might be the translational potential of my work? Endothelial dysfunction is a poorly 
understood feature of COPD, associated with substantial cardiovascular comorbidity and 
mortality. Having demonstrated endothelial damage caused by hypoxic neutrophil 
supernatants, suggested a novel mechanism of enhanced neutrophil secretion under hypoxia, 
and identified specific histotoxic protein targets, my work has the potential to inform the 
development of disease-modifying therapeutics in COPD, which could be extrapolated to a 
wide range of neutrophilic inflammatory diseases underpinned by hypoxia and endothelial 
dysfunction. In the setting of respiratory medicine, it would be relevant to investigate these 
mechanisms in bronchiectasis; this condition is associated with marked neutrophilic airway 
inflammation and hypoxia in an animal model (222), with established correlations between 
airway NE and disease severity (70), and emerging evidence of disproportionate 
cardiovascular morbidity (453,481). My research supports a key role for NE in promoting 
cardiovascular comorbidity in COPD and my work could, therefore, prompt a focus on 
cardiovascular endpoints for small molecule NE inhibitors (and other anti-protease strategies) 
in clinical trials in COPD and other inflammatory diseases.  
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I have also identified PI3Kγ as a mediator of increased hypoxic neutrophil NE release. 
Increased PI3K signalling has been implicated in COPD: neutrophils isolated from COPD 
patients displayed impaired migratory accuracy (potentially causing bystander tissue damage) 
which could be improved by pan-PI3K inhibition (216); additionally, reduced PTEN protein 
expression, which correlated with the severity of airflow obstruction, and increased AKT 
phosphorylation were identified in peripheral lung tissue from COPD patients (482). 
Furthermore, pan-PI3K inhibition prevented formation and progression of murine abdominal 
aortic aneurysms (483), and genetic PI3Kγ deletion in mice reduced airway inflammation, 
hyper-responsiveness and remodelling in an asthma model (484) and reduced airway 
inflammation and structural lung damage in a CF model, with a mortality benefit (485). As 
several PI3K inhibitors are in Phase 3 clinical trials (mostly in the oncology domain), the 
exciting prospect of translation to COPD and beyond could be realised in the relatively near 
future. Since PI3Kγ is essential for optimal neutrophil function, long term systemic targeting is 
likely to impair host defence and increase infection susceptibility; potential options to mitigate 
such risks include the use of inhaled inhibitors to deliver compounds directly to the diseased 
airway, and perhaps limited short-term use of systemic inhibitors at high-risk times such as 
following exacerbations. More speculatively, identification of hypoxia-upregulated histotoxic 
proteins could inform the development of new targeted treatments, and further exploration of 
the hypoxic control of neutrophil secretion, e.g. using phospho-proteomics, may lead to new 
therapeutic opportunities for a wide range of inflammatory diseases.  
6.3 Future research avenues 
As hypoxia drives neutrophil hyper-secretion of multiple histotoxic proteins and proteases, 
coupled with the fact that inhibition of NE alone has not had a major impact in clinical trials, it 
seems highly relevant to further explore the mechanisms underlying the establishment of this 
destructive neutrophil phenotype and to identify the most damaging effectors. Enhanced 
understanding of this phenomenon may lead to the identification of modifiable 
pathways/targets contributing to tissue injury in situations where inflammation and hypoxia co-
exist.   
6.3.1 Investigating the role of hypoxia-upregulated proteins in mediating 
clinically relevant endothelial damage  
Supernatants derived from hypoxic neutrophils contain a multitude of histotoxic proteins and 
proteases, and cause substantial endothelial cell damage. Having also shown that these 
hypoxia-upregulated proteins are even further increased in neutrophil supernatants from 
exacerbating COPD patients, it would be informative to examine the ability of these patient-
derived supernatants to mediate endothelial injury, compared with supernatants derived from 
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patients with stable disease and those from healthy controls. As well as assessing endothelial 
damage in static culture, it would be interesting to progress these experiments into a more 
physiological flow-based adhesion system, measuring rolling, arrest and transmigration of 
neutrophils perfused over endothelial cells (pre-treated with COPD vs healthy supernatants) 
by time lapse imaging. Pulmonary neutrophil recruitment is associated with changes in 
vascular permeability in vivo (reviewed in (252)) and may further exacerbate endothelial 
damage. Moreover, the endothelial adhesion molecule ICAM-1 correlates with emphysema 
on CT imaging and lung function decline in COPD (486), and I have shown that supernatants 
from hypoxic neutrophils increase HPAEC ICAM-1 expression in static culture, all suggesting 
that supernatants from hypoxic COPD neutrophils would augment neutrophil adhesion and 
transmigration under flow and in the in vivo setting. As well as demonstration of aberrant 
neutrophil behaviours in COPD, pulmonary vascular endothelial cells from COPD patients 
may be intrinsically abnormal, having been shown to display markers of senescence, such as 
telomere shortening, which was linked with lung inflammation (487). Derivation of patient blood 
outgrowth endothelial cells from circulating endothelial progenitors in whole blood could be 
used to investigate whether there is increased susceptibility of these cells to neutrophil-
mediated damage, which could also be combined with perfusion of patient neutrophils.  
Having identified NE, resistin, NGAL and cyclophilin A as candidate histotoxic proteins which 
are upregulated in hypoxic neutrophil supernatants (particularly in COPD), it will be important 
to examine the capacity of these proteins to cause direct endothelial injury. Further 
assessment of a more detailed plasma signature for these proteins in COPD vs healthy 
plasma could be investigated using multiplex electrochemiluminescence technology, which 
has a high sensitivity and wide detection range. Additionally, circulating markers of endothelial 
damage could be measured, such as angiopoietin-2, VEGF and sFlt-1 (soluble VEGF 
receptor) (241,488). The key experiments to establish the role of hypoxic neutrophil secretion 
products in mediating endothelial damage would help to establish whether inhibition of PI3Kγ 
signalling (or other yet-to-be determined mechanistic pathways) or depletion/inhibition of 
specific hypoxia-upregulated proteins alone or in combination, might be able to ameliorate 
endothelial injury.  
Initial in vivo translation of these data could involve trialling inhibitors of PI3Kγ or specific 
proteins in a chronic hypoxia (or COPD) rodent model and assessing both pulmonary 
inflammation and cardiovascular outcomes. Excitingly, several PI3K inhibitors are already in 
oncological clinical trials, paving the way for translation to inflammatory disorders. As noted 
above, the potential for benefit will need to be weighed against possible side effects, and 
mitigation strategies explored, such as targeted delivery of short-duration dosing. Although 
α1AT did not prevent all endothelial injury induced by hypoxic supernatants, it did provide 
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substantial protection, and α1AT augmentation therapy is in clinical use to treat patients 
deficient in this protein. Whilst the impact of this therapy on respiratory outcomes has not been 
overwhelming (489), there is little data on cardiovascular comorbidity and this would be 
plausible to investigate in animal models and in patients.  
Overall, the delineation of the nature and extent of hypoxic neutrophil-mediated endothelial 
damage in the clinical context of COPD, and further identification of the responsible factors 
and degranulation processes, has the potential to inform disease-modifying therapy in a broad 
range of hypoxic inflammatory lung diseases with enhanced cardiovascular risk. 
6.3.2 Investigating how hypoxia impacts neutrophil intracellular signalling 
and granule trafficking pathways to enhance histotoxic protein release 
I have shown that PI3Kγ plays a prominent role in mediating enhanced NE release from 
neutrophils under hypoxia. However, the mechanism by which hypoxia enables enhanced 
PI3Kγ signalling and the responsible downstream pathways remain unclear, and it is likely that 
other signalling events are involved. An initial candidate approach could be employed: for 
example, assessing the hypoxic regulation of PI3Kγ or negative regulator, PTEN, expression 
by western blotting of neutrophil lysates or by measurement of downstream lipid mediators, 
such as PIP3. As a complementary approach, phospho-proteomics is a powerful technique 
which could be utilised to characterise the effect of hypoxia on neutrophil protein 
phosphorylation, allowing large scale bioinformatic network analysis but also with the potential 
to identify new phosphoprotein candidates. As the actin-bundling protein, T plastin, has been 
shown to regulate hypoxia-induced membrane trafficking in a HIF-independent fashion in 
other cell types (147), neutrophil L plastin, which is phosphorylated in response to fMLP-
treatment, represents an example of a plausible phosphoprotein candidate which may be 
implicated in the hypoxic regulation of degranulation.  
Given my proteomic data demonstrating the upregulated release of both selected granule 
proteins and a small subset of cytosolic proteins under hypoxia, it would be valuable to 
understand the mechanism(s) controlling this differential release. My results suggest that this 
phenomenon is not due to NET or NDMV release, but previous data from our group has 
indicated an effect of hypoxia on modulating the neutrophil cytoskeleton, redistributing sub-
cortical actin into a focal cap (315). It would be exciting, though challenging, to visualise the 
effect of hypoxia on neutrophil shape, subcellular structure and granule distribution using live 
cell imaging. New technology exists, which may facilitate these experiments, including the 
development of small transportable containers which maintain the temperature, humidity and 
oxygenation status of the hypoxia workstation.  
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Exploration of neutrophil intracellular vesicle trafficking, which is controlled by Rab family 
proteins, and vesicle membrane docking, which is mediated by interaction of SNAREs, may 
allow enhanced understanding of how neutrophils selectively upregulate protein release under 
hypoxia. Hypoxia can increase the expression and/or activity of Rab27a (which directs 
vesicles for plasma membrane fusion) and the vesicle-associated membrane protein VAMP-
2 (which complexes with membrane SNAREs) in liver and neuronal cells, respectively 
(465,490). Neutrophil total content of these proteins under hypoxia could be determined by 
western blotting, and activity by techniques such as pull-down assays for small GTPases. The 
plasma membrane content of SNAREs under hypoxia vs normoxia could be examined by 
plasma membrane biotinylation and quantification of protein abundance by TMT-MS, a 
technique which has been optimised for neutrophils in our laboratory. Subcellular localisation 
is also key: Rab27a is relatively lacking on neutrophil azurophilic granules, which are hence 
directed for phagosome rather than plasma membrane fusion. Examination of Rab localisation 
during normoxic and hypoxic incubation by immunofluorescence or electron microscopic 
analysis, with co-staining of the relevant granule populations, would enhance our 
understanding of the effect of hypoxia on the localisation of vesicle trafficking proteins. These 
techniques could also be employed to ascertain the effect of hypoxia on granule localisation 
of candidate hypoxia up- and down-regulated proteins (including those of cytoplasmic origin), 
predicting that hypoxia regulates their movement into/between vesicles in a manner 
analogous to the piecemeal degranulation described for eosinophils and mast cells, which 
subsequently impacts their release. These experiments have the potential to identify an 
entirely novel mechanism of neutrophil protein secretion.  
Overall, further investigation of how hypoxia impacts neutrophil signalling and granule 
trafficking pathways would not only add significantly to our scientific knowledge of this largely 
unexplored field but may highlight new research avenues, including identification of additional 
clinically relevant targetable pathways/mechanisms. 
6.4 Conclusions 
Persistent and excessive neutrophilic activation has been implicated in inflammatory damage 
to bystander cells and tissues, contributing to the pathogenesis of both acute and chronic 
inflammatory diseases. Regions of infection and inflammation are profoundly hypoxic and, in 
diseases such as COPD, systemic hypoxia can develop. Hence, a greater understanding of 
how neutrophils function in physiologically and pathologically relevant low oxygen tensions is 
paramount in order to inform the development of new treatments to combat tissue injury and 
disease progression. In this thesis, I have extended our knowledge of the impact of hypoxia 
on neutrophil degranulation by showing that hypoxia enhances the release of damaging 
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granular proteases in an agonist- and PI3Kγ-dependent manner, and that supernatants from 
these hypoxic cells cause substantial injury to endothelial cells. Thus, my results suggest that 
this destructive neutrophil phenotype may promote endothelial dysfunction in a wide range of 
diseases where inflammation and hypoxia co-exist, potentially contributing to increased 
cardiovascular risk. As the endothelial damage from hypoxic neutrophil supernatants was not 
entirely protease-dependent, I performed an analysis of the normoxic vs hypoxic neutrophil 
secretome. This characterisation identified novel hypoxia-upregulated histotoxic protein 
targets, which have the potential to lead to the development of new treatment strategies. 
Translating these results to a clinically relevant patient cohort, I confirmed that the release of 
selected potentially histotoxic proteins was even further increased in supernatants from 
exacerbating COPD patient neutrophils under hypoxia. I hope that these data will create 
further interest in exploring inhibition of new histotoxic protein candidates and/or PI3Kγ 
signalling in this and related disease settings.  
Unexpected and intriguing proteomic results, demonstrating that differential protein secretion 
under hypoxia did not entirely segregate with distinct granule populations and that release of 
certain cytoplasmic proteins was consistently upregulated, generated further questions 
regarding hypoxic control of neutrophil secretion mechanisms. It would be exciting to explore 
the effect of hypoxia on signalling pathways, and granule/vesicle packaging and trafficking in 
neutrophils. These studies may provide a new array of therapeutic targets or mechanisms 





7.1 10-plex TMT-MS and data analysis parameters 
Full parameters for 10-plex TMT-MS and data analysis, provided by Dr Mike Deery and Dr 
Marco Chiapello (CCP), are as follows. 
7.1.1 LC-MS/MS 
The dried sample was resuspended in 30 μl of 0.1% formic acid and placed into a glass vial. 
1 μl was injected by the HPLC autosampler and separated by the LC method detailed below. 
LC-MS/MS experiments were performed using a Dionex Ultimate 3000 RSLC nanoUPLC 
(Thermo Fisher Scientific) system and a Lumos Orbitrap mass spectrometer (Thermo Fisher 
Scientific). Peptides were loaded onto a pre-column (Thermo Scientific PepMap 100 C18, 5 
mm particle size, 100 A pore size, 300 mm x 5 mm length) from the Ultimate 3000 auto-
sampler with 0.1% formic acid for 3 min at a flow rate of 10 ml/min. After this period, the column 
valve was switched to allow elution of peptides from the pre-column onto the analytical column. 
Separation of peptides was performed by C18 reverse-phase chromatography at a flow rate 
of 300 nl/min using a reverse-phase nano Easy-spray column (Thermo Scientific PepMap 
C18, 2 mm particle size, 100 A pore size, 75 mm x 50 cm length). Solvent A was water + 0.1% 
formic acid and solvent B was 80% acetonitrile, 20% water + 0.1% formic acid. The linear 
gradient employed was 2-40% B in 93 minutes.  The total LC run time was 120 min, including 
a high organic wash step and column re-equilibration. 
The eluted peptides from the C18 column LC eluant were sprayed into the mass spectrometer 
by means of an Easy-Spray source (Thermo Fisher Scientific). All m/z values of eluting peptide 
ions were measured in an Orbitrap mass analyzer, set at a resolution of 120,000 and were 
scanned between m/z 380-1500 Da. Data dependent MS/MS scans (top speed) were 
employed to automatically isolate and fragment precursor ions by collision-induced 
dissociation (CID, Normalised Collision Energy (NCE): 35%), which were analysed in the 
linear ion trap. Singly charged ions and ions with unassigned charge states were excluded 
from being selected for MS/MS and a dynamic exclusion window of 70 s was employed. The 
top ten most abundant fragment ions from each MS/MS event were then selected for a further 
stage of fragmentation by Synchronous Precursor Selection (SPS) MS
3
 in the HCD (High 
energy Collisional Dissociation) high energy collision cell using HCD (NCE: 65%). The m/z 
values and relative abundances of each reporter ion and all fragments (mass range from 100-
500 Da) in each MS
3
 step were measured in the Orbitrap analyser, which was set at a 
resolution of 60,000.  This was performed in cycles of 10 MS
3
 events before the Lumos 
191 
 
instrument reverted to scanning the m/z ratios of the intact peptide ions and the cycle 
continued. 
7.1.2 Data analysis 
Proteome DiscovererTM version 2.1 (Thermo Fisher Scientific) and Mascot version 2.6 (Matrix 
Science) were used to process raw data files. Data were aligned with the UniProt Human 
reference proteome (Proteome ID: UP000005640) database, in addition to using the common 
repository of adventitious proteins (cRAP) version 1.0. Database searches were also 
performed using a sequence scrambled decoy database in order to yield a more robust false 
discovery rate (FDR). Protein identification allowed an MS tolerance of ± 20 parts per million 
(ppm) and an MS/MS tolerance of ± 0.6 Da, along with permission of up to two missed tryptic 
cleavages. Fixed modifications were carbamidomethylation of cysteine and TMT 10-plex at 
lysine and N-termini; variable modifications were oxidized methionine, deamidated aspartic 
acid and asparagine, and TMT10-plex at threonine, serine and methionine. Quantification was 
achieved by calculating the sum of centroided reporter ions within a ± 2 millimass unit (mmu) 
window around the expected m/z for each of the TMT reporter ions. For quantification, the 
integration window tolerance was set to 20 ppm. The confidence thresholds were set at a strict 
FDR of 0.01 and a relaxed FDR of 0.05. Finally, the following filters were applied during the 
Proteome Discoverer search: peptide score: 20, peptide rank: 1, peptide confidence: high.  
Labelling efficiency was calculated by setting TMT10-plex as a variable modification and 
expressing the number of peptides with the modification as a percentage of the total number 
of peptides. A labelling efficiency of ≥ 95% was considered acceptable. Principal component 
analysis (PCA) and paired t-test statistical analyses were performed. PCA was used to 
visualise data relatedness by mathematical transformation of the original (possibly correlated) 
variables into a set of linearly uncorrelated variables (principal components). The first principal 
component (PC1) had the largest possible variance (i.e. accounted for as much variability in 
the data as possible), with each succeeding component (e.g. PC2) having the highest 
remaining variance possible. T-test was performed using R limma package software, with p 
values adjusted by the Benjamini-Hochberg FDR correction for multiple comparisons. Using 
this method, the p-values were ranked from smallest (1) to largest (N). Each p-value was 
multiplied by N and divided by its assigned rank to give the adjusted p-values. This method 
provides a good balance between discovery of statistically significant proteins and limitation 




7.2 Proteins identified by 10-plex TMT-MS 
Table 7.1: Proteins increased in normoxia 
Proteins increased in normoxia which were present in all 10 samples with a FDR <0.01 are 
listed below in order of the magnitude of the fold change (FC).  
Accession Description log2FC adjusted 
p value 
FC 
Q5TCU8 Tropomyosin beta chain 3.567 0.001 11.855 
cRAP106 Thioredoxin  1.967 0.017 3.909 
E7EX29 14-3-3 protein zeta/delta 1.943 0.015 3.844 
P52566 Rho GDP-dissociation inhibitor 2 1.927 0.004 3.802 
P08670 Vimentin 1.913 0.006 3.766 
O00299 Chloride intracellular channel protein 1 1.545 0.030 2.918 
P11021 78 kDa glucose-regulated protein 1.523 0.009 2.873 
E9PK25 Cofilin-1 1.461 0.023 2.753 
E7EMB3 Calmodulin 1.315 0.026 2.488 
P62993 Growth factor receptor-bound protein 
2 
1.309 0.004 2.478 
P20700 Lamin-B1 1.284 0.004 2.435 
Q32MZ4 Leucine-rich repeat flightless-
interacting protein 1 
1.224 0.004 2.337 
P06737 Glycogen phosphorylase, liver form 1.149 0.025 2.217 
P32942 Intercellular adhesion molecule 3 1.104 0.015 2.149 
Q9Y490 Talin-1 1.081 0.015 2.116 
O15144 Actin-related protein 2/3 complex 
subunit 2 
1.061 0.031 2.086 
P06702 Protein S100-A9 1.060 0.013 2.084 
P60709 Actin, cytoplasmic 1 1.007 0.164 2.010 
P52209 6-phosphogluconate dehydrogenase, 
decarboxylating 
0.963 0.013 1.950 
P26038 Moesin 0.909 0.019 1.878 
P33241 Leukocyte-specific protein 1 0.909 0.013 1.878 
P18206 Vinculin 0.861 0.015 1.816 
P30740 Leukocyte elastase inhibitor 0.858 0.006 1.813 
Q96C19 EF-hand domain-containing protein 
D2 
0.843 0.027 1.794 
A6NIZ1 Ras-related protein Rap-1b-like 
protein 
0.807 0.009 1.749 
P61160 Actin-related protein 2 0.775 0.178 1.711 
F8VPF3 Myosin light polypeptide 6 0.759 0.069 1.693 
P31946 14-3-3 protein beta/alpha 0.747 0.184 1.678 
P35579 Myosin-9 0.706 0.012 1.631 
A0A140T930 HLA class I histocompatibility antigen, 
Cw-6 alpha chain 
0.702 0.039 1.627 
S4R359 Heterogeneous nuclear 
ribonucleoprotein K 
0.685 0.142 1.607 
P80723 Brain acid soluble protein 1 0.677 0.460 1.598 
P61247 40S ribosomal protein S3a 0.612 0.028 1.528 
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Q14847 LIM and SH3 domain protein 1 0.604 0.050 1.520 
P07237 Protein disulfide-isomerase 0.597 0.071 1.512 
P02042 Hemoglobin subunit delta 0.577 0.049 1.492 
cRAP036 Hemoglobin subunit beta  0.575 0.159 1.490 
P0C0S5 Histone H2A.Z 0.574 0.059 1.489 
E7EQR4 Ezrin 0.558 0.023 1.473 
P31949 Protein S100-A11 0.557 0.179 1.471 
P08133 Annexin A6 0.544 0.035 1.458 
P31146 Coronin-1A 0.537 0.034 1.451 
Q15907 Ras-related protein Rab-11B 0.533 0.015 1.447 
P46781 40S ribosomal protein S9 0.524 0.044 1.438 
P16150 Leukosialin 0.514 0.054 1.428 
P68036 Ubiquitin-conjugating enzyme E2 L3 0.506 0.090 1.420 
J3QRS3 Myosin regulatory light chain 12A 0.501 0.141 1.415 
P46940 Ras GTPase-activating-like protein 
IQGAP1 
0.496 0.049 1.411 
cRAP035 Hemoglobin subunit alpha  0.487 0.050 1.401 
P12814 Alpha-actinin-1 0.481 0.099 1.395 
P46976 Glycogenin-1 0.469 0.105 1.384 
P09382 Galectin-1 0.467 0.108 1.382 
P19878 Neutrophil cytosol factor 2 0.464 0.204 1.379 
P50552 Vasodilator-stimulated phosphoprotein 0.461 0.062 1.377 
P11413 Glucose-6-phosphate 1-
dehydrogenase 
0.460 0.120 1.376 
A0A075B738 Platelet endothelial cell adhesion 
molecule 
0.449 0.163 1.365 
P39687 Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
0.442 0.043 1.358 
P07900 Heat shock protein HSP 90-alpha 0.412 0.089 1.330 
P14618 Pyruvate kinase PKM 0.409 0.249 1.328 
P28065 Proteasome subunit beta type-9 0.408 0.052 1.327 
Q9H4G4 Golgi-associated plant pathogenesis-
related protein 1 
0.398 0.578 1.317 
P16070 CD44 antigen 0.364 0.173 1.287 
P49721 Proteasome subunit beta type-2 0.351 0.052 1.275 
P25788 Proteasome subunit alpha type-3 0.334 0.050 1.260 
Q9ULZ3 Apoptosis-associated speck-like 
protein containing a CARD 
0.324 0.051 1.252 
P25786 Proteasome subunit alpha type-1 0.319 0.298 1.247 
P37837 Transaldolase 0.313 0.147 1.242 
A0A0G2JIW1 Heat shock 70 kDa protein 1B 0.302 0.137 1.233 
G3V5Z7 Proteasome subunit alpha type 0.282 0.119 1.216 
cRAP019 Cathepsin G  0.271 0.646 1.207 
P04083 Annexin A1 0.267 0.106 1.204 
P28070 Proteasome subunit beta type-4 0.255 0.160 1.193 
O14818 Proteasome subunit alpha type-7 0.254 0.113 1.192 
O43707 Alpha-actinin-4 0.242 0.446 1.183 
Q9UJ70 N-acetyl-D-glucosamine kinase 0.212 0.202 1.158 
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P21333 Filamin-A 0.208 0.266 1.155 
P13796 Plastin-2 0.206 0.504 1.154 
P78417 Glutathione S-transferase omega-1 0.196 0.470 1.146 
P06703 Protein S100-A6 0.169 0.406 1.125 
Q9H299 SH3 domain-binding glutamic acid-
rich-like protein 3 
0.169 0.702 1.124 
P29401 Transketolase 0.166 0.278 1.122 
P26447 Protein S100-A4 0.160 0.485 1.118 
J3QQX2 Rho GDP-dissociation inhibitor 1 0.155 0.575 1.114 
P06733 Alpha-enolase 0.152 0.455 1.111 
P60174 Triosephosphate isomerase 0.152 0.575 1.111 
A6NEL0 Non-histone chromosomal protein 
HMG-14 
0.145 0.379 1.106 
P51858 Hepatoma-derived growth factor 0.145 0.365 1.106 
P20618 Proteasome subunit beta type-1 0.141 0.356 1.103 
P11142 Heat shock cognate 71 kDa protein 0.140 0.562 1.102 
O75368 SH3 domain-binding glutamic acid-
rich-like protein 
0.132 0.702 1.096 
P40121 Macrophage-capping protein 0.131 0.491 1.095 
P62979 Ubiquitin-40S ribosomal protein S27a 0.117 0.495 1.085 
P04080 Cystatin-B 0.115 0.715 1.083 
P15531 Nucleoside diphosphate kinase A 0.111 0.687 1.080 
P06396 Gelsolin 0.093 0.522 1.067 
Q01518 Adenylyl cyclase-associated protein 1 0.084 0.687 1.060 
P05089 Arginase-1 0.066 0.767 1.047 
J3KPS3 Fructose-bisphosphate aldolase 0.049 0.840 1.035 
Q6IBS0 Twinfilin-2 0.028 0.933 1.020 
P04040 Catalase 0.027 0.860 1.019 
Q14019 Coactosin-like protein 0.025 0.933 1.017 





Table 7.2: Proteins increased in hypoxia 
Proteins increased in hypoxia which were present in all 10 samples with a FDR <0.01 are 
listed below in order of the magnitude of the fold change (FC).  
Accession Description log2FC adjusted 
p value 
FC 
P62805 Histone H4 1.843 0.004 3.587 
P05164 Myeloperoxidase 1.635 0.006 3.107 
O75594 Peptidoglycan recognition protein 1 1.409 0.185 2.655 
A6NC48 ADP-ribosyl cyclase/cyclic ADP-ribose 
hydrolase 2 
1.303 0.025 2.468 
O75083 WD repeat-containing protein 1 1.252 0.029 2.382 
Q92820 Gamma-glutamyl hydrolase 1.100 0.020 2.143 
cRAP109 Lactotransferrin  1.095 0.033 2.136 
A5A3E0 POTE ankyrin domain family member 
F 
1.052 0.015 2.074 
Q0VD83 Apolipoprotein B receptor 0.995 0.025 1.993 
P19652 Alpha-1-acid glycoprotein 2 0.937 0.233 1.915 
P10124 Serglycin 0.929 0.012 1.904 
Q9HD89 Resistin 0.925 0.004 1.898 
P07737 Profilin-1 0.918 0.015 1.890 
A0A087WXL1 Folate receptor gamma 0.908 0.029 1.877 
P11215 Integrin alpha-M 0.904 0.004 1.872 
P16035 Metalloproteinase inhibitor 2 0.890 0.034 1.853 
X6R8F3 Neutrophil gelatinase-associated 
lipocalin 
0.882 0.004 1.842 
V9GYM3 Apolipoprotein A-II 0.823 0.049 1.769 
G3V3D1 Epididymal secretory protein E1 0.820 0.007 1.765 
P10153 Non-secretory ribonuclease 0.722 0.029 1.650 
G5EA09 Syndecan binding protein 0.702 0.055 1.627 
Q05315 Galectin-10 0.691 0.184 1.614 
P08246 Neutrophil elastase 0.676 0.250 1.598 
P04217 Alpha-1B-glycoprotein 0.673 0.015 1.594 
P05107 Integrin beta-2 0.660 0.018 1.580 
P28799 Granulins 0.644 0.083 1.563 
P01024 Complement C3 0.638 0.032 1.556 
A0A0A0MS08 Ig gamma-1 chain C region 0.611 0.050 1.528 
A0A0G2JMY9 Leukocyte immunoglobulin-like 
receptor subfamily A member 3 
0.598 0.178 1.514 
J3KPA1 Cysteine-rich secretory protein 3 0.594 0.160 1.509 
O00391 Sulfhydryl oxidase 1 0.589 0.050 1.504 
P20061 Transcobalamin-1 0.578 0.042 1.492 
cRAP002 Serum albumin  0.552 0.051 1.466 
P78324 Tyrosine-protein phosphatase non-
receptor type substrate 1 
0.535 0.018 1.449 
J3KNB4 Cathelicidin antimicrobial peptide 0.532 0.039 1.446 
A0A087WW89 NA 0.525 0.050 1.439 
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P62937 Peptidyl-prolyl cis-trans isomerase 
A/Cyclophilin A 
0.524 0.035 1.438 
P14625 Endoplasmin 0.522 0.050 1.435 
Q9UHB9 Signal recognition particle subunit 
SRP68 
0.499 0.216 1.413 
P30086 Phosphatidylethanolamine-binding 
protein 1 
0.491 0.049 1.406 
P02647 Apolipoprotein A-I 0.483 0.460 1.398 
P15144 Aminopeptidase N 0.477 0.083 1.392 
P20160 Azurocidin 0.475 0.081 1.390 
P26022 Pentraxin-related protein PTX3 0.445 0.108 1.362 
A0A075B6H6 Ig kappa chain C region 0.441 0.030 1.358 
P14780 Matrix metalloproteinase-9 0.438 0.081 1.354 
P61626 Lysozyme C 0.436 0.396 1.353 
P09960 Leukotriene A-4 hydrolase 0.422 0.184 1.340 
A0A0A0MTS2 Glucose-6-phosphate isomerase 0.419 0.353 1.337 
P02763 Alpha-1-acid glycoprotein 1 0.415 0.460 1.333 
P36222 Chitinase-3-like protein 1 0.389 0.233 1.309 
P12429 Annexin A3 0.388 0.189 1.309 
A0A075B6K9 Ig lambda-2 chain C regions 0.384 0.049 1.305 
P23284 Peptidyl-prolyl cis-trans isomerase B 0.379 0.061 1.300 
P22894 Neutrophil collagenase 0.378 0.081 1.299 
O43493 Trans-Golgi network integral 
membrane protein 2 
0.350 0.081 1.275 
P41218 Myeloid cell nuclear differentiation 
antigen 
0.348 0.387 1.273 
P12724 Eosinophil cationic protein 0.338 0.549 1.264 
P00558 Phosphoglycerate kinase 1 0.332 0.160 1.259 
P40925 Malate dehydrogenase, cytoplasmic 0.327 0.081 1.255 
A0A087WTS4 Peptidyl-prolyl cis-trans isomerase 
FKBP1A 
0.327 0.178 1.254 
U3KQP0 Brain acid soluble protein 1 0.324 0.561 1.252 
A0A024R6I7 Alpha-1-antitrypsin 0.295 0.397 1.227 
P02787 Serotransferrin 0.283 0.361 1.216 
O15389 Sialic acid-binding Ig-like lectin 5 0.282 0.248 1.216 
P14151 L-selectin 0.270 0.117 1.206 
P00738 Haptoglobin 0.265 0.309 1.202 
O00602 Ficolin-1 0.263 0.185 1.200 
P02750 Leucine-rich alpha-2-glycoprotein 0.259 0.626 1.196 
Q6UX06 Olfactomedin-4 0.256 0.581 1.194 
Q13231 Chitotriosidase-1 0.246 0.565 1.186 
P05204 Non-histone chromosomal protein 
HMG-17 
0.244 0.160 1.184 
P62942 Peptidyl-prolyl cis-trans isomerase 
FKBP1A 
0.223 0.445 1.167 
P27695 DNA-(apurinic or apyrimidinic site) 
lyase 
0.213 0.396 1.159 
cRAP034 Glutathione S-transferase P  0.205 0.565 1.153 
P27797 Calreticulin 0.169 0.314 1.124 
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Q6P4A8 Phospholipase B-like 1 0.160 0.565 1.118 
P04264 Keratin, type II cytoskeletal 1 0.131 0.737 1.095 
Q96G03 Phosphoglucomutase-2 0.120 0.565 1.087 
P31150 Rab GDP dissociation inhibitor alpha 0.103 0.695 1.074 
Q01469 Fatty acid-binding protein, epidermal 0.102 0.695 1.073 
P00338 L-lactate dehydrogenase A chain 0.101 0.745 1.073 
Q31612 HLA class I histocompatibility antigen, 
B-73 alpha chain 
0.097 0.615 1.069 
P50395 Rab GDP dissociation inhibitor beta 0.093 0.606 1.067 
P16083 Ribosyldihydronicotinamide 
dehydrogenase [quinone] 
0.093 0.568 1.066 
H7C2N1 Prothymosin alpha 0.086 0.581 1.061 
Q13442 28 kDa heat- and acid-stable 
phosphoprotein 
0.082 0.615 1.059 
cRAP112 Trypsin  0.078 0.767 1.055 
O95336 6-phosphogluconolactonase 0.073 0.738 1.052 
Q9BRF8 Serine/threonine-protein phosphatase 
CPPED1 
0.054 0.702 1.038 
P00915 Carbonic anhydrase 1 0.034 0.898 1.024 
P14174 Macrophage migration inhibitory factor 0.031 0.898 1.021 
P00491 Purine nucleoside phosphorylase 0.030 0.891 1.021 
A0A024RA52 Proteasome subunit alpha type 0.024 0.885 1.016 
P00441 Superoxide dismutase [Cu-Zn] 0.014 0.935 1.010 
P07910 Heterogeneous nuclear 
ribonucleoproteins C1/C2 
0.011 0.965 1.008 
P17213 Bactericidal permeability-increasing 
protein 





Table 7.3: Differentially regulated proteins identified by 10-plex TMT-MS compared 
with published secretomes and sepsis patient plasma  
Differentially regulated proteins (as indicated), identified by my 10-plex TMT-MS, are listed 
below if also present in published (normoxic) neutrophil secretomes (A-F) or septic plasma 
(G-H), indicated by “Y” if present. Neutrophils in these published secretomes were stimulated 
with A: ionomycin (309); B: S. pyogenes supernatants (305); C: S. aureus leukotoxins 
(LukE/D) (308); D: chromofungin or catestatin (307); E: TNFα/cytochalasin B/heat-killed S 
pyogenes and fMLP (306). F-H: Blood was taken from three patients with sepsis secondary to 
S. pyogenes (erysipelas), E. coli (urosepsis), and N. meningitidis (meningococcal sepsis) 
(306). F: The secretome of ex vivo pooled isolated neutrophils stimulated with cytochalasin B 
and fMLP was examined. G-H: Measurement of the same proteins in pooled plasma showed 
a subset to be up-regulated (G) or down-regulated (H) when compared with healthy control 
plasma. Numbers in square brackets indicate the number of proteins identified in each study. 


























Normoxia significantly increased         
Protein S100-A9  Y Y Y Y Y Y 
 
 
Thioredoxin     Y Y 
  
 
Cofilin-1    Y Y 
   
 
Rho GDP-dissociation inhibitor 2     Y Y 
  
 
Leukocyte-specific protein 1    Y  Y 
  
 
14-3-3 protein zeta/delta      Y 
  
 
Vimentin    Y  
   
 
Chloride intracellular channel protein 
1  
    Y 
  
 
78 kDa glucose-regulated protein     Y 
   
 





    Y 
  
 
Leukocyte elastase inhibitor     Y 
   
 
Myosin-9   Y   
   
 
Annexin A6   Y   
   
 
Hypoxia significantly increased         
Neutrophil gelatinase-associated 
lipocalin  
Y Y Y Y Y Y 
 
Y 
Myeloperoxidase  Y Y Y  Y Y Y  
Lactotransferrin  Y Y Y Y Y Y   
Cathelicidin antimicrobial peptide Y Y Y  Y Y 
 
 
Profilin-1   Y Y Y Y 
  
 
Non-secretory ribonuclease   Y   Y Y 
 
 
Resistin   Y   
 
Y Y  
Peptidyl-prolyl cis-trans isomerase A/ 
Cyclophilin A  
   Y Y 
  
 
Transcobalamin-1      
 
Y Y  
WD repeat-containing protein 1     Y 
   
 
Integrin alpha-M         Y 
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